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Abstract  
 
The field of ocular gene therapy has become one of the most developed areas within the 
wider gene therapy field, however most work to date has focused upon the retina with the 
cornea, by comparison, having seen relatively little application of gene therapy. 
This thesis describes a program of work to further develop viral gene therapy approaches to 
the three cellular layers of the cornea, with particular emphasis upon the application of novel 
vector technologies and overcoming the various challenges presented by each layer. 
Gene therapy of the corneal endothelium has to date largely aimed to increase or maintain 
endothelial cell density to improve the quality of donor corneas for engraftment. Such a 
strategy however carries an inherent risk of oncogenesis and this study has therefore aimed 
to improve the safety profile of endothelial gene delivery methods. 
The transduction profile of various AAV serotypes within the corneal stroma was also 
investigated, and the most promising results applied in an augmentation gene therapy 
approach to prevent corneal neovascularisation. The selected methodology is shown to 
mediate high level transgene expression and, when delivering the antiangiogenic factor 
sFlt1, was highly effective in preventing haem (but not lymph) angiogenesis in a murine 
model of induced corneal neovascularisation.  
If long term gene delivery to the corneal epithelium is to be achieved it must be targeted to 
the limbal epithelial stem cells (LESCs) responsible for the continuous regeneration of the 
layer. This study has convincingly demonstrated gene delivery to these cells in vivo for the 
first time, with the methodology developed leading to a lasting transgene expression 
throughout the LESC daughter cell lineages that comprise the epithelium. In addition to 
potential application in the treatment of congenital epithelial dystrophies this technique may 
also provide new insights into LESC biology and the cellular dynamics of epithelial renewal.  
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1. Introduction 
 
1.1 The Cornea - Overview  
 
The Cornea is a domed, multi-layered, structure located at the front of the eye that in 
combination with the sclera forms the outer “shell” of the eyeball. Due to this shared 
structural role both the cornea and sclera are primarily composed of dense interwoven 
fibrous collagen providing strength and rigidity, beyond this however the two tissues have 
little in common. The primary functions of the cornea are optical; firstly it forms the 
transparent outer “window” through which light can enter the eye and secondly it acts as the 
eye’s primary refractive tissue accounting for approximately two thirds of the eye’s total 
optical power (43/60 dioptres). Maintenance of the optimal optical properties of the cornea 
required for vision requires fine regulation of thickness, structure and hydration of the cornea 
all of which are mediated by the cells of the cornea.  
The cornea is one of the most densely innervated tissues in the body (3-600x more so than 
skin) [1,2] with the majority of these neurons being sensory. This is due in part to the 
requirement of maintaining high sensitivity of the corneal (or blink) reflex which keeps the 
eye moist and protects it from damage.  
The cornea is also one of the relatively few completely avascular tissues in the body, with 
most somatic cells never being more than 200µm from the blood supply. The cells of the 
cornea therefore do not rely heavily upon the circulation to provide their metabolites, but 
instead chiefly rely upon diffusion or active transport from adjacent sources. Glucose and 
other nutrients are provided from the aqueous humour and the majority of the tissue’s 
oxygen derives from the atmosphere via the tear film. Direct exposure of the tear film to 
atmospheric oxygen is therefore vital to maintain adequate oxygenation of the cornea and 
any impairment of free diffusion (for example by prolonged contact lens wear) may lead to 
corneal hypoxia and associated pathology. 
Structurally the cornea is composed of five layers, three of them cellular: the epithelium, 
stroma and endothelium; and two forming basement membranes that separate the cellular 
layers from one another: Bowman’s Layer and Descemet’s Membrane. The work presented 
in this thesis is focused upon the transduction of the corneal cells by gene therapy viral 
vectors so this introduction will focus upon the cellular layers of the tissue, the various 
features of which will be further expounded in the subsections that follow.  
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1.2 The Corneal Endothelium 
 
The endothelium is the most posterior of the corneal layers and consists of a monolayer of 
squamous endothelial cells packed into a regular hexagonal array covering the cornea’s 
entire rear surface. The cells of the endothelium are tightly adhered to one another via 
apically located tight junctions / gap junctions and are separated from the stroma by 
Descemet’s membrane to which they adhere via hemidesmosomes. Descemet’s is an 
exceptionally thick (5-10µM) basement membrane which is secreted by the endothelium [3]. 
In common with the keratocytes of the stroma corneal endothelial cells are derived from the 
neural crest cells located at the periphery of the presumptive cornea, this is in contrast to the 
majority of the body’s endothelial cells (such as vascular endothelium or endocardium) which 
derive from the mesoderm. The corneal endothelium therefore displays none of the cell 
surface markers that typify other endothelial cells. 
The primary function of the endothelium is in the control of corneal hydration and nutrition 
[4]. With the exception of oxygen which enters the cornea via multiple routes the vast 
majority of the corneas nutrients are derived from the aqueous humour and therefore must 
pass through the endothelium [5]. For example the glucose transporter GLUT1 is expressed 
on both the apical and basal sides of endothelial cells to allow transcellular glucose flow [6]. 
Hydration of the stroma is controlled via the so called “Pump–Leak” mechanism and is vital 
to maintain the fine ultrastructure of the stoma required for transparency. The pump side of 
this mechanism is an active, ATP dependent process that results in the generation of a net 
efflux of NaHCO3
− and/or NaCl from the cornea into the aqueous humour; this ion flux 
constitutes the osmotic driving force for water movement out of the stroma. The exact 
mechanism of the pump however is highly complex, involving the regulation of ion / fluid flow 
by many different ion transporters / channels as well as other processes, and the pump 
function’s precise molecular nature remains only partially understood (Reviewed in [7]). The 
leak side of the mechanism merely refers to fluid re-entry into the cornea via passive 
mechanisms. In balance these two forces act to maintain corneal hydration at approximately 
~78% in humans. 
A key feature of the human endothelial cells that is of considerable clinical relevance is that 
they only very rarely undergo mitotic division in a normal eye after foetal development [8], 
they are thus largely considered to be completely non-replicative. Endothelial cells however 
have not left the cell cycle via entry in G0; analysis of the expression and subcellular 
localisation of various cell cycle proteins regulating G1/S phase transition indicates that 
endothelial cells exist in a state of early G1 growth arrest [9]. Endothelial cells can thus be 
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induced to replicate when cultured in vitro isolated from the monolayer and stimulated with 
mitogens [10,11], many of which are also present in the aqueous humour in vivo [12]. This 
might imply that endothelial proliferation in vivo might be primarily suppressed by the 
presence of a strong contact inhibition effect [13]. Indeed in the context of an intact 
monolayer ex vivo it has been shown that EDTA can promote endothelial cell division by the 
loosening of cell / cell contacts [14].  
One emerging means by which the endothelial proliferation has been effectively induced in 
vivo is by the application of small molecule Rho-kinase (ROCK) inhibitors [15]. It has been 
proposed by the authors that these act upon the cell cycle directly but it is equally possible 
that they mediate their effects via contact inhibition, as Rho-kinase activity is also intimately 
linked to the maintenance of cell contacts such as tight junctions [16]. 
 
1.2.1 Endothelial cell density 
The non-proliferative natural state of the endothelium is of particular concern as endothelial 
cell density is known to gradually decrease throughout adult life with an average rate of cell 
loss of 0.3 to 0.6 % per year [17,18]. Once lost, cells are not replaced by cell replication and 
loss must be compensated for by enlargement and spreading of the remaining cells. The 
human endothelium begins with sufficient cells so that despite this loss endothelial function 
is usually maintained for life [19,20]. Various abnormal conditions however can cause 
endothelial cell density to fall to a level where the function of the endothelium is 
compromised and corneal decompensation invariably occurs when the cell density drops 
below 300 to 500 cells/mm2, leading to loss of vision and eventual blindness [21,22]. The 
only available treatment for endothelial decompensation is corneal transplantation. This key 
role of endothelial cell density to corneal function has led to the development of two forms of 
partial thickness corneal transplant; Descemet’s stripping / membrane endothelial 
keratoplasty, (DSEK / DMEK) that aim to replace only the endothelium whilst leaving the 
majority of the host cornea in place. 
Several genetic dystrophies can lead to endothelial decompensation of which Fuchs’ 
endothelial dystrophy is the most common [23,24]. A far more common cause of 
decompensation however is mechanical trauma to the endothelium. Corneal transplantation 
(keratoplasty) itself is invariably accompanied by endothelial cell loss [22] and late 
endothelial failure (LEF) is the primary cause of graft failure within 5 years of surgery and 
accounts for over 90% of the failures between 5 and 10 years after keratoplasty [25,26]. A 
repeat keratoplasty with similar or worse prognosis is the only treatment for a failed graft. 
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Grafts that eventually fail due to low endothelial cell density do not appear to suffer a greater 
rate of endothelial cell loss than grafts that do not fail, but rather have fewer endothelial cells 
pre transplantation [22]. In theory therefore it may be possible to prevent or delay graft 
failure by increasing the number of endothelial cells in donor tissue pre-transplantation.  
 
1.3 The Corneal Stroma 
 
The corneal stroma is the middle of the three cellular layers of the cornea separated from the 
endothelium by Descemet’s membrane and from the epithelium by Bowman’s layer. The 
stroma is the most substantial layer of the cornea comprising around 80-85% of total corneal 
thickness in humans. The stroma’s primary functions are structural and thus around 90% of 
the layer by volume consists of extracellular matrix (ECM) largely in the form of collagen 
fibres. Unlike other such structural collagenous tissues however the cornea is required to be 
transparent and this unique property results from a precise organisation of the collagen 
fibres and other ECM components. The collagen within the stroma is formed into very small 
fibrils (25–30 nm diameter) packed tightly into a regular array and formed into 300-500 
layers termed lamellae. The individual collagen fibrils are composed of both type I and V 
collagen in the adult with each fibril being heterotypic and thus containing both types. Type V 
collagen has been shown to have key roles in the initiation of fibril assembly and regulation 
of their diameter [27,28]. 
In addition to the collagenous component the adult stromal ECM also contains four 
proteoglycans: decorin, keratocan, lumican and mimecan. All these proteoglycans have a 
very similar (possibly homologous) core protein component of approximately the same size. 
All contain leucine rich motifs spaced at regular intervals which upon folding of the proteins 
into their the final coiled 3D conformations leads to the alignment of these motifs down one 
side of the molecule [29]. By contrast most of the asparagine residues that form the 
attachment sites for glycosaminoglycan side chains are located on the other side of the 
molecule and it is thought these highly polarised proteins act to regulate the spacing and 
formation of the collagen fibrils [30]. 
The glycosaminoglycan side chains of corneal proteoglycans primarily consist of keratan 
sulphate although dermatan sulphate is also present; these side chains are thought to play a 
role in regulating corneal hydration. It is vital that the stroma is kept in state of relative 
dehydration in order to maintain the precise ECM structure required for transparency. The 
hydration of the cornea is primarily regulated by actions of the epithelium and endothelium; 
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however, it has been shown that whilst dermatan sulphate is almost fully hydrated in the 
normal cornea keratan sulphate is not, leading to the hypothesis that the remaining hydration 
capacity of keratan sulphate forms a dynamic buffer for corneal hydration [31]. 
The stroma’s primary cell population consists of corneal keratocytes which occupy ~3% of 
the stroma by volume. Developmentally these cells derive from the embryonic neural crest. 
and their primary role is the synthesis and maintenance of the stromal ECM [32]. 
Morphologically corneal keratocytes are broad and flattened with numerous lamellapodia 
through which they connect to one another via gap junctions creating a cellular network [33]. 
Additionally this compact morphology combined a minimal number of organelles and the fact 
that corneal keratocytes express crystallines all act to minimise any light scattering by these 
cells [34], aiding transparency. Other cell types present within the stroma include resident 
macrophage and dendritic cell populations [35] and a very small population of “corneal 
stromal stem cells” localised to the limbal stroma which may act a source of keratocytes for 
repopulation if cells are lost [36]. Unless the cornea is wounded, mammalian corneal 
keratocytes will remain quiescent throughout adulthood [37]. 
 
1.3.1 Wound healing response of the stroma 
Corneal wound healing within the stroma is largely mediated through the predominant cell 
population: the corneal keratocytes. Broadly these cells respond to injury in one of two ways, 
they either undergo apoptosis or transition to various activated repair phenotypes [37]. The 
first response to corneal wounding is rapid apoptosis of the keratocytes immediately 
underlying or adjacent to the wound site, with the majority of cell loss occurring within hours 
of wounding [38]. There is some evidence the keratocytes undergo apoptosis in response to 
secreted signals from the overlying epithelium such as Interleukin 1 (IL1) and tumour 
necrosis factor alpha (TNFα) which mediate apoptosis via induction of Fas ligand production 
within keratocytes [39]. However this finding has not been replicated in cultured cells in vitro 
and thus the exact causative mechanism remains somewhat unclear [37]. The apoptotic 
response is variable in degree depending upon the severity of the inflicted wound and 
species differences. The response can be extremely sensitive and can be triggered by even 
very mild epithelial damage [40].  
Following and triggered by this cell loss, keratocytes adjacent to the wounded area lose their 
quiescence and begin the process of switching to a more fibroblast-like repair phenotype, 
the initial steps in this process such as increase in nucleoli number (a sign of increased bio-
synthetic activity) are observable ~6 hours after injury. These activated cells begin to 
express α5β1 integrin which in combination with fibronectin deposition at the wound site 
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enables their migration towards the wound [32]. Keratocytes also proliferate in response to 
injury as shown by Zieske et al. [41] who followed the time course of keratocyte proliferation 
following a limited epithelial debridement wound by tracking the cell cycle progression 
marker Ki67. Proliferation was first detectable 24 hours after wounding and was largely 
restricted to the posterior stroma close to the area of wounding, the number of Ki67 positive 
cells then increased, peaking at 44 hours post wound, and remaining localised to the areas 
immediately adjacent or posterior to the wound. No proliferating cells were observed in the 
anterior stroma until 5 days after wounding and from this point onwards the overall number 
declined until by day 10 the stroma appeared to have regained quiescence. 
Keratocytes also display a second repair phenotype in response to wounding being able to 
reversibly transdifferentiate into myofibroblast-like cells in response to signalling via 
transforming growth factor beta (TGFβ) [42]. These cells are characterised by a larger size 
and expression of smooth muscle actin and it is thought these myofibroblasts contribute to 
healing process by mediating wound contraction [43] and the reorganisation and deposition 
of stromal ECM. In excess however this process has been shown to be pathogenic with 
extensive myofibroblast differentiation in response to surgical injury being associated with 
loss of corneal transparency and scarring [44]. It was discovered relatively recently however 
that keratocytes are not the only source of myofibroblasts in the context of stromal wound 
healing. In common with the myofibroblasts of many other tissue types they are also formed 
from bone marrow derived cells which have been shown to infiltrate the cornea in large 
numbers upon wounding [45]. 
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1.4 The Corneal Epithelium 
 
The epithelium is the outermost layer of the cornea and thus forms the most anterior surface 
of the eye. As might be expected from this location one of the primary functions of the 
epithelium is that of a barrier protecting the cornea from infiltration by tears (or other fluid) 
and pathogenic material [46,47]. This barrier function is mediated by the formation and 
maintenance of multiple tight junctions between epithelial cells. A healthy epithelium is also 
vital to maintain the optical properties of the cornea. In combination and with the tear film it 
provides a smooth outer surface to the cornea minimising light scatter, and by preventing 
fluid infiltration the epithelium also functions to keep the stroma dehydrated and transparent 
[48,49].  
The cells of the epithelium are broadly organised into 5-7 layers; a basal monolayer of 
columnar cells adhered tightly to the underlying basement membrane via hemidesmosomes, 
and several layers of supra-basal cells [47,50,51]. The cells within the supra-basal layers 
closest to the basal layer are termed wing cells due to their alar cross-sectional shape, and 
the cells of more apical layers become increasingly more differentiated, larger, flatter and 
more tightly adhered to one another. These are usually referred to as superficial or 
squamous cells.  
 
1.4.1 Limbal Epithelial Stem Cells (LESCs) 
Unlike the other two cellular layers of the cornea the cells of the epithelium are actively 
replicative due to the tissue as a whole suffering continuous cellular attrition in the form of 
desquamation from the corneal surface and thus requiring constant renewal and 
regeneration. Whilst the cells of the basal layer have long been known to be mitotic, this 
activity alone is insufficient to maintain the layer [52]. An extrinsic source of new epithelial 
cells must therefore exist and for many years it was thought that the conjunctiva fulfilled this 
role, generating new corneal epithelial cells by the transdifferentiation of conjunctival 
epithelial cells which migrated into the cornea [53,54]. This was largely based upon studies 
of corneal injury in which both the involvement of the conjunctiva and epithelial renewal 
apparently proceeding from the direction of the corneal periphery inward [55] was observed. 
This hypothesis however could not fully explain clinical observations of failed epithelial 
healing in which the layer became conjunctivalised due to the ingrowth of 
untransdifferentiated conjunctival epithelial cells.  
The alternative explanation of epithelial renewal proceeding from the limbal epithelium itself 
was first proposed by Davanger & Evensen in 1971 [56] and gained substantial support 
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when it was shown by Schermer et al. in 1986 [57] that the corneal specific keratin K3 was 
not expressed in the most basal limbal cells of the epithelium in contrast to the rest of the 
tissue in which this protein is highly expressed. It was also demonstrated that this specific 
keratin was one of the earliest to be expressed during the process of epithelial cell 
maturation thus indicating that the cells resident in the basal limbus were maintained in a 
less differentiated state than the majority of the cornea. These cells were therefore 
suggested to be “Corneal epithelial stem cells”, and subsequently became known widely 
within the field as “Limbal epithelial stem cells” (LESCs). The identity of these basal limbal 
cells as stem cells rapidly gained a large body of supporting evidence. Cells from this 
location where shown to retain nucleoside labels [58], displayed an increase proliferative 
capacity compared to the rest of the epithelium [59], and be capable of colony formation [60]. 
Additionally the cells of the basal limbus were also shown to express the ATP binding 
cassette transporter protein ABCG2 [61] which is also expressed by hematopoietic stem 
cells and has been proposed to have a role in the protection and isolation of stem cells from 
extrinsic chemicals [62]. 
 
Within the various animal models (chiefly rabbits) used in most studies of epithelial renewal 
there does not appear to be any specific macroscopic anatomical structure that is associated 
with LESCs, with the niche commonly being described as located at the basal corneoscleral 
junction. Within humans however there is such a structure located at the limbus in the form 
of radially-oriented fibrovascular ridges present around the circumference of the limbus 
called the palisades of Vogt. These structures were in fact proposed as a putative site of 
epithelial cell renewal in the same paper that first suggested the limbal epithelium as the 
source for this process [56]. The palisades of Vogt possess many features that might 
encourage cell growth and maturation such an extensive vascular supply, structural / 
physical protection, and pigmentation acting to protect against light damage. It has been 
suggested that specialised substructures called “limbal epithelial crypts” that extend out from 
palisades of Vogt beneath the conjunctiva might be especially enriched in LESCs [63] . 
There is also substantial evidence of other anatomical structures constituting the LESC 
niche. Two such structures were identified in a study by Shortt et al. [64] in which the 
structure of the human limbus was examined at a very high level of detail by in vivo confocal 
microscopy. The features identified were invaginations of the epithelium into the limbal 
stroma associated with a blood supply termed “limbal crypts” (distinct from the “limbal 
epithelial crypts” in the palisades of Vogt although this similarity in terminology is confusing) 
and a similar reversed structure in which the stroma projected into the epithelium termed 
“Focal Stromal Projections”. Both these structures were associated with what appeared to be 
a high number of LESC’s on the basis of the cells morphology and in vitro analysis of 
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biopsied tissue. Recently it was also proposed that a population of corneal epithelial stem 
cells resides outside the limbus, distributed throughout the epithelium [65]. This suggestion 
however has generated some controversy [66] and has not been widely accepted. 
 
The basement membrane (BM) of the epithelium in the limbal LESC niche has also been 
shown to incorporate a large number of extracellular matrix components not found more 
widely across the BM which likely constitute a tightly controlled and highly specific 
microenvironment for the maintenance of LESCs [67]. Of particular note were osteonectin 
and tenancin C which appeared especially closely associated with putative stem cell 
clusters. It should be noted that despite extensive effort and many candidates having been 
proposed [68] that there is no single molecular marker that defines the LESC population. 
LESCs are therefore usually defined on the basis of the co-expression of multiple markers 
combined with the non-expression of others and specific cellular morphology [69]. This lack 
of a precise, incontrovertible definition has often made it difficult for definitive conclusions to 
be drawn relating to LESCs biology.  
 
The identification and increasingly complex characterisation of both LESCs and the 
microenvironment of their niche has led to extensive clinical application and development. 
Shortly after the cells were first identified the concept of a limbal epithelial cell transplant was 
proposed and shown to be more effective in the treatment of disorders resulting from limbal 
aplasia than the similar transplantation of the bulbar conjunctiva previously performed for 
such conditions [70,71]. The first such transplants performed were autografts for the 
treatment of unilateral limbal deficiency. In bilateral cases autologous material is unavailable 
for engraftment and thus allografts from cadaveric sources are used and shown to be 
effective in such cases [72]. Since this initial development LESC transplantation has become 
a relatively standardised surgical procedure [73]. 
A further refinement of LESC transplantation technique was made by Pellegrini et al. in 1997 
[74] who cultivated autologous graft material ex vivo pre-transplantation to expand LESCs 
and minimise the size of the donor biopsy required. Since this initial proof of concept a 
substantial body of further work has focused upon the culture and expansion of LESCs ex 
vivo and techniques for their engraftment (reviewed in: [75]). Much of the development of ex 
vivo culture techniques has aimed to provide as biomimetic an environment as possible for 
LESC expansion whilst maintaining “stemness”. In attempting to mirror the highly specific 
structural and chemical nature of natural LESC niche the bioengineering involved in such 
cultures has also become increasingly complex [76].  
Whilst transplantation of ex vivo cultured LESCs can be undeniably effective in restoring the 
ocular surface, the means by which this beneficial effect is mediated maybe somewhat 
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ambiguous. It was initially (logically) assumed that the observed treatment effect of epithelial 
regeneration and subsequent maintenance was due to the successful engraftment of the 
transplanted cells into the LESC niche providing sustained restoration of normal LESC 
function. Whilst this assumption has been supported by analysis of the restored epithelium 
post transplantation [77], there is also some evidence to suggest that this may not happen in 
every engraftment. In some cases at least the transplanted cells do not appear to remain 
engrafted over the long term, with no donor derived DNA sequences being detected after 9 
months post-transplantation [78,79] within the host epithelium. The clinical outcome of a 
much longer lasting restoration of an apparently normal host-derived epithelium is therefore 
hard to explain. It has been postulated that the transplanted cells may stimulate the 
remaining host LESC or that bone marrow derived stem cells may be recruited to the cornea 
to function as LESCs [50,78], but further studies are required to more fully explain this 
anomalous finding. 
 
1.4.2 Epithelial maintenance and renewal 
The limbal epithelial stem cells are vital to epithelial maintenance and their loss leads to 
complete epithelial failure. However, the LESCs themselves remain resident within their 
niche at the limbus and only function as the source of cells for epithelial renewal. In this 
capacity they are able to undergo either symmetric division to expand themselves or 
asymmetric division to both self-renew and produce differentiated daughter cells. It is the 
behaviour and dynamics of these daughter cell lineages therefore that form the fine detail of 
the processes by which the epithelium is maintained. 
The driving force for epithelial renewal is the continuous desquamation of cells from the 
corneal surface during normal wear and tear which in turn drives a requirement for cell 
division, migration and differentiation of cells for the purposes of replacement. The “X,Y, Z 
Hypothesis of Corneal Epithelial Maintenance“ proposed by Thoft & Friend in 1983 [80] has 
formed the basic theory behind most investigations of this renewal cycle and has become 
very well supported. The hypothesis proposes that the epithelial cell volume is likely to be 
near constant and that a balance of three forces (all previously observed) is responsible for 
maintaining this homeostasis of the layer. 
1) The proliferation of the basal cells of the epithelium (X) 
2) The centripetal movement of epithelial cells (Y)  
3) The loss of cells from the corneal surface (Z) 
To maintain homeostatic equilibrium X+Y = Z. 
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Thoft & Friend however did not define within X LESCs as the source of new cells stating only 
“peripheral tissues” of either the cornea or conjunctiva as such a source. This was due to the 
fact that at the time the involvement of the bulbar conjunctiva had not been ruled out. 
Subsequent mathematical modelling of the system by Sharma & Coles [52] indicated that 
the replication of the LESCs should be solely sufficient to account for the regeneration 
without any conjunctival involvement. 
The daughter cells of LESCs are termed transient amplifying cells (TACs) on the basis that 
whilst they maintain some capacity to replicate they have lost the near indefinite replicative 
potential that defines a stem cell. These TACs appear to compose the entirety of the most 
basal columnar cell layer of the epithelium with cell division being almost exclusively 
restricted to this layer [55]. As they migrate centripetally they divide and progressively lose 
replicative capacity as shown by Lehrer et al. [81] who proposed that TACs were limited to 
~3 divisions (although Lehrer et al. also acknowledged that this figure was “likely an 
underestimate”) and that under normal homeostatic conditions cell cycle time was around 60 
hours. Lehrer et al. also hypothesised that not all TACs realised their full replicative potential 
before differentiating into post-mitotic cells.  
It is clear from multiple studies that when wounded the epithelium is able to profoundly 
change its usual regenerative profile, becoming far more active in order to rapidly respond to 
the insult and facilitate wound closure and healing [47]. It is thought that the replicative 
aspects of this wound healing response proceed via the shortening of cell cycle times for 
both LESCs and TACs (to <18 hours in the case of TACs), and all TACs fully utilising their 
“replicative reserve” by dividing the maximum of three times [81]. It is important to note 
however that any observations of epithelial behaviour made under such circumstances are 
almost certainly inapplicable to the normal homeostasis of the tissue. 
The more superficial layers of the epithelium are generated by the differentiation of TACs 
into more mature post-mitotic cell types which then become increasingly mature as they 
move apically before being lost from the corneal surface. Once they have left the basal layer 
and begun this process the cells of the epithelium have an average lifespan of around 4-5 
days [55]. Using the incorporation of nucleoside labels Beebe & Masters [82] studied the 
profile of TAC division with regard to daughter cell fate in some detail. They found that 
following division both daughter cells either remained within the basal layer (and thus 
remained TACs) or simultaneously migrated into the immediately apical wing cell layer. 
Segregation of daughter cells between the basal and wing cell layers post division was not 
observed, indicating that TAC division is always symmetric. More long term follow up of 
these experiments revealed that this synchronicity between the daughter cells of the last 
TAC division was maintained throughout their subsequent apical migration and 
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differentiation, always appearing to do the same thing at the same time. This may indicate 
that the final TAC division constitutes a key regulatory point after which there is little 
deviation from a pre-set “program” under normal homeostatic conditions. Later it was shown 
that upon leaving the basal layer the cells do indeed become committed to terminal 
differentiation and begin to express specific markers such as Keratin K12. 
 
 
Figure 1. Schematic of 
epithelial renewal 
proceeding from the 
limbus 
LESCs residing in the 
limbus give rise to eTACs 
which migrate 
centripetally, continuing 
to divide generating the 
TACs which form the 
basal layer of the 
epithelium.  
Upon their terminal 
symmetrical division the 
TACs give rise to post-
mitotic wing cells and 
leave the basal layer. The 
wing cells then migrate 
anteriorly becoming 
more differentiated 
before being lost from 
the corneal surface. 
 
The centripetal migration that forms the Y component of epithelial maintenance has been 
extensively observed. The very first such observation was made by Mann in 1944 [83] who 
observed the centripetal movement of limbal pigmented cells in response to epithelial injury. 
The exact mechanisms driving centripetal movement remain unclear although population 
pressure from the periphery due to the increased proliferative capacity of LESCs / early 
TACs, increased loss of cells from the central cornea and chemotaxis have all been 
proposed [81,84,85] 
There have been few direct measurements made of the rate of centripetal migration in the 
unwounded state. Work by Buck in 1985 [84] provided the first such direct measurement; 
murine epithelial cells were injected with india ink enabling their migration to be tracked over 
7 days, in which time they moved ~94µm, equating to 17µm per day. The rate of centripetal 
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migration in the mouse was also evaluated by Nagasaki & Zhao in 2003 [86] using a 
transgenic model ubiquitously expressing GFP. A rate of cell movement of 26µm per day 
was calculated, although cell tracking relied on the ability to distinguish cell lineages based 
upon variable expression levels of the transgene. 
The use of such transgenic models has formed the primary source of insight into the 
patterning of the epithelium resulting from centripetal migration of cells and streak-like 
patterns of labelled of cells stretching from limbal to central cornea are typically observed. 
One such transgenic model in which much of this work has been performed is based upon 
the X-inactivation of a Lac-Z gene resulting in a clonal mosaic of marker expression 
throughout the adult animal. Observations made in this model include: 
 Time for total epithelial turnover estimated to be ~3-4 weeks [87]. 
 Whorl like patterns being formed when multiple streaks meet in the central cornea 
that are reminiscent of effects seen in certain pathological human conditions thought 
to be patterned by epithelial migration [88]. 
 An apparent decrease in the number of labelled streaks with age [89]. This might 
indicate a reduction in the number of active LESCs with age, but is not conclusive. 
There is also evidence from such murine models that epithelial renewal via centripetal 
migration of cells from the limbus is not a mechanism that is present from birth. For a period 
extending up to 10-12 weeks postnatally the streak-like patterns typical of centripetal 
migration are not seen to develop, with more random mosaic patterns being present instead 
[87,90]. It has been hypothesised therefore that during this period an alternative embryonic 
mechanism of epithelial renewal remains in place proceeding from corneal epithelial stem 
cells present throughout the basal layer of the epithelium, a mechanism that is eventually 
replaced by the adult program of centripetal migration of cells derived from LESCs [90,91]. 
Unfortunately there is very little quantitative data available for the final aspect of epithelial 
maintenance and renewal: The desquamation of cells from the epithelial surface (Z). Two 
studies by Ren & Wilson [92,93] attempted such quantification in a rabbit model and 
established a range for rate of loss of between 5-100 cells/min/cornea depending on the 
methodology used. This large range results from difficulty in controlling for normal processes 
such as blinking. 
It is worth mentioning that combining all of the various published data regarding the 
dynamics of epithelial turnover in such a way that it all fits together into a coherent model of 
the system is difficult, and some contradictions are apparent. It is likely therefore that some 
of this data is inaccurate and that the cellular dynamics of epithelial turn over remains only 
partially understood. 
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1.4.3 Inherited disorders of the epithelium  
One of the most common applications of gene therapy is to the correction of an inherited 
genetic defect and a number of such conditions have been described affecting the 
epithelium. All of them, however, are extremely rare and are thus often only described in the 
form of case / familial reports with no broader prevalence data available. When the 
molecular genetics of various dystrophies was elucidated it was revealed that the degree of 
heterogeneity in causative genes / loci was lower than might have been implied by the 
number of conditions described. This was due to different conditions often being shown to be 
associated with the same gene or locus. For example both Reis-Bücklers and Thiel-Behnke 
dystrophy have been linked to mutations in TGFBI, and Meesmann and Stocker-Holt 
dystrophies to KRT12 mutations. This perhaps implies that rather than being entirely 
separate these are in fact the same condition presenting with (usually small) variations in 
phenotype.  
As a rule epithelial dystrophies generally follow an autosomal dominant pattern of 
inheritance with only two exceptions to date; Lisch epithelial dystrophy, which appears to 
follow an X-linked recessive pattern and Gelatinous drop-like corneal dystrophy (GDLD) 
which is inherited via an autosomal recessive pattern. This latter condition is also the most 
prevalent of the epithelial dystrophies (although still rare) and forms the primary research 
focus of our collaborator Dr Satoshi Kawasaki (Kyoto Prefectural University of Medicine). For 
these reasons the epithelial work presented here was primarily directed towards developing 
a therapy for this condition and it will thus be described in more detail below. 
 
1.4.4 Gelatinous drop-like epithelial dystrophy 
Gelatinous drop-like corneal dystrophy (GDLD) is a congenital disorder following an 
autosomal recessive pattern of inheritance. It is globally rare but more prevalent within the 
Japanese population with an estimated rate of occurrence of between 1 in 30,000 [94] and 1 
in 300,000 [95] within this demographic. The disease is characterised by the development of 
sub-epithelial amyloid deposits which eventually lead to opacification of the cornea and 
visual impairment [96]. 
The gene locus linked with GDLD was established in the late 1990’s as being located upon 
chromosome 1 [97] with further work establishing the disease to be caused by loss of 
function mutations within the gene TACSTD2 (aka M1S1 or Trop2) which lead to truncation 
of the gene product and cellular mislocalisation [98]. 
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Clinical presentation of the disorder is variable with several subtypes characterised, named 
for their appearance: Typical mulberry type, Kumquat-like type, Band keratopathy type and 
Stromal opacity type (Figure 2). There does not seem to be an association however between 
the specific TACSTD2 mutation present and the subtype presented, as shown by the most 
commonly occurring mutation (Q118X) having been associated with all 4 clinical subtypes. 
[99] 
 
Figure 2. The variable phenotypes of Gelatinous drop-like corneal dystrophy 
A: Typical mulberry type, in this patient a keratoplasty has clearly been performed (incision line 
highlighted by white arrow heads) and the condition has recurred covering the graft. 
B: Kumquat-like type 
C: Band keratopathy type 
Images in this figure adapted from references: [100,101] 
 
The pathological mechanism of GDLD has been partially elucidated. Epithelial permeability 
to chemicals such as fluorescein [102] or horse radish peroxidase [103] is increased in the 
condition indicating that epithelial barrier function is impaired. Immunohistological data 
obtained from GDLD corneal samples also tend to support this conclusion [104]. The 
expression and localisations of various tight junction related proteins have been shown to be 
disrupted in the GDLD epithelium. ZO-1 and occludin are entirely absent from the most 
superficial epithelial cells and claudin-1 and desmoplakin are abnormally expressed and 
localised in both superficial and basal cells. The localisation patterns of various integrins, 
collagen types and laminin-5 are also abnormal in the GDLD epithelium with many of these 
patterns indicating a thickened, involuted basement membrane. 
The mechanism by which mutations in TACSTD2 leads to impairment of epithelial barrier 
function has been determined. In 2010 Nakatsukasa et al. [105] showed that the TACSTD2 
protein is present throughout the normal corneal epithelium but is entirely absent from GDLD 
corneas. The protein is able to bind directly to tight junction related proteins, claudins 1 and 
7 and colocalises with these proteins in vivo. Knock down of TACSTD2 mediated via shRNA 
in vitro leads to a drop in transepithelial resistance and a reduction in levels of claudin 1 and 
 
A 
 
B 
 
C 
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7 at both the mRNA and protein level. Additionally other tight junction related proteins such 
as claudin 4 and occludin became mislocalised to the cytoplasm. 
The exact mechanism by which TACSTD2 loss mediated disruption of tight junctions and the 
resulting impairment of epithelial barrier function leads to the primary phenotype of sub 
epithelial amyloid deposition is not well understood however. It has been hypothesised the 
deposits consist of lacoferrin [106] or apolipoprotein [107] which may have infiltrated from 
the tear film. 
The only currently available treatment for GDLD is a corneal allograft, although this 
procedure does not resolve the disease permanently. Corneal grafts only replace the central 
portion of the cornea whilst leaving the host’s more peripheral corneal tissue in place. The 
host’s limbal stem cells therefore remain in situ and the transplanted healthy donor 
epithelium is replaced over time by the host’s diseased epithelial cells via the process of 
normal corneal renewal. Recurrence of the condition thus usually occurs within 1-2 years. 
Re-engraftment is then required, although due to the risk of graft failure increasing with each 
subsequent engraftment [108], treatment by repeated corneal transplantation has a very 
poor long term prognosis. 
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1.5 Corneal Neovascularisation  
 
The healthy cornea is maintained in an avascular state due to the functional requirement for 
optical transparency and minimal light scatter. This avascularity is maintained by a complex 
balance of both pro and anti-angiogenic factors present within the cornea [109] with soluble 
VEGF receptor 1 (sVEGFR1 / sFlt1) in particular having been shown to play a key role. 
Conditional knockout of this factor alone is sufficient for murine corneas to lose their 
avascularity and the only species known to have a vascular cornea, the Florida manatee, 
lacks sFlt1 in the cornea [110]. 
The cornea’s closest contact to the circulation is located at the corneal limbus where it is 
ringed by a vascular arcade formed of an episcleral anastomotic circle, the arterial supply of 
which derives from the anterior ciliary arteries extending from the rectus muscles. Extending 
from this ring are looping arterioles that supply many structures located in or close to the 
limbus such as the palisades of Vogt, the conjunctiva, the ciliary muscle and anterior uvea. 
The limbal arcade is drained by an almost directly parallel venous system which exits the 
limbal region via the anterior ciliary veins.[111] 
It is from this vascular plexus that pathological corneal neovascularisation proceeds via the 
sprouting of new vessels and can fall into one of three categories based upon the extent and 
depth of neovascular growth [112]. Vascular pannus is limited to the peripheral cornea and is 
usually associated with disorders of the ocular surface, superficial vascularisation extends 
only through the epithelium and, as its name implies, stromal invasion involves the 
penetration of neovascular vessels into the stroma. The generation of pathological blood 
vessels is clearly the result of an unregulated and misdirected process, and this is reflected 
in the resulting blood vessels themselves which are functionally immature and lacking in 
structural integrity. Therefore in addition to their own negative impact upon corneal 
transparency they are also often associated with lipid keratopathy, a condition in which lipid 
leaks from the vessels to forms opaque deposits within the cornea. 
Pathological corneal neovascularisation is present within an extremely wide range of 
different conditions such as: extended contact lens wear, trauma, alkali burns, infections 
(bacterial or viral), parasitosis, or immunological conditions. Within the developed world the 
extended wear of soft hydrogel contact lenses is the most common cause, although the 
vascularisation observed is these cases is usually very mild, non-sight threatening and 
treatable merely by modification of the regime of contact lens use. Far more serious is the 
corneal neovascularisation / inflammation that results from corneal injury or infection. In the 
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developed world the most common corneal infection is herpes simplex keratitis although 
prevalence is relatively low; however in the developing world a bacterial infection associated 
with corneal neovascularisation, trachoma, constitutes the primary cause of corneal 
blindness and is prevalent to such a degree that this condition is also the leading cause of 
corneal blindness worldwide. 
With the exception of contact lens wear (in which corneal hypoxia is thought to be the 
responsible) corneal neovascularisation is almost always a secondary disease phenotype 
resulting from a primary inflammation. The inflammatory response to injury or infection is 
associated with the cascading activation of numerous cytokine pathways within the cornea 
initiated by IL1 secretion from the cells of the corneal epithelium and infiltrating innate 
immune cells [113,114]. Many of these cytokines are potent pro-angiogenic factors 
themselves (IL1-β for example has been shown to comparable to VEGF-A as an angiogenic 
factor in the cornea [115]) and also lead to the widespread downstream up-regulation of the 
VEGF pathway [116]. This prolific cytokine activation therefore strongly disregulates the 
angiogenic homeostasis of the cornea leading to neovascularisation. In most cases 
inflammation related pathogenesis is not limited to neovascularisation with the up-regulation 
of TGF-β in particular often also resulting in the activation of stromal keratocytes which can 
lead to stromal fibrosis and scarring [42]. 
If the pathology in these conditions progresses to the point of becoming blinding often the 
only means to restore vision is via corneal transplantation, and it is in reference to this 
procedure that corneal neovascularisation is of particular relevance. 
Under ideal conditions the prognosis of penetrating keratoplasty is excellent with 5-year graft 
survival rates of up to 95-99% achievable in conditions such as keratoconus which present 
with no inflammatory complications [117]. As discussed however corneal transplantation 
may be indicated for the treatment of a condition in which the host cornea is inflamed and / 
or vascularised at the point of transplantation, and the presence of neovascular vessels in 
two or more quadrants of the cornea is one of several factors leading to a corneal 
engraftment being classified as “high risk”. Another major risk factor is the regrafting of a 
previously failed transplant. This classification is due to the very well characterised negative 
impact of pre-existing corneal vascularisation on long term graft survival [117–120]. Probably 
the most extensive study demonstrating this association was a meta-analysis of nearly 
25,000 penetrating keratoplasty procedures [121] in which the presence of pathological 
corneal neovascularisation at the point of surgery was shown to increase the risk of graft 
failure or rejection with pooled risk ratios of 1.32 and 2.07 respectively, with the data also 
indicating that risk increased in proportion to degree of neovascularisation. 
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The high success rate of corneal transplantation under ideal conditions without the need for 
tissue typing and only minimal immune suppression is due to the immune privilege enjoyed 
by the cornea [122,123], and it is thought that corneal neovascularisation increases the 
probability of graft failure by compromising this privileged status [124,125]. The neovascular 
vessels facilitate a greater exposure of the grafted tissue to the host immune system by 
providing conduits for both the egress of alloantigens for presentation to the peripheral 
immune system and ingress of immune effector cells such as T-cells into the graft.  
Whilst the clinical focus upon corneal neovascularisation has very much been upon the 
clearly visible blood vessels, such haemangiogenesis has been shown to almost invariably 
be accompanied by lymphangiogenesis [126] and there is a growing body of evidence to 
suggest that these vessels may in fact be of greater relevance in the context of immune 
mediated graft rejection [127–129], a logical assertion due to the key role of the lymphatic 
system in antigen presentation. 
Treatments for neovascularisation are highly varied and at the point of initial insult are 
usually focused upon the suppression of the inflammatory response via the topical 
application of steroids, which are often most effective when applied shortly after the onset of 
inflammation before neovascularisation has become established. In the case of infections 
drugs targeted towards inhibition of the pathogen are also applied although in such cases a 
careful balance must be struck with regard to steroid application as excessive inhibition of 
the immune system may act to aid the pathogen.  
Once neovascularisation is more established more direct treatments can be applied 
including the direct ablation or occlusion of vessels by means of lasers, fine needle 
diathermy [130] or photodynamic therapy [131]. More recently the extensive clinical use of 
VEGF binding based therapeutics for the treatment of choroidal neovascularisation in wet 
AMD has led to these drugs also being directed towards corneal neovascularisation both in 
the clinic and in animal models (reviewed in [132]). Initial results from these studies are 
promising overall but treatment regimens often involve repeated administration at relatively 
high doses. 
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1.6 Gene therapy 
 
Gene therapy is the term applied to any treatment that mediates its primarily therapeutic 
effect via application of a nucleic acid based product, be it DNA, RNA or various synthetic 
analogues such as morpholinos. The technique usually aims to modify the gene expression 
within a target cell, either to directly correct a deleterious mutation or to mediate a more 
general beneficial effect such as the promotion of cell survival. Perhaps the most promising 
aspect of gene therapy as a methodology is that it allows the gene defects that constitute the 
underlying causes of congenital disorders to be targeted directly and thus the approach has 
the potential to be curative. Other treatment methodologies can only aim to target and 
alleviate the symptoms of such conditions.  
For a gene therapy approach to be effective a number a conditions must be met: 
 The nucleic acid products must be efficiently delivered to the target cells, ideally 
whilst avoiding transduction of non-target cells.  
 The nucleic acid must then mediate its effects at a physiologically appropriate 
therapeutic level. 
 Immune mediated reactions to the therapy, which can be directed at either vector 
components or transgene product should be avoided or minimised. 
Additionally in most cases it is desirable for the treatment effect to be effective over the long 
term without the need for re-administration of the therapeutic construct. 
Gene therapy methodologies to date can be broadly split into two categories, non-viral and 
viral and each has its advantages and disadvantages in relation to these conditions for 
efficacy. 
Non-viral methods (reviewed in [133,134]) can constitute the simplest approaches to gene 
therapy, in many cases involving direct physical delivery of nucleic acids to cells. The nucleic 
acids themselves are usually unable to cross the cell membrane of the target cells due to the 
cells themselves not tending to actively take up naked nucleic acids and the negative charge 
of acids leading to their inability to cross the hydrophobic interior of the plasma membrane. 
This latter limitation however is overcome by some modern synthetic DNA/RNA analogues 
which are uncharged. Physical non-viral techniques usually aim to transiently disrupt the 
target cell’s plasma membrane to allow entry of the nucleic acid and such disruption has 
been induced by the application of energy in the form of electric currents, ultrasound, 
ballistics or lasers. 
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Many chemical non-viral methods to mediate cellular nucleic acid uptake have also been 
developed including the coupling of nucleic acid to cationic polymers, or their encapsulation 
within engineered liposomes or other forms of nanoparticle. This latter approach in particular 
has become advanced with the nanoparticles design often being highly structurally complex 
or incorporating ligands to promote endocytosis via a specific cell surface receptor [135]. 
The chief advantage to non-viral methods is that they are usually completely non-
immunogenic, however they also present with several substantial disadvantages most 
significant of these being their limited efficacy in vivo. Effective gene delivery by non-viral 
methods is hampered by many factors including vector instability in vivo, loss of vector to 
interaction with non-target tissues, intra-cellular processing leading to mislocalisation or 
destruction of the transgene and loss of transgenic construct upon cell division [134]. Whilst 
much progress has and continues to be made, non-viral methods currently lag behind the 
alternative of virally mediated gene therapy [136], with inspiration for improvements of non-
viral systems often being gleaned from viruses themselves [137]. 
The majority of work in the gene therapy field (especially in regard to clinical application) has 
utilised viral methods of gene delivery, in which the natural ability of various viruses to 
deliver DNA/RNA to cells has been co-opted and exploited for use in therapeutic gene 
delivery, achieved via the replacement of viral genomes with transgenic constructs. The 
main advantage of this approach is that the natural history of viral evolution has led to the 
genesis of wide variety of viral species all of which are highly optimised to mediated gene 
transfer to their target cell of choice and which have developed complex and often elegant 
mechanisms to overcome many problems that have limited the efficacy of non-viral gene 
therapy. A large “toolkit” is therefore available for use in gene therapy which has in many 
cases been further refined towards specific therapeutic application. 
A natural viral infection is of course often pathogenic and thus all organisms have evolved 
both systemic and intracellular defences against viral infections which constitute the chief 
disadvantage of the use of viruses as gene therapy vectors, their immunogenicity, which can 
both limit efficacy or induce pathology [138,139]. Whilst most gene therapy vectors are 
heavily modified to prevent any possibility of pathogenesis and reduce immunogenicity as far 
as possible, due to the coevolution of viral virulence and host immunity it is likely that any 
modification that promotes immune tolerance might also reduce the vector’s efficacy. A 
number of specific viral vectors of particular relevance to this thesis will be further discussed 
in 1.6.2 
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1.6.1 Gene Therapy Strategies 
Once effective transgene delivery to the target cell has been achieved there are a number of 
means by which a therapeutic effect might be mediated, either upon the transduced cell itself 
or the wider tissue or system of which it is a part. Some of these will be briefly outlined 
below.  
 
1.6.1.1 Gene Supplementation 
This constitutes one of the simplest and most widely utilised approaches to gene therapy 
and is generally applied in the context of a recessively inherited disease causing loss of 
function mutation. The strategy aims to restore the lost function and correct the defect by the 
delivery of functional wildtype copies of the mutated gene. This strategy might also be 
effective in the correction of dominant disorders resulting from haploinsufficiency and has 
been shown to be effective in a hypomorphic mouse model of retinal disease [140].  
Once the gene delivery to the target cells has been achieved the transgene should then be 
expressed in such a way that the normal wildtype function is mimicked as closely as possible 
for the best chance of therapeutic effect. This is not always desirable however, in some 
conditions patients are protein null and thus completely immunologically naïve to the 
wildtype transgene product. In these cases it is best to aim for the minimal effective dose of 
transgene delivery to avoid adverse immune responses. Many supplementation strategies 
are relatively crude in regard to fine regulation of transgene expression level, often utilising a 
virally derived promoter sequence able to induce a very high level expression but in a 
relatively uncontrolled, non-specific or ubiquitous fashion [141]. This is often effective but 
has the potential to cause toxicity resulting from overexpression or disregulation of a finely 
controlled processes [142]. 
More controlled expression is often achieved placing the transgene under the control of a 
cell or tissue-specific promoter, ideally the endogenous promoter of the gene in the wildtype 
context [143]. In addition to more physiological control of transgene expression within target 
cells this also acts to limit or prevent transgene expression within any non-target cells that 
may also be infected by the vector. Such promoter driven control is often not possible 
however as an appropriate promoter may not be known, only partially defined, or too large to 
be contained within the vector’s packaging capacity. Additionally even the use of the 
transgenes exact endogenous promoter is unlikely to result in a precise recapitulation of the 
wildtype expression pattern due to the transgenic copy not being present within the same 
complexly regulated genomic context as the endogenous gene.  
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In recent years this distinction has led to a subtle change in the terminology applied to this 
approach. Gene supplementation is now the term of choice for the traditional approach that 
leaves the defective host gene in place and adds functional copies either episomally or at 
other sites within the host genome. The formerly used term of gene replacement is now 
more accurately applied to various attempts to mediate a physical replacement of the 
defective gene copy within the host genome via approaches based on combination of 
homologous recombination with engineered nucleases targeting specific sites. This 
approach whilst far more complex presents with multiple advantages such as: 
 Removal of any possible deleterious function of the defective copy. 
 Transgene being regulated in the precise endogenous genomic context. 
 Transgene being copied upon cell replication and thus maintained in replicating cell 
types 
This technology is still however at a very early stages of development and has not yet seen 
extensive application [144], especially in vivo. 
 
1.6.1.2 Gene suppression 
Gene supplementation is likely to be ineffective for the treatment of dominant disorders 
resulting from gain of function or dominant negative mutations. For gene therapy to be 
effective in such cases the expression of the mutated gene product must be supressed. 
This approach is usually mediated via the gene therapy vector delivering a nucleic acid 
construct designed to act via RNA interference (RNAi). This system works by co-opting an 
endogenous system in all mammalian cells which enacts post transcriptional gene silencing 
via the enzymatic destruction of RNA species. This silencing is mediated by a large 
multicomponent RNA/protein complex called the RNA induced silencing complex (RISC). 
RISC functions by processing dsRNA species into small (19-21bp) ssRNA species which are 
then incorporated into the structure of the complex in order to act as a template for the 
recognition of larger ssRNA species by complimentary base pairing. Upon such recognition 
an RNAase component of the complex becomes active and the target molecule is degraded. 
It was initially thought that this system may have evolved as a host defence against viral 
infection which seems to be the case in plants and invertebrates, however support for this 
idea in the mammalian context has recently been challenged as relatively weak and the 
discovery of endogenous microRNAs (miRNAs) that act through RISC forming a vital post 
transcriptional gene regulatory mechanism suggests that mammals may have repurposed 
RNAi/RISC to a different primary function [145]. 
42 
 
Gene suppression constructs are often based upon a short hairpin RNA structure (shRNA), 
in which two inverted repeat sequences are separated by a short sequence designed to fold 
into a hairpin loop and thus the whole construct is capable of folding into dsRNA by a self-
complimentary base pairing of the inverted regions, designed to be specific to the gene to be 
silenced. The dsRNA transgenic construct is processed by RISC which then mediates the 
destruction of endogenous target gene mRNA resulting in reduced translation. As the 
shRNA transgene is required to be delivered in the form of a very short RNA molecule 
without a poly A tail the promoters used in such constructs bind RNA polymerase III as these 
enzymes are designed to transcribe such RNA species. Commonly used promoters are U6 
and H1 although these induce a ubiquitous expression profile and thus control is limited. 
There is evidence however that in the case of RNAi based gene knockdown the effects of 
overexpression may be of greater concern than is the case for gene supplementation. This 
appears to be due to the relatively limited capacity of the RISC complex as artificial short 
interfering RNAs and expressed shRNAs have both been shown to inhibit both each other 
and the endogenous miRNAs by competition for access to RISC components [146]. This 
competition results in combinatorial shRNAs approaches proving less effective than either 
component in isolation and overexpression potentially causing toxicity via the deregulation of 
endogenous miRNA function. Another study showed that such shRNA overexpression 
mediated miRNA dysfunction can prove fatal in a murine model and identified a nuclear 
dsRNA exporter (karyopherin exportin-5) as a particular bottleneck prone to saturation within 
the system [147]. Dosing within shRNA based gene knockdown approaches is therefore of 
critical importance. 
Some modulation of dosing might be achieved by the use of gene silencing constructs based 
upon miRNA structure. These do not appear to be expressed as highly as more traditional 
shRNA-based designs and do not result in as substantial a gene knockdown when 
compared under tightly controlled conditions [148]. Whilst this may act to limit their efficacy it 
also reduces their toxicity, and it has been shown that such miRNA mediated RNAi can 
result in an effective gene knockdown whilst showing no signs of competitive interference 
with other constructs [146]. 
 
1.6.1.3 Gene Augmentation 
Augmentation gene therapy is an approach whereby gene transfer does not aim to directly 
address a genetic defect by replacement or inhibition of the mutated gene product. 
Augmentation approaches instead aim to express factors which might be able to mediate a 
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beneficial effect on a pathological process via direct modulation of the process itself or 
stimulation of other endogenous systems or responses to act antagonistically to the 
pathology. This approach is therefore not limited to application solely to congenital disease, 
as pathological processes that may be amenable to amelioration via such a mechanism are 
present in almost every disease state. 
The target systems of augmentation gene therapy approaches have therefore been 
incredibly varied and include: promotion of cell survival [149], induction of cell death [150], 
induction of cell proliferation [151], inhibition of neovascular growth [152], neuroprotection 
[153], inhibition of immune responses [154], retargeting of cytotoxic T-cells to specific 
epitopes[155] and the prevention of amyloid deposition [156] to name but a few. 
In common with every other gene therapy approach appropriate regulation of the transgene 
expression is key and indeed such control may be especially vital in the case of 
augmentation-based approaches. Off-target transgene expression in the context of a gene 
supplementation may have little pathogenic effect as the transgene is often highly specific 
only functioning within the target cell type. The target systems of augmentation-based 
approaches however are usually far more widely applicable and off-target or excessive 
expression could be highly deleterious, for example in cases where the approach aims to 
induce cell death or immunosuppression. 
Therefore in addition to the transgene regulation afforded by tissue or cell-specific promoters 
or vector tropisms, augmentation approaches have also seen the development of promoter 
sequences designed to be able to modulate transgene expression in direct response to the 
severity of the pathology in effect. For example NFκB responsive promoter sequences have 
been used to drive transgene expression specifically in response to inflammation [157] and 
the GFAP promoter has been used to up-regulate transgene expression at the site of CNS 
lesions.[158] 
A commonly employed approach in augmentation gene therapy is often not to target directly 
the cell type (or even tissue or organ) which is most affected by the pathology but instead 
aim to act at a distance via a secreted product, providing said product can be delivered to 
the target site in sufficient quantity by normal physiological processes. Such an approach 
may be of particular benefit if for example: 
 Transduction of the affected cells themselves would not result in the production of 
physiologically relevant amounts of secreted transgene product. 
 The affected area has been rendered especially sensitive to further damage (such as 
that which might result from gene delivery itself) by the ongoing pathology. 
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 The cells or tissues directly affected are physically difficult to access. 
 The cells in question cannot be currently be transduced by any available gene 
delivery system. 
 The site of disease itself is especially exposed to the immune system leading to a 
high probability of vector or transgene directed immune responses. 
It should be noted however that whilst this secretion based approach is more common in 
augmentation approaches, supplementation gene therapy can also share this mechanism of 
action. For example the gene defects in factor IX that are causative of haemophilia B result 
in a systemic dysfunction and supplementation of factor IX does not have to be directed to 
the natural site of production in the liver with other tissues such a muscle having been 
targeted instead [159]. 
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1.6.2 Vectors for viral gene therapy 
 
1.6.2.1 Adenoviral vectors 
Adenoviruses are non-enveloped viruses with a linear double stranded 37kb DNA genome 
contained within an icosahedral capsid with fibres extending from each vertex of the capsid 
structure. There are 57 distinct serotypes identified and in their wildtype forms are 
associated most commonly with mild respiratory infections. 
Infection is primarily mediated via interactions between the fibre knob domain with the 
coxsackie and adenovirus receptors [160]. Internalisation of virions then proceeds by binding 
of cellular integrins to an RGD motif in the adenovirus penton base protein, and subsequent 
endocytosis [161]. Adenoviruses became a popular gene therapy vector based upon a 
number of factors. They display a wide tropism to both quiescent and proliferating cell types, 
have a relative large genomic packaging capacity of between 8 and 38Kb for transgenic 
inserts, are stable [162] and are relatively easy to both genetically manipulate and produce. 
Adenovirus serotype 5 in particular has emerged as the adenoviral vector of choice and is 
used in the majority of approaches employing adenoviral vectors. 
Adenoviruses do present with a significant disadvantage however, they have been shown to 
mediate extensive innate immune responses [163]. This issue was tragically highlighted by 
death of a patient taking part in a gene therapy trial for ornithine transcarbamylase (OTC) 
deficiency due to a massive systemic immune response to the adenoviral vector [138]. Even 
in the absence of such an extreme response the transgene expression mediated by 
adenovirus is often lost due to adaptive immune responses eliminating transduced cells 
[164,165], a response directed towards either viral antigens or transgene product with the 
latter potentially having been potentiated by the former. 
Modification of adenoviral vectors in order to reduce or mask their immunogenicity is 
therefore an area that has received some significant attention [166] with improvements in 
production techniques and a greater understanding of the virology of adenovirus leading to 
the development of 2nd and 3rd generation vectors. These newer generations have been 
engineered to package an increasingly minimal set of adenoviral gene sequences within the 
final vector and thus have minimised immune responses directed at these sequences and 
their products. Such an approach however does little to reduce the immunogenicity induced 
by the capsid proteins themselves and thus a significant immune response can still be 
induced [167]. 
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Adenoviral vectors have not seen widespread use within the eye due to both concerns over 
their immune profile and the fact that they do not generally display tropism to 
photoreceptors, the cell type most commonly targeted within the eye [168]. More recently 
adenoviruses have been generated with modifications made to the capsid which appear to 
mediate a more extensive retinal transduction [169] but these have not yet seen application. 
Adenoviruses do effectively transduce corneal endothelial cells however and this will be 
further discussed in 1.7.2. 
Adenoviruses continue to see widespread use within the field of cancer gene therapy, in 
which rather than being deleterious to gene expression any adaptive immune response 
generated is likely to be advantageous as such gene therapy usually aims to destroy the 
target cells; innate responses however remain a concern. 
 
1.6.2.2 Adeno-associated viral vectors (AAVs) 
Adeno-associated viruses (AAV) are members of the family Parvoviridae which are all non-
enveloped viruses with a single-stranded DNA genome contained within an icosahedral 
capsid; collectively the Parvoviridae also constitute some of the smallest, simplest eukaryotic 
viruses. The AAV's are the sole members of the Dependovirus genus within the family, a 
genus so named due to the inability of its members to independently replicate. 
Dependoviruses are dependent for replication upon gene functions provided in trans by the 
co-infection of a so called "Helper virus". This role is most commonly fulfilled by 
adenoviruses (leading to the group’s species name) although helper function can also be 
fulfilled by herpes or vaccinia virus.  
AAV displays multiple features that make it highly attractive as a gene therapy vector. Firstly 
and in common with the rest of its family, AAV is an exceptionally small, deceptively simple 
virus, allowing relatively easy genetic manipulation and production. A single AAV virion is 
around 22nm in diameter and is formed of 60 protein subunits, consisting of three individual 
capsid proteins, VP1-3 in the ratio 5:5:50 [170]. Genomically AAV is equally economical, its 
genome being 4.7kb long containing only two open reading frames, the genes Rep and Cap. 
As their names imply Rep encodes proteins required for AAVs replication and other cellular 
functions whilst Cap encodes the structural capsid proteins. Both genes are extensively 
alternative spliced meaning that 3 cap and 4 rep protein products are produced. Genomic 
packaging is mediated by short (145 base) inverted terminal repeat sequences (ITR) flanking 
the genome and all sequences lying between these ITRs will be effectively packaged 
meaning the design of transgenic constructs for packaging into AAV is extremely easy. 
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Infection with wildtype AAV is generally not associated with any form of pathogenesis and 
although they do induce humoral immunity, innate and cellular responses are limited, 
possibly due to AAVs limited antigen presentation [139]. As a vector these characteristics 
lead to an excellent safety profile although the presence of neutralising antibodies may limit 
the efficacy of both repeated applications and treatment of those individuals already 
seropositive.  
Upon infection wildtype AAV is capable of proceeding down either lysogenic or lytic routes 
depending upon the presence or otherwise of its helper virus [171]. If present, infection will 
proceed via the lytic pathway but in the absence of helper virus AAV is able to integrate its 
genome into the host’s and establish a latent infection. The integration of AAV is unique 
amongst all known eukaryotic viruses, in that it integrates only at a single highly specific site 
(a 4kb region) on human chromosome 19 and is mediated by either Rep78 or Rep68. 
Recombinant AAV (rAAV) vectors however do not generally encode the Rep gene, with the 
entirety of the genome save the ITRs having been replaced with transgenic construct for 
reasons of both maximising packaging capacity and safety. Recombinant AAVs are 
therefore incapable of this site specific integration and do not integrate to any substantial 
degree, maintaining their genomes episomally. Such integration however could be of great 
utility in a vector, potentially allowing the stable infection of a replicative cell type with 
minimal risk of insertional mutagenesis. Unfortunately the mechanisms by which AAV 
mediates this unique integration are currently too poorly understood to be applied. 
To date twelve different human serotypes of AAV and more than 100 serotypes from 
nonhuman primates have been isolated and identified. Of these, the human serotypes AAV 
1-9 have been the most extensively characterised and adapted for use as vectors and 
between them display tropism to a very wide variety of different tissue / cell types leading to 
potential utility in the treatment of an equally wide range of genetic disorders [172]. 
AAV9 is of particular note in regard to tropism having been shown to be able to mediate 
transduction in many different tissues throughout the entire murine soma when delivered 
systemically [173] opening the intriguing possibility that treatment of syndromic conditions or 
gene delivery to widely distributed organ systems (such as muscle) might be possible by 
such means. Whilst such widespread transduction has only thus far proven possible at 
embryonic stages, transduction of the retina via this route in the adult has also been 
demonstrated [174]. 
When produced as vectors, AAV particles are usually composed of a genome based upon 
the AAV2 ITR sequences combined with the capsid best suited to the application. The 
convention for vector nomenclature is therefore: AAV genome / capsid, e.g. AAV2/8 
48 
 
AAV does however have two major disadvantages for use as a vector. Firstly AAV is unable 
to package much more than its wildtype genomic capacity, limiting the size of the transgenic 
constructs that can be packaged to 4.7 - 5.0kb. Relatively recently it had been reported this 
limit may not be as absolute as previously assumed, with larger genomic packing possible 
albeit at reduced efficiency [175]. These results however could not be replicated and may 
have been artifactual [176]. Secondly as already mentioned rAAV is not able to integrate its 
genome within the host’s, and whilst this might reduce any potential for genotoxicity via 
insertional mutagenesis it also results in dilution of episomal transgenic constructs upon cell 
division and eventual loss of expression in dividing cells. Application of AAV has therefore 
been largely limited to non-dividing cell types. 
Use of AAV within the context of gene therapy has been extensive and it has rapidly become 
the vector of choice within the field, especially for gene supplementation approaches. At the 
time of writing AAV vectors are in use in at least 38 clinical trials for conditions as diverse as 
haemophilia, muscular dystrophy, Alzheimer disease and arthritis [177]. Additionally in 2012 
the first (and thus far only) gene therapy based pharmaceutical (Glybera), which is based 
upon an AAV1 vector, was approved for use in the treatment of familial lipoprotein lipase 
deficiency [178]. 
AAV is also by far the most commonly used vector in ocular gene therapy due to multiple 
serotypes (2, 8, 5 and 9) having been shown to mediate a substantial, and long lasting gene 
delivery to both photoreceptors and retinal pigment epithelium (RPE) following injection into 
the subretinal space (reviewed in [179,180]). AAV-based vector technology has now 
improved to the point where a near 100% transduction of these cell types is achievable in 
mice. 
Clinically, four trials have begun aiming to treat Leber’s congenital amaurosis (LCA) due to 
RPE65 deficiency via an AAV2/2 or AAV2/4 based gene supplementation. These trials have 
progressed to Phase I / II and have thus far demonstrated safety and some initial indications 
of efficacy [141,143,181].  
Due the fact that AAV based gene therapy has enjoyed so much success there have also 
been multiple attempts made to improve AAV vectors through modification of their capsids 
and genomes to further expand their utility. Self-complimentary AAV vectors (scAAV) are 
one such modification. These vectors carry inverted repeat genomes which are capable of 
folding upon themselves to form double stranded DNA. Upon infection this allows the rate 
limiting step of second strand synthesis to be circumvented leading to more rapid onset of 
transgene expression [182,183]. This however comes at the cost of halving the already 
49 
 
limited packaging capacity of the vector. Two capsid modifications of AAV will be discussing 
in greater detail in 1.6.2.3 & 1.6.2.4. 
 
1.6.2.3 Engineered capsid mutants of AAV (tyrosine mutants) 
The work that lead to the inception of the various tyrosine mutant AAVs was initially based 
upon the finding that the cellular chaperone protein FKBP52, when phosphorylated by 
epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK), inhibits second strand 
synthesis of the AAV genome [184] which constitutes a major rate-limiting step accounting 
for the inefficient transduction of certain cell types by AAV vectors [185]. 
This finding led Zhong et al. [186] to examine the role of this signalling pathway upon AAV 
transduction in greater detail. As a first step in the investigation of this pathway’s role in 
second strand synthesis the effects of its pharmacological inhibition upon both normal single 
stranded (ssAAV) and self-complimentary (scAAV) AAV2 vectors was assessed in vitro. It 
might have been expected that the scAAV would be unaffected by such inhibition as this 
modification of the AAV genome eliminates the need for second strand synthesis. 
Surprisingly however this was found not to be the case, inhibition of the EGFR-PTK pathway 
was shown to improve the transduction efficiency of both ssAAV and scAAV2 significantly, 
with the effect upon scAAV being only marginally reduced. This therefore implicated the 
EGFR-PTK pathway in a substantial additional role in AAV transduction beyond that of 
inhibiting second strand synthesis. 
Zhong et al. then examined the role of the EGFR-PTK pathway in intracellular trafficking of 
AAV. Inhibition of the EGFR-PTK pathway in vitro was shown to increase the proportion of 
AAV sequences localised to the nucleus to a similar degree as treatment with a proteasome 
inhibitor. Additionally the effects of EGFR-PTK pathway inhibition and proteasome inhibition 
were shown not to be additive and inhibition of the EGFR-PTK pathway also decreased the 
ubiquitination of AAV2 capsid proteins. It was therefore hypothesised that in addition to its 
role inhibiting second strand synthesis the EGFR-PTK pathway also mediates 
phosphorylation of the capsid proteins at tyrosine residues of AAV particles that have 
escaped the late endosome, resulting in their ubiquitination and subsequent degradation in 
the proteasome. 
To test this hypothesis Zhong et al. [187] identified seven exposed tyrosine residues on the 
AAV2 capsid and generated an equal number of mutant AAV2 vectors in which each 
tyrosine was conservatively substituted with phenylalanine (Y to F). All seven mutant vectors 
displayed transduction in vitro significantly improved over wildtype although this varied 
widely from < 2-fold to >11-fold depending on which residue was mutated. When tested in 
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vivo on mouse hepatocytes broadly the same pattern was apparent with an even further 
enhanced efficacy over wildtype AAV2. It was also shown that for the two most promising 
mutants (Y730F and Y444F) in vitro translocation of vector DNA to the nucleus was 
increased and ubiquitination of the capsid was reduced. 
Since this initial development work, application of capsid tyrosine mutations to improve 
transduction efficacy or modify viral tropism has been applied to a number of different AAV 
serotypes with varying degrees of success [188–190]. The majority of these studies have 
been directed towards application within the eye, likely due to the large volume of AAV 
based gene therapy approaches to retinal dystrophies published to date [191]. 
Petrs-Silva et al. [192] examined the retinal transduction efficacy of the two most effective 
mutants identified from previous work (Y44xF and Y73xF) in scAAV serotypes 2, 8 and 9 
following intravitreal administration in mice. In all cases ganglion cell transduction by the 
mutant was superior to the equivalent wildtype vector and it was claimed expression was 
visible across the entire retina although direct evidence of this was not shown convincingly. 
They also showed that AAV2/2(Y444F) was capable of mediating expression in all layers of 
the retina following an intravitreal injection, although again it was not made clear how 
widespread this transduction was. Following sub-retinal injection AAV2/8(Y733F) was shown 
to result in the strongest and most widespread transduction of the serotypes/mutants tested 
and following this route of administration both this mutant and the AAV2/2(Y444F) were 
shown to transduce cells in all layers of the retina, although it would appear that expression 
beyond the outer nuclear layer did not extend throughout the whole retina. 
Kay et al. [193] further examined the potential of combined tyrosine mutant scAAVs to 
transduce the retina following an intravitreal injection in mice and showed a quadruple 
tyrosine + T491V scAAV2/2 to be by far the most effective both in terms of retinal 
penetration and spread of transduction, with scAAV2/5 and scAAV2/8 based mutants only 
mediating transduction near the optic nerve head. This led them to hypothesise that the 
inner limiting membrane (ILM) and the differential ability of the different serotypes to bind to 
it was of crucial importance. It is worth noting that these results from Kay et al. [193] are 
generally far less impressive than the comparable data presented by Petrs-Silva et al. [192]. 
Kay et al. do however include the following statement: “Due to the small size of the mouse 
eye, it is not uncommon for trans-scleral, intravitreal injections to result in damage to the 
retina that might allow delivery of some vector directly to the subretinal space” perhaps 
hinting at a possible explanation for this disparity. 
Delivered subretinally AAV2/8(Y733F)-mediated gene delivery has also been demonstrated 
to rescue two mouse models of retinal degeneration. Firstly the rd10 model of autosomal 
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recessive retinitis pigmentosa (RP), which carries a spontaneous mutation in the β subunit of 
rod cGMP-phosphodiesterase (PDEβ) [194] and secondly in a RetGC1/RetGC2 double 
knockout mouse model of Leber congenital amaurosis [195]. 
To date there is only one example of published data regarding application of these tyrosine 
mutants AAV vectors to the cornea, a mention in a review by Mohan et al. [196] who show a 
single image of extremely limited transduction of the mouse corneal endothelium in vivo with 
AAV2/8(Y733F). This data has not been subsequently published in a more comprehensive 
format. 
 
1.6.2.4 Engineered capsid mutants of AAV (AAV2/6[ShH10]) 
This serotype of AAV is a one of the newest engineered serotypes to have been developed 
having been first generated and published in 2009 by Koerber et al. [197] . Rather than 
approaching capsid engineering from a perspective of rational design founded upon insights 
from AAV virology (such as that utilised to generate the Tyrosine mutants), Koerber et al. 
employed an approach that combined such design principles with directed evolution. 
The authors first generated five highly diverse libraries (107) of mutant AAV capsids 
produced by different methodologies: 
1) Random mutations within the AAV2 cap gene mediated by error prone PCR 
with staggered extension steps (AAV2-EP library). 
2) Random shuffling of the cap genes from AAV serotypes 1, 2, 4–6, 8, and 9 
resulting in hybrid cap genes (ShH library). 
3) Insertion of a random 7 amino acid polypeptide within the heparin sulphate 
binding motif of AAV2 (7mer library). 
4 & 5)  Semi random replacement of 4 important surface loops present on the 
surface of AAV2. 
Recombinant AAV was then generated in such a way that each virion packaged a transgene 
encoding its own capsid, thus allowing for linkage of successful infection with the genomic 
cap mutations responsible. The AAV libraries were subjected to 4 rounds of selection 
focused upon the identification of AAV mutants that favoured the transduction of glial cells by 
positively selecting those capsids able to mediate transduction of primary human astrocytes 
in vitro. Those capsid mutations that made it through these initial 4 rounds of selection then 
under went further diversification by shuffling and random mutagenesis before 1 final round 
of selection. 
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The approach generated several novel capsids that demonstrated improved levels of glial 
transduction both in vitro and in vivo. Some of the most promising of these capsid mutants 
were then specifically assessed for their ability to transduce the resident glial cell type within 
the eye, the Müller glia, via an intravitreal administration route [198]. Somewhat surprisingly 
none of the most promising candidates from the selection proved especially effective when 
administered via this route leading the authors to conclude that transduction was being 
limited by additional physiological extracellular barriers present within the retina which these 
variants were not selected to overcome. 
A partial rescreening of the library in this new context then revealed a capsid variant 
(ShH10) that displayed both efficient and highly specific transduction of Müller glia from an 
intravitreal injection. Mutational analysis of this capsid mutant revealed ShH10 to be 
extremely similar to wildtype AAV2/6, differing from this parent at only 4 residues which were 
shown to act largely synergistically to produce the transduction observed.  
At no point during this work was the capacity of any of these variants to transduce the 
anterior segment of the eye assessed, a perhaps logical oversight as there are no glia 
present within the non-neural tissues of the eye. 
Due to its relative novelty, application of ShH10 to date has been extremely limited; it has 
thus far been utilised to promote the survival of retinal neurons via secretion of the 
neurotropic factor GDNF from Müller glia [153], and as a Müller cell-specific means of 
cytotoxic gene delivery in a study of the effects of optogenetic ablation of Müller cells upon 
the retina [199]. 
 
1.6.2.5 Lentiviral vectors 
The lentiviruses are a genus of retroviruses characterised by and named for their long 
incubations periods. Uniquely among the retroviruses the lentiviruses are able to infect non-
dividing cell types in addition to the tropism for mitotically active cells displayed by the rest of 
the family. Lentiviruses are able to transduce cells within target organs including the eye, 
heart, pancreas, and liver [200].  
Structurally lentiviruses are one of the more complex viruses to have been utilised as a 
vector. The lentiviral genome constitutes two positive strand RNA molecules of between of 7 
– 12 kb in length associated in a dimer. The capsid is dual layered consisting of an inner 
cone-shaped nucleocapsid enclosing both the genome and various proteins required post 
infection for replication, and an outer spherical matrix which interacts with the final 
component of the virion, a lipid bilayer envelope derived from the host cell’s plasma 
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membrane and containing virally encoded glycoproteins. A single complete lentiviral virion 
measures around 100-120nm in diameter [201]. 
Genomically lentiviruses are organised around three key genes, gag, pol and env which 
encode all the major structural (gag and env) and replicative (pol) aspects of virus. 
Additionally the genome contains two regulatory genes (tat and rev) and four accessory 
genes (nef, vif, vpr and vpu). The genome is flanked by two long terminal repeat sequences 
(LTRs) which are key mediators of many aspects of the lentiviral life cycle. Other key 
genomic sequences are the packaging signal (ψ) and the central polypurine tract (cPPT) 
which is implicated in both DNA synthesis and nuclear import. 
The lentivirus life cycle proceeds by the following steps: 
1. Virion binding and entry: Mediated by interactions between viral envelope 
glycoproteins and receptors exposed on the host cell’s surface. 
2. Reverse transcription: Due to the requirement for DNA synthesis to be primed 
reverse transcription occurs via an extremely complex sequence of repeated self-
priming. The following features of this process are of particular relevance: 
a. Firstly that the RNA genome packaged within the virion is in a pre-primed 
state, with the transfer RNA tRNAlys derived from the host cell bound to a 
specific primer binding site. Without this interaction reverse transcription 
cannot be initiated. 
b. During the cascade of self-priming the U3 sequence of the 3’ LTR is copied to 
the 5’ end as the original 5’ proviral U3 sequence was lost during virus 
production. In wildtype virus the two LTRs are identical so this is of little 
functional significance but this feature is exploited in lentiviral vector design. 
3. Provirus trafficking and nuclear import: Reverse transcription results in a linear 
dsDNA version of the lentiviral genome termed the provirus, which is then trafficked 
to the nucleus. 
4. Integration: The provirus is integrated into the host gene by the viral enzyme 
integrase which was delivered to the host cell packaged within the capsid in 
association with the genome. Integration occurs semi-randomly within the genome, 
showing preference for genomic areas undergoing active transcription [202] and 
certain sequence motifs [203]. 
5. De novo expression of virally encoded genes: In a wildtype infection this process 
proceeds from the promoter activity of the 5’ LTR and results in virus replication. In 
vectors transgene expression is under the control of an exogenous promoter forming 
part of the transgenic construct. 
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This ability of lentiviruses to integrate into the host genome is key to their utility as a vector 
allowing them to yield a high level, stable and long term transgene expression within actively 
dividing cells. Lentiviruses are the only viruses commonly used as vectors for which this is 
the case. Use of non-integrating vectors in dividing cell lines leads to loss of transgene 
expression over time due to dilution of the non-replicative transgenic construct. 
Many different lentiviruses have been adapted for use as vectors including equine infectious 
anaemia virus (EIAV), simian immunodeficiency virus (SIV), caprine arthritis encephalitis 
virus (CAEV), and both bovine and feline immunodeficiency viruses (BIV / FIV). Predominant 
in the field however is human immunodeficiency virus type1 (HIV1). 
The development of HIV1 as a vector has progressed through three main vector generations 
with each subsequent iteration primarily focused upon improvement of the vector’s safety 
profile. Each generation has both removed as many viral sequences as possible from 
transgenic genomic constructs and provided an increasingly minimal set of viral genes in 
trans (via helper constructs) during production, whilst maintaining efficiency of production 
and vector infectivity. 
All generations of lentivirus packaging systems have included the genes gag and pol as 
these genes encode indispensable structural and assembly functions. During vector 
production these functions however are provided in trans upon a “helper” construct which 
lacks the packaging signal (ψ) to ensure no HIV sequences were packaged within the 
vector. First generation lentivirus systems did not include the HIV1 env gene upon the helper 
plasmid but this was the only gene deleted. The second generation further improved upon 
biosafety by the deletion of all accessory genes from helper constructs but preserved 
regulatory functions provided by tat and rev, which in the third generation were separated 
from gag and pol being provided upon a second trans acting plasmid, in order to further 
minimise the risk of inadvertent packaging of complete viral functionality via unintentional 
recombination between a helper construct and a ψ containing plasmid [204]. 
As mentioned earlier, the process of reverse transcription duplicates the U3 element of 3’ 
LTR in such a way that this sequence flanks both ends of the DNA provirus; this feature of 
the lifecycle has been exploited to further improve lentivector safety [205]. Transgenic vector 
genomic constructs carry a 3’ LTR in which the U3 region has been deleted. Whilst this has 
no effect on the first round of viral infection or in vitro production once integrated into the 
target cell this modification eliminates the promoter activity of the 5’ proviral LTR. 
Transcription can only therefore be initiated from a transgenic promoter inserted downstream 
of the ψ signal, meaning that even in the unlikely event of superinfection with wild type HIV1 
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the transgenic construct can never be mobilised and repackaged. Most generations of 
lentivirus carry this modification and are termed self-inactivating (SIN).  
Few lentiviral vectors utilise the wildtype envelope genes encoded by env, partly for reasons 
of safety but also because these envelope glycoproteins would restrict vector tropism to the 
natural target of HIV1, CD4+ T-cells. Vectors are therefore pseudotyped with envelope 
proteins from other viruses and by such modification tropism can (within limits) be restricted 
or broadened as desired. The most commonly used envelope (VSV-G) derives from 
vesicular stomatitis virus as this results in a vector with a broad tropism to almost any cell 
type [206]. 
As a result of this extensive safety orientated vector engineering HIV1 based lentiviruses are 
in use in phase I clinical trials aiming to treat systemic disorders such as X‐linked 
adrenoleukodystrophy [207], β-thalassaemia [208], adenosine deaminase severe combined 
immunodeficiency (ADA‐SCID) [209], and Wiskott Aldrich Syndrome (WAS) [210]. 
One major concern regarding the clinical use of retroviral vectors was however highlighted 
within another trial for X-linked SCID utilising a gamma retroviral vector. A number of 
patients developed leukaemia as a result of treatment due to the malignant transformation of 
vector transduced cells [211]. This oncogenesis was caused by integration of the provirus 
into the LMO2 proto-oncogene resulting its upregulation via the promoter activity of the 
proviral 3’ LTR. Whilst oncogenesis by this exact mechanism could not have occurred with a 
SIN lentivector (and no lenti related oncogenic events have thus far been reported [212]) it is 
still possible that disruption of the host genome by integration could lead to such deleterious 
effects [213]. 
This possibility has led to the development of a Lentiviral generation in which the integrase 
gene used for vector production has been rendered defective [214]. The genomes of these 
vectors therefore do not integrate and are maintained episomally. Although this reduces the 
risk of genotoxicity it also eliminates the ability of the vector to stably transduce dividing cell 
types and would therefore have been inapplicable to any clinical approach to date. 
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1.7 Gene therapy of the cornea  
 
1.7.1 The eye as a target for gene therapy 
The eye has long been considered an extremely attractive target for gene therapy [191]. 
Firstly the organ is eminently accessible with vector delivery to all parts of the eye being 
possible via minimally invasive techniques, many of which are already routine within 
ophthalmic surgery. This accessibility also allows for easy, non-invasive observation of the 
phenotypic effects of therapy in vivo and, due to the optical properties of the eye enabling 
direct observation, such assessments are often possible at a high level of detail and 
resolution. Indeed recent advances in imaging technology such as adaptive optics have 
allowed the live imaging of individual cells within the living eye [215]. The highly 
compartmentalised anatomy of the eye also facilitates tissue-specific vector targeting with 
the added advantage that several compartments of the eye such as the anterior chamber 
and subretinal space are also considered to be immune privileged sites [216,217]. This 
privilege is highlighted by remarkable success rate of corneal allografts which are both the 
most commonly performed transplant surgery [120] and the only such procedure that is 
routinely performed without graft tissue typing or systemic immunosuppression. This 
privileged status is the result of a combination of features such as the blood retinal barrier, a 
relative lack of lymphatic and/or haematic vascularisation in some ocular tissues and the 
presence of secreted immunomodulatory factors, all features promoting immune tolerance. 
These qualities, combined with the fact that a large number of inherited retinal dystrophies 
have been identified and characterised, has led to the posterior segment of the eye 
becoming one of the predominant target tissues within the gene therapy field, with some 
such approaches having progressed to clinical trial [218]. Gene therapy directed at the 
cornea however has not seen nearly such extensive development in part due to the success 
enjoyed by corneal transplantation surgery for the treatment of many corneal pathologies. 
Transplantation is not however applicable to all disease states and graft outcomes also have 
the potential to be further improved by gene therapy. A substantial number of gene therapy-
based approaches to the cornea have thus been developed and the subsections that follow 
will outline some of the notable work within the field to date. 
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1.7.2 Endothelium directed gene transfer 
The majority of corneal endothelium-directed gene therapy approaches to date have been 
based upon transduction mediated by viral vectors. Certain non-viral approaches such as 
electroporation [219], liposomal vectors [220], polyamidoamine dendrimers [221] and 
synthetic peptides [222] have all been shown to transduce the endothelium although in all 
cases the transgene expression achieved was both of limited duration and inefficient, only 
transducing a very small proportion of the endothelium. 
Of the commonly used viral gene therapy vectors AAV on balance appears unable to 
efficiently transduce the endothelium ex vivo [223,224], despite a single report to the 
contrary [225]. One study reported that whilst AAV might transduce the rabbit corneal 
endothelium in vivo, significant transgene expression was only seen in the context of severe 
ocular anterior segment inflammation induced by injection of lipopolysaccharide [226]. So 
the efficacy of gene delivery to the endothelium via AAV is somewhat unclear and has seen 
no application in functional transgene delivery. 
Herpes simplex virus-based vectors also have not seen widespread application in gene 
delivery to the corneal epithelium. The level of gene delivery they can mediate in the 
endothelium is superior to that of AAV but is still relatively low at around 5% of cells ex vivo 
[223]. Additionally HSV based vectors are often highly immunogenic and this may be of 
particular concern in the cornea which is a known site of naturally pathogenic herpes simplex 
infections. 
The majority of endothelium directed gene therapies of the cornea have therefore utilised 
either adenovirus or lentivirus based vectors both of which have been shown to transduce 
corneal endothelial cells with high efficiency. Adenoviral vectors were first demonstrated to 
transduce rabbit corneal endothelium with 75-100% efficiency [227] in vivo and later human 
endothelium with a similar level of efficiency ex vivo [151,228,229]. Similar efficacy of 
endothelial transduction mediated by adenovirus has also been shown almost every other 
animal system tested, including large animal models such as the sheep [230]. 
Lentiviral vectors appear equally effective having been shown to efficiently transduce the 
endothelium across an equally wide range of species both in vivo [231] and ex vivo [232]. 
Critically in regard to clinical application lentiviruses appear able to mediate a near 100% 
transduction of human corneal endothelium ex vivo [228]. 
Beyond demonstrating simple transduction efficacy, endothelial gene therapy has also seen 
application in functional gene delivery. Most such studies have constituted augmentation 
gene therapy approaches aiming to improve corneal graft survival, this focus being due both 
to the high level of clinical relevance of such a strategy and the fact that donor corneas are 
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commonly stored in organ culture pre-transplantation providing an ideal window of 
opportunity for gene therapy to be applied ex vivo. 
Promotion of graft survival has been attempted by the direct modulation of immune mediated 
rejection of the graft by the gene delivery of various factors promoting immune tolerance 
such as IL10 [230], soluble TNF receptor [233], NGF [234] and others. Such approaches 
have seen some success in animal models and perhaps the most promising results having 
been obtained in the following studies. Klebe et al. [230] delivered the anti-inflammatory 
cytokine IL10 to the endothelium of donor tissue with an adenoviral vector pre-
transplantation in an ovine corneal allograft model and demonstrated an improvement in the 
median graft survival time from 21 to 55 days with two animals demonstrating exceptional 
survival times of >150 days. Beutelspacher et al. [235] achieved a similar level of 
improvement in median graft survival time from 11 to 21 days in a murine allograft model in 
which indoleamine 2,3-dioxygenase, a well-known mediator of immune tolerance via the 
inhibition of T-cells, had been delivered via a lentivirus to the donor endothelium one hour 
before transplantation. 
In these immune modulatory gene therapy approaches acting via secreted factors the 
endothelium is simply serving as an accessible, transducible site for production of transgene 
product, a role that could likely be equally well served by other potentially less critical or 
sensitive cells of the cornea such as stromal keratocytes. Of more direct relevance to the 
endothelium itself however are approaches that aim to improve the quality of graft tissue or 
prevent graft failure via gene delivery aiming to maintain or increase endothelial cell density. 
As discussed in 1.2.1 endothelial cell density is of critical importance to corneal transplant 
survival as post-operative endothelial cell loss represents a major cause of graft failure and 
insufficient endothelial cell density is the primary reason donor tissue is rejected for 
transplantation. Whilst there is general agreement that endothelial cell density decreases 
during organ culture, it is less clear by what mechanism the cell loss proceeds. A study by 
Albon et al. [236] concluded that apoptosis constituted the primary mechanism of endothelial 
cell loss, however a separate study by Crewe et al. [237] (which utilised a similar 
methodology) conversely found very little evidence of endothelial apoptosis during organ 
culture. 
However, despite this uncertainty a number of studies have nonetheless focused upon 
apoptosis and thus aimed to preserve endothelial cells in donor tissue by the delivery of anti-
apoptotic factors. Lentiviral delivery of one such factor, Bcl-xL to the endothelium has been 
shown to both inhibit experimentally induced apoptosis and improve graft survival at 8 weeks 
from 40% to 90% when delivered pre-transplantation in a murine allograft model [238]. 
Potentially even more effective than Bcl-xL when delivered by the same methodology is the 
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baculovirus caspase inhibitor P35 which was shown to mediate a greater anti-apoptotic 
effect in endothelial cells than Bcl-xL [239] and prevented experimentally induced apoptosis 
more effectively in human tissue stored under eyebank conditions [240].  
Rather than trying to prevent cell death an alternative approach is to increase endothelial cell 
density directly, inducing cell replication by modulation of the cell cycle. This is possible 
since the naturally non-replicative endothelial cells have not completely left the cell cycle via 
G0 and exist in a state of early G1 arrest, thus retaining some proliferative potential [8]. 
Several studies have attempted such induction of endothelial proliferation via gene therapy 
and have largely focused upon overexpression of the transcription factor E2F2 which is 
known to regulate the transition from G1 to S phase. Such overexpression in rabbit corneas 
ex vivo via a lipid based non-viral vector showed some signs of cell cycle progression but 
any increase in cell density was masked by a substantial toxic effect of the vector [241]. 
Subsequent studies therefore utilised an adenoviral vector for E2F2 delivery to human tissue 
ex vivo and observed a significant increase in cell density without any apparent toxicity [151].  
An alternative approach to E2F2 overexpression is the RNAi mediated knockdown of p21 
and p16, negative regulators G1 progression. When tested in vitro upon primary endothelial 
cultures with small interfering RNAs delivered by electroporation cells showed signs of cell 
cycle progression such as Ki67 expression but as in the case of previous non-viral methods 
no increase in cell density could be noted due to a very high level of transfection induced cell 
death [242]. 
Gene therapy to promote endothelial cell survival or induce their replication clearly holds 
promise for the improvement of corneal graft quality however all such gene delivery by its 
very nature carries with it a substantial risk of oncogenic transformation, especially if 
delivered with an integrating viral vector such as lentivirus. Therefore before such an 
approach can see clinical application, mechanisms must be developed to substantially 
reduce the inherent risk. 
 
1.7.3 Stroma directed gene transfer 
Effective gene delivery to the cells of the corneal stroma has been demonstrated with a wide 
range of gene therapy vectors both non-viral and viral. Non-viral techniques such as 
electroporation [243,244], ultrasonication [245], direct injection of plasmid DNA [245,246] or 
nanoparticles [247] have all been shown to mediate transgene expression within the stroma, 
although as is often the case for such methods, transgene expression is relatively short lived 
in all cases. Non-viral transduction of the stroma might therefore be of useful application to 
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very acute conditions but is likely to be less effective in treatment of any more chronic 
pathology. 
Adenovirus has been shown to mediate a very substantial transduction of the stroma in the 
mouse when delivered by intrastromal injection [248], however transgene expression was 
relatively short lived. Loss of expression is probably due to the immune-meditated clearance 
that is commonly seen with transgene delivery via adenovirus and this is likely the reason 
this vector has seen limited further application to the stroma. 
There is only one example to be found within the literature of lentivirus mediated 
transduction of the stroma, Bemelmans et al. [249] compared two modes of delivery, 
intrastromal injection and injection into a corneal pocket created by a femtosecond laser. 
They showed that whilst both methods resulted in transgene expression sustained up to 
three weeks post injection, the corneal pocket method appeared more effective. Lentiviruses 
are therefore a potentially effective vector for stromal gene delivery and may merit further 
investigation. 
Transduction of the stroma by AAV appears to be heavily serotype and context dependent. 
Sharma et al. examined the transduction efficacy of AAV 2/6, 2/8 and 2/9 on corneal 
keratocytes both in vitro [250] and in vivo [251]. The in vitro study on human cells found that 
AAV2/6 was by far the most effective mediating up to 50-fold greater transgene expression 
than either 2/8 or 2/9. However this finding was not translated to their in vivo study in which 
the same serotypes were applied topically to the murine stroma after epithelial debridement. 
In this context the order of transfection efficacy appeared to be 2/9 >2/8 > 2/6 with all 
serotypes exhibiting an increase in expression over time up to 30 days post injection. 
Sharma et al. explained this difference largely in terms of the in vitro vs in vivo although it is 
worth noting that a species difference was also present between the two studies. 
The same group also examined the effect of stromal drying on AAV vector solution uptake 
and transgene expression in murine and rabbit corneas in vivo and human corneas ex vivo 
[252]. The technique applied was as follows: The epithelium was surgically removed and the 
underlying stroma was then subjected to increasingly long periods of hot air mediated drying 
before topical application of AAV2/8 to the stroma. It was shown that vector solution 
absorption and subsequent expression of transgene (14 days post vector delivery) were both 
increased in proportion to the period of drying; however the technique also increased the 
amount of inflammatory cells present in the cornea. Mohan et al. logically attributed the 
increase in expression to the increased absorption; however, work by Hippert et al. [253] has 
also shown that inflammation within the stroma can act to transiently hyper-activate AAV2/8 
expression, indicating this too may have played a role. This work by Hippert et al. also 
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represents the longest follow-up of an AAV mediated transduction of the stroma to be found 
in the literature showing some level of transgene expression to be sustained for up to 17 
months in vivo in mice. 
Gene therapy of the stroma has been applied most widely to modulation of corneal 
keratocytes to reduce corneal scarring and opacification / haze during the process of corneal 
wound healing, and McDonnell et al. appear to have progressed the furthest with such an 
approach. Following work in which they demonstrated that herpes simplex virus (HSV) was 
able to transduce corneal keratocytes both in vitro and in vivo at an efficiency of around 
20%-40% [254], they developed a strategy utilising a gammaretrovirus, murine leukaemia 
virus (MLV), to inhibit keratocyte proliferation in response to phototherapeutic keratectomy 
(PTK)-associated injury. The MLV vector was applied topically to the stroma after the PTK 
procedure had ablated the overlying epithelium. The transgene delivered was a mutant 
cyclin G1 designed to act in a dominant negative fashion on the endogenous protein and 
thus inhibit cell cycle progression. Pre-clinical work in a rabbit model showed this approach 
to be effective in reducing the development of corneal haze, preventing keratocyte 
proliferation / subepithelial fibrosis and reducing extracellular matrix protein deposition [255]. 
This technique subsequently progressed to a phase I/II clinical trial [256] the results of which 
have not yet been published. 
Other gene therapies directed at the stroma (and elsewhere [257]) to ameliorate corneal 
scarring / fibrosis have targeted the TGF-β pathway due to the well characterised role of 
TGF-β1 in the differentiation of corneal keratocytes into myofibroblasts in the stromal wound 
healing response [42]. Mohan et al. [258] achieved a significant reduction in corneal haze 
and stromal structural improvement via topical stromal application of AAV2/5 delivering 
decorin, a small, leucine-rich proteoglycan endogenous to the stroma that has been shown 
to inhibit TGF-β. The same group has more recently demonstrated similar results targeting 
the TGF- β pathway via a different route: the delivery to the stroma of a BMP7 transgene, a 
factor thought to act antagonistically to TGF- β, using a non-viral nanoparticle based vector 
system [259]. 
 
Corneal neovascularisation is a pathology that has more commonly been targeted by gene 
transfer to other tissues such as the conjunctiva [260–263]. Several studies however have 
targeted gene transfer to the stroma to ameliorate this condition including Mohan et al. [264] 
who utilised exactly the same decorin based approach they previously applied to reduction 
of corneal fibrosis. This study demonstrated some significant inhibition of corneal 
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angiogenesis although the effect appeared highly localised, likely due to the means of 
corneal neovascular induction via a VEGF secreting implant also being highly localised. 
Two studies have directly targeted the stroma for gene delivery via intrastromal injection of 
either naked plasmid DNA or nanoparticles. Stechschulte et al. [265] showed that the 
injection of plasmid DNA alone was able to rapidly lead to transgene expression across up to 
50% of the stroma (as assessed by area) although this transduction was short lived having 
dropped to half this level by 48 hours post injection and being almost undetectable by 10 
days. This gene delivery was shown to significantly inhibit angiogenesis induced by VEGF 
pellet implantation; however given that the therapeutic transgene’s (sFlt1) mechanism of 
action is VEGF sequestration this result is perhaps to be expected and its relevance to more 
physiological neovascularisation is somewhat questionable. 
Qazi et al. [266] delivered a shRNA construct targeting VEGF via intrastromal injection in the 
form of both naked RNA and incorporated into a poly(lactic co-glycolic acid) based 
nanoparticles. Angiogenesis was induced via an alkali burn and vector delivered 4 weeks 
later. Both methods of transgene delivery were shown to significantly reduce neovascular 
area although as might be expected the nanoparticle appeared the more effective. The 
regression of vascularisation was relative mild although critically substantial improvement 
was noted in the central area of the cornea most vital for vision. 
Finally Yu et al. [267] did not appear to target the stroma directly in their study in which they 
injected adenovirus encoding the anti-angiogenic factor sFlk1 into the anterior chamber; the 
target tissue for gene delivery via this combination of vector / delivery route was likely the 
corneal endothelium. Transduction of the stroma was however claimed on the basis of 
immunohistological staining showing transgene product to be present within the stroma. As 
the transgene in question encodes a soluble factor, transduction of the stroma in this case is 
questionable. 
 
1.7.4 Epithelium directed gene transfer 
Gene therapy approaches directed towards the corneal epithelium to date have thus far 
been extremely limited with almost all such studies having limited themselves to 
demonstrating the transduction efficacy achievable with various vectors when delivering a 
marker gene, while only a very few have attempted any kind of functional gene delivery 
[268]. This relative lack of application in epithelial gene therapy is possibly due to the rarity of 
genetic diseases of the epithelium and the difficulties involved in mediating a stable gene 
delivery to such a highly dynamic tissue.  
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dIn order to effect any long term or permanent transduction of the corneal epithelium it will 
clearly be necessary to target limbal epithelial stem cells (LESC) for gene delivery as it is 
from these cells that all other epithelial cells are derived. Gene transfer to any other epithelial 
cell type would eventually be lost as a result of normal cell turnover. Despite its accessibility 
the epithelium has proven difficult to transduce due to its natural function as a barrier 
designed to prevent the infiltration of material such as gene therapy vectors. Many attempts 
to transduce the corneal epithelium have utilised non-viral vectors (reviewed in [269,270]) 
and very few have demonstrated any in vivo transduction. Most studies that have shown 
some level of gene delivery in vivo have utilised ballistic delivery via a “gene gun” [268,271] 
perhaps indicating the efficacy of the epithelial barrier function against less traumatic means 
of gene delivery. Other non-viral methods utilising a carrier peptide [272] or engineered 
nano-polymeric micelles [273] have also demonstrated gene delivery to the epithelium in 
vivo; in all cases however the degree of gene transfer could be characterised as relatively 
low. 
The ability of many different viral gene therapy vectors to transduce the epithelium has also 
been assessed and many have demonstrated some transduction efficacy. However almost 
all such approaches have either been conducted ex vivo or utilised some means of 
disrupting epithelial barrier function prior to vector delivery in vivo. Most of the in vivo data 
shows only very limited transduction: Herpes simplex virus has been shown to mediate a 
very isolated transduction around areas of epithelial scarification made to facilitate vector 
access [274]. Adenovirus when applied topically to an unwounded cornea only transduced 
the occasional epithelial cell although gene delivery to the conjunctiva was more substantial 
[275]. Both adenovirus and AAV have also been applied topically to the epithelium in the 
context of epithelial wounding and have been found to either only infect the edges of the 
wound [276], or mediate a more widespread transduction [224] although in the latter case 
the GFP transgene was only visible upon signal amplification. The transduction of the 
epithelium shown ex vivo with both adenovirus and AAV is far more convincing with 
extensive epithelial transduction visible in this context without the need for any signal 
amplification [224]. This difference is likely due to both the increased exposure of the tissue 
to the vector present in the culture medium and impairment of the epithelial barrier function 
under organ culture conditions due to tissue oedema and the absence of the tear film. 
Probably the best results to date regarding viral vector transduction of the epithelium have 
been achieved using lentiviral vectors. Wang et al. showed efficient gene transfer to all 
layers of human cornea in the context of an isolated fragment of the corneal rim ex vivo 
[277]. The duration of expression achieved is a little unclear; however, the following 
statement implies 60 day duration of epithelial transduction:  
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“Fluorescent microscopy reveals eGFP expression in endothelial and epithelial cells by 3 
post- transduction days in situ. This pattern of expression was undiminished for the duration 
of organ culture (60 days).”  
Whilst the figures included do show endothelial transduction at the 60 day time point the 
figures shown for the epithelium state they were taken at 3 days in the legend (7 days in the 
text). The claim of lasting transduction of the epithelium is therefore somewhat dubious. 
More convincing data was presented by Igarashi et al. who after inflicting an epithelial wound 
at the limbus applied topically adenoviral, AAV or lentiviral vectors encoding eGFP. Whilst 
transgene expression from adenovirus and AAV was lost within 2 weeks, lentiviral 
transduction was shown to be sustained for up to 6 weeks. 
Igarashi et al. claim that a 6 week duration of expression is sufficient to indicate LESC 
transduction although we feel this is an insufficient period of follow-up to rule out the 
possibility of transduction being limited to transient amplifying cells (TACs) as it has been 
shown to take up to 10 weeks for labelled cells to migrate from the limbal to central cornea 
[90]. Igarashi et al. also did not show any evidence of such centripetal migration of labelled 
cells that would be expected to result from either LESC or TAC transduction over a 6 week 
period. Irrespective of the interpretation of their results though Igarashi et al’s study does 
represent the sole example of any form of sustained epithelial gene delivery via any method 
shown to last beyond the very short term. 
 
1.8 Overall aims 
This thesis will describe a program of work aiming to further develop viral gene therapy 
approaches to the three cellular layers of the cornea, with particular emphasis upon the 
application of novel vector technologies. 
 In regard to the endothelium work will be directed toward improving the safety profile 
of gene transfer with potential application to increase endothelial cell density via cell 
cycle manipulation. 
 In the stroma work will be undertaken to develop and characterise an AAV based 
gene augmentation approach to prevent corneal neovascularisation. 
 To date no effective method exists by which to mediate a long lasting gene transfer 
to the epithelium, work here will aim to develop such a method based upon 
transduction of LESCs with an integrating lentiviral vector. 
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2. Materials and Methods 
 
2.1 Molecular biology 
 
2.1.1 General cloning strategy 
Wherever possible cloning was achieved by excising the insert fragment and opening the 
backbone vector with restriction enzymes that created mutually compatible “sticky ends” to 
facilitate easy ligation in the correct orientation. If this was not possible one following 
alternative approaches was taken: 
 More suitable sites introduced using site directed mutagenesis.  
 Blunting of digestion products using Klenow DNA polymerase to fill in 5’ overhangs. 
All cloning products were validated by both diagnostic restriction enzyme digests and 
sequencing. Concentration of all DNA was measured by photospectroscopy at 260 nm using 
a NanoDrop ND1000 Spectrophotometer (LabTech Int.) 
 
2.1.2 Restriction digests 
To characterize DNA plasmids or fragments, or to isolate fragments of interest, DNA was 
selectively cut using restriction enzymes (Promega, or New England Biolabs,). The following 
digestion mix formulation was typical: 
0.5 – 1 μg of DNA 
0.5 μL of each restriction enzyme (10 U/μL) 
1.6 μL of appropriate 10x Buffer 
1.6 μL of 10x BSA 
Sterile, deionized water added to a total volume of 16 μL 
The mix was incubated for 2-4 hours at the recommended temperature. 
In the case of double digests using enzymes requiring different buffer conditions a sequential 
digest was performed. The first digest was performed as above and following digestion 
ethanol precipitation was performed by addition of 3.2 µL of 3M sodium acetate (in dH2O) 
and 40 µL of 100% Ethanol. This was thoroughly mixed before being spun in a 
microcentrifuge at 20,000g for 30 minutes. Supernatant was discarded and pellet washed 
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with 50 µL of 70% ethanol before being respun at 20,000g for 10 minutes. Supernatant was 
discarded and pellet resuspended in 10 µL of dH2O. This was used as the DNA for digestion 
by the next restriction enzyme. 
 
2.1.3 DNA electrophoresis and gel extraction of DNA 
DNA fragments resulting from restriction enzyme digests were separated by size as follows: 
Samples of 16 μL had 4 μL of loading dye (Blue/Orange Loading Dye, 6x: Promega) added 
to them before being loaded on to a 1-2 % (w/v) agarose gel prepared in 1 x TBE buffer 
containing ethidium bromide (1 μL of 10 mg/mL EtBr per 50 mL of gel).  A 1 kb or 100 bp 
DNA ladder (Promega) was run alongside to evaluate the size of the fragments.  
For a 200-250 mL gel volume, a voltage of 180 V was applied across the gel for 30 to 120 
min, according to the expected size of the DNA bands. Gels were photographed digitally on 
an ultraviolet transilluminator (BioRad).  
When required for cloning DNA fragments were excised from the gel and extracted using a 
using silica gel based purification kit (QIAquick Gel Extraction Kit: Qiagen) according to the 
manufacturer’s instructions.  
 
2.1.4 DNA ligation  
Ligation of the gel purified DNA fragments into the appropriate vector backbone was 
performed using 1:5 – 1:20 molar ratio of backbone to insert. DNA was first heated to 45 °C 
for 5 minutes to melt any annealed cohesive ends, and then rapidly cooled on ice.  
Ligations were performed in a mix formulated as follows: 
4 μL of DNA (insert and backbone in appropriate ratio) 
5 μL of 2x Ligation Buffer (LigaFast: Promega) 
1 μL of T4 DNA Ligase (3U/mL, LigaFast: Promega) 
Ligations were then incubated overnight at 4 °C after which the ligase was heat inactivated 
for 10 minutes at 65 °C. The entire ligation mixture was then used to transform competent 
bacterial cells. 
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2.1.5 Transformation of bacteria with DNA  
All plasmids used contained one or more antibiotic resistance genes as a selection marker 
for successfully transformed bacteria.  
For transformation, chemically competent DH5α cells (α-Select, Bioline) from -80 °C were 
thawed on wet ice. 50 μL of cells were incubated with 5 -10 μL DNA to be transformed for 30 
min. on ice. Cells were heated shock for 60 seconds at 42 °C in a heat block then returned 
to ice for 5 min. 1 mL SOC medium (Invitrogen) was added and cells were incubated for 1 
hour at 37 °C to allow sufficient expression of the resistance gene. Bacteria were then plated 
on lysogeny broth (LB) 10 cm agar plates containing the appropriate antibiotic(s) and 
incubated at 37 °C overnight.  
Bacterial colonies were then picked using a sterile pipette tip and DNA was amplified and 
extracted at the mini-prep scale for analysis by diagnostic restriction enzyme digests and 
sequencing. Clones containing the desired plasmid products were prepared as Glycerol 
stocks for long term storage at -80 °C 
 
2.1.6 Amplification of plasmid DNA in bacteria 
When required, all plasmids were amplified from frozen transformed bacterial stock in LB 
medium (supplemented with appropriate antibiotic(s)) at a variety of scales depending on 
application. Scales and kits used are listed below; all kits used according to manufactures 
instructions. 
5-10 mL of bacterial culture   - GenElute Plasmid Miniprep Kit, Sigma-Aldrich 
50-200 mL of bacterial culture  - GenElute Plasmid Maxiprep Kit, Sigma-
Aldrich 
500-1000mL of bacterial culture - EndoFree Plasmid Megaprep Kit, Qiagen  
 
2.1.7 Sequencing of plasmid DNA  
Plasmid DNA prepared at the mini scale was used for sequencing. 
All primers were designed by hand and synthesized by Sigma‐Aldrich. Enough primers were 
designed/used so as to give a complete sequencing read (with sizable overlaps) through the 
entire region of interest within the plasmid. Regions of interest ranged in size from an entire 
viral genome to a single ligation site. Sequencing reactions were formulated as below: 
1µL of Primer (3 µM)   
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1µL of Big Dye3.1 dNTP mixture (Applied Biosystems) 
3.5 µL of Sequencing Buffer (Applied Biosystems) 
6 µL of DNA (10-300ng / µL) 
8.5 µL of dH2O  
Sequencing reaction was performed in a PCR machine on the following cycle: 
96C 1 min. 
96C 10 sec. 
50C 10 sec.    x35 cycles 
60C 4 min. 
4C  Hold until clean up. 
After this reaction the labelled DNA was cleaned up as follows: 
To each sample was added: 
0.5 µL of 0.5mM EDTA pH8 
2 µL of 3M CH3COONa pH5.2 
50 µL of 100% Ethanol  
This was incubated at room temperature, covered with foil for 15 min. before spinning down 
the DNA in a microcentrifuge at 20,000g for 30 min. Supernatant was discarded and 70 µL 
of 70% EtOH added. This was then spun down again at 20,000g for 15 min. Supernatant 
was discarded as before and the pellet dried at 65C for 30 minutes covered with foil before 
resuspension in 13 µL of deionised formamide and loading onto a sequencing plate. 
Sequencing was then run on a 3730 DNA Analyser (Applied Biosystems), traces analysed 
and contigs constructed using CodonCode Aligner. 
 
2.1.8 Site directed mutagenesis 
All site directed mutagenesis of plasmid DNA was performed using the Quikchange 
Lightening Kit (Agilent Technologies) according to the manufacturer’s instructions. Primers 
used with this kit were designed by hand and synthesized by Sigma‐Aldrich.   
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2.1.9 Polymerase chain reaction (PCR) 
Primers for PCR reactions were designed either by using by PrimerSelect software, version 
7.0.1 (DNAStar) or by hand. All primers used shown in (2.1.10). A standard PCR reaction 
mix (25 μL total volume) consisted of the following components:  
2.5 μL 10x buffer 
2.5 μL MgCl2 (25 mM) 
1 μL dNTP mix (10 mM) 
1 μL of each forward and reverse primer (10 μM) 
0.5 – 1 μL polymerase enzyme (GoTaq DNA polymerase, 5 U/μL, Promega),  
10 – 20ng template DNA from plasmid (50 – 100ng for genomic DNA) 
dH2O to make up 25 μL.  
For all reactions a negative control with dH2O instead of the template was run alongside. 
Typical PCR cycling conditions were:  
95C  1 min.  -  Initial Denaturation 
95C  30 sec. 
50-60C 30 sec.     x35 Cycles 
72C  1 min. 
4C     - Hold until analysis 
For use in cloning products of PCR were split, with a sample being analysed and validated 
by electrophoresis (2.1.3) and the remainder being purified by ethanol precipitation before 
use in cloning steps. 
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2.1.10 Primers used in PCR, sequencing and site directed mutagenesis 
Name  Sequence 5’ to 3’ Intended use 
MB-MidLUC2-F GCATGTACACCTTCGTGAC Sequencing Primer binding to LUC2 
MB-MidLUC2-R GTCACGAAGGTGTACATGC Sequencing Primer binding to LUC2 
MB-StaLUC2-R CTTCATGGCTTTGTGCAGCTGC Sequencing Primer binding to LUC2 
MB-SFFV-R GTCATTTCAGGTCCTTGG Sequencing Primer binding to SFFV 
MB-SFFV-F CCAAGGACCTGAAATGAC Sequencing Primer binding to SFFV 
MB-SFFV2-F CTTCCCGAGCTCTATAAAAG Sequencing Primer binding to SFFV 
MB-WPRE-1F GACAATTCCGTGGTGTTG Sequencing Primer binding to WPRE 
MB-WPRE-1R CAACACCACGGAATTGTC Sequencing Primer binding to WPRE 
PBKOMUTGEN01 
GACCCTTTTAGTCAGTGTGGAAAATCTCTAGCTT
GAAAGCGAAAGGGAAACAAGAGGAG 
Mutagenesis Primer to remove lenti 
Primer binding site. 
PBKOMUTGEN01-RC 
CTCCTCTTGTTTCCCTTTCGCTTTCAAGCTAGAGA
TTTTCCACACTGACTAAAAGGGTC 
Mutagenesis Primer to remove lenti 
Primer binding site. 
SALIKOMUTGEN GCGACTCTAGAGTCAACCTGCAGGCATGCAAG Mutagenesis Primer to remove SalI site. 
SALIKOMUTGEN-RC CTTGCATGCCTGCAGGTTGACTCTAGAGTCGC Mutagenesis Primer to remove SalI site. 
PCRRRE-F1 
CAGTCGACGATAGAGGAAGAGCAAAACAAAAGT
AAG 
PCR Primer to amplify  lenti RRE 
PCRRRE-F2 CAGTCGACCAAGCGGCCGCTGATCTTC PCR Primer to amplify  lenti RRE 
PCRRRE-R CAGTCGACGTCCCACTCCATCCAGGTCG PCR Primer to amplify  lenti RRE 
END-R2 CACATACGATTTAGGTGAC 
Sequencing Primer binding to  lenti 
backbone 
 
2.2 Cell culture and virus production, purification and validation 
 
2.2.1 Cell culture 
All cells used in vitro were either HEK-293T (293T) or HeLa cells both of which were grown 
and maintained as follows. Cells were maintained in DMEM supplemented with 10 % FCS, 
100 U/mL penicillin G, 100μg/mL streptomycin, and 0.25μg/mL amphotericin B (all 
Invitrogen). This medium will be referred to henceforth as “D10”. To keep cells healthy and 
their transfection efficacy high cells were split frequently three times a week at a ratio of 1:3 
to 1:5, and were not grown above 90% confluency.  
All viruses were produced by transient transfection of 293T cells and for virus production 
purposes cells were only used between passages 10 and 24 and grown on 150cm2 plates 
(Nunclon Surface, Nunc), for other purposes growth format varied. 
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2.2.2 Adeno-associated virus production (all serotypes) 
All serotypes of adeno-associated virus (AAV) were produced by transient transfection of 
293T cells using a three plasmid system and then purified by FPLC. Plasmids where as 
follows: 
Viral Genomic plasmid based upon pd10 backbone. This plasmid contains the viral genome 
to be packaged sandwiched between AAV2 based inverted terminal repeat sequences. 
Providing this plasmid in trans to the replication and packaging genes minimizes the risk of 
generating replication competent viral particles. 
Packaging Plasmid. This plasmid contains the AAV2 Rep78 gene and Viral Capsid gene. 
The viral capsid gene will depend upon the serotype of AAV being produced. Different 
packaging plasmids are used to produce different AAV serotypes. 
Helper Plasmid (pHGTI-Adeno1). This plasmid contains 3 large chunks of the Adenovirus 4 
genome ligated together. This plasmid provides all the adenovirus genes that AAV requires 
to package and assemble. 
The day before transfection, cells in 150cm2 plates at 80-90% confluency were split 1:2 in 20 
mL of D10. A typical AAV production batch consisted of 10-20 x 150cm2 plates. 
Cells were transfected using polyethylenimine (PEI) at a PEI to DNA ratio of 2.25 : 1 (w/w). 
Linear PEI (MW 40,000, Polysciences) was prepared at 2 mg/mL in H2O, adjusted to pH 7.4 
with HCl, and stored at -80 °C.  
Per 150 cm2 plate the following transfection mix was made: 
A total of 50 μg of total plasmid DNA with the 3 plasmids in the ratio 1:1:3, Genome : 
Packaging : Helper. 
PEI in the ratio of 2.25:1, PEI : DNA by μg 
2.5 mL of DMEM (no supplements)  
Transfection mix was mixed and incubated at room temperature for 15 min to allow DNA/PEI 
complex formation. This mix was then added to the plates drop-wise.  
Transfections were left for a minimum of 4hrs to a maximum of overnight, medium was then 
replaced with 15 mL of fresh D10.  
Cells were physically detached from the plates 72hrs after transfection by scraping and 
collected suspended in their growth medium. Cells were then pelleted at ~1000g for 10 
minutes in a centrifuge. Supernatant medium was then discarded and the cell pellet 
resuspended in Tris density buffer at a concentration of 0.5-1 plates of cells / mL. 
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Cells were then lysed to release the AAV virions, by 4 cycles of Freeze / Thaw / Vortex as 
follows: 
Freeze – 20 min. in Dry Ice / Isopropanol Bath at -77°C 
Thaw – 20 min. in Water Bath at 37°C 
Vortex – 10 min. at full speed 
Any non-packaged DNA remaining in the cell lysate was destroyed by digestion with 
Benzonase (Sigma-Aldrich) which was added to the lysate to a working concentration of 
50U/mL and incubated at 37°C for 30 minutes. 
Before purification by FPLC cell lysate was clarified by centrifugation and filtration as follows: 
Spun at 3220g for 10 minutes, pellet discarded. 
Spun at 7500g for 15 minutes, pellet discarded. 
Syringe filter 5µM dead-end. 
Spun at 7500g for 15 minutes, pellet discarded. 
Syringe filter 0.45µM dead-end. 
Syringe filter 0.22µM dead-end. 
Spun at 20,000g for 30 minutes, pellet discarded. 
Clarified Lysate was then purified by a 2 step FPLC procedure performed on an AKTA Pure 
(GE Healthcare) FPLC machine using pre-programmed protocols. 
The lysate was first run upon a large (~400 mL column volume) size exclusion column 
(Sephacryl S300HR, GE Life Sciences) and the first peak collected, this contains all material 
larger than 1.5x106 Da including the AAV virions. 
This peak was them loaded upon a (10 mL column volume) strong anion exchange column 
(Poros HQ50, Invitrogen) and the material that eluted from this column at a NaCl 
concentration between 0.045M and 0.18M was collected. 
This eluate was them concentrated down to a volume of 200 µL by centrifugation at 5000g in 
a 10,000 MW cut off Vivaspin 4 centrifugal concentrator (GE Healthcare), 2 mL of PBS-MK 
was then added (to dilute out high salt elution buffer) and the eluate re-concentrated back to 
~200µL using the same concentrator. 
This material constituted the purified AAV virus and was aliquoted as appropriate and stored 
at -80°C 
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2.2.3 Titering of AAV 
Purified AAV was titered using a genomic dot blot. Different amounts of purified virus (1 µL 
and 3 µL were typical) were first digested with Proteinase K to release the viral genomes 
from the capsid. Digests formulated as follows and incubated at 56°C for ~2 hours 
100 µL – 2x Proteinase K Buffer 
1 or 3 µL – Virus 
98 or 96 µL – dH2O 
1 µL – Proteinase K (10mg/mL) 
The released genomes were then precipitated by addition of 0.1 volume 3M NaOAc and 2.5 
volumes of ethanol and pelleted by centrifugation at 20,000g for 30 minutes. DNA pellet was 
then resuspended in 200 µL of 0.4M NaOH + 10mM EDTA. 
A 10-fold standard series was also prepared from the genomic plasmid used to produce the 
virus. The highest standard was calculated to contain 1012 copies of the plasmid; each 
standard was also prepared in 200 µL of 0.4M NaOH + 10mM EDTA. 
Both samples and standards were then denatured at 95°C in a heat block for 10 minutes 
and then stored on ice before being blotted onto a Hybond N+ membrane (Amersham) using 
the dotblot apparatus (Bio-Rad). The membrane was then dried, before being wetted with 
Hybridisation Buffer (Church mix) and incubated in a hybridisation oven at 65°C with a 
biotinylated DNA probe specific for a sequence contained within the genome for at least 
16hrs. Probe was made using NEBlot Phototope labelling kit, used according to 
manufacturer’s instructions.  
 
Probe binding was then visualised by chemiluminescence using a NEBlot Phototope 
detection kit according to manufacturer’s instructions and quantified using densometery 
(using Image-J, NIH) of images taken using a FujiFilm Intelligent Dark Box 2. Virus titre was 
then calculated by comparing integrated density of samples against standards.  
 
2.2.4 Lentivirus (VSV-G envelope) production 
HIV1 based lentiviral vectors were produced using a second generation system, to minimize 
the risk of generating replication competent viral particles. Plasmids where as follows: 
1) As packaging (helper) plasmid, pCMVR8.74 (11.921 bp) was used delivering gag, 
pol, tat, and rev (HIV accessory genes having been deleted or inactivated). 
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pCMVR8.74 is a derivative of pCMVR8.91, in which a splice donor site has been 
deleted from the CMV derived region upstream of the HIV sequences to optimize 
expression. 
2) The envelope plasmid pMD2.G (5824 bp) was used to pseudotype the virus with the 
vesicular stomatitis virus G envelope (VSV‐G). 
3) The standard genome vector was based on the self-inactivating lentiviral vector, 
pHR’SIN-cPPT. It contains the 5’ and 3’ LTR sequences and central polypurine tract 
(cPPT) fragment from wild type HIV1 virus. To mediate self-inactivation (SIN), the U3 
region of the 3’ LTR is deleted. The transgene delivered by the vector was under the 
control of a promoter based upon the U3 region of the spleen focus forming virus 
(SFFV) long terminal repeat sequence. The transgene was flanked downstream by 
the enhancer, woodchuck hepatitis virus posttranscriptional regulatory element 
(WPRE). 
Three days before transfection, cells were seeded at a density of 2.5 × 106 cells per 150 cm2 
plate in 25 mL of D10 medium. This is roughly equivalent to a 1:7 split of a near confluent 
150 cm2 plate. A typical production consisted of 16 x 150cm2 plates. 
Medium was changed one hour before transfection. Cells were transfected using 
polyethylenimine (PEI) at a PEI to DNA ratio of 2.25 : 1 (w/w). Linear PEI (MW 40,000, 
Polysciences) was prepared at 2 mg/mL in H2O, adjusted to pH 7.4 with HCl, and stored at -
80 °C 
Per 150 cm2 plate the following transfection mix was made: 
A total of 80μg of plasmid DNA with the 3 plasmids in the ratio 50 : 17.5 : 32.5, 
Genome : Envelope : Helper. 
PEI in the ratio of 2.25:1, PEI : DNA by μg 
1.3 mLs of OPTIMEM (no supplements)  
Transfection mix was mixed and incubated at room temperature for 15 min. to allow 
DNA/PEI complex formation and was added drop wise to the 150cm2 plates containing the 
cells in 20 mLs of D10.  
After 4‐6 hours of transfection, medium was replaced with 22 mL of fresh D10. Culture 
medium was harvested 48 hours post transfection and immediately replaced with fresh 
medium for a second harvest at 72 hours. 
Virus was purified and concentrated from supernatant medium by centrifugation and filtering. 
First the medium was spun 3500g for 10 min. to pellet larger cell debris before supernatant 
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was passed through a vacuum driven 0.45μm filter (Stericup-HV PVSF 500mL, Millipore) to 
remove finer contaminants.  
Filtrate was then transferred into polyallomer ultra‐centrifuge tubes (UltraClear, 38.5 mL, 
Beckman Coulter) and ultra‐centrifuged at 23,000 rpm for 1 hour 45 min. (rotor SW 32 Ti, 
Beckman Coulter), corresponding to an average relative centrifugation force of ~90,000 g. In 
the safety cabinet the supernatant was decanted off and the tubes maintained upside down 
on tissue paper to drain the remaining supernatant. The last drops around the rim were dried 
with tissue paper. 100 μL of OptiMEM were added to each tube (6 tubes was usual for a 16 
plate prep), pipetted up and down carefully ten times to dislodge the pellet. Tubes were 
sealed with parafilm and left on ice for 45 min. to allow virus resuspension. After pipetting 
another ten times, all tubes were pooled and mixed. A final clarifying centrifugation step (10 
min at 3220g) was only done when a higher purity of virus was required, as this resulted in a 
lower yield.  
Aliquots of concentrated virus were stored at –80 °C. The average yield of a 16 plate virus 
preparation was approximately 600 μL of concentrated virus of 107 to 108 infectious particles 
per mL.  
For production of LeGO lentiviruses this procedure was identical but transformed bacterial 
stocks of the three LeGO genomic plasmids was purchased from Addgene. 
 
2.2.5 Titering and validation of lentivirus 
All lentiviral vectors produced contained a reporter gene by which the virus’ infectivity could 
be assessed. 
For vectors containing fluorescent proteins, the infectious titre (infectious viral particles per 
mL of virus preparation) was determined by counting fluorescent protein positive cells post 
infection. 293T cells were seeded at 50,000 cells per well in a 24 well plate one day before 
infection. In duplicate, a 10 fold dilution series of concentrated virus was prepared in D10 
and added to the cells in such a way that the highest dilution was equivalent to 1 uL Virus / 
well (containing cells and 1 mL of D10). 
Virus dilutions were incubated with the cells for 3 days. Medium was then replaced with 2% 
PFA and the number of fluorescent protein positive cells per well counted under an inverted 
microscope (Axio Observer.Z1, Zeiss, 10x objective). As lentivirus is integrating multiple 
cells in contact with each other were counted as a single infection event. Counts for 
duplicate dilutions were averaged and the infectious titre was calculated. 
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For vectors containing Luciferase a similar methodology was used. Instead of counting 
fluorescent protein positivity, cells in each well were instead lysed with 150 uL of GloLysis 
Buffer (Promega). This lysate was then assessed for presence of Luciferase using BrightGlo 
(Promega) substrate mixed 1:1 with the lysate. Emission of Light was quantified 6 minutes 
after addition of the substrate using a TD20/20 Luminometer (Promega). 
The last dilution at which the Luciferase was detectable above background was used to 
calculate infectious titre. 
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2.3 Animal experiments and surgery 
 
2.3.1 Animals (mice)  
All mice used were of the strain C57Bl/6J and were housed in University College London 
facilities. All animal experiments were conducted according to the ARVO Statement for the 
Use of Animals for Vision and Ophthalmic Research. 
 
2.3.2 Anaesthesia 
Animals were anaesthetised using a mixture of medetomidine hydrochloride (1 mg/mL, 
Domitor, Pfizer Pharmaceuticals) and ketamine (100 mg/mL, Fort Dodge Animal Health) and 
sterile water in the ratio 5:3:42. Adult mice weighing 20g received an intraperitoneal injection 
of 0.2 mL. After the surgical procedure, anaesthesia was reversed with 0.2 mL of 
intraperitoneal atipamezole hydrochloride (0.10 mg/mL, Antisedan, Pfizer Pharmaceuticals).    
 
2.3.3 Intrastromal injection of vectors (mouse, in vivo) 
Intrastromal injections were performed under general anaesthesia under an operating 
microscope. The eye was held in place by holding extraocular muscle or conjunctiva with 
corneal notched forceps (Acrofine). Vector or control solution was injected with a 34 gauge 
hypodermic needle mounted on a 5 μL Hamilton syringe (Hamilton).  
The tip of the needle (bevel up) was positioned about a half, to quarter of the corneal radius 
in from limbus and penetrated the cornea in this position. The needle was then carefully 
pushed into the cornea (taking care not to penetrate through the cornea into the anterior 
chamber) towards the centre of the cornea (Schematic of injection route shown in Figure 
3B). Once the needle tip was positioned centrally within the stroma 2μL of purified virus or 
control solution was injected. Upon injection the cornea became opaque in the area of the 
injected bleb (usually extending over the whole cornea), this was completely resolved 48hrs 
post injection. After treatment, 1 % chloramphenicol ointment (FDC International) was 
carefully applied topically to the cornea and anaesthesia reversed. 
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Figure 3. Schematic representation of different routes of injection 
used in vivo upon the murine eye 
 
2.3.4 Intrastromal injection of vectors (human, ex vivo) 
Intrastromal injections were performed upon human corneal tissue obtained from Moorfields 
eye bank, for this procedure only cultured donor corneas (as described in 2.4.2) could be 
used. Corneas were stored in Culture Medium I w/o dextran T500 (BiochromAG) at 37°C 
until use.  
The procedure was undertaken using a plastic artificial anterior chamber (Barron) to secure 
the cornea for injection. These devices are designed as a disposable, sterile medical device 
but for this purpose reuse of the same device was deemed to be acceptable. Between uses 
the device was stored disassembled and submerged in 70% IMS.  
Intravitreal Subretinal
IntrastromalIntracameral
A B
C D
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The device was prepared as follows. It was removed from storage under 70% IMS and 
sterile MilliQ dH2O was used to both rinse it thoroughly and flush out the two injection ports 
in the base. Syringes (2mL) containing sterile dPBS were then attached to the two injection 
ports and both lines were filled with dPBS they formed a continuous circuit via a droplet on 
the top of the base. A small blob of Viscotears (Novartis Pharmaceuticals) was then placed 
on top of the dPBS droplet. The cornea was then placed on top of the device taking care to 
form a connection with the liquid droplets that excluded any air bubbles. The tissue retainer 
was then placed in position and the locking ring attached and secured. 
With both clips in the injection tubes unfastened dPBS was slowly injected through one of 
the ports to check for leaks, if the circuit was sealed then depressing one syringe would 
result in fluid flowing into the other. If the system leaked then cornea’s position was adjusted 
until it did not. Once a sealed circuit was established one of the injection tube clips was 
fastened and the opposing syringe used to carefully inject dPBS into the device increase the 
pressure within and “inflating” the cornea. Pressure was monitored by assessing resistance 
upon gentle depression of the corneal surface. Once an approximately physiological 
pressure was obtained dPBS injection was stopped and the remaining injection tube clip was 
fastened. 
Intra stromal injection of vector or control solution was then performed using a ½ cc 
Tuberculin syringe with permanently attached 27G x ½ in. needle and an operating 
microscope. The tip of the needle (bevel up) was positioned about a half, to quarter of the 
corneal radius in from limbus and penetrated the cornea in this position. The needle was 
then carefully pushed into the cornea (taking care not to penetrate through the cornea into 
the artificial anterior chamber device) towards the centre of the cornea. Once the needle tip 
was positioned centrally within the stroma 50 μL of purified virus or control solution was 
injected. Upon injection the cornea became opaque and in the area of the injected bleb and 
this was completely resolved 48hrs post injection. 
After injection the cornea was returned to Culture Medium I and incubated at 37°C / 5% CO2 
until further use / analysis. The artificial anterior chamber was thoroughly washed and 
flushed out with sterile MilliQ dH2O and then stored under 70% IMS.  
 
2.3.5 Limbal intrastromal and subepithelial injection of vectors (mouse, in vivo) 
Limbal intrastromal and subepithelial injections were performed under general anaesthesia 
using an operating microscope. The eye was mildly prolapsed and secured in position with 
an elasticated Vinyl drape.  
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Virus or control solutions were injected using a glass needle pulled from borosilicate glass 
capillaries (1.0mm O.D. x 0.78mm I.D. – Harvard Apparatus) and an injection holder set (IM-
H1 Narishige). The exact specifications of the needle varied between experiments. Flow of 
solution to be injected was continuous through the needle, driven by air pressure applied 
from a 50 mL Luer Lock Syringe compressed to the 5 mL position. For this reason no exact 
volume per injection could be recorded. Whilst solution was flowing the multiple injections 
were performed (~30-50) around the entire limbal region of the cornea. To achieve this, the 
mouse was rotated whilst the needle remained in essentially the same position. The needle 
tip was placed at different depths within the cornea to vary between limbal intrastromal and 
subepithelial injection, assessment of depth was guided by the feel and resistance of the 
tissue to the needle tip. All injections of this type were performed by Dr Satoshi Kawasaki 
(Kyoto Prefectural University of Medicine). After injections were complete, 1 % 
chloramphenicol ointment (FDC International) was carefully applied topically on the cornea 
and anaesthesia reversed. 
 
2.3.6 Subretinal injection of vectors (mouse, in vivo) 
Subretinal injections were performed under general anaesthesia using an operating 
microscope. The eye to be injected was dilated by topical application of tropicamide 1% 
(Chauvin Pharmaceuticals). Corneal refractive power was neutralized by placing a 5 mm 
coverslip on the cornea covered with a coupling medium solution (Viscotears, Novartis 
Pharmaceuticals) and the fundus brought into focus. The eye was secured in position by 
grasping the conjunctiva using corneal notched forceps (Acrofine). A 10mm, 34 gauge 
needle mounted on a 5 µL Hamilton syringe (Hamilton) was used to inject material 
subretinally. The tip of the needle was placed underneath the cover slip and penetrated the 
eye tangentially through the sclera below the equator of the globe into the subretinal space. 
The needle tip could be observed entering the eye and guided into position in the subretinal 
space using the microscope (Schematic of injection route shown in Figure 3D). Material was 
then injected and a retinal detachment could be observed to develop. The needle was then 
withdrawn and any reflux of material out through the needle tract was noted, although this 
was a rare occurrence. After injection, 1 % chloramphenicol ointment (FDC International) 
was carefully applied topically on the cornea and anaesthesia reversed. 
 
2.3.7 Intravitreal injection of vectors (mouse, in vivo) 
Intravitreal injections were performed under general anaesthesia using an operating 
microscope. The eye to be injected was dilated by topical application of tropicamide 1% 
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(Chauvin Pharmaceuticals). Corneal refractive power was neutralized by placing a 5 mm 
coverslip on the cornea covered with a coupling medium solution (Viscotears, Novartis 
Pharmaceuticals) and the fundus brought into focus. The eye was secured in position by 
grasping the conjunctiva using corneal notched forceps (Acrofine). A 10mm, 34 gauge 
needle mounted on a 5 µL Hamilton syringe (Hamilton) was used to inject material 
intravitreally. The tip of the needle was placed underneath the cover slip and penetrated the 
eye tangentially through the sclera just below the limbus just above the edge of peripheral 
retina. The needle tip could be observed entering the eye and guided into a position as close 
as possible to the optic nerve head within the vitreous, whilst taking care not to touch the 
lens at any point (Schematic of injection route shown in Figure 3C). Material was then 
injected and the needle withdrawn. After injection, 1 % chloramphenicol ointment (FDC 
International, UK) was carefully applied topically on the cornea and anaesthesia reversed. 
 
2.3.8 Intracameral injection of vectors (mouse, in vivo) 
Intracameral injections were performed under general anaesthesia using an operating 
microscope. The eye to be injected was dilated by topical application of tropicamide 1% 
(Chauvin Pharmaceuticals). The eye was secured in position by grasping the conjunctiva 
using corneal notched forceps (Acrofine). A 10mm, 34 gauge needle mounted on a 5 µL 
Hamilton syringe (Hamilton) was used to inject material intracamerally. The tip of the needle 
was positioned on the cornea about a third of the cornea’s radius in from the limbus. The 
needle penetrated the anterior chamber tangentially through the cornea in this position. The 
needle tip could be observed entering the anterior chamber and guided into a central 
position beneath the cornea, taking care not to touch the iris (Schematic of injection route 
shown in Figure 3A). Material was then injected and the needle was then withdrawn. Reflux 
of liquid out of the injection tract was a relatively common occurrence. After injection, 1 % 
chloramphenicol ointment (FDC International, UK) was carefully applied topically on the 
cornea and anaesthesia reversed. 
 
2.3.9 Induction of corneal neovascularisation by placement of corneal sutures 
(mouse, in vivo) 
Corneal sutures were placed under general anaesthesia using an operating microscope. The 
eye to be sutured was dilated by topical application of tropicamide 1% (Chauvin 
Pharmaceuticals) and mildly prolapsed and secured in position with an elasticated Vinyl 
drape. Suturing was performed using a 6.5mm, 3/8 circle, spatula, advanced micro-point 
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double needle with attached 11-0 nylon (non-absorbable) thread (Ethilon), the needle being 
held with a needle holder. Sutures were placed by penetrating the full thickness of the 
cornea as close to the limbus as possible with the needle. The needle tip was then moved 
within the anterior chamber, taking care not to damage the iris, until positioned beneath the 
central cornea. Once in position the needle was pushed back through the cornea and out of 
the eye. Nylon thread was then drawn through the tract created by the needle until only a 
small length (2 – 3 cm) was left protruding from the limbal entrance to the suture tract. 
Suture was then tied and secured with a 2-1-1 knot taking care not to over tighten and 
deform the cornea. Sutures were not buried and a small length (3-5mm) protruding from the 
knot was left to aid with suture removal at a later date if required.  
The following factors were revealed as critical to inducing a high level of neovascularisation. 
 Initial penetration of the cornea as close to the limbus as possible. 
 Full thickness penetration of the cornea. During initial test phase of the procedure the 
needle tract passed within the cornea and not penetrate the anterior chamber. This 
approach did not induce neovascularisation reliably.  
 Sutures should be as long as possible; from limbus to central cornea. Shorter sutures 
did not induce neovascularisation reliably. 
Figure 4 below illustrates how sutures (in red) were placed:  
 
 
 
 
 
Figure 4. Schematic of corneal suture placement 
to induce neovascularisation 
 
 
After suturing, 1 % chloramphenicol ointment (FDC International) was carefully applied 
topically on the cornea and anaesthesia reversed. Over the following 2 weeks corneal 
neovascularisation should develop. By one week post induction neovascularisation was 
visible but not fully developed, by 2 weeks post induction neovascularisation was well 
developed and this time point was usually chosen for analysis. By 5 weeks post induction 
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the sutures were usually no longer present in the cornea (having worked their way out) and 
little to no neovascularisation was visible. 
If removal of sutures was required at any point it this was undertaken as follows. The animal 
was placed under general anaesthesia and an operating microscope was used. The length 
of suture protruding from the knot was grasped with fine forceps and gently pulled a small 
distance away from the eye to expose the loop of the suture. The tip of a 25G needle was 
then positioned within the loop of the suture and the sharp edge of the needle tip used to 
sever the suture, which could then easily be withdrawn from the tissue. 
 
2.3.10 Imaging of corneal GFP fluorescence by fundoscopy (mouse, in vivo)  
Fundoscopy was performed under general anaesthesia to ensure the animal remained still 
throughout the procedure. The instrument used was a slit lamp (SC-16, Keeler) modified as 
follows. The chin rest designed for human patients was replaced with a flat platform upon 
which to place the animals. The filter wheel was modified so that the incident light could pass 
through a 475±25nm filter, a wavelength range optimised to excite GFP. Images were taken 
using an attached DC500 digital camera and its software (Leica). 
Once anaesthetized, pupils were dilated with 1 % topical tropicamide (Chauvin 
Pharmaceuticals). Corneal refractive power was neutralized by placing a 5 mm coverslip on 
the cornea covered with a coupling medium solution (Viscotears, Novartis Pharmaceuticals).  
Under bright light the instrument was adjusted and the animal positioned so that the retina 
was in sharp focus and the optic disk was centred in the field of view. The focus was then 
adjusted to bring the cornea into sharp focus and an image taken under bright light (200ms 
exposure). Immediately after this the light source was filtered with the 475±25nm filter, all 
other light sources extinguished and the GFP image was taken (30s exposure). After the 
procedure the animal was either culled or allowed to recover. 
 
2.3.11 In vivo imaging of corneal GFP fluorescence by Scanning Laser 
Ophthalmoscopy (SLO) (mouse, in vivo) 
SLO was performed under general anaesthesia to ensure the animal remained still 
throughout the procedure. The instrument used was a Spectralis HRA2 with a 55° lens 
(Heidelberg engineering) modified as follows. The chin rest designed for human patients has 
been replaced with a flat platform upon which to place the animals. The 488 excitation laser 
has been modified to increase its power. 
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Once anaesthetized, the animal was positioned and the machine adjusted so that:  
- The eye filled the majority of the image 
- The pupil was centred  
- As far as possible the axis of the eye and camera were directly aligned.  
All images were taken using 25° angle setting. Infrared (790nm) images were taken using a 
power setting of 76% and 30 images were averaged and normalized. GFP (488nm) images 
were taken using a power setting of 95% and 30 images were averaged and normalized. For 
each eye a single infrared image was taken in order to visualise the positioning of the entire 
eye. To visualise GFP expression between one and five 488nm images were taken. This 
was because the focal plane of the instrument does not allow the entire cornea to be 
simultaneously in focus; therefore multiple images are required to build a composite of the 
entire cornea if expression is widespread. After the procedure the animal was either culled or 
allowed to recover. 
 
2.3.12 Fluorescein angiography of cornea imaged by SLO (mouse, in vivo) 
The initial stages of this procedure with regard to anaesthesia, instrumentation and 
alignment of the animal’s eye are identical those described in 2.3.11. 
Once the animal was positioned with one eye aligned to the machine it was injected intra- 
peritoneally with 0.2mL of 2% Fluorescein in sterile water for injection. As soon as injection 
began the SLO’s in built timer function was started.  
Once imaging of one eye was complete the animal was repositioned to image the other eye. 
This was done as quickly as possible but due to the extremely rapid spread and leakage of 
the dye through the tissues it was inevitable that the second eye to imaged would always 
appear brighter with vessels less well defined. The order in which the eyes were images was 
therefore randomised on a per animal basis in an attempt to ensure this inherent property of 
the technique did not affect the results. 
All images were taken using 25° angle setting. Infrared (790nm) images were taken using a 
power setting of 76% and 30 images averaged and normalized.  
Fluorescein (488nm) images were taken using various power settings. This was due to the 
increasing brightness and leakage of the fluorescein visible with increasing time after 
injection. Generally speaking the longer after injection the lower the power setting used. 
Power setting ranged between 70 – 90%. Again 30 images were taken and averaged but not 
normalized. For each eye a single infrared image was taken in order to visualise the 
positioning of the entire eye. To visualise fluorescein expression between one and five 
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488nm images were taken. This was because the focal plane of the instrument does not 
allow the entire cornea to be simultaneously in focus; therefore multiple images are required 
to build a composite of the entire cornea if vascularisation is widespread. After the procedure 
the animal was either culled or allowed to recover. 
 
2.3.13 BrdU / EdU administration 
Incorporation of these 2 thymidine analogues into genomic DNA is used to label cells 
undergoing cell division. BrdU solution for injection was made up to 10mg/mL in sterile PBS 
and animals received a dose of 100ug/g of body weight. EdU solution for injection was made 
up to 2.5mg/mL in sterile PBS and animals received a dose of 25ug/g of body weight. Both 
BrdU and EdU were administered via intra-peritoneal injection daily for a maximum period of 
4 consecutive days.    
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2.4 Histology, immunohistochemistry and microscopy 
 
2.4.1 Ethical requirements  
Approval by the local NHS Research Ethics Committee was obtained to use human corneal 
samples for research. Samples were treated according to the Human Tissue Act (2004) and 
the Human Tissue Authority’s codes of practice (2009, see 
http://www.hta.gov.uk/policiesandcodesofpractice/codesofpractice.cfml). All samples were 
disposed of by incineration at the end of each experiment. Samples from living donors were 
anonymised through the Human Research Tissue Database of the pathology department of 
the Institute of Ophthalmology. For corneas of deceased donors, the anonymisation process 
was already performed by the eye bank. A consecutive number was allocated to each 
corneal specimen.  
 
2.4.2 Types of human corneal samples available 
Three types of corneal tissue were available, each type displaying different advantages and 
disadvantages. 
Fresh corneal specimens. During corneal transplantation surgery, the patient’s diseased 
central cornea is cut out at a diameter of 7 to 8.5 mm. This “button” would normally be 
discarded or, if the diagnosis was unclear, fixed in formalin for further histopathological 
examination and testing. Before surgery, written informed consent was obtained from the 
patient after the purpose of this study had been explained to them. None of the patients 
approached during the course of this work declined to give consent. Under sterile conditions 
in the operating room the buttons were usually de-epitheialised by brief exposure of the 
anterior surface to ethanol, before being immediately transferred into a vial with room 
temperature medium (DMEM + 2% FCS, or Culture Medium I (Biochrom AG)) and then 
stored in the tissue culture incubator at 37°C / 5% CO2 until use.  
Cultured donor corneas. Whole corneas with the surrounding scleral rim were obtained from 
deceased eye donors via Moorfields Eye Bank. These corneas were always those that had 
been deemed unsuitable for transplantation for a number of reasons. Common exclusion 
causes were: 
- Insufficient donor medical history 
- Missing serology tests 
- Donor receiving chemotherapy, high dose steroid medication. 
- Patient having received brain surgery before 1990. 
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- Tissue having spent too long in organ culture. 
- Tissue having being rejected due to low endothelial cell density. 
Tissues rejected due to these last two criteria were generally avoided for this work due to the 
high probability that the tissue would be of low quality. Consent for use of tissue in research 
was obtained from relatives before eye retrieval.  
Corneoscleral donor rims. For corneal transplantation, only the central cornea with a 
diameter of 7 to 8.75 mm is punched out from the donor cornea and engrafted. The 
remaining corneoscleral rim comprised the peripheral cornea of ~ 3 mm width with the 
adjacent trabecular meshwork is not used and is usually discarded. This tissue whilst 
obviously compromised can still be of use in research.  
 
2.4.3 Preparation of corneal flatmounts (mouse) 
Mice were killed using an approved Schedule 1 method (usually cervical dislocation) and the 
eyes enucleated. The globe of the eye was then punctured at the posterior pole using a 25G 
needle and the eye was placed in 1-4% (depending on the intended antibody staining) PFA 
in PBS pH 7.4. The cornea was dissected away from the rest of the globe with an orbital cut 
just posterior to the limbus. Any non-corneal tissue that came away attached to the cornea 
was carefully removed. Dissection was performed under PFA using corneal notched forceps 
(Acrofine) and Vannas Capsulotomy Scissors (Albert Waeschle). Once dissection was 
complete the cornea was further fixed for 30 minutes. Throughout the procedure, great care 
was exercised to touch the corneal layer of interest as little as possible. Before 
immunostaining (see 2.4.3), four radial cuts were made in the 3, 6, 9 and 12 o’clock 
positions using a scalpel (No.15 Swann-Morton) to allow the cornea to be flattened. After 
any staining had been performed the sample was placed in a drop of PBS upon a 
microscope slide. It was then manipulated so the layer of interest was upper most, the PBS 
removed and the cornea carefully flattened. The cornea was then allowed to very briefly dry 
(to adhere to the slide) before a 20-50µL drop of fluorescent mounting medium (DAKO) was 
placed upon the sample. A coverslip was then carefully placed upon the tissue and flattened 
on to the cornea by a combination of capillary action and gentle pressure. The slide was 
then incubated at 4°C for 30minutes to allow the mounting medium to partially harden before 
edges of the cover slip were sealed with nail polish. 
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2.4.4 Preparation of corneal flatmounts (human) 
Tissue samples were washed briefly in dPBS before fixation in 1–4% (depending on the 
intended antibody staining) PFA in PBS, pH 7.4, for 30 min. Throughout the procedure, great 
care was exercised to touch the corneal layer of interest as little as  possible. Before 
immunostaining (see 2.4.3), radial cuts were made using a scalpel (No.15 Swann-Morton) to 
flatten corneoscleral rims or corneal buttons. 
After staining was complete the sample was attached to a glass microscopic slide 
endothelium side up using a small drop of cyanoacrylate glue at the edge. A long cylinder of 
1 mm diameter was prepared from a pressure sensitive adhesive (BluTac) and used to 
encircle the tissue sample. Further small balls of BluTac were placed in the corners of the 
slide. A drop of fluorescent mounting medium (DAKO, UK) was added on the endothelium 
and a glass coverslip pressed down on to the sample with even pressure, sticking to the 
BluTac.  
Human corneas swell during 37°C culture, resulting in folds and an irregular surface. To 
flatten the cornea, mounted samples were placed under a 5 kg weight for a minimum of 4 
hours to overnight. A spacer between weight and base surface limited the compression to 
the physiological thickness of the cornea.  
 
2.4.5 Staining of corneal blood vessels by DiI perfusion 
This method is described in detail in application to the retina in reference [278]. Described 
here is a simplification / modification of the protocol applied to the cornea.  
DiI solution stock solution was made to ~6 mg/mL in ethanol, this was protected from light 
and stored at room temperature. Once made this solution was considered stable for up to a 
year. Immediately before use this stock solution was diluted 1:50 in diluent with the following 
formulation: PBS (pH7.4) + 5% w/v glucose in dH2O, mixed in the ratio 1:4. This constituted 
the working DiI solution. 
Mice were euthanized via terminal anaesthesia with pentobarbital (Euthatal, Merial Animal 
Health) before intracardiac perfusion was performed. During the surgery preparing the 
animal for perfusion the descending aorta was clamped so as to limit the perfusion to the 
upper body. Each animal was perfused with the following three solutions in the following 
order. 
1) ~5-6mLs of PBS (pH7.4) 
2) ~5-6mLs of working DiI solution 
3) ~5-6mLs of 4% PFA   
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Perfusion of all three solutions was performed at a rate of ~2.5 mLs/min controlled by a 
syringe driver, smooth switch over between solutions was achieved by use of a device very 
similar to that shown in Figure 1 of reference [278].  
Once perfusion was complete eyes were enucleated and cornea dissected from the rest of 
the globe with an orbital cut significantly posterior to the limbal vascular arcade (essentially 
around the eyes equator) and the anterior pole further fixed in 4% PFA for 1 hour. The tissue 
was then further stained and / or flat mounted (2.4.3). 
Note: The entire method post perfusion was performed taking care to place an absolute 
minimum of mechanical stress upon the perfused tissues, the DiI is NOT rigidly fixed within 
the endothelial membranes of the vasculature and physical damage to stained vessels can 
cause it to “leak” into surrounding cells. For the same reason heavy permeabilisation is not 
recommended, the maximum that was well tolerated was 1% Triton X-100 for 10 minutes.  
 
2.4.6 Cryosections 
Tissue fixed in 4 % PFA for 1 hour was embedded in O.C.T. medium (R.A. Lamb) and frozen 
in isopentane, which had been precooled in liquid nitrogen. Specimens were stored at - 20 
°C and 18 μm thick sections were cut using a Bright cryostat. Slides were stored at -20 °C. 
Sections were air dried for 10 min and marked with a hydrophobic pen before 
immunostaining.  
 
2.4.7 Homogenisation of ocular tissue 
All tissues that were homogenised were later used as samples for ELISA (2.4.8) and thus 
were homogenised in ELISA reagent diluent (1x PBS + 1% BSA), the volume of which 
varied. Murine tissue was homogenised using a plastic pestle with matched microcentrifuge 
tube (Anachem). Human corneas were homogenised using a glass pestle and matched test 
tube. All tissues were homogenised using a stroke and twist motion which was repeated until 
no pieces of tissue large enough to be visible to the naked eye remained. 
Corneal tissue (human in particular) often proved extremely difficult to completely 
homogenise and often a large fibrous mass remained despite extremely aggressive 
homogenisation. This was accepted as a limitation of the tissue. 
Homogenate was then spun at 200 x g for 5 minutes in a microcentrifuge and the 
supernatant treated as the sample for ELISA. 
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2.4.8 DuoSet ELISA kits for murine IL10 and sFlt1 
Both these ELISA’s were carried out using DuoSet kits (R&D Systems). These kits are 
supplied as three components required for the specific ELISA: Capture antibody, detection 
antibody and recombinant protein standard. All the reagents further required for the 
colorimetric quantification reaction are supplied separately and can be used interchangeably 
with any DuoSet kit. 
Upon arrival the specific reagents (antibodies and standards) were diluted from stock 
aliquots as shown in the table below. All aliquots were designed to be sufficient for one 96 
well plate reaction and stored at -80°C until use: 
 
 Recommended 
working conc. 
Stock conc. made Dilution of stock to working 
Mouse IL10 DuoSet (Cat. #DY417) 
Capture antibody. 4 µg / mL 720 µg / mL 
55.5 µL Aliquots 
1:180 
55.5 µL / 10 mL 
Standard. 2 ng / mL as 
highest standard 
16.6 ng / mL 
60 µL Aliquots 
1 : 8.3 
60 µL / 500 µL 
Detection antibody. 300 ng / mL 54 µg / mL 
55.5 µL Aliquots 
1:180 
55.5 µL / 10 mL 
Mouse sVEGFR1 / Flt1 DuoSet (Cat. #DY471) 
Capture antibody. 1.6 µg / mL 320 µg / mL 
50 µL Aliquots 
1 : 200 
50 µL / 10 mL 
Standard. 10 ng / mL as 
highest standard 
73.3 ng / mL 
68 µL Aliquots 
1 : 7.35 
68 µL / 500 µL 
Detection antibody. 0.5 µg / mL 100 µg / mL 
50 µL Aliquots 
1 : 200 
50 µL / 10 mL 
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Before the procedure was started the following buffers were made up fresh 
Reagent Diluent: 1x dPBS + 1% BSA, stored at 4°C 
Wash Buffer: 1x dPBS + 0.05% Tween 20, stored at room temperature 
The capture antibody was diluted to working concentration in dPBS, and 100 µL was 
pipetted into each well of a 96 well plate (MaxiSorp, Nunc) before being covered and left 
overnight at room temperature. 
The following day the capture antibody solution was removed and each well was then 
washed. All washes in this procedure were performed by filling each well with 400 µL wash 
buffer using a squirt bottle, immediately discarding the wash and removing any liquid 
remaining from the wells by concussively blotting the plate against clean paper towels. All 
washes were performed in triplicate.  
Each well was then blocked with 300 µL of reagent diluent for a minimum of 1 hour at room 
temperature. During this time the standards were thawed and diluted to working 
concentration in reagent diluent. From working concentration a 2 fold dilution series was 
then made (250 µL in 250 µL) down to 1:64. If dilutions of sample was required these were 
made either in reagent diluent or another appropriate buffer (e.g. the same buffer as the 
undiluted sample was in). Block was then removed and wells washed before 100 µL of either 
standard, NTC or sample was added to each well as required. All standards, NTC’s and 
samples were run in at least duplicate, higher numbers of replicates were performed if the 
amount of sample available allowed. Samples / standards were incubated on the plate for 
two hours at room temperature. 
Samples / standards were then removed and wells washed. Detection antibody was then 
thawed and diluted to its working concentration in reagent diluent before 100 µL was added 
to each well and incubated on the plate for two hours at room temperature. 
Detection antibody was then removed and wells washed. Streptavidin HRP (Part # 890803) 
was then diluted to working concentration (either 1:100 or 1:200 depending on the bottle 
supplied, correct dilution is always indicated on the label) in reagent diluent before 100 µL 
was added to each well and incubated on the plate for 20 minutes at room temperature. 
Streptavidin HRP was then removed and wells washed. Substrate solution was then made 
up (1:1 Mixture of mixture of Colour Reagent A (H2O2) and Colour Reagent B 
(Tetramethylbenzidine) (R&D Systems Cat. # DY999) and 100 µL was added to each well. 
Plate was covered so exposure to light would be minimised. Development of colour was then 
monitored by eye and the reaction stopped by addition of 50 µL of 2 molar H2SO4 to each 
well. Development usually took between 5 and 20 minutes. 
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The optical density of each well was then determined immediately, using a microplate reader 
and associated software (Emax Microplate reader and SoftMax Pro software, Molecular 
Devices). Plate was read at 450 nm with a reference reading taken at 650nm subtracted. 
Data was analysed and quantified against the standards using the software’s HRP+TMB 
setting.  
 
2.4.9 Immunostaining of corneal flatmounts and cryosections 
Tissue was briefly washed in TBS and the cell membranes were permeabilised with 1% 
Triton X100 in TBS for 10-15 minutes. After another brief wash with TBS the tissue was 
placed in block solution (2% normal goat serum (or serum of the species the secondary 
antibody was raised in) + 2% foetal calf serum in TBS) for 1 hour. Primary antibody was 
diluted in blocking solution and incubated with the sample overnight at 4 °C. A complete list 
of antibodies and their staining conditions can be found in (2.4.10).  
After washing 5 times in TBS for 5 minutes, secondary antibody (usually raised in goat, 
Alexa Fluor Secondary Antibodies, Invitrogen, UK) diluted 1:500 in block solution was added 
and incubated for 2h at room temperature. Finally the tissue was washed a further 5 times in 
TBS for 5 minutes. Some stains were also included in the 3rd of these washes, if used the 
wash was extended to 15 minutes. A list of these is also found in (2.4.10). 
 
2.4.9.1 To-Pro-3 Iodide Staining 
To-Pro-3 (Invitrogen) is a carbocyanine monomer nucleic acid stain that is commonly used 
as a high sensitivity nuclear counterstain that fluoresces in the far red. Upon testing it was 
found that this stain also stains cytoplasmic RNA leading to high background. In order to 
minimise this the following step in the staining protocol was added before the final wash 
steps in which the To-Pro-3 was present 
- Incubation in 1 mg / mL RNAse A (Sigma-Aldrich) @ 37°C for 30 mins 
Additionally To-Pro-3 requires the staining step to last for 30 minutes rather than 15. 
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2.4.10 Antibodies and stains 
Name / Epitope 
Supplier / 
Cat # 
Source 
Target 
Species 
Dilution Application Notes 
F4/80 
Abcam / 
Ab16911 
Rat 
Monoclonal  
Mouse, 
Human  
1:100 None 
LYVE1 
Affymetrix 
eBioscience / 
53-0443 
Rat 
Monoclonal 
Mouse 1:200 
1° Conjugated Alexa 
488, no 2° required. 
CD34 
Affymetrix 
eBioscience / 
14-0431  
Rat 
Monoclonal 
Mouse 1:200 None 
BrdU 
Abcam / 
Ab6326 
Rat 
Monoclonal 
N/A 1:100 
Denature DNA / 
HCL wash required 
Phalloidin TRITC 
Sigma / 
P1951 
Amanita 
phalloides 
F Actin 
Human, 
mouse and 
others 
Used at 
1 µg / mL 
Include either with 
2° antibody or in 
TBS wash 
DAPI 
(4’,6‐Diamidino‐
2‐phenylindole 
dihydrochloride) 
Sigma / 
D9542 
n/a All DNA 
Used at 
5 µg / mL 
Include either with 
2° antibody or in 
TBS wash 
To-Pro-3 Iodide 
Invitrogen / 
T3605 
n/a 
All DNA, 
RNA at 
lower 
efficiency. 
Used at 
10 µM in 
TBS 
Include either with 
2° antibody or in 
TBS wash. Requires 
additional steps 
described in 2.4.9.1 
 
2.4.11 Click-iT EdU detection  
EdU incorporation was stained using the Click-iT® EdU Alexa Fluor® 647 Imaging Kit 
(Invitrogen) used according to the manufacturer’s instructions after any other 
immunostaining had been performed. The kit is designed for use upon cells in culture but 
was adapted without difficulty for use with corneal flat mounts with 60 µL of the Click-iT 
reaction cocktail used per corneal flat mount. 
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2.4.12 TUNEL Staining 
Samples for TUNEL staining were cryosectioned as described in 2.4.6 but unfixed. Once 
sectioned the tissue was very lightly post fixed upon the slide by coving with 1% PFA for 10 
minutes. 
TUNEL labelling was then performed using an ApopTag Red in situ Apoptosis Detection Kit 
(Chemicon International), used largely according to the manufacturer’s instructions although 
with the following modifications made to the protocol which have been found to increase the 
kits efficacy and utility. 
 Within the manufacturer’s instructions the volumes of all reagents to be applied to the 
tissue are given as volumes to be applied per 5 cm2 of area. This was modified so 
that the same volumes were instead applied per slide (an area of ~13cm2) 
 Equilibration buffer was applied to the tissue for 60s rather than the 10s specified in 
the manual 
 
2.4.13 Microscopy  
Microscopy of most specimens was performed using an upright confocal laser scanning 
microscope (Leica TCS SPE DM5500 Q, Leica Microsystems) and the manufacturer’s 
software (Leica LAS AF, Version 2.4.1). Large specimens such as whole corneal flat mounts 
where imaged using the microscopes tiling function to combine multiple fields of view. 
Alternatively, an inverted fluorescence microscope with phase contrast was used (Zeiss Axio 
Observer.Z1, Zeiss), which also allowed imaging of live cells grown in 6 or 24-well plates.   
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2.5 Image analysis and statistics 
 
2.5.1 Statistical Analysis 
In all case where statistics were applied no more than two groups were compared. The test 
applied in all cases to determine the probability of obtaining the observed (or more extreme) 
results if there was no relationship / difference between the two groups (p-value) was the 
Mann-Whitney U test. This test is non-parametric and thus does not assume the data being 
analysed is normally distributed. The statistical and graphing software package Prism 5 
(Graphpad) was used for most statistical analysis. 
 
2.5.2 Quantification by integrated density of eGFP expression observed by slitlamp 
fundoscopy. 
The camera attached to the slitlamp fundoscope takes images in full RGB colour mode. As a 
first step the image was opened in GNU Image Manipulation Program (GIMP, open source) 
and converted to greyscale mode (Image tab) and inverted (Colours tab). This image was 
then saved in .tif format which was then reopened in ImageJ (NIH, open source). The globe 
of the eye selected as the region of interest (ROI) using the elliptical selection tool. The 
“Area” and “Integrated density” values were then recorded using the measure tool. 
For each image a data value was generated using the following equation: 
(Integrated density / Area) – Mean (Control integrated density / Area) 
Dividing by the area controls for the fact the ROI is likely to be a different size for each 
image. Subtracting the mean value for all the relevant control images essentially sets the 
control values as a baseline at zero. The images below illustrate the process: 
 
  
Raw Image Greyscale + Inverted ROI Defined 
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2.5.3 Compilation of SLO images taken in different focal planes 
The SLO’s 55° angle lens has too limited a focal plane to get the entire murine cornea from 
limbus to centre in focus at the same time. Therefore, in order to obtain an overview image 
of the entire cornea multiple images had to be combined. Usually between 3 and 5 images 
were required to cover the entire depth of the cornea. 
The images were then compiled using GIMP. First the separate images were opened as 
layers within one image, layers were ordered from top to bottom as follows: Limbal cornea 
focused  Central cornea focused. The uppermost (Limbal) layer’s mode was then changed 
to “screen” which renders darker areas more transparent. In this case this rendered areas of 
no signal transparent whilst leaving the signal (in white) solid. If the uppermost layer and the 
layer below it were obviously out of alignment for reasons such as mouse movement or 
variations in focus then the move layer tool was used to align them correctly by hand. The 
two aligned layers were then merged to one layer and the process repeated down the layers 
until all layers were merged as one image. The images below illustrate the process. 
 
2.5.4 Quantification by area of regions of interest 
This analysis technique (with minor variations) was applied to images obtained from both 
fluorescein angiography (SLO) and immunohistological staining.  
For images of fluorescein angiography taken by SLO, images were usually combined as 
described in the previous section (2.5.3). For quantification the process was as follows. The 
image to be quantified was opened in GIMP, and a circular selection tool was used to 
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highlight the region of interest (ROI), usually the whole globe of the eye. Stroke selection 
(Edit tab) was used to permanently mark the area. All further manipulations will only apply to 
the ROI. The mode (Image tab) of the image was then switched to “Grayscale” as the mode 
most suitable for the monochrome SLO images. The levels tool (Colour tab) was then used 
to remove all pixels with a value below 40, this helped to de-noise the image and make the 
background an even black (value 0).  
The threshold tool (Colour tab) was then used to highlight only the pixels with a value 
between 100 – 255. This range was chosen as in all images it seemed to nicely separate 
signal from background and also dampened down the signal resulting from leakage of 
fluorescein from vessels seen in late stage fluorescein angiography images. The histogram 
dialogue (Windows tab) was then used to quantify both the total pixels within the ROI and 
the number of pixels within the threshold. The images below illustrate the process.  
A very similar process was used upon images of immunohistological staining. In this case 
each channel was treated as a separate greyscale image for analysis. No fixed threshold 
values were used due to the greater variability in the staining and signal strength between 
samples. The best threshold settings to separate background from signal were assessed on 
an image by image basis. 
 
Raw Image ROI Defined Leveled and Thresholded 
Histogram for pixel quantification 
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Raw Confocal z-projection 
(2 channels) 
Red channel thresholded 
(80-255) 
Green channel 
thresholded (20-255) 
Pixels shared between 
thresholded channels 
Thresholded channels 
overlaid and ROI defined 
Due to the images being confocal z-projections and certain stains being extremely high 
signal (causing bleed through) it was not uncommon to observe pixels in the image that were 
shared between channels once they had been thresholded. These were also defined as a 
third channel as follows. All the thresholded pixels from one channel were selected using the 
magic wand tool, the inverse of this selection was then applied to the other channel and all 
pixels within this inverse selection were deleted. The remaining pixels are those shared 
between the channels. All three channels could then be overlaid as layers, a circular region 
of interest selected (usually the central cornea, i.e. area inside the limbal vascular cascade) 
and the non-black pixels in each channel quantified. After quantification the channels were 
false coloured back to the colours appropriate to the channel. Shared pixels between the red 
and green channels were coloured yellow. The images below illustrate the process. 
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3. Development of novel vectors and application to 
the corneal endothelium. 
 
3.1 Introduction  
 
Viral gene therapy of the corneal endothelium to date has largely utilised either adeno or 
lentiviral vectors, these being the only two viruses reliably shown to mediate a substantial 
transduction of this tissue. Reports within the literature regarding the efficacy of adeno-
associated virus (AAV) for endothelial transduction are limited and somewhat mixed, 
although on balance the published work indicates that AAV is only able to mediate an 
extremely limited transduction of the endothelium. This would also reflect our own 
experience within the lab. 
The use of both adeno and lentivirus present concerns for application in a clinical context, 
adenovirus virus is well known to be highly immunogenic and transgene expression is often 
lost over a relatively short timescale due to the immune mediated destruction of transduced 
cells. In the context of a non-replicative cell type critical to maintaining the optical 
transparency of the cornea any possibility of such an immune reaction would constitute an 
unacceptable clinical risk. 
Lentivirus as a retrovirus is able to integrate into the host genome in a semi-random fashion; 
the process of integration displaying a preference for actively transcribed DNA regions and 
certain genomic sequence motifs. Integration has the potential therefore to result in 
insertional mutagenesis and past use of a retroviral gene therapy vector in the clinic has 
resulted in the malignant transformation of transduced cells. Due to the critical effect of 
endothelial cell density in maintaining corneal transparency and endothelial decompensation 
being a major cause of graft failure, many gene therapy approaches to the endothelium have 
attempted to increase or maintain endothelial cell density and such an approach presents an 
additional inherent risk of oncogenesis. 
If such gene therapy of the endothelium is ever to be translated to the clinic the safety profile 
of gene transfer must be improved, potentially by ensuring transduction is temporary and 
self-limiting. Thus work in this chapter will focus upon developing means by which this might 
be achieved via the modification of lentivirus and the application of novel recombinant AAV 
serotypes. 
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3.1.1 Aims 
The aim of work presented in this chapter was, firstly, to develop a lenti-based vector 
modified in such a way as to render it incapable of undergoing the reverse transcription 
portion of the retroviral lifecycle. The vector would be expected to be unable to integrate and 
only to mediate an extremely limited gene transfer both in terms of expression level and 
duration and should therefore minimise any risk of oncogenic transformation 
Secondly in recent years there have been great developments made in the field of capsid 
engineering of AAV; however, none of these engineered serotypes have thus far been 
applied to the cornea. This work will therefore aim to assess the capacity of these vectors to 
transduce the corneal endothelium, with a view to application in gene therapy based 
treatment of corneal endothelial disease. 
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3.2 Methods and results 
 
3.2.1 Molecular cloning to produce a lentiviral construct designed to be incapable of 
undergoing reverse transcription 
In order to produce a lentivirus genome incapable of undergoing reverse transcription post 
infection a number of modifications to the standard 2nd generation backbone will be required. 
First and foremost the elimination of reverse transcription will be primarily achieved by the 
deletion of the primer binding site that is required to initiate reverse transcription, however a 
number of other modifications can also be made to further optimise transgene expression. 
The ssRNA genome of the modified lentivirus will be required to act directly as mRNA. Thus 
ribosome binding will take place at the end of the capped 5’ LTR. In order to maximise the 
likelihood of initiation of translation of the transgene the distance between ribosome binding 
at the 5’ end of the genome and the start codon of the transgene sequence will be 
minimised. The following sequences are present in this region: 
Primer Binding Site – This sequence is to be removed. 
Psi (ψ) – This is the lentiviral packaging signal and must be preserved if the modified 
genome is to be packaged.  
Rev response element – This sequence functions to aid the export of viral RNA sequences 
from the nucleus [279]. Whilst this function will not be required post infection with a reverse 
transcription defective virus, it is likely to be useful during the virus production process in 
vitro and should be preserved. 
Central poly purine tract (cPPT) – This sequence both acts as a secondary site of initiation of 
2nd strand synthesis and plays an important role in the import of DNA provirus into the 
nucleus [280]. It would therefore be desirable to remove this sequence from our modified 
vector. 
Spleen focus forming virus (SFFV) promoter – If functioning as designed the viral genome 
will never form a DNA provirus and will never be trafficked to the nucleus, thus the promoter 
sequence will never have a chance to function and is therefore expendable. 
It would not be expected that a reverse transcription incompetent lentivirus would mediate a 
very high level of transgene expression and indeed in the context of the intended application 
high levels would be undesirable. Thus a highly sensitive reporter gene may be required to 
detect any expression and for this reason firefly luciferase was selected. 
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Below are described the steps undertaken to produce such a construct. At each step that 
generated a new plasmid, sequencing (2.1.7) was undertaken to ensure the identity of the 
product. A schematic of the process is shown in Figure 5. The sequences of all primers used 
are shown in 2.1.10. 
The two starting plasmids used for this cloning were: 
pGL4.10[Luc2] – A commercially available (Promega) construct encoding firefly luciferase. 
LNT-SFFV-MCS – The 2nd generation lentiviral backbone in use within the lab. It has no 
transgene and a multiple cloning site positioned immediately after the promoter to allow ease 
of transgene insertion. 
Maps of both plasmids are available in Appendix 1 (9.1) 
The first cloning step was to excise the luciferase gene (Luc2) from pGL4.10 and clone it into 
the lentiviral backbone. This was achieved by first cutting pGL4.10 with BamHI and XbaI, 
before blunting with Klenow and religating the larger 3980bp fragment. This step excised the 
SV40 PolyA from pGL4.10 and thus moved a SalI site into a position immediately 
downstream of the Luc2 gene. The resulting construct was named “Product 1”. 
Product 1 was cut with SalI and BglII excising the Luc2 gene in a 1721bp fragment. LNT-
SFFV-MCS was then cut with BamHI and XhoI, opening the back bone. The Luc2 fragment 
was ligated into the lentiviral backbone using the compatible sticky ends of BamHI & BglII 
and XhoI & SalI. The resulting construct was a 2nd generation lentiviral backbone delivering a 
firefly luciferase transgene under the control of the SFFV promoter. This construct was 
named “LNT-SFFV-Luc2”. 
LNT-SFFV-Luc2 was cut with NruI and PflFI. These enzymes required different buffer 
conditions and thus a sequential digest was performed. The 8766bp fragment resulting from 
this digestion was then blunted with Klenow and religated. This step has the effect of 
removing much of the sequence upstream of the Luc2 transgene, including the rev response 
element (RRE), the central poly purine tract and SFFV promoter. The resulting contract was 
named “Product 3” 
The next step was to reintroduce the RRE in a different position downstream of the 
transgene. As a first step in this procedure Product 3 underwent site direct mutagenesis to 
remove a SalI site located immediately downstream of the Luc2 gene. This made the 
remaining SalI site downstream of the woodchuck hepatitis virus regulatory element (WPRE) 
a unique site. The resulting construct was named “Product 3a”. 
The RRE was then amplified by PCR (using original LNT-SFFV-MCS plasmid as the target) 
using primers modified to include SalI sites on their 5’ ends. Both the PCR product and 
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Product 3a were cut with SalI and the PCR product ligated into Product 3. The resulting 
construct was named “Product 4” and was sequenced to ensure correct orientation of the 
RRE. 
Product 4 then underwent site directed mutagenesis to remove all 20 bp of the Primer 
Binding Site. The resulting final construct was named “LNT-dPBS-Luc2” 
The result of sequencing of LNT-dPBS-Luc2 to confirm its identity is shown in Figure 6. The 
extent of the sequencing was sufficient to cover the entire genomic construct from mid 5’ 
LTR to end of 3’ LTR. Sequencing confirms the cloning procedure has been successful. All 
rearrangements are exactly as predicted in silico and the primer binding site has been 
removed. Only a single base pair mismatch was revealed in the sequence of the Luc2 
transgene although this point mutation should be silent (AAG  AAA, both Lysine). 
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Figure 5. Schematic plan of cloning steps performed in order to produce a lentivirus genomic 
construct in capable of undergoing reverse transcription post-infection 
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TGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATATCCTTGATCTGTGGATCTACCACACACAAGGCTACTTCCCTGATTAGCAGAACTACAC
ACCAGGGCCAGGGGTCAGATATCCACTGACCTTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGAGGCCAATAAAGGA
GAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGGATGGATGACCCGGAGAGAGAAGTGTTAGAGTGGAGGTTTGACAGCCGCCTAGCAT
TTCATCACGTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAACTGCTGATATCGAGCTTGCTACAAGGGACTTTCCGCTGGGGACTTTCCAGG
GAGGCGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGA
CCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCC
CGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAG====================TTGAAA
GCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGC
CAAAAATTTTGACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGGAGTCGCCCGGGGG
GGATCTGGCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGTTGGTAAAGCCACCATGGAAGATGCCAAAAACATTAAGAAGGGCCCAGCGCCAT
TCTACCCACTCGAAGACGGGACCGCCGGCGAGCAGCTGCACAAAGCCATGAAGCGCTACGCCCTGGTGCCCGGCACCATCGCCTTTACCGACGC
ACATATCGAGGTGGACATTACCTACGCCGAGTACTTCGAGATGAGCGTTCGGCTGGCAGAAGCTATGAAGCGCTATGGGCTGAATACAAACCAT
CGGATCGTGGTGTGCAGCGAGAATAGCTTGCAGTTCTTCATGCCCGTGTTGGGTGCCCTGTTCATCGGTGTGGCTGTGGCCCCAGCTAACGACA
TCTACAACGAGCGCGAGCTGCTGAACAGCATGGGCATCAGCCAGCCCACCGTCGTATTCGTGAGCAAGAAAGGGCTGCAAAAGATCCTCAACGT
GCAAAAGAAGCTACCGATCATACAAAAGATCATCATCATGGATAGCAAGACCGACTACCAGGGCTTCCAAAGCATGTACACCTTCGTGACTTCC
CATTTGCCACCCGGCTTCAACGAGTACGACTTCGTGCCCGAGAGCTTCGACCGGGACAAAACCATCGCCCTGATCATGAACAGTAGTGGCAGTA
CCGGATTGCCCAAGGGCGTAGCCCTACCGCACCGCACCGCTTGTGTCCGATTCAGTCATGCCCGCGACCCCATCTTCGGCAACCAGATCATCCC
CGACACCGCTATCCTCAGCGTGGTGCCATTTCACCACGGCTTCGGCATGTTCACCACGCTGGGCTACTTGATCTGCGGCTTTCGGGTCGTGCTC
ATGTACCGCTTCGAGGAGGAGCTATTCTTGCGCAGCTTGCAAGACTATAAGATTCAATCTGCCCTGCTGGTGCCCACACTATTTAGCTTCTTCG
CTAAGAGCACTCTCATCGACAAGTACGACCTAAGCAACTTGCACGAGATCGCCAGCGGCGGGGCGCCGCTCAGCAAGGAGGTAGGTGAGGCCGT
GGCCAAACGCTTCCACCTACCAGGCATCCGCCAGGGCTACGGCCTGACAGAAACAACCAGCGCCATTCTGATCACCCCCGAAGGGGACGACAAG
CCTGGCGCAGTAGGCAAGGTGGTGCCCTTCTTCGAGGCTAAAGTGGTGGACTTGGACACCGGTAAGACACTGGGTGTGAACCAGCGCGGCGAGC
TGTGCGTCCGTGGCCCCATGATCATGAGCGGCTACGTTAACAACCCCGAGGCTACAAACGCTCTCATCGACAAGGACGGCTGGCTGCACAGCGG
CGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTGGACCGGCTGAAGAGCCTGATCAAATACAAGGGCTACCAGGTAGCCCCAGCC
GAACTGGAGAGCATCCTGCTGCAACACCCCAACATCTTCGACGCCGGGGTCGCCGGCCTGCCCGACGACGATGCCGGCGAGCTGCCCGCCGCAG
TCGTCGTGCTGGAACACGGTAAAACCATGACCGAGAAGGAGATCGTGGACTATGTGGCCAGCCAGGTTACAACCGCCAAGAAGCTGCGCGGTGG
TGTTGTGTTCGTGGACGAGGTGCCTAAAGGACTGACCGGCAAGTTGGACGCCCGCAAGATCCGCGAGATTCTCATTAAGGCCAAGAAGGGCGGC
AAGATCGCCGTGTAATAATTCTAGGATCCGTCGAGAGGCCTGGTACCACGCGTGCGGCCGCGACTCTAGAGTCAACCTGCAGGCATGCAAGCTT
GATATCAAGCTTATCGATAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTG
GATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTA
TGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGT
CAGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGC
TGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGAC
GTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTT
CGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGATACCGTCGACCAAGCGGCCGCTGATCTTCAGACCTGGAGGAGGAGA
TATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTG
GTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGC
TGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACT
CACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCT
GGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGCATCCAGG
TCGCAGTCGACCTCGACTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAA
TTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGG
GAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC
AGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGCATCTAGAATTAATTCCGTGTATTCTATAGTGTCACCTAAATCGTATGTGTATGATACA
TAAGGTTATGTATTAATTGTAGCCGCGTTCTAACGACAATATGTACAAGCCTAATTGTGTAGCATCTGGCTTACTGAAGCAGACCCTATCATCT
CTCTCGTAAACTGCCGTCAGAGTCGGTTTGGTTGGACGAACCTTCTGAGTTTCTGGTAACGCCGTCCCGCACCCGGAAATGGTCAGCGAACCAA
TCAGCAGGGTCATCGCTAGCCAGATCCTCTACGCCGGACGCATCGTGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCGCCTATATCGC
CGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTTCGGCGTGGGTATGGTGGCAGGCCCCGTGGCCGGGGGA
CTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTCAACCTACTACTGGGCTGCTTCCTAATGCAGGAGT
CGCATAAGGGAGAGCGTCGAATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTG
ACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTC
ATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTC 
 
Key: 
Sequencing features: 
ATCG = Sequence confirmed by one sequencing pass 
ATCG = Sequence confirmed by >1 sequencing pass 
ATCG = Binding site of sequencing primer 
ATCG = Mismatch of sequencing result with expected sequence 
==== = Site of lenti primer binding site removal 
Genes / regulatory elements: 
ATCG = Lentivirus long terminal repeat sequences (LTR’s) 
ATCG = Psi sequence 
ATCG = Luciferase gene (LUC2) 
ATCG = Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) 
ATCG = Rev response element (RRE) 
 
Figure 6. Sequencing result confirming the identity of the final product (LNT-dPBS-Luc2) of 
cloning described in 3.2.1 
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3.2.2 Testing of reverse transcription defective lentiviral vector on 293T cells in vitro 
In order to prove the reverse transcription defective lentivirus was functioning as designed it 
was tested in vitro on HEK293T cells. The expression of the transgene (luciferase) would be 
assessed at regular time points post infection to monitor the infection profile of the virus. 
Initially time points at 4, 8, 19, 24, 28, 52 and 68 hours post infection were selected. 
A total of six 24-well plates were seeded with 2x105 293T cells / well and the cells were left 
to attach to the plate for a total of 19 hours before being infected with virus. 
For each of the 7 time points a total of 19 wells were required which were treated as follows: 
6-wells were infected with 1 µL of unmodified lentivirus delivering luciferase under control of 
the SFFV promoter (LNT-SFFV-Luc2) – Titre of 1x107 vg / mL. These will act as a positive 
control 
6-wells were infected with 1 µL of reverse transcription incompetent lentivirus (LNT-dPBS-
Luc2) – Titre of 1x107 vg / mL 
6-wells were left uninfected to act as a negative control / background. 
1 additional well was also left uninfected so the cells could be counted at each time point 
At each time point the 12 lentivirus infected and 6 uninfected wells were assayed for the 
presence of firefly luciferase activity. The cells in each well were lysed in 150 µL of GloLysis 
Buffer (Promega) and a third of these lysates (50 µL) was assayed for presence of luciferase 
by addition of an equal volume of BrightGlo substrate (Promega). Emission of light was then 
quantified in a TD20/20 Luminometer (Promega) 6 minutes after addition of substrate. At 
each time point the cells in 1 well were trypsinised and counted with a haemocytometer. 
Figure 7 shows the results of the luciferase activity assessment. For the time points initially 
assessed (darker points and lines) it was apparent that at the first time point at 4 hours post 
infection the luciferase activity for both reverse transcription incompetent and unmodified 
virus was significantly raised above the controls, and the unmodified virus was also 
significantly raised above the reverse transcription incompetent. This resulted in a gap in the 
data set in which the initial deviation in infection profile between the reverse transcription 
competent and unmodified virus may have occurred. It was therefore decided that earlier 
time points were required. The experiment was thus repeated for the following time points 
0.5, 1, 2, 4, 6, 8 hours post infection, these are shown as paler points and lines in Figure 7. 
Infection with the positive control unmodified virus (LNT-SFFV-Luc2) resulted in luciferase 
activity detectable significantly above background again from the first time point at 0.5 hours 
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post infection. Luciferase activity then increased exponentially until it rose above the upper 
detection limit of the assay at 24 hours post infection. 
Infection with the reverse transcription defective virus (LNT-dPBS-Luc2) resulted in 
luciferase activity rising significantly above background at 1 hour post infection and 
continued to rise to a maximal level at 19 hours post infection at which point the level was 
~400 fold lower than the positive control. The level of luciferase activity remained above 
background until the end of the experiment at 70 hours post infection but between 19 and 70 
hours declined approximately 2.3 fold. 
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Figure 7. Time course of luciferase expression in vitro post infection with LNT-SFFV-Luc2 and LNT-
dPBS-Luc2 
A – Data shown on log scale 
B – Data shown on a linear scale (most LNT-SFFV-Luc2 data out of range) 
Both graphs show 2 repeats of the experiment. 
Paler lines: 0.5, 1, 2, 4, 6, 8 hrs post infection 
Darker lines: 4, 8, 19, 24, 28, 52, 70 hrs post infection   
B 
A 
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3.2.3 Assessment of corneal endothelial transduction by AAV2/6(ShH10) following 
intravitreal and intracameral injection in the mouse 
Recombinant adeno-associated viruses (rAAV) have not been widely reported to transduce 
the corneal endothelium, with the majority of gene therapy directed towards the endothelium 
having utilised Adenoviral [151] or Lentiviral [232,281] vectors for gene delivery. 
What has been published regarding AAV transduction of the endothelium is confusing and 
sometimes contradictory. AAV has been variously reported to transduce the endothelium; 
poorly [223,224], “highly efficiently” [225] or only in the presence of ocular inflammation 
[226]. 
In our hands no serotype of AAV in common use within the lab (2/2, 2/8, 2/8(Y733F) and 
2/9) has ever shown any significant transduction of the corneal endothelium in murine tissue 
(in vivo) or human tissue (ex vivo). 
A large library of AAV capsid mutations was recently generated by Koerber et al. who used 
an artificial selection technique to isolate those mutants displaying a tropism towards glial 
cells. [197]. The serotype AAV2/6(ShH10) was one of those developed by this technique and 
has been shown to mediate extensive Müller glia transduction following intravitreal injection 
into the eye [198].  
We received this serotype as a kind gift from Professor John Flannery (University of 
California, Berkeley) and evaluated its ability to transduce the corneal endothelium. 
Four mice were injected bilaterally with 2 µL of AAV2/6(ShH10)-CMV-eGFP, vector titre was 
4 x 1012 vg/mL (total vector dose: 8 x 109 vgs) one eye was injected by the intravitreal route 
and the other by the intracameral route, giving a total of 4 eyes injected per route. 
After 9 days all animals were culled and 2 eyes per route of injection were prepared for 
corneal flat mounting whilst the other two were prepared for cryosectioning. 
Figure 8 shows the result of intravitreal injection. Extensive endothelial transgene (eGFP) 
expression is visible across the entire endothelium in all 4 eyes injected intravitreally.  
Figure 9 shows the result of intracameral injection. Some endothelial eGFP expression is 
visible although it appears weaker and less widespread than that following intravitreal 
injection. Additionally there is extensive transduction of stroma and epithelium by this route 
of injection, although from the flat mount it is apparent that all transduction appears limited to 
an area near the site of injection (Figure 9D). 
  
 
1
1
0
 
 
Figure 8. Representative histology showing endothelial eGFP expression in the murine cornea 9 days post intravitreal injection of AAV2/6(ShH10)-CMV-
eGFP 
A: Transverse cryosection (18µm), confocal z-projection at 10x magnification.  
B: Green (eGFP) channel only of image presented in A 
C: Corneal flat mount of murine cornea showing endothelial transgene (eGFP) expression. Confocal z-projection at 40x magnification.  
In all images:  Blue = DAPI, Green = Vector mediated eGFP 
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Figure 9. Representative histology showing endothelial eGFP expression in 
the murine cornea 9 days post intracameral injection of AAV2/6(ShH10)-
CMV-eGFP 
A: Transverse cryosection (18µm), confocal z-projection at 40x 
magnification.  
B: Green (eGFP) channel only of image presented in A 
C: Corneal flat mount of murine cornea showing endothelial transgene 
(eGFP) expression. Orthographic projection at 40x magnification.  
D: Overview of entire corneal flat mount. Confocal z-projection at 10x 
magnification. Edge of flat mount is delineated in red. Transgene expression 
(eGFP) is restricted to the area of the white dotted circle. 
In all images:  Blue = DAPI,  Green = Vector mediated eGFP 
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3.2.4 Assessment of corneal endothelial transduction by AAV2/6(ShH10) in human 
tissue ex vivo 
Following the observation of widespread transduction of the murine corneal endothelium by 
AAV2/6(ShH10) following intravitreal injection the capacity of this serotype to transduce 
human corneal endothelial cells was assessed. A fresh de-epithelialised corneal button was 
obtained from the operating room and bisected using a razor blade. Each half was placed in 
300 µL of culture medium I (Biochrom AG). To one half an additional 300 µL of medium was 
added supplemented with 4 µL AAV2/6(ShH10)-CMV-eGFP, (total vector dose: 1.6 x 1010 
vgs) to the other half 300 µL of medium alone was added to act as a negative control. 
Both halves of the corneal button were then incubated at 37°C + 5% CO2 for 48 hours, 
before a further 1 mL of culture medium I was added to each half. Button halves were then 
incubated at 37°C + 5% CO2 for a further 5 days, before being fixed, flat mounted and 
assessed for transgene (eGFP) expression by confocal microscopy. 
Figure 10 shows the confocal images. In the AAV treated half of the corneal button a large 
number of eGFP positive endothelial cells were seen in areas where endothelium was 
present. (Figure 10A & B). 
Any further analysis proved difficult as the cornea used for this experiment proved to be of a 
very poor quality. Endothelium was extremely patchy over both halves and in areas where 
cells were present their density was low. Many pyknotic nuclei (white arrow heads) were also 
visible in both the infected (Figure 10B) and uninfected (Figure 10C) halves. Such a level of 
deterioration would not be expected from a 1 week culture period and is likely indicative of a 
poor initial quality.  
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Figure 10. Flat mounted human cornea 
showing endothelial eGFP expression after 7 
days incubation with AAV(ShH10)-CMV-eGFP 
in vitro 
A: Endothelial eGFP transgene expression 
shown in confocal z-projection taken at 40x 
magnification. 
B: Orthographic projection of confocal z- stack 
in A showing restriction of eGFP to the 
endothelial layer. White arrow heads highlight 
pyknotic nuclei. 
C: Endothelial layer of control corneal flat 
mount to which no AAV was added. Single XY 
plane of confocal z-stack. White arrow heads 
highlight pyknotic nuclei. 
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3.3 Discussion 
 
3.3.1 Reverse transcription defective lentivirus 
The development of this vector was initially undertaken with the intention of utilising it to 
improve the safety profile of the potentially oncogenic gene transfer that would be required to 
trigger corneal endothelial cell replication. 
Specifically it was to be used in the context of work undertaken within the lab to adapt over 
expression of the cell cycle control factor E2F2 shown to induce endothelial cell replication 
via adenovirus [151,241] to a lentiviral vector platform. In 2007 Haberichter et al. [282] 
calculated by mathematical modelling of their observations of G1 cell cycle progression that 
some cell cycle regulatory factors (especially E2F2) may trigger cell cycle progression even 
if only present at extremely low levels (<10 molecules / cell). For this reason we believed 
that the limited transduction achievable by the reverse transcription defective lenti vector 
may be sufficient for this purpose. 
This prediction was not borne out by experiment however. Work by Dr Daniel Kampik 
(unpublished) revealed that even E2F2 gene delivery by an unattenuated lentivirus was not 
always effective in triggering endothelial cell replication but was in fact dependent upon virus 
titre. Only high MOI’s of unattenuated lentivirus were successful in triggering endothelial cell 
replication and it was therefore deemed extremely unlikely that the up to 1000-fold lower 
expression levels mediated by the RT defective vector would ever be effective in triggering 
endothelial cell replication via E2F2. The work to develop and characterise this vector was 
therefore suspended before fully complete. 
Nonetheless the progress that was achieved will be discussed below including areas that 
require further development or characterisation, and it is possible that the low level, transient 
gene delivery mediated by the reverse transcription defective vector might prove of future 
utility in an alternative application. 
 
The cloning strategy designed and presented in this chapter has successfully produced a 
lentiviral genomic construct that should be unable to undergo the reverse transcription 
portion of the retroviral lifecycle due to the deletion of the primer binding site required to 
initiate reverse transcription. Reverse transcription is essentially the very first step in the 
retroviral lifecycle post cell entry and uncoating, and thus if eliminated all subsequent steps 
should also be prevented. It has not been conclusively demonstrated here however that this 
vector undergoes no reverse transcription although the vastly reduced transgene expression 
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level mediated by the vector is certainly indicative of a substantial impairment. More 
conclusive proof could be obtained by performing PCR upon the DNA of infected cells to 
determine the presence or absence of proviral DNA.  
Even if proviral DNA were shown to be experimentally undetectable it remains unlikely that 
prevention of reverse transcription will ever be 100% complete so the vector designed here 
has been additionally modified to attenuate any downstream processing in case of any 
residual reverse transcription. 
In common with most other 2nd generation lentiviral vectors the defective vector generated 
here has been rendered self-inactivating (SIN) by the deletion of the U3 sequence in the 3’ 
long terminal repeat (LTR). During normal lentivirus reverse transcription this portion of the 
3’ LTR is copied to the 5’ end of the provirus from which position it acts as a promoter driving 
the expression of viral genes in the nucleus [283]. Recombinant lentiviral vectors are usually 
designed to include an additional non-lentiviral promoter to drive transgene expression in the 
nucleus. The reverse transcription defective vector contains no known promoter of any kind 
and thus even if a residual level of provirus is produced and trafficked to the nucleus then 
transgene expression should be minimal. 
As a further modification the central polypurine tract (cPPT) has also been removed from the 
reverse transcription defective vector’s genome. The cPPT acts as a second initiation site of 
reverse transcription and 2nd strand synthesis [284] and thus its removal was vital in 
rendering the vector fully incapable of undergoing reverse transcription. The function of this 
second initiation site is primarily to generate what has been termed the “central DNA flap” 
which has been shown to be an important feature facilitating the nuclear import of provirus 
[285]. Its removal therefore should act to both prevent any alternative initiation of reverse 
transcription that might result in proviral forms and attenuate any nuclear trafficking of this 
DNA. 
When the transduction profile of the defective vector was assessed in vitro by luciferase 
transgene expression (3.2.2) it was found that as expected the defective virus mediated a 
level of expression several orders of magnitude below an unmodified vector. This low level 
was still however easily detectable above background (uninfected), and the level of 
expression remained above background until the end of the experiment at 70 hours post 
infection. Between 19 and 70 hours post infection the luciferase level dropped approximately 
2.3 fold, indicating a possible genome half-life of around 44 hours. This is somewhat longer 
than average [286] for an mRNA but still well with in normal range [287]. Unfortunately it was 
not possible to extend the experiment to witness the complete extinction of the signal due to 
the cells in culture reaching confluency and losing viability as a result. 
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The experiment presented in 3.2.2 does not eliminate the possibility that the lentiviral 
genome had in fact degraded and continued “expression” of luciferase was due to stable 
luciferase protein rather than de novo translation. The half-life of luciferase in vitro (in the 
absence of live cells) at 37°C / 5% CO2 was therefore determined by incubation and 
assessment of (highly expressing) LNT-SFFV-Luc2 infected cell lysate over time. Half-life 
was determined to be ~40 minutes (see Figure 11 below). Such a half-life would lead to the 
complete decay of the reverse transcription defective vector mediated signal in 
approximately 2 hours 40 minutes and it is therefore unlikely that residual luciferase is 
responsible for the signal. 
 
Figure 11. Stability of Luc2 at 37°C / 5% CO2 
 
The results obtained characterising the reverse transcription defective lentivirus are in 
general agreement with work by Galla et al. [288] in which a murine leukaemia virus was 
modified in a very similar manner to eliminate reverse transcription. Direct comparison of the 
two data sets is difficult due to variation in the cell type, transgene, and multiplicity of 
infection (MOI) between the two experiments. There is a clear difference however in the 
level of transgene detected over background. The work presented here detected a maximal 
expression of approximately 12-fold over background whereas Galla et al. demonstrated a 2-
fold difference at best. This is likely to be due to the increased sensitivity and decreased 
background of the luciferase detection over eGFP fluorescence rather than reflective of any 
difference between the two viruses themselves, although this possibility cannot be 
discounted. 
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3.3.2 Adeno-associated virus 
The adeno-associated virus serotype ShH10 has only very recently been acquired by the lab 
(a kind gift from Prof. John Flannery) and this work has demonstrated that this serotype is 
able to mediate significant levels of transgene expression in the corneal endothelium in both 
murine and human tissue. We believe this transduction to be far more convincing than any 
previously seen from any other AAV serotype in this tissue, either in our hands or in the 
literature [223–226]. 
The far lower endothelial transduction efficiency resulting from an intracameral injection 
when compared to intravitreal administration was initially surprising. An intracameral 
injection should have resulted in delivery of vector closer to the endothelium and thus a 
better transduction profile may have been expected. Instead a transduction of the whole 
thickness of the cornea was noted which was limited to an area close to the site of injection. 
This is likely due to the fact that the intracameral injection route involves a full thickness 
penetration of cornea. We believe that following intracameral injection the majority of the 
vector likely refluxed back up the injection tract driven by the force of the increased ocular 
pressure resulting from the injection. This both limited the spread of transduction and 
exposed the stroma and epithelium to the vector. The transduction observed, whilst off-
target, is nonetheless interesting, demonstrating the capacity of the ShH10 vector to 
transduce other corneal cell types. 
Whilst the transduction demonstrated in murine endothelium in vivo following intravitreal 
injection was both widespread and caused no obvious pathology or reduction in endothelial 
cell density the same cannot be concluded with certainty from the data obtained for 
incubation of human tissue with vector ex vivo. Analysis of this data was complicated by the 
poor quality of the corneal tissue available for this experiment. Large numbers of pyknotic 
nuclei indicative of cell death were observed in both the ShH10 treated and the untreated 
control sample, and in both cases the endothelium was patchy and of low density. From the 
small number of images obtained it may appear that both abnormalities may be worse in the 
AAV infected tissue but no firm conclusion can be drawn. It is possible that such damage 
may have been caused by the high MOI used in these experiments, which was selected to 
maximise the chances of observing transduction. Now that AAV2/6(ShH10) has been shown 
to transduce the corneal endothelium the MOI can be reduced in future experiments. This 
experiment should be repeated with better quality of corneal tissue in order to confirm 
whether or not any damage is indeed caused by the vector. Unfortunately this has not been 
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possible to date due to the limited availability of human tissue and its use in higher priority 
experiments. 
 
3.3.3 Conclusions 
Genetic manipulation of the lentiviral genomic backbone has been successful in producing a 
vector from which transgene expression is heavily attenuated, although still detectable 
significantly above background. Characterisation of this vector is however incomplete and 
further work is required to establish if it is indeed functioning as designed. 
The novel AAV serotype AAV2/6(ShH10) has been found to be able to transduce both 
murine and human corneal endothelial cells, a quality not convincingly demonstrated for any 
other serotype of this vector. 
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4. AAV transduction profile in the corneal stroma 
following intrastromal injection 
 
4.1 Introduction  
 
The stroma comprises the largest compartment within the cornea with the primary role of its 
largest cell population, the corneal keratocytes, being biosynthetic in the production of 
stromal extra cellular matrix; under normal conditions these cells are considered to be 
largely quiescent. This cell population is therefore potentially the best suited of any corneal 
cell type for transduction in an augmentation gene therapy approach aiming to act upon 
corneal pathology via a secreted transgene product. The cells of both the epithelium and 
endothelium are likely ill-suited to such an approach as they act either to exclude or remove 
material from the cornea. Previous such approaches to alleviate corneal pathology have 
often targeted tissues adjacent to the cornea such as the conjunctiva and whilst some 
promising results have been demonstrated in animal models it is likely that the production of 
transgene product within the affected tissue itself might prove more efficacious. 
Based upon the work published to date adeno-associated virus (AAV) based vectors appear 
to represent the optimal means by which to transduce the stroma due to their relative lack of 
immunogenicity and various serotypes of AAV (AAV2/8 in particular) having been shown to 
be able to effectively transduce the stroma. In this study therefore AAV2/8 will represent the 
current gold standard to which other serotypes will be compared.  
In recent years AAV-based vectors have been the subject of a substantial body of work 
aimed at further increasing their utility. As a result of this research a number of capsid 
mutant AAV serotypes have been produced which have been shown to mediate improved 
gene delivery to many tissues. These capsid mutants however have not yet been applied to 
the cornea and this study will assess one such mutant (Y733F) shown to be especially 
promising within other ocular tissues for its ability to transduce the stroma. 
 
4.1.1 Aims 
Work in this chapter aims to determine the profile of AAV mediated gene transfer to the 
corneal stroma following vector administration by intrastromal injection, in particular for the 
Y733F tyrosine mutant of AAV2/8.  
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Vector transduction profile will be assessed for suitability in application in an augmentation 
gene therapy approach to corneal pathology in which the stroma acts as a site of production 
for a secreted transgene product. Primarily therefore this work aims to effect a long lasting 
AAV mediated gene transfer to the stroma capable of producing physiologically useful levels 
of soluble transgene product. 
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4.2 Methods and results 
 
4.2.1 Comparison of corneal transduction by three different AAV serotypes following 
2µL intrastromal injection 
As a basis for further work this experiment aimed to determine which of the AAV serotypes 
in use within the lab could induce the highest and most widespread gene expression within 
the corneal stroma. 
The three serotypes chosen for comparison were: 
AAV2/8 and AAV2/9 – Two serotypes in common use within the lab both noted to mediate a 
high level of transgene expression within other ocular tissues such as retina and retinal 
pigment epithelium. AAV2/8 has also been previously shown to be effective in the stroma 
[253] 
AAV2/8(Y733F) – A relatively novel serotype carrying a tyrosine to phenylalanine mutation in 
the viral coat protein VP3 which is reported to result in increased expression level and 
broadened tropism. 
Each serotype was prepared using the same viral genomic plasmid (pd10-pst2.2, see 
Appendix 1 (9.1)) encoding eGFP under the control of the CMV promoter and titre matched 
to 4x1012 vg/mL for injection.  
For each serotype tested two mice received bilateral intrastromal injections of 2µL of vector, 
resulting in viral dose per injection of 8x109 vgs. A time point of fourteen days post injection 
was chosen for analysis. Based upon previous experience of retinal transduction this should 
be sufficient time for AAV8 and AAV9 to reach near maximal expression level. AAV8(Y733F) 
had not previously been tested by ourselves in ocular tissue its onset of expression was 
assumed to be either similar AAV8 or more rapid. 
At fourteen days post injection all animals were assessed for corneal eGFP expression using 
slitlamp fundoscopy (Figure 13A-C’). After this procedure the mice were sacrificed and eyes 
prepared for either corneal flatmounting (Figure 13D & E) or cryosectioning (Figure 12). A 
total of 4 eyes were available per vector serotype so two were prepared for each post 
mortem analysis. 
Figure 12 shows that all three serotypes tested mediate expression of transgene (eGFP) 
throughout the entire thickness of the corneal stroma. In addition AAV2/8 and 
AAV2/8(Y733F) appear to have mediated some limited transduction of the more anterior 
portions of the epithelium.   
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Of the three vector serotypes tested AAV2/9 appears to mediate the lowest level of corneal 
transduction as shown by all means of assessment. What transduction there is however 
appears relatively widespread across the entire cornea although perhaps stronger in one 
hemisphere, likely close to the injection site. (Figure 12A, Figure 13A-A’ & D). 
AAV2/8 and AAV2/8(Y733F) both mediate a higher and relatively comparable level of 
transgene expression as shown by all means of assessment. (Figure 12B/B’ & C/C’, Figure 
13 B, C and E).  
AAV2/8 mediated expression however appeared to be slightly less widespread than that of 
AAV2/8(Y733F) as shown by fundoscopy (Figure 13B/B’ vs C/C’). To a less obvious degree 
this result was also duplicated in the cryosections (Figure 12B vs C). 
AAV2/8 mediated expression was the only one of the three that showed any variability 
between replicates, for example the two replicate fundoscopy results shown in Figure 13B & 
B’, although as the n number for this pilot experiment was rather low (4) this is perhaps not 
significant.  
Unfortunately due to a tissue processing error a representative flatmount of an AAV2/8 
transduced eye cannot be shown in Figure 13 
 
Based on the combination of its high transgene expression level, widespread stromal 
transduction and apparent reproducibility, AAV2/8(Y733F) was chosen for further 
investigation.  
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Figure 12. Transverse sections (18µm) through murine corneas showing eGFP expression 14 days 
after intrastromal injection of 2µL of three AAV serotypes. Total virus dose matched at 8x109 vgs 
A: Transduction with  AAV2/9-CMV-eGFP 
B: Transduction with AAV2/8-CMV-eGFP 
C: Transduction with AAV2/8(Y733F)-CMV-eGFP 
All images: Projection of confocal z-stacks taken at 10x magnification (insert 40x magnification) 
Blue = DAPI,  Green = Vector mediated eGFP 
C
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Figure 13. Fundoscopy in vivo and corneal flatmounts showing vector mediated 
eGFP expression in murine cornea 14 days after intrastromal injection of 2µL of 
three AAV serotypes. Virus dose matched at 8x109 vgs 
A & A’: Fundoscopy of 2 eyes injected with AAV2/9-CMV-eGFP 
B & B’: Fundoscopy of 2 eyes injected with AAV2/8-CMV-eGFP 
C & C’: Fundoscopy of 2 eyes injected with AAV2/8(Y733F)-CMV-eGFP 
D: Flatmount of Cornea injected with AAV2/9-CMV-eGFP 
E: Flatmount of Cornea injected with AAV2/8(Y733F)-CMV-eGFP 
A C B D 
A’ B’ C’ 
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4.2.2 Time course of AAV2/8(Y733F) mediated expression following 2µL 
intrastromal injection, up to 37 days post injection 
To establish the temporal profile of transgene expression mediated by intrastromal injection 
of AA2/8(Y733F) a vector encoding eGFP under the control of the CMV promoter was 
injected and fluorescence assessed longitudinally at regular time points by slitlamp 
fundoscopy. 
A total of 4 animals received bilateral intrastromal injections of 2µL vector, resulting in viral 
dose per injection of 7x109 vgs. As a sham control a single animal was injected in one eye 
with 2 µL of PBS-MK, the other eye being left uninjected. 
All animals / eyes were assessed by fundoscopy at 2, 7, 9, 12, 22 and 37 days post 
injection. 0A-F shows the fluorescence observed at each time point in the 8 vector injected 
eyes, whilst 0G-L shows the PBS-MK injected control. The uninjected control is not shown 
as the sham is more relevant. 
Figure 15 shows the level of fluorescence above background observed quantified by 
integrated density as described in 2.5.2. 
Transgene expression increases rapidly from 2 to 7 days post injection reaching a peak at 
around the 7 day time point. Between this point and day 22 post injection expression falls 
rapidly to around a third the level seen at day 7. This basal level was then maintained 
significantly above control (defined by 0 on the y axis) until the end of the experiment at day 
37 post injection. 
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Figure 14. Fundoscopy in vivo showing time course of vector mediated eGFP expression in murine cornea after intrastromal injection of 2µL 
of AAV2/8(Y733F)-CMV-eGFP. Total virus dose: 7x109 vgs 
A-F: Time course of 8 virus injected eyes. Time points are 2, 7, 9, 12, 22 and 37 days post injection respectively. 
G-L: Time course of 1 PBS-MK injected eye as a control. Time points are 2, 7, 9, 12, 22 and 37 days post injection respectively. 
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Figure 15. Quantification of eGFP expression in AAV injected eyes based upon densitometry of 
images shown in 0A-F 
Densitometry was performed as described in 2.5.2, with relevant control eye (0G-L) used for 
baseline subtraction. 
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4.2.3 Time course of AAV2/8(Y733F) mediated expression following 0.5µL 
intrastromal injection, up to 148 days post injection 
Following on from the data presented in 4.2.2 the time course was essentially repeated with 
the following modifications: 
 The volume of virus injected was reduced from 2µL to 0.5µL. This was in attempt to 
reduce the tissue trauma associated with the injection and perhaps ameliorate the 
loss of transgene expression observed. 
 The time course was extended with the final time point taken at 148 days (~5 
months) post injection in order to gain a more extensive insight into the duration of 
transgene expression. 
 A greater number of control eyes were included. In this experiment a total of 8 eyes 
were injected, 5 with vector and 3 with PBS-MK 
All animals / eyes were assessed by fundoscopy at, 7, 12, 18, 28, 61, 90 and 148 days post 
injection. 
Figure 16B-H shows the fluorescence observed in the 5 vector and 3 control injected eyes at 
each of the time points  
Figure 17 shows the shows the level of fluorescence over background observed quantified 
by integrated density as described in 2.5.2. The data from the previous experiment (4.2.2) is 
also presented on the same graph for comparison. 
The pattern of transgene expression over time appears to mirror the results obtained in 4.2.2 
although the earliest time point was not repeated in this experiment. 
The drop in transgene expression observed between 7 and 12 days post injection in 4.2.2 is 
replicated between days 7 and 18 in this experiment. The reduced injection volume has had 
no effect to reduce this loss. 
The level of expression at 7 days in this experiment is considerably lower than that observed 
at the same time point in the previous experiment (4.2.2). 
Once the decline in expression was over by 28 days post injection a basal residual level of 
expression was maintained until the end of the experiment at 148 days post injection. The 
variability in the data did seem to increase over time which would seem to be due to the 
basal level being better maintained in some eyes, for example those highlighted by white 
asterisks in Figure 16H.
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Figure 16. Fundoscopy in vivo showing time course of vector mediated eGFP expression in murine cornea after intrastromal injection of 0.5µL of 
AAV2/8(Y733F)-CMV-eGFP. Total virus dose: 1.75x109 vgs 
A: Schematic showing the position of virus and PBS-MK (control) injected eyes in panels B-H. 
B -H: Time course after injection, time points are 7, 12, 18, 28, 61, 90 and 148 days post injection respectively. 
The two white asterisks in H highlight two eyes in which the eGFP fluorescence appears highest. 
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Figure 17. Quantification of eGFP expression in AAV injected eyes based upon densitometry of 
images shown in Figure 16A-H (red line) 
Densitometry was performed as described in 2.5.2, with relevant control eyes used for baseline 
subtraction. For comparison, the blue line representing data from experiment (4.2.2) shown in 
Figure 15 is also included. 
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4.2.4 Histological assessment of basal level of transgene expression remaining at 
148 days post intrastromal injection of AAV2/8(Y733F) 
The eGFP fluorescence observed in the final time point in 4.2.3 (Figure 15) appeared 
extremely low. Slit lamp fundoscopy however is not an especially sensitive technique so 
eyes from animals injected in the previous experiment (Figure 15) were sacrificed after the 
final time point and their eyes prepared for analysis by cryosectioning and stained for DAPI. 
Figure 18B shows eGFP expression within the stroma at 148 days post intrastromal injection 
of 0.5µL of eGFP encoding vector. For the sake of comparison Figure 18A shows a section 
of an eye taken at 14 days post injection although this eye received the higher injection 
volume of 2µL. 
At 148 days post injection a relatively high level of eGFP expression can still be observed by 
histology. No especially high gain settings etc. were required to record this image; those 
used were broadly similar to that used to record the image in Figure 18A. The eGFP 
expression also appears to be restricted to the posterior stoma closest to the endothelium as 
shown in Figure 18C, in contrast to the full thickness stromal transduction seen at 14 days 
post injection in Figure 16A. 
A large area of corneal scarring is also apparent (highlighted by an asterisk in Figure 18B); 
however this is likely unrelated to the vector injection. Such scarring is commonly observed 
in the eyes of mice that have undergone repeated anaesthetics and ocular imaging even if 
otherwise unprocedured.  
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Figure 18. Transverse sections (18µm) through murine corneas showing eGFP expression 14 days 
after intrastromal injection of AAV2/8(Y733F)-CMV-eGFP 
A: 14 days post injection  
B: 6 months post injection, white asterisk highlight area of fibrotic scarring associated with 
repeated anaesthetic and ocular imaging. 
C: Highlighted area of B shown in more detail. 
All images: Projection of confocal z-stacks taken at 10x magnification.  
Blue = DAPI, Green = Vector mediated eGFP 
  
B A DAPI 
eGFP 
C 
* 
 133 
 
4.2.5 Immunohistochemistry to determine whether corneal keratocytes are the cells 
transduced by AAV2/8(Y733F) 
Corneal keratocytes represent the primary cell population of the stromal and it is therefore 
highly likely that the extensive transgene expression observed after intrastromal injection of 
AAV2/8(Y733F)-CMV-eGFP is the result of keratocytes transduction, however this could be 
confirmed by co-localisation of transgene with a keratocyte marker. 
The antigen CD34 has been found to be expressed by corneal keratocytes [289] and is now 
commonly used as a marker of quiescent keratocytes [253]. It is important to note however 
that CD34 is also associated with the haematopoietic cell lineage and thus may also stain 
certain cell types from this lineage that may be present within the stroma [290]. Keratocytes 
however will constitute the vast majority of CD34+ cells in the stroma.  
Three mice were injected intrastromally with 2 µL of AAV2/8(Y733F)-CMV-eGFP (viral dose 
7x109 vgs) bilaterally. At 7 days post injection all animals were culled and their eyes 
prepared for cryosectioning and staining. 
Figure 19 shows a representative example of the staining. Widespread eGFP transgene 
expression is visible throughout the stroma and is also extremely bright within the corneal 
epithelium. This level of epithelial transduction had not thus far been observed at any later 
time point sectioned and this discrepancy is likely due to transduced epithelial cells being 
lost to normal epithelial turnover of the layer between 7 days post injection and later time 
points. 
Within the stroma almost every eGFP positive cell is also CD34 positive. Due to variability in 
the level of eGFP transgene expressed on a cell by cell basis not all cells are a uniform 
yellow colour, however upon close examination the co-localisation is near 100%. This 
indicates that corneal keratocytes are the primary stromal cell type transduced.  
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Figure 19. Transverse sections (18µm) through murine corneas showing co-localisation of eGFP 
transgene expression with CD34+ cells 7 days after intrastromal injection of AAV2/8(Y733F)-
CMV-eGFP 
A: eGFP channel only 
B: CD34 channel only  
C: Merged image eGFP + CD34 channel 
All images: Projection of confocal z-stacks taken at 40x magnification.  
Green = Vector mediated eGFP, Red = CD34 staining.  
A B C CD34
eGFP
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4.2.6 Assessment of cell turnover in the corneal stroma following intrastromal 
injection of AAV2/8(Y733F) 
Based upon the observed results so far the large drop off in transgene expression between 
days 7 and 18 post intrastromal injection in experiments 4.2.2 and 4.2.3 is likely largely due 
to the loss of transduced corneal epithelium due to the normal turnover of this layer. This is 
shown by comparison of the epithelial transgene expression in Figure 19A (7 days post 
injection) and Figure 18A (14 days post injection). The transduction of the epithelium in 
these experiments was off-target and its loss due to turnover is to be expected. However 
transduction of the stroma was expected to be more stable and thus any loss of expression 
from keratocytes is more significant as this would negatively impact the long-term efficacy of 
gene transfer. 
Whilst quiescent under normal conditions, stromal keratocytes can become proliferative as 
part of the stromal wound healing response so it is possible this process may also be 
contributing to the observed loss of transgene expression. Replicating keratocytes will not be 
lost from the cornea in the same manner as the epithelial cells but due to recombinant AAV’s 
inability to integrate into the host cell’s genome replication of transduced cells will lead to 
loss of expression via dilution of AAV episomes.  
To assess this potential cause of stromal transgene expression loss keratocyte cell turn over 
following intrastromal injection was assessed by uptake of the thymidine analogues BrdU 
and EdU. These were administered to mice via intra-peritoneal injection in 4 day pulses at 
various time points post intrastromal injection of 2µL of AAV2/8(Y733F)-CMV-eGFP resulting 
in a vector dose per injection of 7x109 vgs.  
Four cohorts of 4 mice (8 eyes) were injected as follows: 
5 x Eyes – 2µL AAV2/8(Y733F)-CMV-eGFP 
2 x Eyes – 2µL PBS-MK control 
1 x Eye – Uninjected control  
Each cohort received 4 day pulses of both BrdU and EdU separated by 8 days. The 
experiment was designed so that a 25 day time period post injection was covered. A 
schematic of BrdU and EdU administration is shown in Table 1 
At the end of experiment 28 days post intrastromal injection all animals were culled and their 
corneas fixed, stained for BrdU and EdU, flat mounted (endothelium uppermost) and imaged 
by confocal microscopy. 
* 
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The area of each cornea imaged had x/y dimension of ~3mm x 71.58µm and was located 
upon the flatmount as shown in Figure 22A’. The area was imaged in the z-axis to a depth of 
the entire corneal thickness.  
 
Unfortunately due to a defective batch of PFA fixative in the vast majority of eyes analysed 
the BrdU staining did not work. A small number of eyes (3 out of a total of 32) were fixed 
using a different batch of PFA. Figure 20 shows BrdU staining in the corneal epithelium 
(which is replicative under normal conditions) compared between the two batches of PFA 
fixative, illustrating this issue. 
Additionally for reasons unknown (possibly also related to the defective fixative) all the 
corneas imaged displayed a high level of autofluorescence in the red and green channels in 
both the corneal epithelium and endothelium. This is shown in Figure 21. Note that the green 
autofluorescent signal is unrelated to the virus mediated eGFP expression as it also occurs 
in the PBS-MK injected control (Figure 21B).  
Fortunately neither of these issues affected the EdU staining in the blue channel, although 
due to the loss of all the BrdU data there is a gap in the data set between 6 and 13 days 
post injection. 
Representative images for EdU for 4 periods post injection are shown in Figure 22. These 
images shown have been rotated 90° around the x-axis and projected in the y axis to 
produce pseudo transverse sections through the cornea. This image manipulation was 
performed using Leica LAS AF software. These pseudo sections have the advantage over 
cryosections that a greater depth (y axis in original image) can be visualised. 
There is little to no incorporation of EdU in the corneal stroma when.it was administered 2-5 
and 14-17 days post intrastromal injection of AAV (Figure 22B & C). There is however some 
significant incorporation of EdU in the corneal stroma when administered 18-21 days post 
injection (Figure 22D) This EdU uptake appears to be localised to the posterior stroma. 
There is also incorporation of EdU in the corneal stroma when administered 22-25 days post 
injection of AAV although less than at 18-21 days. This too appears to be localised to the 
posterior stroma. No uptake of EdU was observed in any of the PBS-MK injected or 
uninjected controls (Figure 22F-I). 
Figure 23 shows the eGFP expression resulting from the transduction at the end of the 
experiment (28 days). Stromal Transgene expression was always widely observed 
throughout the entire x/y axis of every injected cornea although there was some variation in 
the strength of fluorescent signal observed. In the z-axis however it appears that virus 
 137 
 
mediated eGFP is restricted to the posterior stroma closest to the endothelium. This result is 
in agreement with that the similar restriction observed at 148 days post injection in the 
previous experiment (4.2.4) and shown in Figure 18 
As a point of interest Figure 24 shows long fibre like structures that have been transduced by 
the vector highlighted by white arrow heads. These are likely to be corneal nerve axons. 
 
Days 
P.I. 
Cohort 01 Cohort 02 Cohort 03 Cohort 04 
0 All Cohorts injected with AAV2/8(Y733F)-CMV-eGFP 
1         
2 BrdU     EdU 
3 BrdU     EdU 
4 BrdU     EdU 
5 BrdU     EdU 
6   BrdU     
7   BrdU     
8   BrdU     
9   BrdU     
10     BrdU   
11     BrdU   
12     BrdU   
13     BrdU   
14  EdU     BrdU 
15 EdU     BrdU 
16 EdU     BrdU 
17  EdU     BrdU 
18    EdU     
19   EdU     
20   EdU     
21    EdU     
22     EdU   
23     EdU   
24     EdU   
25     EdU   
26         
27         
28 All Animals Culled 
Table 1. Schematic of experiment to evaluate turnover of cells in the corneal stroma following 
Intrastromal injection of 2µL AAV2/8(Y733F)-CMV-eGFP 
All animals were injected Intra-peritoneally with 4-day pulses, separated by 8 days of both BrdU and 
EdU according to the schedule shown above. 
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Figure 20. Images to illustrate the effect of variable fixation upon BrdU staining in the murine 
cornea obtained during experiment to assess cell turnover in the corneal stroma following 
intrastromal injection of AAV2/8(Y733F)-CMV-eGFP 
A: Orthographic projections of confocal z-stack through the cornea with x/y plane focused upon the 
proliferative basal epithelium. Tissue fixed with pre-made 4% PFA (Santa Cruz) which was used for 
the majority of tissue in this experiment. 
B: Orthographic projections of confocal z-stack through the cornea with x/y plane focused upon the 
proliferative basal epithelium. Tissue fixed with lab-made 4% PFA which was used for only 3 corneas 
in this experiment. 
 
 
Figure 21. Images to illustrate the autofluorescence observed during experiment to assess cell 
turnover in the corneal stroma following intrastromal injection of AAV2/8(Y733F)-CMV-eGFP 
A: Schematic showing the orientation of images presented in B&C, which are x/z images projected in 
the y-axis. 
B: Representative image of a PBS-MK injected eye, white arrow heads show high levels of signal in 
the red and green channels (yellow) in the Endo and Epithelium. 
C: Representative image of a vector injected eye, white arrow heads show high levels of signal in the 
red and green channels (yellow) in the Endo and Epithelium. 
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Figure 22. Representative images showing EdU uptake in the corneal stroma following intrastromal 
injection of 2µL of either AAV2/8(Y733F)-CMV-eGFP or PBS-MK at various time points post injection 
A: Schematic showing the orientation of images presented in B-I, which are x/z images projected in 
the y-axis. 
A’: Schematic showing x/y area imaged on confocal. Z-depth was the whole thickness of the cornea. 
B-E: Representative images showing EdU uptake at the following time points post injection of vector 
respectively: 2-5 days, 14-17 days, 18-21 days and 22-25 days. 
F-I: Representative images showing EdU uptake at the following time points post injection of PBS-MK 
respectively: 2-5 days, 14-17 days, 18-21 days and 22-25 days. 
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Figure 23. Representative image to illustrate restriction of stromal transgene expression to the 
posterior stroma at the end of experiment 28 days after intrastromal injection of AAV2/8(Y733F)-
CMV-eGFP 
A: Schematic showing the orientation of image in B, which is an x/z image projected in the y-axis. 
B: Image showing eGFP transgene expression in the stroma 28 days after intrastromal injection of 
AAV2/8(Y733F). Note the lack of expression in the anterior stroma between the red dotted lines. 
 
 
 
Figure 24. Images to illustrate corneal nerve /axon transduction in the corneal stroma following 
intrastromal injection of AAV2/8(Y733F)-CMV-eGFP 
A: Confocal z-projection in the x/y plane through the stroma of a vector injected eye. White arrow 
heads highlight fibrous structures observed; red arrow heads highlight transduced stromal cells. 
B: Representative images of vector injected eyes as x/z projection, white arrow heads highlight 
fibrous structures observed.  
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4.2.7 Assessment of cell death in the corneal stroma by TUNEL assay 10 days after 
intrastromal injection of AAV2/8(Y733F) 
There is evidence from both 4.2.4 and 4.2.6 that eGFP transgene expression is becoming 
restricted to the posterior stroma over time. It is possible that this might be due to the death 
of transduced cells in the anterior stroma by apoptosis, possibly as part of the corneal wound 
healing response. It is also possible that this cell death might be a contributing factor to the 
loss of transgene expression observed over time. 
Apoptosis within the stroma was assessed by TUNEL staining within the cornea at 10 days 
post injection. This time point was chosen as it is: 
a)  Approximately half way between the peak of transgene expression at 7 days post 
injection and beginning of the basal plateau at 14 days post injection so any 
contribution to loss of transgene expression can be assessed. 
b) Before the wave of posterior stromal proliferation at 18-21 days post injection 
observed in 4.2.6, which may have been triggered by the apoptosis of more anterior 
cells. 
Four mice were injected intrastromally with 2 µL of AAV2/8(Y733F)-CMV-eGFP (viral dose 
7x109 vgs) whilst the contralateral eye was left uninjected. Uninjected was chosen as the 
control state for this experiment as it is highly likely that some apoptosis will be triggered by 
the process of injection itself in addition to any vector related process. For this initial study 
this complicating factor was not examined, the effects of vector + injection being examined in 
combination. At 10 days post injection all animals were culled and their eyes prepared for 
cryosectioning without fixation (as required by the TUNEL assay).  
The TUNEL assay proved to be highly unreliable with even similar tissues processed entirely 
in parallel not always producing comparable levels / quality of staining. Good quality staining 
was rare. The experiment was therefore repeated several times in an attempt to achieve 
acceptable staining in a reasonable number of eyes. The apical corneal epithelium has been 
shown to undergo apoptosis prior to desquamation of mature cells from the corneal surface 
[291]. This area was therefore chosen to act as an internal control for the unreliable staining; 
only in tissue where this was clearly visible was the staining deemed to have worked. 
Figure 25 shows examples of the best staining achieved in both an injected and uninjected 
corneas. Whilst staining in the uninjected controls was reasonably reproducible staining was 
less consistent in injected eyes. The staining shown in the injected condition therefore whilst 
indicative may not be truly representative. In the uninjected control condition the only TUNEL 
staining visible is in apical epithelial cell nuclei as would be expected. In the vector injected 
condition TUNEL staining is visible in apical epithelial cell nuclei and extensively within 
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stromal nuclei. Additionally some level of background in which TUNEL stain does not 
colocalise with the nuclear marker DAPI is also visible; although this is less extensive than 
properly colocalised staining. No eGFP transgene expression is visible due to TUNEL 
requiring only very light fixation conditions which does not fix the eGFP. 
 
 
Figure 25. Transverse sections (18µm) through murine corneas showing TUNEL positive 
(apoptotic) cells in the stroma 10 days after 2µL intrastromal injection of AAV2/8(Y733F) 
A: Uninjected cornea. Confocal z-projection at 40x magnification. 
A’: Highlighted area in A shown in greater detail. Single confocal image in z-plane at 40x 
magnification. 
B: Injected cornea Confocal z-projection at 40x magnification. 
B’: Highlighted area in B shown in greater detail. Single confocal image in z-plane at 40x 
magnification. 
In all: Purple arrows highlight DAPI/TUNEL colocalisation, Red arrow show non-colocalised TUNEL. 
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4.2.8 Immunohistochemistry to determine whether macrophages are present in the 
corneal stroma at 10 days post intrastromal injection of AAV2/8(Y733F) 
The data thus far indicates that a corneal wound healing response may have been triggered 
by the intrastromal injection of vector as shown by an increase in stromal apoptosis (4.2.7), 
the subsequent proliferation of stromal cells (4.2.6) and the restriction of transgene 
expression to the posterior stroma over time (4.2.4 & 4.2.6). This is unlikely to be the result 
of the acute injury of injection itself the responses have only become apparent long after this 
initial insult. Thus the observed responses may be driven by a vector induced inflammation. 
To further examine this possibility immunohistological staining for F4/80 was performed upon 
corneal tissue at 10 days post injection. F4/80 is well established as a specific marker of 
activated macrophages [292], and as a critical cell type in both innate and adaptive immunity 
the presence of activated macrophages would act as a good indicator of any inflammatory 
process or immune response that may be occurring. 
Three mice were injected intrastromally with 2 µL of AAV2/8(Y733F)-CMV-eGFP (viral dose 
7x109 vgs), the contralateral eye was injected with 2 µL of PBS-MK to act as a negative 
control. At 10 days post injection all animals were culled and their eyes prepared for 
cryosectioning and staining. 
Figure 26 shows representative examples of the staining for both an AAV and control 
injected corneas. In the PBS-MK injected control tissue (Figure 26A) very few F4/80 positive 
cells can be seen, whereas in the AAV injected cornea (Figure 26B) a large number of cells 
stain positive for F4/80 indicating the presence of activated macrophages. The eGFP 
transgene was not imaged in this experiment. 
.  
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Figure 26. Transverse sections (18µm) through murine corneas showing F4/80 positive cells 
(mature macrophages) in the stroma 10 days after 2µL intrastromal injection 
A: Post injection with PBS-MK as a control. 
B: Post injection with AAV2/8(Y733F)-CMV-eGFP. 
All images: Projection of confocal z-stacks taken at 10x magnification.  
Blue = DAPI,  Red = F4/80 
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4.2.9 Amounts of soluble protein resulting from transgene translation within the 
murine eye (in vivo) at 7 days post intrastromal injection of AAV2/8(Y733F) as 
assessed by ELISA  
The intended application of gene delivery to the corneal stroma via AAV2/8(Y733F) in this 
study is for transduced cells to act as production sites for continuous expression of soluble 
factors to ameliorate corneal disease. 
Interleukin 10 (IL10) was chosen as a test transgene firstly because it is a potential 
therapeutic gene, shown by some studies to have beneficial effects in the cornea for the 
amelioration of corneal allograft rejection [230] and herpetic keratitis [293]. Secondly murine 
IL10 encoding vector constructs already existed within the lab and a reliable ELISA assay for 
murine IL10 had been well established. 
To establish the levels of soluble protein that might be produced by this approach the 
amount of transgene product (muIL10) present in the murine eye 7 days post intrastromal 
injection was assessed by ELISA. As a positive control and for purposes of comparison the 
vector was also injected subretinally. As a negative control eGFP encoding virus was also 
injected both intrastromally and subretinally. 
A total of 6 mice (12 eyes) were injected as follows 
3 eyes – 2µL Intrastromal AAV2/8(Y733F)-CMV-IL10-IRES-eGFP 
3 eyes – 2µL Subretinal AAV2/8(Y733F)-CMV-IL10-IRES-eGFP 
3 eyes – 2µL Intrastromal AAV2/8(Y733F)-CMV-eGFP 
3 eyes – 2µL Subretinal AAV2/8(Y733F)-CMV-eGFP 
At 7 days post injection all animals were sacrificed and all eyes enucleated. Each eye was 
then surgically trimmed of all extraneous tissue such as ocular muscle and optic nerve 
before being placed in 200 µL of ELISA reagent diluent (1xPBS + 1%BSA) and 
homogenised (2.4.7). All samples were then diluted 1 in 10 in reagent diluent and run in 
triplicate. ELISA plate loading volume was 100µL / well. 
 
Figure 27 shows the ELISA data. The results for the intrastromally injected muIL10 encoding 
virus are both well within the range of the standard curve and relatively consistent giving an 
average 0.14 ± 0.05ng/mL for the sample.  
  
 146 
 
Two of the three data points (including the one highlighted by the red circle in Figure 27) for 
the subretinally injected muIL10 encoding virus were well beyond the range of the standard 
curve and are therefore unreliable. It is clear however that subretinal injection results in 10-
100 fold more transgene product than intrastromal injection. 
All of the data points for the control eGFP encoding virus were below the range of detection 
and can be considered negative for muIL10 by ELISA. 
 
 
 
 
 
Figure 27. Levels of vector mediated muIL10 detected in the murine eye 7 days post either 
intrastromal or subretinal injection of 2 µL of either AAV8(Y733F)-CMV-muIL10-IRES-eGFP or 
AAV8(Y733F)-CMV-eGFP . Assessed by ELISA of whole eye homogenates 
A: ELISA data plot showing absolute concentration of muIL10 against absorbance at 450nm-650nm 
for the standard curve (blue points) and concentration of muIL10 calculated from standards against 
absorbance at 450nm-650nm for samples (red and green points) 
B: Average concentration of muIL10 detected in the different samples.  
Subretinal / IL10 
vector 
Intrastromal / 
IL10 vector 
Subretinal / eGFP 
vector 
Intrastromal / 
eGFP vector 
31.1 ng / mL 
(Out of Range - 
High) 
0.14 ng /mL 0.0085 ng/mL 
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Low) 
0 .004 ng/mL 
(Out of Range – 
Low) 
A 
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4.2.10 Histological assessment of AAV2/8(Y733F)-mediated expression in human 
cornea 7 days post intrastromal injection ex vivo 
Having established the transgene expression profile mediated by AAV2/8(Y733F) 
transduction in the murine cornea following intrastromal injection, this experiment was 
undertaken to ensure similar results are obtainable in human tissue. 
A pair of human corneas were obtained from the eyebank, at the point they were obtained 
they had been in organ bank culture for only 48 hours making them extremely fresh for this 
kind of sample. 
As a human cornea is so much larger than a murine cornea a larger volume of virus will be 
required to mediate a similar area of transduction, based on some approximate calculations 
(below) a volume of 50µL was selected as roughly equivalent. The human corneas were 
mounted on an artificial anterior chamber and injected intrastromally with 50µL of diluted 
AAV2/8(Y733F)-CMV-eGFP, total dose 4.38x1010 vgs.  
Corneas were incubated at 37°C / 5% CO2 in Culture Medium I (BiochromAG) for 7 days 
before being fixed in 4% PFA. One cornea was prepared for cryosectioning and the other flat 
mounted. 
The approximate calculations below illustrate the difference in volume between human 
murine corneas in relationship to injection volume and virus titre. Data on dimensions of 
murine cornea taken from reference [294]. 
Murine cornea 
Surface area of ~21mm2 and an average thickness of ~0.15mm, resulting in a volume of 
~3.15mm3. Injected: 2µL of vector of titre of 3.5x1012 vg/mL, total virus dose 7x109 vgs 
Injection volume: Cornea volume = 1 : 1.575 
Vector / unit volume: 2.22x109 / mm3 
Human cornea 
Surface area of ~135mm2 and an average thickness of ~0.5mm, resulting in a volume of 
~67mm3. Injected 12.5µL of vector of titre of 3.5x1012 vg/mL diluted up to 50µL in PBS-MK, 
total virus dose: 4.38x1010 vgs 
Injection volume : Cornea volume = 1 : 1.34 
Vector / unit volume: 6.54x108 / mm3 
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Figure 28A & A’ show orthographic projections of z-stacks taken through the endothelium 
and posterior stroma of the flat mounted cornea. The entire thickness could not be imaged 
as the sample was too thick. Transgene (eGFP) expression is widespread throughout the 
stroma in the area imaged which was representative of the majority of the tissue. Note that in 
Figure 28A the endothelium is patchy. 
Figure 28B shows a representative cryosection. Transgene (eGFP) expression is again 
widespread although appears brighter in the posterior stroma closest to Descemet’s 
membrane (most of the endothelium has been lost from the area imaged). The red bar 
shows the approximate thickness of a human cornea in vivo, thus the cultured tissue has 
swollen considerably to almost 4x this thickness 
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Figure 28. Images showing vector mediated eGFP expression in human cornea 7 days after ex vivo intrastromal injection of 50 µL of AAV2/8(Y733F)-
CMV-eGFP. Total virus dose: 4.23x1010
 
vgs 
A & A’: Orthographic projections of confocal z-stack taken through flat-mounted cornea at 10x magnification. Only  XY (single plane) and XZ shown. 
B: Transverse section (18µm) through injected human cornea. In All: Blue = DAPI, Green = Vector mediated eGFP 
A A’
B
↑
Epithelium
↑
Descemet’s
Membrane
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4.2.11 Short term assessment by ELISA of the amount of soluble transgene product 
within the human cornea (ex vivo) post intrastromal injection of 
AAV2/8(Y733F) 
In translation from the murine in vivo to the human ex vivo conditions it is not feasible to 
sample corneal tissue itself for transgene expression over time due to the extremely limited 
supply of human samples. An alternative approach would be to sample the conditioned 
tissue culture medium for secreted transgene product in order to assess vector mediated 
expression over time. 
This experiment was designed as a short term pilot to establish if such an approach was 
feasible, i.e. if transgene product was indeed secreted from the tissue ex vivo, and if the 
resulting levels in the conditioned media would be detectable by ELISA. 
The transgene used in this experiment (as in 4.2.9) was muIL10 as it was both convenient 
and a potentially useful transgene product. 
A pair of fresh (~48 hours in culture) human corneas were obtained from the eyebank. One 
was injected intrastromally with 50 µL of diluted AAV2/8(Y733F)-CMV-muIL10-IRES-eGFP, 
total dose 1 x 1011 vgs. The other was injected with PBS-MK to act as a control 
Both corneas were incubated at 37°C / 5% CO2 in Culture Medium I (BiochromAG) and the 
concentration of muIL10 in the conditioned medium assessed by ELISA at various time 
points shortly post injection. The culture media was replaced after each time point. 
Below are the time points at which conditioned media was taken and the total volume of 
media for each point. As it was unknown what muIL10 concentration might be expected the 
sample volume and incubation time was varied in an attempt to ensure that at least one 
point fell within the range of ELISA standard curve. 
Time sample taken post injection Total conditioned media / sample volume. 
55 hours (55 hour incubation) 20 mL 
96 hours (41 hour incubation) 20 mL 
120 hours (24 hour incubation) 3 mL 
 
After 120 hours the corneas were placed in 10 mL of fresh medium and incubated for a 
further 24 hours. At this 144 hour time point they were removed from culture and rinsed 
briefly with 1xPBS. They were then blotted as dry as possible using tissue paper and 
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weighed using an analytical balance. A 4mm biopsy punch (Stiefel) was then used to 
remove a disk from the central cornea, this too was then weighed. These corneal disks were 
then homogenised in 400 µL of ELISA reagent diluent and assayed for muIL10 
concentration by ELISA 
All samples (both conditioned media and tissue homogenate) were assayed at the same 
time, earlier samples had been stored at -20°C between collection and ELISA. All samples 
were run in triplicate both neat and diluted 1:10 in reagent diluent. ELISA plate loading 
volume was 100 µL / well. 
Figure 29 shows the ELISA data. Only results for the neat samples are presented as they 
were all well within the range of the standard curve rendering the dilutions irrelevant. Figure 
29A shows the raw concentration data obtained whereas in Figure 29B the same data is 
presented as total amount of muIL10 in the entire volume of conditioned media, thus 
adjusting for the variable total volume of conditioned media at different time points. The total 
amount of muIL10 released into the culture medium from the transduced tissue appears 
relatively consistent over the period measured at between 6 and 8 ng. The final 96-120 hour 
period appears reduced compared to the two previous time points in Figure 29B however it 
should be noted that the incubation time for this point is roughly half that of those previous. 
Data corrected for incubation time is not shown as there is the additional factor of IL10 half-
life within the medium to consider.  
Figure 29C shows the concentration of muIL10 detected within the tissue homogenates 
144hours post injection. Figure 29D shows the recorded masses of both the whole corneas 
and the excised 4mm discs. It also shows the amount of muIL10 calculated to be present in 
both based by extrapolating the amount detected in the assayed sample to the total volume / 
mass.   
The amount of muIL10 that remains in the tissue at this one time point appears be roughly 
one order of magnitude lower than that assayed in the conditioned media at any time point 
(0.47ng vs 2.7 – 8.1ng) This perhaps indicates that the majority of soluble protein produced 
does not remain within the tissue under these circumstances 
All of the PBS-MK injected control samples were below the range of detection and can be 
considered negative for muIL10 by ELISA. 
Based upon these results it is clear that following intrastromal injection of AAV in the context 
of human tissue ex vivo transgene product is released from the tissue into the conditioned 
media in easily detectable amounts. A more long term experiment is therefore feasible.  
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Figure 29. Levels of vector mediated muIL10 released into culture medium and retained within 
the tissue over 144 hour period following intrastromal injection of 50 µL of either AAV8(Y733F)-
CMV-muIL10-IRES-eGFP or PBS-MK. Human corneas ex vivo assessed by ELISA 
A: Concentration of muIL10 in conditioned culture medium at three time periods; 0-55hrs, 55-
96hrs, 96-120hr. Media changed between time points. 
B: Data in A corrected for different culture medium volumes at different time points which were as 
follows; 0-55hrs = 20mLs, 55-96hrs = 20mLs, 96-120hrs = 3mLs 
C: Concentration of muIL10 in homogenised, centrally positioned, 4mm diameter tissue disk 
excised at 144hrs post injection, 400µL volume. 
D: Table presenting the masses of the whole corneas and excised buttons and calculated amount 
of muIL10 present in both. 
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4.2.12 Very long term assessment by ELISA of the amount of soluble transgene 
product within the human cornea (ex vivo) post intrastromal injection of 
AAV2/8(Y733F) 
Following on from the experiment in 4.2.11 the amount of transgene product (muIL10) 
produced in the human cornea was assessed over a much long time period. Initially a period 
of 4 months (120 days) was selected but based upon initial results this was extended to 1 
year. 
A human cornea (~1 week in organ bank culture) was obtained from the eye bank and 
injected intrastromally with 50µL of diluted AAV2/8(Y733F)-CMV-muIL10-IRES-eGFP, total 
dose 1 x 1011 vgs. The corneas were incubated at 37°C / 5% CO2 in 25mL of Culture 
Medium I (BiochromAG). Approximately every 6-9 days following procedure was performed: 
 The conditioned media (25mLs) was removed and replaced with a fresh 25mLs 
(preheated to 37°C). Cornea was returned to the incubator in this fresh media. 
 The conditioned media was passed through a 0.22µm filter to remove any cellular 
contaminants. 
 From the 25mL filtrate 1.4mL samples were taken in triplicate the rest was discarded. 
 Samples were stored at -80°C until assayed. 
 For one time point (192 days post injection) the remainder of the conditioned media 
was returned to the incubator for a further 7 days in the absence of the corneal 
tissue. This was to gain some insight into how much muIL10 might be degraded over 
this time. 
Periodically the container (100mL sterile plastic bottle) in which the injected cornea was 
stored was changed. All samples were assayed for muIL10 concentration by ELISA at the 
same time at the end of the experiment. All samples were run neat in quadruplicate. ELISA 
plate loading volume was 100µL / well. 
 
Figure 30A shows the ELISA data. Between 0 and 70 days post injection the muIL10 
concentration assayed is consistently high between 1 and 2 ng / mL. Between 70 and 180 
days post injection this level has decreased and remains consistent between 0.5 and 1 ng / 
mL. After 180 days post injection the level increases dramatically to a level beyond the upper 
limit of the ELISA standard curve reaching a peak at around 200 days post injection before 
dropping off to nothing by 270 days post injection. No muIL10 was then detected in any 
sample between 270 days and the end of the experiment at 367 days post injection. 
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Red bars represent samples taken from incubation periods >9 days and thus are likely 
incomparable. 
Figure 30B shows that the concentration of muIL10 detected in one sample (192 days) 
decreased by approximately 6 fold when the conditioned media was incubated for a further 7 
days in the absence of the corneal tissue. 
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Figure 30. Levels of vector mediated muIL10 released into culture medium over 52 week period following intrastromal injection of 50 µL of AAV8(Y733F)-
CMV-muIL10-IRES-eGFP.  Human cornea ex vivo, assessed by ELISA 
A: Concentration of muIL10 in conditioned culture medium over time, each grey bar represents a 7±2 day culture period. Media was changed between time 
points. Red bars represent time points with a > 9 day culture period. 
B: Concentration of muIL10 in conditioned media the 192 day post injection time point compared with itself after a further 7 days incubation at 37°C in the 
absence of the corneal tissue. 
C: ELISA assay standard curve. 
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4.3 Discussion 
 
The work in this chapter focused upon characterising AAV based transduction of the corneal 
stroma to establish the feasibility of utilising stromal cells as production sites for a 
therapeutic transgene product to be secreted into the cornea. The keratocytes of the stroma 
are traditionally considered to be quiescent undergoing no cell division, cell death or any 
significant change under normal circumstances. The primary role of stromal keratocytes 
under normal circumstances being the synthesis and maintenance of the stromal extra 
cellular matrix (ECM).They are therefore an attractive target cell population to be co-opted 
into an additional role in the production and secretion of transgenic product. 
Initial experiments were indicative of the serotype AAV2/8(Y733F) mediating a higher level 
of transgene expression in the stroma than either of the other two serotypes chosen for 
comparison, particularly AAV2/9 which mediated a markedly lower level of transgene 
product at the time point assessed. This finding was in line with expectation, and the tyrosine 
mutant AAV vectors are described to mediate a higher level of transgene efficiency due to 
their more efficient escape from the endosome [187], a process that should be relatively cell 
type independent. Additionally an increased level of transgene expression in other ocular 
tissues such as the retina has been observed by both ourselves and others [295]. 
However the number of animals / eyes used in this initial trial was small and perhaps the 
observed difference between AAV2/8 and AAV2/8(Y733F) was not especially significant. 
Nonetheless both serotypes mediated a high level of expression and thus the selection of 
AAV2/8(Y733F) as the candidate for further development remains valid. 
The time course of transgene expression following intrastromal injection with 
AAV2/8(Y733F) was well characterised in two separate experiments using different doses of 
vector delivering eGFP. The onset of transgene expression is rapid, being easily detectable 
by slit lamp imaging only 2 days post injection. Expression reaches its peak around 7 days 
post injection; however, this level is not maintained and falls off rapidly, with the majority 
having been lost by 12 days post injection. After this a basal level of expression is 
maintained for at least 148 days (~5 months) post injection.  
This exact pattern of transduction has not to our knowledge been replicated in the literature. 
Sharma et al. [251] showed that expression from various AAV serotypes (applied topically 
following epithelial removal in vivo) continued to increase over time up to 30 days post 
transduction beyond which they did not follow up. Work by Hippert et al. in which vector was 
injected intrastromally [253] is in broad agreement with this pattern as they too observed a 
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slow increase of transgene expression over time up to 4 weeks post injection which then 
persisted up to 17 months post injection. The different pattern of transgene expression 
observed here is likely the result of a combination of factors.  
Firstly it is clear that this combination of vector and injection methodology has resulted in 
transgene expression not only in the stroma but also off-target within corneal epithelial cells. 
A very high level of transgene expression is seen within the epithelium at 7 days post 
injection (Figure 19) and the patterns of transgene expression observed by fundoscopy at 
the 7 day time point in both 4.2.2 and 4.2.3 are reminiscent of epithelial cells labelled by 
transgenic means [90]. This epithelial transduction is however lost relatively rapidly due to 
the normal turnover processes of the epithelium as shown by the relative lack of epithelial 
transduction at 14 days post injection (Figure 18) or at any later time point. This process 
likely accounts for the majority of the loss of transgene expression observed by fundoscopy 
between days 7 and 14 post injection.  
This off-target transduction of the epithelium was not the focus of this study and was a highly 
unexpected result. Intrastromal injection would be expected to only result in a very limited 
exposure of the epithelium to vector so the means by which such a large proportion of the 
epithelium became transduced is unknown. Additionally AAV vectors have not previously 
been shown to mediate anything more than a very limited transduction of the epithelium as 
discussed in 1.7.4. Such widespread off-target transduction of the epithelium has also not 
been reported in any other study targeting the stroma for transduction by AAV. In the case of 
Sharma et al. [250] this is perhaps unsurprising as in their studies the epithelium was 
removed prior to application of vector, however Hippert et al. [253] injected vector 
intrastromally by an almost identical method to ourselves and observed only extremely 
limited epithelial transduction at 3 days post injection. This study by Hippert et al. used a 
different vector serotype (AAV2/8) and whilst this serotype was assessed in our initial pilot 
experiments we did not at that time focus upon or compare epithelial transduction. Some 
transduction of the epithelium is seen with both AAV2/8 and AAV2/8(Y733F) at 14 days post 
injection (Figure 12) however by this time point most transduced cells may have already 
been lost. It remains possible therefore that AAV2/8(Y733F) displays a greatly increased 
epithelial tropism compared to AAV2/8 or any other serotype tested to date although further 
work is required to confirm this. 
For the intended purpose of expressing a soluble transgene for augmentation gene therapy 
this reproducible off-target expression in the epithelium is likely beneficial as it will initially 
increase the amount of soluble transgene produced, boosting the therapeutic effect albeit 
transiently. If however application required that transduction be limited to the stroma then a 
tissue specific promoter could be utilised to eliminate this off-target transgene expression. 
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The pattern of transgene expression observed here within the stroma is also at odds with 
that widely reported within the literature. The study by Hippert et al. is the most directly 
comparable to that presented here as they used a near identical vector titre, injection volume 
and vector delivery method in combination with a very similar AAV serotype. At seven days 
post injection however Hippert et al. did not achieve the a high level of stromal transgene 
expression shown here, and whilst they report transgene expression increasing over time, 
even by 1 month post injection expression was still far lower than that seen here at early 
time points. This disparity cannot be explained by the serotype difference between the two 
studies. Whilst the majority of this study utilised AAV2/8(Y733F), exactly the same serotype 
used by Hippert et al. (AAV2/8) was tested in initial experiments and was also found to 
mediate a high level of stromal transgene expression at 14 days post injection (Figure 12). 
Hippert et al. did achieve a high level of stromal expression comparable to that shown here 
via a subsequent intrastromal injection of PBS in procedure they termed “hyper-activation” 
and they hypothesised that this induced increase in AAV mediated expression proceeded 
from inflammatory processes. As a concept this has merit as AAV has previously been 
shown to increase its transgene expression within inflammatory environments in the cornea 
[226].  
The very high level stromal transgene expression observed here could therefore be a result 
of a similar hyper-activation but mediated by the initial injection without the requirement for 
any subsequent boosting by PBS injection. This discrepancy might result from a difference in 
vector purity as our vectors may contain a greater number of inflammatory impurities than 
those used by Hippert et al. Their paper does not describe their AAV production and 
purification protocol in full detail but does mention final concentration by iodixanol gradient. 
This method would be expected to result in virus of a high purity, whilst we are aware that 
our ion exchange based method, whilst producing higher titres, may not be as pure. Our 
initial injection may therefore have constituted a sufficiently inflammatory event for transgene 
production by AAV to be essentially hyper-activated as described by Hippert et al. almost 
immediately upon injection. Thus the dampening down or resolution of this event may also 
have contributed to the observed reduction in transgene expression over time. 
Due to the fact that they observed no difference in the capacity of PBS and LPS to stimulate 
hyper-activation Hippert et al. concluded that “It is the lesion rather than the substance that 
causes the inflammation”. The results presented here would tend to partially contradict that 
statement. If indeed we are observing hyper-activation after the initial injection it cannot be 
solely a result of the injection itself as in that regard our procedure was essentially identical 
to that performed by Hippert et al. who observed no immediate hyper-activation. Hippert et 
al’s results show that whilst the injection itself is certainly effective in promoting hyper-
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activation of an established rAAV transduction the results presented here indicate that some 
additional factor must be required to produce such the effect from an initial injection. Further 
experiments are required to confirm this hypothesis. Our vector purification methodology has 
recently been improved / modified to utilise an affinity based FLPC column specifically 
designed for AAV purification which has resulted in a marked improvement in vector purity. 
An experiment could therefore now be undertaken where by a highly purified vector is co-
injected with either LPS or vehicle to confirm whether hyper-activation is indeed occurring 
and dissect the factors influencing the initial inflammatory response.  
Following our injections we observed no obvious macroscopic evidence of inflammation, 
such as clouding / haze of the cornea, redness or neovascularisation at any early time point. 
All corneas initially appeared healthy and fully transparent. At later time points some but not 
all eyes developed fibrotic corneal scarring as shown in Figure 18; however this is a 
commonly observed event within the lab primarily associated with repeated general 
anaesthetic and ocular imaging with bright light sources rather than any other intervention. 
At the cellular level we did observe an increase in F4/80 positive cells (activated 
macrophages) in the corneal stroma in the case of AAV injected eyes at 10 days post 
injection which was not observed in the control. Hippert et al. did not observe any increase in 
F4/80 positive cells in the stroma following either their initial injection or subsequent hyper-
activation by PBS injection, providing further evidence that our initial injection provided a 
stronger inflammatory drive than either injection by Hippert et al. and is thus producing a 
hyper-activated response. It should be established however whether these cells remain 
present once transgene expression has plateaued to the lower level sustained over the long 
term. 
Another factor that is likely involved in the observed changes in transgene expression in the 
stroma over time is the wound healing response of the stroma to the insult of the injection. 
The normal response of corneal keratocytes to injury has been well characterised, although 
has only been extensively studied in two distinct injury types due to their clinical relevance; 
epithelial injuries of various severity and direct incisions into the stroma itself of a type 
associated with refractive surgery. Most stromal wound healing responses have been 
characterised as occurring very rapidly after injury; keratocyte apoptosis occurs with hours 
[38,39], repair responses begin shortly afterwards [32] and the majority of healing process 
being well established or essentially over by 1 week post injury [41].  
This timescale does not fit with the observed changes in this study, which did not become 
apparent until 7 to 12 days post injection at the earliest. By this time the main events of a 
typical corneal wound healing response would be expected to be complete. Surprisingly 
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however the pattern of results that emerged around this time point and later was in many 
respects extremely similar to what has been observed to be associated with a typical stromal 
wound healing response to an epithelial injury, although much delayed. 
Assessment of transgene (eGFP) expression in two separate experiments (flat mount 
imaging at 28 days post injection - Figure 23, and cryosectioning at 148 days post injection - 
Figure 18) showed that expression becomes largely restricted to the posterior stroma. This is 
in contrast to images taken earlier at 7 and 14 days post injection where full thickness 
stromal transduction is visible. There are two possible explanations for this finding; anterior 
cells are either being lost or are down regulating transgene expression. The former of these 
two possibilities is perhaps the most likely. 
Following an intrastromal injection two distinct insults to the cornea have been made that 
might trigger anterior keratocyte apoptosis and a wound healing response, firstly the acute 
process of injection and secondly a potential low level inflammation to the vector itself 
developing over time. During the process of intrastromal injection the needle causes a 
penetrating injury to both the epithelium and stroma, although epithelial involvement is 
localised to a single point. The injection then causes a widespread separation of the stromal 
matrix and opacification of the cornea, although this rapidly resolves appearing 
macroscopically normal within 24 hours. 
It is conceivable that the damage to the stromal matrix resulting from intrastromal injection is 
somewhat focused upon the anterior stroma. During injection the needle tip was not guided 
to any specific position within the Anterior - Posterior axis of the cornea, although care was 
taken to avoid penetration of the anterior chamber which may have favoured anterior 
positioning of the needle tract. Additionally for reasons of ease of corneal penetration the 
needle was positioned bevel upward during injection and therefore expulsion of liquid from 
the needle will have been initially directed anteriorly. Anterior keratocyte apoptosis is 
regularly observed as the initial event in normal stromal wound healing in the case of 
anterior (epithelial) injuries and it is extremely likely that intrastromal injection would trigger 
some apoptosis given that even relatively minor corneal wounds such as epithelial scrapes 
do so [40,296]. 
However, given that anterior stroma transgene expression is widespread at 7 days post 
injection, and that apoptosis to the acute injury of injection should have occurred within 
hours, it is unlikely that the injection itself has resulted in apoptosis unless the process is 
greatly delayed in the case of this specific insult. 
At 10 days post injection TUNEL staining revealed a relatively widespread apoptosis 
occurring within the stroma. This staining whilst of sufficient quality to be convincing of 
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increased apoptosis overall could not be said to be sufficiently clear to establish whether 
apoptosing cells were anteriorly restricted. The TUNEL assay proved to be highly unreliable 
so attempts were made to use immunohistological staining for the apoptosis marker 
activated caspase 3 in order to confirm the TUNEL result and better reveal any anterior 
localisation of the apoptosis. Unfortunately despite multiple attempts under different 
conditions no positive cells for activated caspase 3 were ever observed in the positive 
control region (the apical epithelium) or elsewhere in the cornea using this antibody, 
suggesting it is ineffective in this tissue. This is in line with the experience within the lab 
which suggests that whilst this antibody works well for staining of cells grown in vitro, its 
application to cryosectioned ocular tissue is limited. The apoptosis observed at 10 days post 
injection likely is too late to be injection related and may well be induced by the same 
inflammatory response within the cornea that may be driving a hyper-activation of transgene 
expression from AAV. 
At the later time point of 18-21 days post injection of vector, a wave of EdU uptake indicative 
of cell proliferation was observed to occur within the stroma. This proliferative wave is 
localised to the posterior stroma across the entire corneal diameter. This is again extremely 
similar to what is observed following an epithelial injury to the cornea [41] but much delayed. 
Such proliferation is indicative of the keratocytes transitioning to an activated wound healing 
state to repopulate and repair the stroma. In the context of stromal wound healing this is a 
process that initiated by the apoptosis of adjacent keratocytes [38,41] and thus the pattern of 
proliferation observed is strongly indicative of extensive anterior keratocyte apoptosis having 
taken place. 
Additionally this posterior proliferation was only observed in the AAV injected cornea and not 
in the vehicle injected control. This was also the case with the increase in F4/80 staining 
(indicative of an inflammatory event) that was discussed earlier. This response is therefore 
specific to the vector solution and unrelated to the trauma of intrastromal injection, adding 
more weight to the hypothesis of vector induced inflammation being primarily responsible for 
driving all of the effects observed. 
It is difficult to explain in this context why a widely distributed vector induced inflammation is 
driving a response typical in many respects of a wound to the anterior cornea such as an 
epithelial debridement. It has been hypothesised that stromal keratocytes directly underlying 
the epithelium undergo apoptosis readily in response to even minor epithelial wounds or 
infections to act as a “firebreak” against spread of infection [297] and do so in response to 
cytokine factors released by the epithelium such as soluble Fas ligand and IL1 in particular 
[298]. Any kind of inflammation we have induced is likely to result in the production of IL1 
possibly mediated by the activated macrophages we have observed within the stroma post 
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injection [299]. This could potentially mimic the epithelial derived signal to induce anterior 
keratocyte apoptosis and it is also possible that due to their “firebreak” role anterior 
keratocytes are perhaps more sensitive to undergoing apoptosis in response to such signals 
than those more posteriorly. 
This hypothesis could be tested in a number of ways. Firstly experiments aimed at delivery 
of recombinant IL1 or Fas ligand to the stroma in various doses to determine if anterior 
keratocytes preferentially apoptose in response could be undertaken, although it is difficult to 
conceive of a method by which the cytokines might be delivered to this location whilst 
avoiding the complicating factors of epithelial or injection damage. Secondly the properties of 
the anterior and posterior keratocytes could be assessed for any differences that might 
indicate a variable response to cytokine signals, such as differential expression of cell 
surface receptors to cytokines. 
In conclusion the effects of the low level inflammation in the stroma induced by AAV injection 
are twofold: On the one hand the effect may be beneficial, leading to hyper-activation of AAV 
transgene expression and an increased production of transgene product. By contrast the 
process may also be mildly deleterious as this inflammation eventually results in the 
activation of a stromal wound healing response and the loss of transduced keratocytes from 
the anterior stroma. With regard to the expression sustained over the long term (up to ~5 
months) by which time any inflammation related processes should have resolved it has not 
been established here whether the level of transgene expression remaining at this time 
would have been comparable had there been no inflammation that may have triggered 
hyper-activation. Data from Hippert et al. [253] suggests levels pre and post hyper-activation 
would be comparable as this is what was observed in their study.  
Given that no macroscopic evidence of damage was ever observed in response to the vector 
induced inflammation then perhaps the initial increase in stromal expression that results 
could be utilised therapeutically. However if a technique known to induce a limited stromal 
inflammation is to be of utility then it is important that the process be very tightly controlled 
due to its inherent pathogenic nature. 
 
Despite this extensive discussion regarding the possible effects of an AAV2/8(Y733F)-CMV-
eGFP mediated stromal inflammation upon transgene expression there can be no doubt that 
a widespread transgene expression profile remained evident up to 148 days (~5 months) 
post injection in vivo localised to the posterior stroma (Figure 18B). Whilst not truly 
quantitative the eGFP signal observed was not obviously weaker on a cell by cell basis than 
comparable imaging at earlier time points. This remaining expression also appears to be of a 
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higher level than the most extensive non-hyperactivated expression reported in the literature 
[253] and is thus likely still of use for application to production of a therapeutic protein for 
secretion over the long term.  
The most convincing evidence for this comes from the data on human tissue ex vivo 
(4.2.12). After intrastromal injection of a comparable AAV dose (scaled up by volume from 
mouse tissue) a large amount of transgene product (muIL10) was detected by ELISA in the 
conditioned media for the first 50 days post injection. During this initial period concentrations 
of muIL10 close to the upper detection limit of the assay (1-2 ng / mL) were detected. The 
cornea was cultured in 25 mLs of medium that was replaced weekly meaning that at the 
point of assay a total of 25-50 ng of muIL10 was present in the total volume. This level 
represents an underestimate of the amount produced over the whole week in culture due to 
degradation of secreted muIL10 over time. To illustrate this the concentration of muIL10 
present in conditioned media was shown to be reduced 6-fold after 1 week of incubation at 
37°C in the absence of transduced tissue. Assuming one-phase decay kinetics this would 
give muIL10 a half-life of approximately 65 hours under tissue culture conditions. 
These initial results exceeded expectations both in terms of level and duration of transgene 
expression produced. Duration in particular was surprising. Corneas are rejected for 
transplantation as a matter of course after only 2-4 weeks in organ culture for reasons of 
insufficient quality. This is usually due to decreasing endothelial cell density over time in 
culture. Initially therefore this experiment was planned to last for 2 months, as we expected 
corneal viability to have decreased too much to be of further use by this time. This period 
elapsed however with no real change or drop off in transgene expression being noted so 
these results would suggest that the cells of the stroma must be substantially more robust 
than those of the endothelium under these conditions. The experiment was thus extended 
until such a time as expression could no longer be detected up to a maximum of 1 year post 
injection. 
Between 50 and 85 days post injection the concentrations of muIL10 detected steady 
dropped to around half the previous level to 0.5 and 1 ng / mL which then maintained until 
180 days. This somewhat mimics the decrease observed in vivo although much delayed. 
Any extrapolation of mechanisms between the murine in vivo and human ex vivo condition is 
however likely to be invalid due to the dramatic differences between these two conditions. 
Nonetheless there is some indication that the posterior restriction of stromal transgene 
expression also occurs in the human tissue provided by the cryosectioning of human tissue 
7 days post injection (Figure 28B) although it is possible this is merely an artefact of the high 
level of tissue oedema that occurs in culture. 
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After 180 days a dramatic increase in muIL10 level was observed, to concentrations beyond 
the range of the assay standard curve. This could perhaps be attributed to the cells dying 
and tissue integrity failing both of which might result in release of any muIL10 retained within 
the tissue. This hypothesis would be supported by the fact that after this pulse of high 
muIL10 levels dropped to zero with no further muIL10 detected between 279 days and the 
end of the experiment at 367 days. However, the fact that the high level pulse lasted for over 
2 months is perhaps an unfeasibly long period to be attributed to the process of tissue death 
/ failure. The event of the high level pulse is therefore difficult to explain and it would be 
important to establish whether it is reproducible, or a one off event observed in this 
experiment only. 
 
Conclusions 
 Intrastromal injection in vivo of the vector AAV2/8(Y733F)-CMV-eGFP results initially 
in a high level transduction of corneal keratocytes over the entire thickness and 
diameter of the cornea. In addition widespread off-target transduction of the corneal 
epithelium also occurs. 
 Transgene expression peaks at 7 days post injection before dropping off to a basal 
level which is maintained in vivo for at least 148 days post injection.  
 The drop off in transgene expression is largely the result of the loss of transduced 
epithelium to turnover, however the resolution of an inflammatory induced hyper-
activation of AAV expression and the apoptosis of some transduced keratocytes may 
also contribute. 
 In multiple respects the response of the stromal cells to the inflammation induced by 
the vector injection mimics that typical of a wound to the anterior cornea such as an 
epithelial scrape, although much delayed. 
 Transgene expression in the stroma after drop off is still spread across the entire 
diameter of the cornea but has become restricted to the posterior stroma. 
 Data obtained in both murine tissue in vivo and human tissue ex vivo indicated that 
intrastromal injection is capable of mediating a long lasting transgene expression in 
the stroma at moderate to high levels. The approach is therefore likely to be 
applicable in an augmentation gene therapy approach to corneal disease acting 
through a secreted product. 
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5. Intrastromal injection of AAV2/8(Y733F) delivering 
sFlt1 to treat corneal neovascularisation 
 
5.1 Introduction 
 
Work in this chapter will develop the AAV2/8(Y733F) mediated transduction of the cornea by 
intrastromal injection (Chapter 4) for application in prevention of corneal neovascularisation, 
a pathology of high clinical relevance as discussed in the introduction (1.5).  
A gene augmentation approach will be applied in which gene transfer via AAV2/8(Y733F) 
will result in the production of a soluble anti-angiogenic factor within the stroma over the long 
term. The soluble molecule chosen for expression is soluble fms-like tyrosine kinase-1 
(sFlt1) also known as soluble vascular endothelial growth factor receptor 1 (sVEGFR1). This 
molecule was selected as it is a potent anti-angiogenic factor which has seen widespread 
use in the suppression of angiogenic responses in the eye, additionally it has been shown 
that the expression of sFlt1 within the cornea is critical to the tissue’s naturally avascular 
state [110]. This molecule therefore seems an ideal candidate for corneal overexpression in 
order to ameliorate pathological corneal neovascularisation. In order to minimise any 
potential complications arising from species differences it was decided that the murine sFlt1 
protein (musFlt1) would be used. The human protein whilst sharing 77% identity with the 
murine is still dissimilar enough to potentially result in sub-optimal efficacy.  
To assess the effectiveness of the approach it will be tested within a commonly used murine 
(C57Bl/6J) model system in which corneal neovascularisation is induced by the placement of 
multiple sutures penetrating the full thickness of the cornea. Whilst obviously artificial, this 
model has the benefit of inducing neovascularisation via stimulation of the same 
physiological processes that generate a corneal neovascular response in many clinical 
cases, i.e. via trauma and inflammation. 
 
5.1.1 Aims 
The aim of the work presented in this chapter is to determine whether the corneal 
neovascularisation induced by the corneal suture model can be reduced or prevented via 
augmentation gene therapy in which intrastromal injection of AAV2/8(Y733F) mediates the 
production of murine sFlt1 within the cornea.  
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5.2 Methods and results 
 
5.2.1 Confirmation of murine sFlt1 transgene expression in vitro from 
AAV2/8(Y733F)-CMV-musFlt1 vector 
Before use in vivo the vector AAV2/8(Y733F)-CMV-musFlt1 was tested and validated in 
vitro. 
293T cells were seeded into a 6-well plate and grown until approximately 80% confluent. At 
this point 2 of the wells were infected with 5 µL of AAV2/8(Y733F)-CMV-musFlt1 vector total 
dose (6 x 109 vgs). The remaining 4 wells were left uninfected as controls. 
After 48 hours both cells and the conditioned media were harvested from all wells. Cells 
were scraped off the bottom of the wells with a cell scraper and collected in the conditioned 
media (5 mL per well). The conditioned media + cells underwent 2 rapid freeze / thaw cycles 
(Dry ice + isopropanol bath at -77°C, followed by water bath at 37°C) to lyse the cells. 
Cellular debris was pelleted by centrifugation at 1000g and discarded. The supernatant from 
virus infected wells was diluted 2 x 10-fold in ELISA reagent diluent (1x PBS+1% BSA). For 
infected wells both diluted and neat supernatant was used as sample in an ELISA for murine 
sFlt1 (2.4.8). Supernatant from uninfected wells was only used neat.  
All samples were run in quadruplicate and ELISA plate loading volume was 100µL / well. 
Figure 31 shows the results of the ELISA, only the undiluted samples from vector infected 
wells gave any detectable level of murine sFlt1. Both infected wells were assayed to contain 
~1.3 ng of musFlt1 / mL of sample. The 1 in 10, 1 in 100 dilutions of sample and all of the 
uninfected controls did not give readings above the lower limit of detection. 
The vector has been demonstrated to mediate transgene expression and translation in vitro, 
with resulting transgene product being detectable by ELISA. The vector has therefore been 
validated for use in vivo. 
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Figure 31. Levels of musFlt1 detectable by ELISA after in vitro infection of 293T cells with 
AAV2/8(Y733F)-CMV-muSFlt1 
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5.2.2 Reduction of neovascular area in a murine model of induced corneal 
neovascularisation by intrastromal injection of AAV2/8(Y733F) encoding sFlt1 
Having established that intrastromal injection of AAV2/8(Y733F) is able to mediate sustained 
expression of transgene within the stroma and produce nanogram scale quantities of soluble 
protein product the technique was applied to the treatment of corneal neovascularisation in 
the suture induced mouse model (2.3.9) which in the course of this work had been optimised 
to reliably induce consistent neovascularisation. 
For use in this experiment two AAV2/8(Y733F) based vectors were prepared. The 
therapeutic vector encoding murine sFlt1 under the control of the CMV promoter and a 
control NULL vector developed within the lab. The sFlt1 encoding vector was validated to 
produce transgene product in vitro in 5.2.1. The NULL vector consisted of a construct 
originally designed to express the gene retinitis pigmentosa GTPase regulator (RPGR) 
which has been modified so that both the start codon of the gene and the promoter region 
are removed. It has been shown in vitro to mediate no gene expression as assessed by 
qPCR. 
The titres of the two vectors assessed by Dotblot (2.2.3): 
AAV2/8(Y733F)-CMV-musFlt  -  1.2x1012 vgs / mL 
AAV2/8(Y733F)-NULL   -  3.5x1013 vgs / mL 
Before injection therefore the NULL vector was diluted 1 in 20 in PBS-MK to approximately 
titre match. Before injection the vectors were randomised by a 3rd party so that those 
undertaking the experiment and analysis did not know which vector was which, knowing 
them only as A and B. They were only unmasked once all analysis was complete. 
A total of 10 animals received bilateral intrastromal injections of 2 µL vector. Each animal 
received murine sFlt1 encoding virus in one eye and NULL in the other. Which vector (A or 
B) was received in which eye was randomised. Three days later all corneas were sutured to 
induce corneal neovascularisation. In the previous chapter it was shown that transgene 
expression mediated by AAV2/8(Y733F) peaks at around 7 days post intrastromal injection 
before falling off. To maximise chances of success the timing of vector injection and 
induction of vascularisation was designed so that the period of peak transgene expression 
should coincide with the strongest neovascular drive. A full schematic of the experimental 
time line is shown in Figure 32 
At 14 days post suture (17 days post injection) all animals were bilaterally assessed for 
neovascular development by scanning laser ophthalmoscope fluorescein angiography (SLO-
FA) before being culled. Due to the extremely rapid spread of fluorescein through the tissue 
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it was inevitable that within each animal the eye imaged first would produce a clearer image 
with less leakage of fluorescein than the second. For every animal the right eye was imaged 
first and the left second. As vector administration was randomised between the eyes this 
should ensure this factor does not significantly affect the result.  
Indocyanine green (ICG) angiography which does not suffer so much from dye leakage was 
trialled however it was found to be both far weaker than fluorescein and in addition ICG 
visualised the iris vasculature, which were hard to distinguish from corneal neovascular 
vessels. 
Each eye was examined immediately post mortem for the presence of the sutures. In the 
majority of cases all 3 sutures were still in place at this time. In the small number of cases 
where 1 or more sutures had been lost the eye was excluded from further analysis. 
Angiography images from the SLO were compiled (2.5.3) and the neovascular area 
quantified (2.5.4). 
The experiment was repeated, being undertaken in 2 cohorts of 10 mice each. 
Figure 33 shows the results of the fluorescein angiography for both cohorts. In both cohorts 
9 mice (18 eyes) were analysed at the end of the experiment, 1 animal from each cohort 
either having died before analysis or was deemed unsuitable for analysis.  
Figure 33A & A’ show the compiled SLO-FA images for the eyes injected with the NULL 
vector for both cohorts. In most cases extensive neovascularisation is visible, and at least 
some has occurred in every eye. 
Figure 33B & B’ show the compiled SLO-FA images for the eyes injected with the musFlt1 
encoding vector for both cohorts. For cohort 1 (Figure 33B) almost no neovascularisation is 
visible in any of the eyes, for cohort 2 (Figure 33B’) the result is less striking however 6 out 
of the 9 eyes display little or no neovascularisation. 
Figure 33C & C’ shows quantification (as described in 2.5.4) of the neovascular area 
comparing the NULL injected with the musFlt1 injected for both cohorts. In both cases the 
observed reduction in neovascular area between the NULL and the musFlt1 groups is very 
significant (p < 0.0001 and p = 0.014 respectively).  
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Figure 32. Schematic representation of timing of procedures in experiment to assess the capacity 
of intrastromal injection of AAV2/8(Y733F)-CMV-musFlt1 vector to ameliorate suture induced 
corneal neovascularisation, Cohorts 1 and 2 (SLO-FA) 
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Figure 33. Effect upon suture-induced corneal neovascularisation of 2µL intrastromal injection of 
AAV2/8(Y733F)-CMV-musFlt1 compared to control vector. Assessed by fluorescein angiography (in 
vivo, SLO) at 17 days post injection / 14 day post induction (Cohort 1 and 2) 
A – A’: Fluorescein angiography of eyes treated with AAV2/8(Y733F)-NULL (Control), in two cohorts 
of 9 mice.  
B – B’: Fluorescein angiography of eyes treated with AAV2/8(Y733F)-CMV-musFlt1 (Treatment), in 
two cohorts of 9 mice.  
C – C’: Quantification and comparison of neovascular area between AAV2/8(Y733F)-NULL (Control) 
and AAV2/8(Y733F)-CMV-musFlt1 (Treatment), in two cohorts of 9 mice.  
 
  
 
 
AAV2/8(Y733F) – NULL AAV2/8(Y733F)-CMV-musFlt1 
C
o
h
o
rt
 1
 
C
o
h
o
rt
 2
 
A’ 
B 
B’ 
A 
C’ 
C 
 172 
 
5.2.3 Histological assessment of reduced neovascular area following treatment of 
corneal neovascularisation by intrastromal injection of AAV2/8(Y733F) 
encoding murine sFlt1 
Following the promising results obtained in 5.2.2 it was decided to induce and treat a third 
cohort and in addition to assessment by SLO-FA collect tissue for histology after 
angiography. 
The initial phase of this experiment was essentially a third cohort of the experiment 
performed in 5.2.2. Vectors were again masked before injection and a total of 10 animals 
received bilateral intrastromal injections of 2 µL vector. Each animal received musFlt1 
encoding virus in one eye and NULL in the other. Three days later all corneas were sutured 
to induce corneal neovascularisation. At 14 days post suture (17 days post injection) all 
animals were bilaterally assessed for neovascular development by SLO fluorescein 
angiography (SLO-FA). Immediately after angiography the sutures were removed. This was 
done as carefully as possibly but if neovascular vessels were well established some 
bleeding was inevitable. After removal, 1 % chloramphenicol ointment (FDC International) 
was carefully applied topically on the cornea and anaesthesia reversed. The animals were 
then allowed to recover for 2 days to allow both the flushing of the fluorescein from the body 
and the healing of any damage caused by suture removal. On the third day the animals were 
culled, and the vasculature stained by DiI perfusion (2.4.5). After perfusion each eye was 
prepared for further staining (2.4.3). The corneas were post fixed in 4% PFA and additionally 
stained for LYVE1 (a marker of lymphatic vessels) and DAPI. Once tissue had been fully 
processed corneal flat mounts were imaged by confocal microscopy. 
A full schematic of the experimental time line is shown in Figure 34. 
Figure 35 shows the results of the fluorescein angiography for cohort 3. In this cohort a total 
of 4 eyes were excluded or lost from the analysis, 1 from the NULL group and 3 from the 
musFlt1 group. 
Figure 35A shows the compiled SLO-FA images for the eyes injected with the NULL vector. 
In 6 out of 9 eyes extensive neovascularisation is visible; only one eye appears relatively 
free of neovascularisation. 
Figure 35B shows the compiled SLO-FA images for the eyes injected with the musFlt1 
encoding vector. Very little neovascularisation is visible with only 3 out of 7 eyes displaying 
relatively minor symptoms. 
Figure 35C shows quantification (as described in 2.5.4) of the neovascular area comparing 
the NULL injected with the musFlt1 injected eyes. The observed reduction in neovascular 
area between the NULL and the musFlt1 groups is very significant (p = 0.0115). 
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Figure 36 shows representative DiI staining of blood vasculature (Figure 36A) and LYVE1 
staining of lymph vasculature (Figure 36B) in an unprocedured murine cornea. Note the 
complete avascularity (blood and lymph) of the central cornea. All visible staining is 
restricted to the region of the limbal vascular arcades. 
Figure 37 shows the DiI and LYVE1 staining obtained in the animals of cohort 3 when culled 
20 days post intrastromal injection (17 days post induction of neovascularisation). All images 
have been thresholded (as described in 2.5.4) to best distinguish signal from background. 
Blood neovasculature (DiI, red) within the central cornea appears far more pronounced in 
the NULL treated group (Figure 37A) than in the murine sFlt1 treated group (Figure 37A’). 
There is no obvious difference in the extent of lymph neovasculature (LYVE1, green) within 
the central cornea between the NULL and murine sFlt treated groups (Figure 37B vs B’). 
Figure 38 shows quantification (as described in 2.5.4) of the neovascular area in the images 
presented in Figure 37 comparing the NULL injected with the musFlt1 injected eyes for both 
blood and lymph vasculature. Figure 38A & B shows quantification of blood and lymph 
neovascular area respectively. This quantification was done upon the basis of the number of 
stained pixels for each as a proportion of the total central area in the image. For blood 
vessels (DiI) there is a highly significant (p=0.0079) reduction in stained area in the musFlt1 
treated group when compared to the NULL treated group. For Lymph vessels there is no 
significant difference between the groups. Figure 38C & D present the same quantification 
as in Figure 38A & B but calculated differently. The DiI stain gave an extremely high 
fluorescent signal and therefore had a tendency to bleed into the other channel, for this 
reason each stained pixel count had subtracted from it the number of pixels that stained 
positive in both the DiI and LYVE1 channels. This should ensure any effects of channel 
bleed through are excluded from the analysis. Figure 38E – E’’ shows an example of the two 
channels (DiI and LYVE1) and the bleed through between them. 
This more stringent method of analysis had no effect on the result, there remains a highly 
significant (p=0.0079) reduction in stained area for blood vessels (DiI) when the murine sFlt1 
treated group is compared to the NULL treated group, and no significant difference in the 
degree of lymph neovascularisation between the groups. 
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Figure 34. Schematic representation of timing of procedures in experiment to assess the capacity 
of intrastromal injection of AAV2/8(Y733F)-CMV-musFlt1 vector to ameliorate suture induced 
corneal neovascularisation. Cohort 3 (SLO-FA and histology) 
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Figure 35. Effect upon suture-induced corneal neovascularisation of 2µL intrastromal injection of 
AAV2/8(Y733F)-CMV-musFlt1 compared to control vector. Assessed by fluorescein angiography (in 
vivo, SLO) at 17 days post injection / 14 day post induction (Cohort 3) 
A: Fluorescein angiography of eyes treated with AAV2/8(Y733F)-NULL (Control), in a 3rd cohort of 9 
mice.  
B: Fluorescein angiography of eyes treated with AAV2/8(Y733F)-CMV-musFlt1 (Treatment), in a 3rd 
cohort of 9 mice.  
C: Quantification and comparison of neovascular area between AAV2/8(Y733F)-NULL (Control) and 
AAV2/8(Y733F)-CMV-musFlt1 (Treatment), in a 3rd cohort of 9 mice.  
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Figure 36. Representative DiI perfusion + LYVE1 
staining of an unprocedured C57Bl/6J murine cornea 
ex vivo 
A: Haem vasculature as visualised by intra-cardiac 
perfusion of DiI. 
B: Lymph vasculature as visualised by 
immunohistological staining for LYVE1 
C: Merged image of panels A & B 
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Figure 37. Haem and Lymph vessels visualised in corneal flatmounts post suture-induced 
neovascularisation and intrastromal injection of AAV2/8(Y733F)-NULL and AAV2/8(Y733F)-CMV-
musFlt1. 19 days post injection / 17 day post induction  
A & A’: Blood vasculature (red) visualised by intra-cardiac perfusion of DiI. NULL and musFlt1 
vector injected corneas respectively. B & B’: Lymph vasculature (green) visualised by LYVE1 
immunohistological staining. NULL and musFlt1 vector respectively. C & C’: Merged images of A+B 
and A’+B’ respectively. 
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Figure 38. Quantification of Haem and Lymph neovascularisation in corneal flatmounts post 
suture-induced neovascularisation and intrastromal injection of AAV2/8(Y733F)-NULL and 
AAV2/8(Y733F)-CMV-musFlt1. 19 days post injection / 17 day post induction. Based upon images 
presented in Figure 37 
A: Comparison of Blood neovascular area between NULL and musFlt treated eyes, calculated as 
follows: No. DiI (Red) pixels / Total pixels in central cornea x 100 
B: Comparison of Lymph neovascular area between NULL and musFlt treated eyes, calculated as 
follows: No. LYVE1 (Green) pixels / Total pixels in central cornea x 100 
C: Comparison of Blood neovascular area between NULL and musFlt treated eyes, calculated as 
follows: (No. DiI (Red) pixels – No. Yellow pixels) / Total pixels in central cornea x 100 
D: Comparison of Lymph neovascular area between NULL and musFlt treated eyes, calculated as 
follows: (No. LYVE1 (Green) pixels – No. Yellow pixels) / Total pixels in central cornea x 100 
E – E’’: Single eye as example of analysis showing the area defined as central cornea (circle), DiI 
Staining (E), LYVE1 Staining (E’) and possible bleed through between the two signals (E’’) 
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5.3 Discussion 
 
Work in this chapter aimed to apply the initially high level, long lasting gene transfer to the 
corneal epithelium / stroma via AAV2/8(Y733F) demonstrated in the previous chapter to an 
augmentation gene therapy based approach to ameliorate or prevent corneal 
neovascularisation in the suture-induced model via the production and secretion of sFlt from 
transduced cells. 
The results achieved convincingly demonstrate that overexpression of sFlt1 mediated by 
intrastromal injection of AAV2/8(Y733F)-CMV-musFlt1 vector is able to significantly reduce 
the amount of haemangiogenesis induced by the suture model. The result proved to be 
highly reproducible, being observed in three independent experiments in which the identity of 
the vector being injected was masked on both injection and analysis. The effect was 
especially marked however in cohort 1 where haemangiogenesis was essentially completely 
eliminated in all eyes injected with the sFlt1 encoding vector. The reason for the especially 
high efficacy in cohort 1 remains unknown and is perhaps best explained as simply falling 
within experimental variation. 
Previous studies within the literature have attempted to treat corneal neovascularisation by a 
number of approaches, many involving the blockade of VEGF-A signalling in a similar 
manner to that performed here.  
The most directly comparable work to that presented here has been performed by the group 
of Lai et al. This group initially aimed to treat angiogenesis induced by silver / potassium 
nitrate cauterisation in rats via anterior chamber injections delivering sFlt1 encoded by either 
adenovirus [300] or AAV2/2 [152]. Some inhibition of neovascularisation was achieved 
however the transgene expression profile from both viruses was extremely limited, AAV in 
terms of extent and adenovirus in terms of duration. 
Lai et al. did not therefore further pursue these approaches and switched to a different 
strategy involving a subconjuntival route of vector administration and an alternative 
transgene. The transgene selected was endostatin, a factor based upon the C-terminal 
fragment of collagen XVIII well characterised to inhibit angiogenesis via disruption of 
endothelial cell migration and proliferation [301]. An AAV2/2 vector encoding endostatin 
under the control of a CMV promoter was injected subconjuntivally in CD1 mice to treat 
angiogenesis induced by the same cauterisation model [260]. In contrast to the previous 
work it was shown that transgene expression was sustained over the long term (8 months) 
and was partially effective in inhibiting induced angiogenesis when induction took place two 
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weeks post injection, significantly reducing the severity of induced neovascularisation 
observed as assessed by in vivo microscopy. 
The approach we have selected has the advantage of utilising a serotype of AAV generally 
regarded to be more effective [187] and mediating production of transgene within the cornea 
itself, rather than in an adjacent tissue. Nonetheless the subconjunctival route represents a 
valid mode of administration and presents the potential advantage of being less invasive. It 
is inapplicable however to use in the context of pre-treatment of corneal grafts to improve 
their survival as during corneal engraftment in clinic no conjunctival tissue is transplanted  
Another study utilising AAV as the gene delivery method was performed by Mohan et al. 
[264]. In this case decorin was the transgene selected as this proteoglycan is both 
endogenous to the corneal stroma and has been shown to be involved in the regulation of 
angiogenesis in other tissues [302]. AAV5 encoding decorin was applied topically to the 
stroma following epithelial debridement, angiogenesis having been induced 1 day earlier by 
the implantation of a device releasing VEGF-A. 
A reduction in induced neovascularisation of around 50% was demonstrated although the 
area analysed appears to be extremely small localised to the extreme limbus. Untreated 
vascularised area covered only around 12mm2 per cornea, a comparatively small proportion 
of an entire rabbit cornea. This was possibly due to the highly localised induction produced 
by the implant. Whilst useful in assessing a molecule’s antiangiogenic potential (as was 
done for decorin in this case) the implant induction methodology is of limited relevance as it 
is not associated with any of the factors that cause neovascularisation clinically, such as 
trauma, injury or infection. The authors themselves acknowledge this limitation.  
A more popular approach to gene therapy based treatment of corneal neovascularisation 
seems to be in the use of various non-viral gene delivery methods ranging from injection of 
naked DNA / RNA species via various routes [265,303–306], the use of lipid based 
transfection reagents [261,307] or more complex nanoparticles [266,308]. Whilst these 
approaches have proved effective, in many of cases (especially those involving naked DNA / 
RNA species) repeated administration of the therapeutic agent at high doses over the course 
of the experiments (usually lasting around 1-2 weeks) was required to produce a therapeutic 
effect. This is the key disadvantage of many non-viral methods; the therapeutic gene 
constructs can be relatively unstable and penetration of target cells is often limited [309]. 
One of the chief advantages therefore of the AAV methodology presented here is that the 
duration and level of expression mediated is superior to that of any current non-viral method 
and should thus provide an enhanced therapeutic effect. 
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In the previous chapter it was shown that expression of transgene product from 
intrastromally injected vector rises rapidly, achieving its maximal level seven days post 
injection before declining. This initial high level expression is likely the result of dual 
transduction of both the epithelium and the stroma and possibly an inflammatory mediated 
hyper-activation of the transgene delivered by AAV. The AAV2/8(Y733F)-CMV-musFlt1 
vector injected in this study was proven to express the correct transgene product in easily 
detectable quantities in vitro (5.2.1) and the strong, reproducible inhibitory effect on the 
induction of neovascularisation leaves little doubt that the transgene is being expressed at a 
physiologically useful level in vivo. However we did not directly determine the expression 
levels of sFlt1 we were achieving in vivo or any variation in this level over time, and thus 
cannot say with certainty that the temporal expression pattern observed in the previous 
chapter was repeated here. Both the murine sFlt1 expressing and control NULL vector were 
made following exactly the same production methodology as the eGFP expressing vector 
used in the previous chapter and delivered in exactly the same manner, therefore a similar 
pattern of transgene expression would be expected. This should be confirmed however by 
the assessment of pan-corneal sFlt1 levels by ELISA at various time points post vector 
injection. 
The experiments presented here were designed to take best advantage of the initial high 
level expression expected to be mediated, with vector being injected pre-induction of 
neovascularisation timed in such a way as to ensure synchronicity of maximal transgene 
expression and neovascular drive. In addition this experimental timescale has the benefit of 
being clinically relevant. The most likely clinical context in which a gene therapy based 
approach to prevent pathogenic corneal neovascularisation would be of utility is in the 
prevention of corneal graft rejection in “high risk” engraftments into hosts with pre-existing 
neovascularisation [121]. Donor corneas are routinely stored in organ culture for up to four 
weeks pre-transplantation, providing an opportune window ex vivo for gene therapy to be 
applied and transgene expression to develop within the graft. 
Whilst the period immediately post transplantation might be expected to represent a period 
of particular graft vulnerability due to the speed of innate responses it would also be 
desirable to determine whether the lower basal level of expression in the stroma alone 
shown in the previous chapter to be established ~12-14 days post injection and maintained 
over the longer term (likely indefinitely) is still able to mediate the strong antiangiogenic 
effect observed over the initial 2 week period, and thus in the clinical context continue to 
protect engrafted tissue from neovascularisation and the associated immunological rejection 
over the long term. This could easily be assessed in the murine suture model by increasing 
the interval between injection and induction of neovascularisation. 
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It has also not been determined if AAV mediated sFlt1 overexpression in the cornea is 
capable of inducing the regression of an already established chronic corneal 
neovascularisation such as that present in hosts receiving high risk corneal transplants. The 
suture model used here however does not model such a situation and is unsuitable for this 
purpose as the angiogenesis induced is relatively acute and temporary. The peak of 
neovascularisation induced by the model occurs at around two weeks post induction (the 
point of analysis in this study) and by 5 weeks most of the sutures are no longer in place and 
the neovascularisation has largely regressed. This time frame is likely too short for any 
treatment induced regression to be distinguished from the normal healing process. If the 
potential of the treatment to induce regression of established vessels is to be assessed a 
more chronic model of corneal neovascularisation will be required. Some published work 
[266] in which a longer interval between induction and treatment (10 days) was left suggests 
that angiogenic induction by alkali burn might constitute such a model, and this methodology 
will be investigated. 
As discussed one of the major clinical applications of this technique would be to improve 
corneal graft survival in high risk grafts and so we should also apply our AAV based 
technique to a murine allograft model to assess its ability to promote graft survival. We do 
not currently process sufficient surgical experience of corneal transplantation in mice to 
begin these experiments but this capacity is being developed. 
Whilst the musFlt1 transgene expression mediated by AAV2/8(Y733F) post intrastromal 
injection proved highly effective in ameliorating corneal haemangiogenesis induced in the 
corneal suture model in repeated experiments, it appeared to have little to no effect in 
preventing lymphangiogenesis, as shown by immunohistological staining for the lymph 
vessel marker LYVE1 in cohort 3. 
Whilst it has been well established that haemangiogenesis is associated with corneal graft 
failure [121], and there is no doubt that haemangiogenesis is deleterious to vision in of itself, 
there is an increasing weight of evidence to suggest that to focus solely upon 
haemangiogenesis may be somewhat misdirected. Haemangiogenesis is often very 
apparent, easily observable in clinic and causes obvious impairment of vision. By contrast 
lymphangiogenesis will generally pass unnoticed as lymph vessels are invisible to 
macroscopic examination. Indeed until relatively recently the lymph vasculature was also 
difficult to visualise histologically due a lack of immunohistological markers and this likely 
exacerbated the lack of attention they received. The advent of more definite and reliable 
markers for lymph vessels has made it clear however that lymphangiogenesis almost 
invariably accompanies the more obvious haemangiogenesis [126,310] and that in fact it is 
likely lymphangiogenesis is the primary driving force behind immune mediated graft failure 
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[127]. It would therefore be highly desirable to inhibit lymphangiogenesis in addition to 
haemangiogenesis and there are a number of gene products that might be delivered to 
achieve this. 
The VEGF family of ligands and receptors is the primary regulatory pathway of both 
haemangiogenesis and lymphangiogenesis [311] and is summarised in simplified form in 
Figure 39 below. Broadly speaking haemangiogenesis is mediated through ligand binding to 
either VEGFR1 or VEGFR2 whilst lymphangiogenesis through binding to VEGFR3. As can 
be seen from Figure 39 however there are many points of cross over between these two 
basic pathways. 
 
Figure 39. Simplified schematic 
of the VEGF pathway as it 
relates to Haem / 
Lymphangiogenesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
There is generally considered to not be any direct interaction between VEGF-A and the 
lymphangiogenesis pathway mediated through VEGFR3, however there are multiple lines of 
evidence suggesting that VEGF-A may affect lymphangiogenesis via an alternative 
mechanism either directly or indirectly. An overexpression of VEGF-A has been shown to 
stimulate lymphatic development in the absence of VEGF-C/D detection [312] although the 
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lymph vessels generated were abnormal, and possibly only of relevance to malignancy. The 
mechanism of action, if direct, is unknown although Nagy et al. [312] proposed that it may 
proceed via VEGFR2 binding due to high expression levels of this receptor on normal 
lymphatic endothelium. Further evidence supporting the effect being mediated via VEGFR2 
mechanism has subsequently been found in the context of the skin [313]. Additionally, 
VEGF-A is involved in the recruitment of macrophages [314], which are able to directly 
stimulate lymphangiogenesis by production of VEGF-C/D and subsequent VEGFR3 pathway 
activation. This indirect action of VEGF-A has also been shown to be of relevance to the 
cornea [310,315]. 
Within the cornea it has been demonstrated by Bock et al. [316] that the VEGF-A binding 
antibody based therapeutic Bevacizumab (Avastin) is capable of dual inhibition of both 
haemangiogenesis and lymphangiogenesis in the suture model. As Bevacizumab does not 
bind either VEGF-C or VEGF-D, the two members of the VEGF family primarily responsible 
for driving lymphangiogenesis it cannot be mediating its effect by a direct blockade of 
VEGFR3 signalling. Bock et al. therefore hypothesize that the inhibitory effect they observed 
on lymphangiogenesis may have occurred either indirectly via the two mechanisms 
discussed previously, a reduction in macrophage recruitment (leading to diminished 
secretion of VEGF-C/D) or directly via an as yet unknown VEGFR3 independent action of 
VEGF-A, possibly via VEGFR2 as has been shown in other tissues. 
Additionally it has been claimed that the drug VEGFTrap which comprises binding motifs 
from both VEGFR1 and VEGFR2 is able to inhibit lymphangiogenesis as well an 
haemangiogenesis [306]. Whilst the VEGFR2 motif might have been expected to bind 
VEGF-C and thus mediate inhibition of lymphangiogenesis via reduced VEGFR3 signalling, 
VEGFTrap was in fact shown not to bind either VEGF-C or D [310]. 
The results presented here partially dispute these findings, at least within the context of the 
animal model used. Bock et al. themselves demonstrated that Bevacizumab binds to murine 
VEGF-A at a far lower (10-1000x) affinity that it does to the human form [316]. The treatment 
we have applied with sFlt1 acts via an identical mechanism to that of Bevacizumab; the 
binding and sequestration of VEGF-A resulting in inhibition of its pro-angiogenic signal. 
Additionally as the native murine form of sFlt1 was used here it might be expected that the 
greater binding affinity would lead to VEGF-A sequestration being more efficient / complete 
and yet we observed no reduction in lymphangiogenesis. Additionally the widespread, florid 
lymphangiogenic induction we observed here in the controls is striking upon comparison with 
almost all published data in the field (including Bock et al’s Bevacizumab study) in which the 
lymphangiogenesis induced appears far more modest. 
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These differences are likely due, at least in part, to strain specific difference between mouse 
models used. The work presented here was performed in C57Bl/6J animals which have 
been shown to exhibit both more extensive pre-existing lymphatics at the corneal limbus 
[317] and a more pronounced lymphangiogenesis upon stimulation [318] than the BALB/C 
animals that appear more commonly used within other studies. 
We would therefore conclude that any action of VEGF-A directly or indirectly upon 
lymphangiogenesis is a relatively minor factor within the context of the strong 
lymphangiogenic drive present within this strain, or induced by our methodology. Any effect 
of sFlt1 mediated VEGF-A blockade is likely being overcome by stronger signalling mediated 
through VEGF-C / VEGFR3. The effects of VEGF-A blockade upon lymphangiogenesis 
observed by Bock / Bachmann et al. were perhaps only evident due to a combination of very 
high, repeated doses of therapeutic agent being applied and a relatively limited 
lymphangiogenic drive being in effect within the mouse model used. 
This raises the question of which strain of animals is best suited for further experiments. A 
treatment effect would be easier to observe in BALB/C animals due to a reduced baseline 
response, although the albinism of this strain is a complicating factor. It would be best 
therefore to continue to work within C57’s, at least initially. This strain lacks the obvious and 
far reaching genetic defect of albinism and due to its more robust lymphangiogenic response 
any treatment effect achieved is likely to be of high efficacy and thus of wider utility to more 
severe disease. If treatment of lymphangiogenesis within the C57Bl/6J strain proves 
unfeasible, BALB/C’s could form a second line of investigation  
There is a single example of an inhibitory effect upon lymphangiogenesis mediated via 
VEGF-A within the C57/Bl6J model found within the literature. Tarallo et al., (2012) 
demonstrated reduced lymphangiogenesis when VEGFR1 signalling was blockaded via a 
modified form of PIGF1, unable to bind VEGFR1 but still able to sequester VEGF-A by 
heterodimerisation. A result that was not replicated in the VEGF-A / PIGF1 blockade via 
sFlt1 presented here.  
In conclusion any further attempts to inhibit lymphangiogenesis via the VEGF-A pathway 
alone represent a sub-optimal approach as any effects of this pathway upon 
lymphangiogenesis are either secondary to the pathways primary function or indirect. Direct 
modulation of other VEGF pathways is likely to be more effective. 
 
Soluble VEGFR2 (sFlk1) is an alternative candidate for overexpression that should be able 
to bind and sequester factors that promote both haemangiogenesis and lymphangiogenesis 
such as VEGF-A, VEGF-C and VEGF-D, and thus may be effective in ameliorating both. 
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Indeed a soluble monomeric form of VEGFR2 that can function to inhibit corneal 
lymphangiogenesis has been found to be expressed endogenously [320]. It was found 
however that the endogenous form was not able to inhibit haemangiogenesis as it is 
monomeric and in this form is unable to bind VEGF-A. 
In contradiction to this finding Yu et al. [267] had earlier shown that delivery of an artificial 
form of sVEGFR2 via adenovirus to the anterior chamber was able effectively inhibit 
haemangiogenesis in a alkali burn model of corneal neovascularisation in the rat. This 
disagreement perhaps indicates the sVEGFR2 form used by Yu et al. may have been 
dimeric. In Yu et al’s study lymphangiogenesis was not assessed.  
Work by Uehara et al. in 2013 [321] utilised a morpholino antisense oligomer delivered 
subconjunctivally to shift the endogenous splicing of VEGFR2 in favour of the soluble form, 
simultaneously increasing sVEGFR2 and decreasing VEGR2 to potentially inhibit both 
lymphangiogenesis and haemangiogenesis respectively. This elegant approach proved to be 
effective within the cornea, increasing the survival of corneal allografts and reducing both 
forms of angiogenesis induced in both the transplants and the suture model within BALB/C 
mice.  
Whilst is has certainly proven to be effective increased expression of sVEGFR2 (monomeric 
or dimeric) is likely to constitute a suboptimal approach to the inhibition of both 
haemangiogenesis and lymphangiogenesis. This is due to the fact the ligands to which it 
binds and sequesters (VEGF-A, and VEGF-C/D) have endogenous receptors with much 
higher affinity (VEGFR1 and VEGFR3 respectively) which may outcompete sVEGFR2 if 
lymphangiogenic drive is sufficiently strong, such as that seen in C57Bl/6J mice. We believe 
a superior approach would be to deliver soluble forms of both VEGFR1 (sFlt1) and VEGFR3 
(sFlt4) simultaneously in order to maximise sequestration of VEGF-A, C & D and thus 
inhibition of both forms of angiogenesis. Additionally delivery sVEGFR1 (sFlt1) has the 
advantage over sVEGFR2 of being able to bind and sequester other molecules that act to 
promote haemangiogenesis through VEGFR1, but which do not bind to VEGFR2, such as 
PIGF. In the context of AAV mediated delivery this could be achieved either by the 
simultaneous injection of two vectors each encoding one of the two factors, or a bicistronic 
construct encoding both. In this case the bicistronic approach would be feasible as the 
sequences for both sFlt1 and sFlt4, plus promoters and polyadenylation signals would fit 
within AAV’s maximum packaging capacity of 4.7kb. This proposed strategy of sVEGFR3 + 
sVEGFR1 combination gene therapy was very recently shown to be of considerable merit. 
Whilst soluble forms of both VEGFR1 and VEGFR2 have been found to be expressed 
endogenously, until recently the soluble form of VEGFR3 was thought only to be found in 
vivo as a biomarker of malignancy [322]. We had thus begun the process of producing an 
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AAV genomic plasmid encoding an artificial soluble form of VEGFR3 based upon genetic 
manipulation to remove the transmembrane and intracellular domains. 
This year however Singh et al. [323] demonstrated that a natural form of sVEGFR3 is 
expressed endogenously within the cornea and is essential for the maintenance of corneal 
alymphaticity. Additionally they showed using a non-viral gene therapy approach in BALB-C 
mice that over expression of sVEGFR3 was able to improve corneal allograft survival and 
reduce corneal lymphangiogenesis in the suture model. A reduction in haemangiogenesis 
was observed although this was less pronounced, and mediated through sequestration of 
VEGF-C, reducing its binding to VEGFR2. Despite these extremely promising results a 
substantial area of the cornea remained vascularised in the treatment group, which we are 
confident maybe improved by the application of a viral gene therapy method.  
The proposed approach of dual viral mediated gene therapy to overexpress both sVEGFR1 
(sFlt1) and sVEGFR3 (sFlt4) therefore shows great promise. If sVEGFR3 mediated inhibition 
of lymphangiogenesis via this route proves as effective as the sFlt1 mediated inhibition of 
haemangiogenesis already demonstrated, then near complete inhibition of both forms of 
neovascular response should be achievable. Additionally the long lasting expression 
mediated by AAV may lead to both effects being sustained over the long term. Work upon 
this approach is on-going. 
 
Finally it is possible that a soluble factor expressed within the stroma may reach therapeutic 
levels within more posterior tissues of the eye. Such an approach has previously been 
demonstrated within a different context. Injection of a lentiviral vector into the anterior 
chamber encoding an IL10 (which is both anti-inflammatory and anti angiogenic) has been 
shown to effectively reduce the infiltration of inflammatory cells into the vitreous in murine 
model of uveitis via transgene product production in the corneal endothelium and iris [154]. 
Thus intrastromal injection of AAV may provide an additional minimally invasive method by 
which more posterior pathogenic conditions such as uveitis or choroidal neovascularisation 
might be treated. This possibility is being investigated although it must first be established 
whether a soluble protein produced in the stroma is able to exit the cornea via the 
endothelium and reach an appropriate therapeutic level in the posterior segment. 
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5.3.1 Conclusions 
 Overexpression of musFlt1 mediated by AAV delivery by intrastromal injection is able 
to convincingly and reproducibly inhibit corneal haemangiogenesis in the corneal 
suture model. In many cases this inhibition is near complete. 
 Such an overexpression of musFlt1 had no significant effect upon the induction of 
lymphangiogenesis indicating that in the context of C57/B6J animals at least the 
contribution of VEGF-A (and other sFlt1 binders) to lymphangiogenesis is minimal. 
 The intrastromal delivery route of AAV is able to deliver physiologically relevant 
levels of soluble transgene product to the cornea and is validated for use with other 
potentially useful soluble factors such as sVEGFR3 to inhibit lymphangiogenesis.  
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6.  Lentiviral gene transfer to limbal epithelial stem 
cells for permanent epithelial transgene 
expression 
 
6.1 Introduction 
 
Due to the highly dynamic nature of the corneal epithelium, achieving long lasting gene 
transfer to this layer is highly challenging as transduced cells will inevitably be lost over time 
during the normal turnover processes of the tissue. The only way a lasting transduction 
could be achieved is by gene transfer to the limbal epithelial stem cells (LESC) with an 
integrating vector. The epithelium is composed entirely of the daughter cell lineages of the 
LESCs and thus genomic integration of a transgenic construct within these cells should lead 
to a sustained pan-epithelial transduction.  
The work presented in this chapter was therefore focused upon development of a technique 
by which the LESCs might be transduced in vivo with a gene therapy vector, something 
which as far as we are aware has never been convincingly demonstrated previously. Only 
one study to date has attempted such a transduction, Igarashi et al. [324] demonstrated 
epithelial cell transduction lasting up to 6 weeks post gene delivery via a lentiviral vector 
applied topically after limbal epithelial debridement. In the course of work preliminary to that 
presented here these results could not be replicated, and we do not believe that 6 weeks is a 
long enough period of follow-up to claim LESC transduction with certainty.  
Limbal epithelial stem cells (LESC’s) are known to reside in the far peripheral epithelium, at 
the corneoscleral junction between the cornea, trabecular meshwork and conjunctiva. In 
humans a specific limbal structure called the palisades of Vogt is associated with the LESC 
niche, however whilst these structures have been identified in some non-human corneas 
such as the pig, they do not appear to be present in the mouse [325]. 
Despite being located near the outer surface of the eye this compartment can be extremely 
difficult to access surgically. Firstly the target area is extremely small, the entire murine 
epithelial thickness at the limbus being only ~20µm, [294] with the stem cell niche being a 
smaller sub division within this thickness. Secondly all the structures proposed as the niche 
of LESC’s in humans at least are highly convoluted structures, further complicating access 
for both surgical instruments and vector solutions. In point of fact it is likely that the LESC 
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niche is specifically structured to protect the stem cells from exactly the type of access this 
work aims to achieve. 
The work in this chapter attempted to mediate lentiviral LESC transduction in vivo by direct 
injection of vector in or very close to the LESC niche using an ultrafine glass pipette and 
formed part of collaboration with Dr Satoshi Kawasaki of Kyoto Prefectural University of 
Medicine. 
 
6.1.1 Aims 
The primary aim of the work presented in this chapter was to achieve a permanent 
widespread gene transfer to the corneal epithelium, a tissue that undergoes continuous 
regeneration, via lentiviral gene transfer to the limbal epithelial stem cells (LESC’s) in vivo. 
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6.2 Methods and results 
 
6.2.1 Comparison of two different injection methodologies to target limbal epithelial 
stem cells for lentiviral transduction 
To deliver vector as close as possible to the LESC niche it was decided to inject with an 
ultrafine glass needle produced with a micropipette puller, pulled from borosilicate glass 
capillaries of 1mm O.D. x 0.78mm I.D.(Harvard Apparatus) approximate dimensions of which 
are shown in Figure 40. This work was performed in collaboration with Dr Satoshi Kawasaki 
(Kyoto Prefectural University of Medicine) who prepared the needles and took the Scanning 
Electron Micrograph (SEM) of the tip shown in Figure 40. 
The two target routes of injection to be compared in this experiment were: 
 “Limbal-intrastromal” which aimed to inject vector into the anterior limbal stroma, to 
target the LESC niche located immediately anterior to this area. 
 “Limbal-subepithelial” which aimed to essentially inject directly into the LESC niche itself. 
Both are represented in Figure 41 
Figure 40. Schematic (not to scale) and SEM image of glass needle morphology used to deliver 
vector in 6.2.1  
  
 
 
 
6-7mm 
1mm 0.78mm ~10 µM 
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Figure 41. Schematic representation of the two routes of injection trialled in 6.2.1; Limbal-
intrastromal and limbal-subepithelial 
 
A total of 16 mice were injected bilaterally, 8 via the limbal-intrastromal route and 8 via the 
limbal-subepithelial route. Unfortunately one animal from each group did not recover from 
the procedure. 
The vector injected was a lentivirus encoding eGFP under the control of the ubiquitous 
spleen focus forming virus (SFFV) promoter. The vector had a titre of 1x107 vg / mL and was 
injected as described in 2.3.5. 
Each needle had a capacity of ~50 µL and this volume of vector was preloaded immediately 
prior to injection. During injection the vector was continuously expressed from the tip by air 
pressure which was applied via a 50 mL volume syringe compressed to 5-10 mL. Due to this 
continuous flow no vector dose per eye can be accurately calculated. Repeated injections 
were preformed around the entire circumference of the limbus, approximately 30-50 
injections were performed per eye. 
Stroma
Epithelium 
Basal Epithelium 
- Target injection site of limbal
intrastromal delivery
- Target injection site of limbal
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The glass needles were extremely fragile and slender, because of this they had a strong 
tendency to break or become clogged during the procedure. If this occurred the needle was 
replaced and if clogging became frequent the vector solution was occasionally diluted up to 
10 fold in OptiMEM (Gibco) to ameliorate the issue. 
After injection the mice were initially assessed weekly for the eGFP expression in the cornea 
by Scanning Laser Ophthalmoscopy (SLO) (2.3.11). 
Figure 42 shows SLO results from the first 4 weeks post injection from four representative 
eyes. For those injected limbal-intrastromally strong expression is seen around the limbus at 
week 1, however in all cases this expression is severely reduced or lost completely by week 
2 onwards. For those injected limbal-subepithelially in some cases (7 / 14 eyes) the 
development of streak like expression patterns extending from the limbus to the central 
cornea were observed, such as those seen in Figure 42E & G. 
At one week post injection a single animal (chosen upon the basis of an intermediate level of 
eGFP expression, i.e. neither the most nor the least promising) from each injection group 
was selected to be culled and assessed by histology, one eye was cryosectioned whilst the 
other was flatmounted. 
Figure 43 show transverse cryosections imaged by confocal microscopy through both an 
intrastromally (Figure 43A) and subepithelially (Figure 43B, C & C’) injected eye taken one 
week post injection. The intrastromally injected eye shows no evidence of epithelial 
transduction, however a large area of transduction around the posterior of the eye is 
apparent. Possible tissues transduced include conjunctiva, sclera and ocular muscle. The 
subepithelially injected eye shows several small patches of epithelial transduction in the 
cornea. These are located relatively centrally and all layers of the epithelium appear to have 
been transduced. No transduction of other layers of the cornea, or of other ocular tissues 
was noted. 
Figure 44 & Figure 45 show corneal flat mounts taken at 1 week post injection and imaged 
by confocal microscopy for an intrastromally and a subepithelially injected eye respectively. 
In Figure 44A & D a large area of non-epithelial limbal tissue appears to have been 
transduced. This appears to be mostly conjunctiva. A very small amount of epithelial 
transduction has also been achieved in highlighted area 1 of Figure 44A. This area is shown 
in greater detail in Figure 44C & C’ revealing a small number of epithelial cells transduced in 
all layers of the epithelium. 
In Figure 45 a larger (although still relatively small) area of epithelial transduction can be 
seen in highlighted area 1. This area is shown in greater detail in Figure 45C & C’ revealing 
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a larger number of epithelial cells transduced in all layers of the epithelium. No significant 
expression was noted in any other layer of the cornea or more peripheral tissues. 
Figure 46 shows a more limbal area (highlighted area 2) of the same eye presented in 
Figure 45. In this location too there is transduction evident in all epithelial layers. Of 
particular note are transduced cells shown in Figure 46E which appear to be located close to 
involuted structures in the limbus reminiscent of structures associated with the LESC niche 
in humans [64], although it is possible these folds are merely an artefact of the flat mounting 
procedure. 
After 4 weeks of SLO follow up of the limbal intrastromal group with no expression being 
seen past week one. Observations were terminated and the animals culled. 
Due to the promising results obtained from the subepithelial group, follow up was continued. 
This group will henceforth be referred to as “Subepithelial Cohort 1”. 
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Figure 42. Representative images showing lentivirus mediated corneal eGFP expression assessed 
by SLO weekly after either limbal-intrastromal or limbal-subepithelial injection of vector 
A-D: Four representative eyes showing lenti-mediated eGFP expression over 4 weeks following 
limbal-intrastromal injection  
E-F: Four representative eyes showing lenti-mediated eGFP expression over 4 weeks following 
limbal-subepithelial injection  
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Figure 43. Transverse section (18µm) through eyes showing vector 
mediated eGFP expression 1 week after limbal intracorneal injection 
A:  Overview of expression mediated by limbal-intrastromal injection 
route. Confocal z-projection taken at 10x magnification. 
B: Overview of expression mediated by limbal-intraepithelial injection 
route. Confocal z-projection taken at 10x magnification.  
C & C’: Area 1 in B shown in greater detail at higher magnification. 
Confocal z-projection taken at 40x magnification. 
In all images:  Blue = DAPI,  Green = vector mediated eGFP  
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Figure 44. Corneal flatmount showing vector mediated eGFP expression 1 week after limbal-intrastromal injection of LNT-SFFV-eGFP 
A: Overview of the whole flat mount with 2 areas highlighted. Confocal z-projection taken at 10x magnification. 
B: Comparable SLO image of the same eye taken shortly before animal was culled and tissue fixed. 
C & C’: Orthographic projection of confocal z-stack taken at position 1 in A at 40x magnification, C = Superficial epithelium, C’ = Basal epithelium. 
D: Orthographic projection of confocal z- stack taken at position 2 in A at 40x magnification.   
In A, C, C’ & D: Blue = DAPI,  Red = TRITC-Phalloidin,  Green = vector mediated eGFP. In B: White = vector mediated eGFP 
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Figure 45. Corneal flatmount showing vector mediated eGFP expression 1 week after limbal-subepithelial injection of LNT-SFFV-eGFP 
A: Overview of the whole flatmount with a single area highlighted. Confocal z-projection taken at 10x magnification. 
B: Comparable SLO image of the same eye taken shortly before animal was culled and tissue fixed. 
C & C’: Orthographic projections of confocal z-stack taken at position 1 in A at 40x magnification, C = Basal epithelium, C’ = Superficial epithelium.  
In A, C & C’: Blue = DAPI,  Red = TRITC-Phalloidin,  Green = vector mediated eGFP 
In B: White = vector mediated eGFP 
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Figure 46. Corneal flatmount showing vector mediated eGFP expression 1 week after limbal subepithelial injection of LNT-SFFV-eGFP 
A: Overview of the whole flat mount with a single area highlighted. Confocal z-projection taken at 10x magnification. 
B: Comparable SLO image of the same eye taken shortly before animal was culled and tissue fixed. 
C: Confocal z-projection of area 2 in A of green channel only showing all eGFP transduced cells in the area. Taken at  40x magnification. 
D: Orthographic projections of confocal z-stack taken at position 2 in A at 40x magnification.  
E: XZ axis of D shown in more detail 
In A, C, D & E: Blue = DAPI,  Red = TRITC-Phalloidin,  Green = vector mediated eGFP 
In B: White = vector mediated eGFP 
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6.2.2 Subepithelial cohort 2; Refinement of needle morphology to maximise 
lentiviral transduction of epithelial cells / LESCs 
Following on from the initial promising results obtained in 6.2.1 with the subepithelial 
injection route a second cohort of mice was injected via this route. 
The long thin glass needle morphology used in 6.2.1 (termed “slow taper”) had proven to be 
prone to breakage and clogging during the injection procedure. The needle tip was also 
difficult to position, being more prone to amplify operator movements. 
For these reasons a different shorter needle morphology was trialled, this was termed “fast 
taper”. The difference between slow and fast taper needles is illustrated in Figure 47 
Figure 47. Schematic (Not to Scale) and SEM image illustrating “fast taper” glass needle 
morphology used to deliver vector in 6.2.2 
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A total of 21 mice were injected bilaterally, all via the limbal-subepithelial route. As in 6.2.1 
the vector injected was lentivirus encoding eGFP under the control of the SFFV promoter. 
The vector had a titre of 1x107 vg / mL and was injected as described in 2.3.5. After injection 
the mice were initially assessed at 1, 2, 4 and 7 weeks post injection for the eGFP 
expression in the cornea by SLO (2.3.11). 
Figure 48 shows four representative eyes from cohort 2 for the first 4 time points imaged; 1, 
2, 4 and 7 weeks post injection. Large areas of a static punctate transgene expression are 
visible, highlighted by red asterisks. These do not appear to be epithelial as the areas do not 
move or change in anyway over time. Some streak-like expression (red arrowhead) was also 
visible in some eyes (6 / 38 eyes at week 7). 
Figure 49 shows a corneal flat mount from an animal in subepithelial cohort 2 taken at 4 
weeks post injection and imaged by confocal microscopy. A large area of the punctate 
transgene expression pattern is apparent a small area of which is highlighted in Figure 49A 
area 1. Figure 49C shows this area in greater detail and reveals the eGFP expression to be 
localised to cells of the anterior stroma. 
Figure 50 shows an epithelial streak (highlighted area 2) present in the same eye presented 
in Figure 49. Note that the streak appears discontinuous (area of discontinuity highlighted by 
red marker in Figure 50D). Please note that in these images the DAPI stain has not fully 
penetrated the whole tissue, likely due to incomplete permeabilisation. 
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Figure 48. Representative images showing lentivirus mediated corneal eGFP expression assessed 
by SLO after limbal-subepithelial injection of vector (Cohort 2) 
Red asterisks highlight areas of a static punctate transgene expression which are likely non-
epithelial. Red arrowhead highlights streak-like transduction pattern that is likely epithelial.  
Week 1 Week 2 Week 4 Week 7 
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Figure 49. Corneal flatmount showing vector mediated eGFP expression 4 weeks after limbal-
subepithelial injection of LNT-SFFV-eGFP (Cohort 2) 
A: Overview of the whole flatmount with a single area highlighted. Confocal z-projection taken at 
10x magnification. 
B: Comparable SLO image of the same eye taken shortly before animal was culled and tissue fixed. 
C: Orthographic projection of confocal z-stack taken at position 1 in A at 40x magnification.  
In A & C: Blue = DAPI,  Green = Vector mediated eGFP 
In B: White = vector mediated eGFP  
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Figure 50. Corneal flatmount showing vector mediated eGFP expression 
4 weeks after limbal-subepithelial injection of LNT-SFFV-eGFP (Cohort 2) 
A: Overview of the whole flatmount with a single area highlighted. 
Confocal z-projection taken at 10x magnification. 
B: Comparable SLO image of the same eye taken shortly before animal 
was culled and tissue fixed. 
C: Confocal z-projection of area 2 in A of green channel only showing all 
eGFP transduced cells in the area. Taken at 40x magnification. 
D: Orthographic projection of confocal z-stack taken at position 1 in A at 
40x magnification.  Only XY (single plane) and XZ shown. 
In A, C & D: Blue = DAPI,  Green = Vector mediated eGFP 
In B: White = vector mediated eGFP 
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6.2.3 Injection of subepithelial cohort 3 and long term follow up by SLO of all 3 
cohorts 
Follow up of the 2 cohorts injected in 6.2.1 and 6.2.2 revealed that the number of eyes 
displaying the epithelial streaks of transgene expression (henceforth referred to a epithelial 
streaks) that might indicate LESC transduction was a relatively small proportion of the total 
injected. Therefore in order to both increase the numbers and make use of the expertise 
gained to date with this highly challenging procedure, a third cohort was injected via the 
subepithelial route. 
The fast taper needle morphology trialled in 6.2.2 did not appear to result in any 
improvement in the amount of epithelial transduction achieved. In addition the use of fast 
taper needles resulted in large areas of stromal transduction, which obfuscate the desired 
result. Therefore it was decided that for the injection of a third cohort the original slow taper 
needle morphology would be used. 
For cohort 3 a total of 19 mice were injected bilaterally, all via the limbal -subepithelial route. 
As in 6.2.1 and 6.2.2 the vector injected was lentivirus encoding eGFP under the control of 
the SFFV promoter. The vector had a titre of 1x107 vg / mL and was injected as described in 
2.3.5. 
Due to the relative lack of epithelial streaks observed to develop in the earlier time points of 
the previous 2 cohorts it was decided that the first time point imaged by SLO for cohort 3 
would be taken at 3 weeks post injection, followed by 7 and then 10 weeks post injection. 
After this assessments would be made monthly. 
Those animals still alive from Cohorts 1 and 2 would also be assessed for eGFP transgene 
expression by SLO monthly. If any animal displayed no eGFP expression at all bilaterally for 
two consecutive time points then the animal was excluded from further follow up and culled. 
The epithelial streaks thus far observed to develop in some eyes could be a result of either 
LESC transduction or early transient amplifying cell (eTAC) transduction. To distinguish 
between these two possibilities a long term follow-up was required. LESC transduction 
would be expected to result in an essentially permanent expression, whilst eTAC 
transduction would be expected to disappear with time. Exactly how long will be required to 
make this distinction is unclear. The longest recorded timeframe for complete corneal 
epithelial turnover under non-wounded conditions found in the literature is 12-13 weeks 
(Buck, 1985). This therefore represents a minimum timeframe, but a much longer follow-up 
would be preferable if permanent transduction is to be claimed. It was therefore decided that 
a 1 year follow-up period should be assessed  
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All the SLO data collected for all three cohorts is presented in Appendix 9.2 
Figure 51 shows the long term follow-up of four eyes that displayed some of the most 
extensive epithelial streaks observed over all 3 cohorts injected. In these four examples the 
streaks persisted until the final 1 year time point. 
Observations were also made that might provide some insight into the normal cellular 
dynamics of corneal epithelial homeostasis. Without continuous observation it is impossible 
to be certain that a streak observed at one time point is in fact temporally continuous with 
one observed at the next. However streaks that appeared consistent in terms of point of 
origin in the limbus and overall morphology between time points were assumed to be the 
same streak. 
Figure 52 shows one eye in which the temporal continuity of streaks was particularly difficult 
to assess. 
Upon detailed analysis streaks were subdivided into two subtypes. 
Type 1: Were defined as highly consistent in appearance over time, being strong, 
continuous and always connected to the limbus. An example is presented in 
Figure 53. 
Type 2: Were defined as appearing more variable in terms of length, continuity and 
attachment to the limbus. An example is presented in Figure 54. 
In cohort 3 in particular, but also throughout the other 2 cohorts it was noted that epithelial 
expression patterns that were initially patchy and discontinuous appeared to “firm up” into 
distinct streak like patterns over time. Two of the clearest examples of this are shown in 
Figure 55. Failure of this process was also observed but only rarely; Figure 56 shows an 
example in which widespread patchy expression only results in very limited subsequent 
streak formation. 
Figure 57 shows a single clear example in which the development of both a type 1 and a 
type 2 streak is delayed until 12 to 18 weeks post injection of vector, after which they persist. 
Figure 58 shows a corneal flat mount from an animal in subepithelial cohort 3 which died at 
10 weeks post injection imaged by confocal microscopy. Multiple epithelial streaks are 
visible the largest of which is shown in more detail in Figure 58C 
Figure 59 and Figure 60 show corneal flat mounts of the eyes of a single animal from 
subepithelial cohort 3 which was culled at 52 weeks post injection. This animal was chosen 
for sacrifice due to an intermediate number of epithelial streaks being present. Those with 
more extensive streaking or single streaks were preserved for more extensive analysis at a 
later date.  
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Imaging of the eye shown in Figure 59 was attempted in vivo using a two-photon microscope 
immediately post SLO imaging whilst the animal was under terminal anaesthesia. 
Unfortunately, as the two photon microscope is a very new piece of equipment within the lab 
its use in vivo is still being optimised and thus during the procedure a large amount of 
damage was caused to the epithelial layer. This was likely due to the laser power being set 
too high or suboptimal imaging technique. Areas of damage are highlight by red arrow heads 
and delimited by red dotted lines in Figure 59B, and account for why only the limbal portion 
of the streaks could be imaged in Figure 59B, C & D. Please note that in Figure 59 the 
TRITC-Phalloidin stain has not fully penetrated the whole tissue, likely due to incomplete 
permeabilisation. 
 
Figure 61 shows that the off-target stromal transduction produced can be highly variable in 
terms of longevity of expression. In some cases such as that shown in Figure 61A the 
stromal transduction lasted for the entire duration of the experiment, in other cases such as 
in Figure 61C it was lost after only a few weeks. Stromal loss of transgene expression when 
it occurred was always rapid, with complete loss usually occurring over the space between 
consecutive time points. Figure 61B shows the only example in which a possible 
intermediate phase of loss was observed. 
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Figure 51. SLO images showing time course of vector mediated eGFP expression in vivo up to 52 weeks after limbal-subepithelial injection of LNT-SFFV-
eGFP 
A-D: Four eyes representing some of the most extensive, long lasting transduction achieved. Green text inlayed into week 52 image indicates proportion 
of visible area transduced. 
Time points showing no image (black) indicate that this animal / cohort was not imaged at that time point. 
In All: White = vector mediated eGFP. Red ring delimits the globe of the eye. 
Week 1 Week 2 Week 3 Week 4 Week 7 Week 14 Week 18 Week 22 Week 26 Week 30 Week 34 Week 38 Week 42 Week 46 Week 52 Week 10 
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Figure 52. Example eye in which streak continuity over time was extremely difficult to assess due 
to close proximity of multiple streaks 
Blue arrowheads at the 18 week time point highlight up to 4 distinct streaks in close proximity to 
each other. 
The eGFP expression highlighted by the red arrowheads may indicated stages of loss of one or 
more of these streaks. 
The streak highlighted by the green arrowhead maybe either a recurrence of the one or more of 
the streaks that appeared to be being lost, or an entirely new streak. 
In All: White = vector mediated eGFP. Red ring delimits the globe of the eye. 
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Figure 53. Example of a “Type 1“ epithelial streak, characterised by always appearing strong, continuous and 
connected to the limbus 
The example shown here is likely to be 2 such type 1 streaks which become increasingly merged over time.  
Red arrowheads highlight some images in which two points of streak origin can be seen. 
In All: White = vector mediated eGFP. Red ring delimits the globe of the eye. 
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Figure 54. Example of a “Type 2” epithelial streak, characterised by being variable in appearance in regard to 
length, continuity and connection to the limbus 
Red arrowheads highlight the streak in question. Blue double-ended arrows highlight areas of discontinuity. 
In All: White = vector mediated eGFP. Red ring delimits the globe of the eye.  
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Figure 55. Two examples from Cohort 3 illustrating the “firming up” of initial patchy discontinuous epithelial 
transgene expression into distinct streaks over time 
In both examples the process of “firming up” appears to have taken place between 10 and 14 weeks post injection. 
In All: White = vector mediated eGFP. Red ring delimits the globe of the eye. 
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Figure 56. One example in which the process of “firming up” largely fails 
Widespread patchy epithelial transduction is seen at 4 weeks post injection. At 7 and 12 weeks post injection these 
patches become increasingly streak-like. After this however few firm streaks develop or persist. In All: White = vector 
mediated eGFP. Red ring delimits the globe of the eye.  
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Figure 57. SLO images showing the late onset of an epithelial streak of LNT-SFFV-eGFP mediated eGFP expression  
Red and Blue arrowheads highlight the progression of two streaks of cell growth beginning from 12(?) to 18 weeks 
after injection. In All: White = vector mediated eGFP. Red ring delimits the globe of the eye. 
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Figure 58. Corneal flatmount showing vector mediated eGFP expression 10 weeks after limbal-subepithelial injection of LNT-SFFV-eGFP 
 
A: Overview of the whole flat mount with a 
single area highlighted. Confocal z-projection 
taken at 10x magnification.  
B: Comparable SLO image of the same eye 
taken shortly before animal was culled and 
tissue fixed. 
C: Confocal z-projection of area 1 in A of green 
channel only showing all eGFP transduced cells 
in the area. Taken at 40x magnification. 
In A & C: Red = TRITC-Phalloidin, Green = 
vector mediated eGFP. In B: White = vector 
mediated eGFP 
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Figure 59. Corneal flatmount showing vector mediated eGFP expression 52 weeks after limbal subepithelial injection of LNT-SFFV-eGFP 
 
A: SLO image of the eye taken shortly before animal was culled and tissue fixed, streak shown in B and C is 
highlighted. 
B: Confocal z-projection of area 1 in A of green channel only showing all eGFP transduced cells in the area. Taken 
at 40x magnification. 
C: Orthographic projection of confocal z-stack taken at position 1 in A at 40x magnification. Two XZ planes are 
shown taken at different depths in z axis. The second one (orange gridlines) shows under lying stromal 
transduction. 
In A: White = vector mediated eGFP 
In C: Red = TRITC-Phalloidin,  Blue = DAPI 
In B & C: White arrow heads highlight transduced non-epithelial cells,  Green = vector mediated eGFP 
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Figure 60. Corneal flatmount 
showing vector mediated eGFP 
expression 52 weeks after limbal 
subepithelial injection of LNT-SFFV-
eGFP 
 
A: SLO image of the same eye taken 
shortly before animal was culled and 
tissue fixed. Area shown in C and D is 
highlighted 
B: Overview of the whole flat mount 
with a single area highlighted. 
Confocal z-projection taken at 10x 
magnification. Red arrowheads / 
dashed areas highlight areas of 
severe tissue damage due to 
attempts a 2 photon microscopy in 
vivo. 
C: Confocal z-projection of area 1 in 
A & B of green channel only showing 
all eGFP transduced cells in the area. 
Taken at 40x magnification. 
D: Orthographic projection of 
confocal z-stack taken at position 1 
in A at 40x magnification. 
 
In A: White = vector mediated eGFP 
In B, C &D: Green = vector mediated 
eGFP 
In C & D, White arrowheads highlight 
transduced non-epithelial cells. 
In B & D: Red = TRITC-Phalloidin,  
Blue = DAPI  
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Figure 61. SLO images showing variability in longevity of expression of vector mediated eGFP in stromal cells transduced as a side 
effect of limbal-subepithelial injection of LNT-SFFV-eGFP 
A-C: Three eyes showing variability in longevity of expression of vector mediated eGFP transduction of stromal cells  
In All: White = Vector mediated eGFP. Red ring delimits the globe of the eye. 
 Animal culled / Eye no longer examined due to total lack of 
expression for period of >2 months 
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6.3 Discussion 
 
6.3.1 Transduction of epithelial cells for application in gene therapy 
The work presented in this chapter primarily aimed to provide proof of concept for pan 
epithelial gene delivery via transduction of the limbal epithelial stem cells (LESC) with an 
integrating lenti vector in the adult mouse. 
The first and most substantial challenge to be overcome in the development of a technique 
to transduce limbal epithelial stem cells in vivo was the delivery of the lentiviral gene therapy 
vector to the putative site where the cells reside. This site whilst extending the whole 
circumference of the cornea at the corneal scleral junction is tightly localised in the anterior / 
posterior axis consisting of a small number of cells in the basal layer of the limbal epithelium. 
It is also relatively well protected from external access from both anterior and posterior 
approaches being overlaid by multiple layers of epithelia and the anterior conjunctiva and 
underlaid by the rest of the corneal thickness. In particular the two acellular posterior layers 
of Bowman’s layer and Decesmet’s membrane are likely to act as significant barriers to 
surgical / needle access. 
An anterior approach was therefore selected as being both technically less challenging and 
presenting fewer barriers to LESC niche access. Initial preparation work for these 
experiments mainly performed by our collaborator Dr Satoshi Kawasaki of the Kyoto 
prefectural university of medicine (and thus not presented here), attempted to gain vector 
access to the LESC niche via approaches such as epithelial debridement or direct incisions 
into the limbus followed by topical application of vector. All such approaches were 
unsuccessful resulting in, at best, a very limited, short-lived transduction of the epithelium. 
Direct injection of vector into the LESC niche was therefore selected as the only viable 
approach. The usual device used within the lab for such delivery of vector to various ocular 
compartments (in particular the subretinal space) is a 10µL Hamilton syringe with attached 
34G microneedle. This device is inappropriate for LESC niche injection as it is far too large. 
The needle has an outer diameter of approximately 200 µm whilst the entire murine 
epithelial thickness at the limbus is only around 25 µm (Henriksson et al., 2009), with the 
epithelial niche being only a small sub division of this,1-2 cells thick at most. 
The only appropriate device for such injections was a glass micropipette of a type commonly 
used for electrophysiology or intracellular injections. Such pipettes can be produced with 
extremely fine tip diameters with submicron tips being achievable. However in order to inject 
fluid through such a small aperture very high application pressures are required. Additionally 
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lentiviral vectors are relative large at ~120nm diameter and our production method does not 
result in especially pure vector relying as it does on ultracentrifugation. A very small tip 
therefore whilst providing the potential benefit of highly specific injection site positioning 
would also be extremely prone to clogging. At the time these experiments were undertaken 
specialised stereotactic equipment was not available and thus the needle tip was to be 
guided manually. Specificity of injection site would therefore be chiefly dependent upon 
surgical skill of the operator with reproducible submicron accuracy likely being beyond what 
is achievable by this method. 
For these reasons a tip diameter of 5-10 µm was selected as an appropriate compromise 
between size relative to target site, accuracy of tip positioning and free fluid flow for injection. 
Initially the needles pulled were relatively long (6-7 mm), with a relatively slow taper to the 
tip. 
Two different target areas were selected, both to be approached from the anterior direction 
and are illustrated in Figure 41. Limbal-intraepithelial aimed to directly target the LESC niche 
itself. Limbal-intrastromal aimed to inject into the very anterior stroma just beneath 
Bowman’s layer in the area of the LESC niche. This second approach was selected as it was 
slightly easier to assess needle depth during injection as penetration of Bowman’s layer into 
the stroma results in a resistance that can be felt and assessed by the operator. It was 
hoped that both the needle tract and the relative thinness of Bowman’s layer in the mouse 
would still allow vector access to the more anteriorly located LESC niche. 
The results from the first cohort of mice injected via the limbal-intraepithelial route were 
promising. Assessment by SLO of transgene (eGFP) expression over the first 6 weeks post 
injection showed that in 5 of the 12 eyes (41.6%) injected convincing streak like patterns 
typical of LESC or early transient amplifying cell (eTAC) transduction were visible and a 
further 3 eyes (14.3%) displayed more limited streak like patterns. In one especially 
promising case several confluent streaks appear to cover roughly a 5th of the entire corneal 
surface.  
The limbal-intrastromal route was far less promising; SLO imaging showed that transgene 
expression was entirely limited to the extreme periphery of the cornea, possibly in more 
posterior, non-corneal tissues.  
When histology was performed at 1 week post injection to supplement these observations in 
vivo it was demonstrated that limbal intraepithelial injection had indeed transduced epithelial 
cells in both the basal and superficial layers. The number of cells observed was relatively 
limited but this was as expected given that only the less promising examples were chosen 
 221 
 
for histological analysis in order to preserve the more promising examples for further follow-
up in vivo. 
Histology also confirmed that limbal-intrastromal injection had resulting in a much more 
limited epithelial transduction, with only a very few cells being observed. It was also showed 
that the majority of transduction had occurred in tissues more posterior to the cornea such 
as the conjunctiva and trabecular meshwork, with transgene expression extending round 
tissues of the entire posterior globe. This possibly indicated that targeting the limbal 
intrastromal area had in fact directed vector into Tenon's capsule, or subconjunctivally. 
Based on these initial results the limbal intrastromal route was abandoned and a second 
cohort was injected intraepithelially. The needle design was modified for this cohort; tip 
diameter was kept within the 5-10 µm range but the needle was made shorter with a faster 
taper to the tip. It was felt that this might result in more accurate tip positioning as the shorter 
length would reduce any amplification of operator movements. 
This proved not to be the case; SLO results from cohort 2 were far less promising that those 
obtained in cohort 1. In the first 7 weeks post injection only 7 of the 42 (16.6%) of the eyes 
injected showed any evidence of streak formation. A large number of eyes (52.4%) however 
displayed a static punctate transgene expression pattern which histology at 4 weeks post 
injection showed was due to off-target transduction of stromal cells. 
The stromal transduction pattern was often visible across an extremely wide area of the 
cornea, including in the central cornea where vector / injection was not intentionally directed. 
Whilst stromal cells do migrate in response to injury this movement is usually very limited 
and localised to the site of injury itself and thus it is unlikely that central stromal transgene 
expression can be explained in terms of migration of transduced cells. Such stromal 
transduction therefore indicates that Bowman’s layer has been frequently accidently 
penetrated and that this has either occurred unknowingly in the central cornea or that vector 
has been able to spread through the stroma itself from limbal to central cornea.  
The frequent accidental penetration of Bowman’s layer is unlikely to be due to any increased 
penetrative pressure. Such an increase in pressure would have to result either from 
increased force originating from the operator or a decrease in tip diameter and both of these 
factors were kept as constant as possible between cohorts 1 and 2. Likewise it is unlikely 
that it is a result of any ballistic effect of vector expulsion from the needle as the two factors 
which might affect particle injection velocity; tip diameter and injection pressure were also 
kept constant. 
The frequent penetration into the stroma observed in cohort 2 is potentially due to a 
difference in rigidity / flexibility between the two needle morphologies. The longer slow taper 
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needle used in cohort 1 was far more flexible than the shorter fast taper design used in 
cohort 2 and thus could be subjected to a certain amount of bending force without breaking. 
It is possible therefore that upon encountering Bowman’s layer at the shallow angle of 
injection used the slow taper needles were able to bend in response to the increased 
resistance essentially being deflected by the stroma and ensuring the tip remained in the 
epithelium. By contrast the much more rigid fast taper needles could not be deflected and 
penetrated into the stroma. 
The fast taper morphology was therefore abandoned and a third cohort was injected using 
the slow taper morphology by the intraepithelial route in duplication of the method used in 
cohort 1. This was to ascertain if LESC/eTAC transduction level could be improved upon and 
confirm that slow taper needle morphology reduced off-target stromal transduction. 
Initial results indeed confirmed that much less of the stromal transduction pattern was 
visible; however in regards to assessment epithelial transduction results in cohort 3 were 
initially disappointing. Up until 10 weeks post injection only 10 out of 38 eyes (26.3%) 
showed any streak like morphology and the majority of these were not especially convincing. 
Figure 58 shows histological imaging of one of the more promising examples at 10 weeks 
post injection. The widespread transgene expression seen is localised entirely to the 
epithelia, however few of the streak like patterns observed are continuous and connect to 
the limbus, the only example to fulfil both criteria is shown in detail in Figure 58C. This is in 
contrast to the most convincing streaks observed by SLO in both cohorts 1 and 2 in which 
appear both continuous and continually connected to the limbus. Upon longer follow up 
however cohort 3 proved to be the most successful cohort injected; by 22 weeks post 
injection 20 of the 38 eyes injected (52.6%) displayed some evidence of streak-like 
morphology 
The next question to be addressed was whether LESCs have truly been transduced. Both 
LESC and eTACs are resident at the target site of injection and if transduced both would be 
expected to produce a streak like transgene expression pattern as daughter cells migrate 
centripetally. It was expected that the only difference by which LESC and eTAC transduction 
might be distinguished is duration of expression. LESC’s do not migrate centripetally and are 
capable of self-renewal, thus streaks derived from LESC transduction might be expected to 
be essentially permanent (there is some evidence that individual LESC lineages are lost with 
age, although this is a slow process [89]) and that the streaks would always remain 
connected to the limbus.  
In contrast an eTAC transduction should result in a streak that becomes disconnected from 
the limbus as the originally transduced cells move centripetally. The entire eTAC derived 
 223 
 
streak would also be expected to eventually extinguish as the whole lineage is lost to 
epithelial turn over. 
The exact timeframe over which transgene expression patterns should be monitored in order 
to observe this difference was not entirely clear. Based upon direct measurements of rate of 
centripetal cell movement in the mouse [86,326] estimates of between ~8-13 weeks can be 
made for cells to traverse the distance from limbus to central cornea. Other studies based 
upon the observations of streak progression labelled from birth by transgenic means have 
given both comparable (~10 weeks from Hayashi et al. [90]) or much shorter (3-4 weeks 
from Collinson et al. [87]) estimates for this process to occur. 
The process of loss is also likely to be stochastic. Whilst the majority of the epithelium may 
have turned over within a particular timeframe it would likely take longer for an entire eTAC 
lineage to become completely extinct. This was shown by Kinoshita et al. [328] who 
concluded that in the case of replacement of donor epithelium by that of the host in corneal 
transplants the loss of donor cells was “time-dependent, but not necessarily linear”. 
It was decided therefore that firstly the follow-up period would have to be at least as long as 
the maximum estimate for epithelial turnover in the literature (13 weeks). This should be 
perhaps doubled (26 weeks) to allow for near complete eTAC lineage extinction and that a 
period of 1 year (52 weeks) post injection would be sufficient to prove beyond any 
reasonable doubt that any remaining streaks must be derived from LESC transduction. 
The use of immunohistochemistry to show co-localisation of eGFP with stem cell markers 
was also considered. Given however that there is no one definitive marker of LESC’s that 
can distinguish between the LESC and an eTAC derived the asymmetric division of a LESC, 
and that even the validity of marker combinations is hotly debated, it was decided that 
duration of expression would form a far more definitive indicator of LESC transduction. 
Of the 92 eyes injected in total over all three cohorts 38 (41.3%) were followed up for the full 
52 week period. Most of those eyes not followed up for the whole period were discontinued 
when no streak-like patterns of any kind being observed at 2 consecutive time points 
(spanning a period of 8 weeks). 
Of those 38, 25 displayed convincing streaks present at the final time point, the best 
examples of which are shown in Figure 51. In these examples between 8 and 25% of the 
corneal surface was covered by transduced epithelium as assessed by comparison of white 
pixels with black within the eye field of the images. This is likely an underestimate as flat / en 
face images do not account for the curvature of the cornea.  
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It can be concluded beyond reasonable doubt therefore that the transduction of a significant 
number of LESC’s by a lentiviral vector in the adult mouse in vivo has been achieved, and 
that gene delivery by such a vector results in transgene expression within the whole clone / 
lineage of the LESC transduced. Additionally the data generated here is far more convincing 
than the only previous report within the literature [324] that has claimed such transduction, 
which only followed up for 6 weeks, did not make it clear where within the epithelium 
transduced cells were located and showed no evidence of centripetal migration. In this study 
we observed a large number of eyes in which epithelial transduction lasted for 6 weeks (or 
longer) but was not sustained beyond ~12-14 weeks indicating that that a 6 week follow up 
is too short a time period to prove LESC transduction. 
 
The technique however still has substantial room for improvement. Even in the best example 
the ultimate goal of 100% epithelial coverage has not been achieved. The results are also 
highly variable, with some eyes displaying widespread LESC transduction patterns, others 
displaying none, and most displaying evidence of more limited LESC transduction. 
Much of this improvement could potentially be made by standardisation of the injection 
technique itself, mainly to remove the current high level of variability due to operator 
dependence. Accurate positioning of needle depth in the anterior posterior axis formed the 
greatest challenge for the operator and this could be more finely controlled through the use 
of stereotactic equipment of a type commonly used for injection into precisely targeted areas 
of the brain. Unlike the brain however the eye cannot be secured firmly immobile by skull 
fixation as it is supported more loosely within the orbit by connective and muscular tissue. 
Nonetheless the more precise needle control enabled by stereotactic equipment would no 
doubt be advantageous to the procedure. 
In these experiments injection was mediated by application of air pressure to the needle 
preloaded with vector solution. Pressure was produce by manual compression of a 50mL 
syringe to ~5 mL marker, resulting in approximately 10 Atm of pressure which resulted in a 
steady slow flow of vector solution. This variable too could be easily standardised by the use 
of a mechanical compressor with a more finely controllable output air pressure. 
In order to maximise LESC transduction injections were placed around the entire 
circumference of the limbus. This was achieved by holding the injection device in a relatively 
fixed position and rotating the whole animal. This was for reasons of operator comfort and 
restricted space although as an approach it is likely sub optimal. A better methodology might 
be to fix the eye as immobile as possible and rotate the needle at a fixed angle around a 
pivot point located directly above the centre of the eye. 
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Figure 62. Schematic design of proposed device to standardise intra epithelial injections to target 
the LESC niche 
 
This would allow for injection into a consistent location in the transverse axis of the cornea. 
An outline design of a specialised instrument to perform the injections is shown in Figure 62 
above. 
During the injection procedure it was also noted that the needle was prone to clogging. This 
is likely a function of both the application pressure and purity of the vector solution itself. As 
stated earlier our lenti vectors are concentrated from clarified tissue culture medium by 
ultracentrifugation and are therefore not likely to be of a high purity. It is likely that the use of 
a more highly purified vector would both ameliorate this issue and also result in greater 
standardisation of the procedure. 
Finally the mouse eye is small and the LESC niche is not coincident with any 
macroscopically observable anatomical feature. The human eye by contrast is much larger, 
the epithelium is thicker at the limbus and the LESC niche has been associated with the 
Palisades of Vogt and other structures which are more easily observable [64,329]. It is likely 
therefore that direct injections into the LESC niche may prove less challenging in a human 
cornea. It is even conceivable as imaging technology improves techniques such as optical 
coherence topography (OCT) [330] or confocal microscopy [64] might be utilised in real time 
at the point of injection to guide the needle to the LESC niche. 
 
Transverse view En face (to cornea) view
A-P Depth of needle tip  
controlled by stereotactic 
equipment. 
Pivot
Needle angle
Pivot
Injections placed at  definable 
intervals around limbal
circumference.  
Pivot height above corneal surface and needle angle 
could be defined and optimised.
Vector injected by application 
of defined/controlled air 
pressure.
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6.3.2 Corneal epithelial cellular dynamics in normal homeostasis  
Whilst it was not the primary aim of this work, the ability to transduce LESCs with a clonally 
inherited label, such as that demonstrated here using Lenti-eGFP also has the potential to 
provide insight into the cellular dynamics of corneal epithelial homeostasis. More specifically 
this technique is capable of selectively labelling a small subset of LESC’s and their progeny 
allowing them to be studied in isolation from the rest of the tissue.  
This is in contrast to almost all previously published studies involving the direct labelling of 
LESC and their progeny with detectable markers which have utilised either transgenic 
approaches [86,87,90], or more non-specific viral labelling during embryogenesis [331]. Both 
of these approaches result in the labelling of a large proportion of LESC’s with the label 
being expressed from birth (or earlier) onwards. Whilst extremely useful in elucidating overall 
patterns within corneal epithelial homeostasis such techniques do not allow the processes 
involved to be easily followed on a cell by cell basis, and are unable to clearly distinguish 
between individual clonal lineages. Additionally these approaches are limited in their ability 
to assess any cell movement over time due to both very large numbers of adjacent cells 
being labelled and there being no point in the adult animal where expression of the marker 
can be “switched on” as such markers are expressed from birth.  
The single comparable technique found within the literature is a study by Buck in 1983 [326] 
in which India ink was directly injected into epithelial cells in order to demonstrate and 
measure centripetal migration speed. This experiment however was very short term, did not 
label LESCs and the marker used would be diluted out by cell division. 
 
The work presented here was not designed to take best advantage of the technique in this 
regard. The experiment was designed for long term follow-up rather than the high temporal 
resolution that might be required to accurately follow cell migration etc. over time. Despite 
this however some insights can nonetheless be drawn from the data. 
Firstly it was noted that streaks fell broadly into two categories: 
Type 1: Those that were highly consistent in appearance over time, being strong, 
continuous and always connected to the limbus. Example shown in Figure 53. 
Type 2: Those that appeared more variable over time in terms of length, continuity 
and attachment to the limbus. Example shown in Figure 54. 
These two different streak patterns could be explained in terms of number of LESCs 
transduced in a particular area at the point of injection.  
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In the case of type 1 streaks the vast majority of LESCs in that particular area may have 
been transduced and thus even if all the LESCs is the area are dividing asynchronously 
every daughter cell that is produced in that area will carry the eGFP label resulting a firm 
uninterrupted patch of transgene expression at the limbus. Subsequent centripetal migration 
is thought not to be the result of any active migratory process (in the non-wounded context) 
but rather a function of the increased proliferative capacity of more peripheral TACs, and 
cells being pushed more centrally over time as a result [52]. Thus in the situation described 
for type 1 streaks both all the new cells produced immediately peripheral to the initial TACs 
and all the daughter cells of the TACs themselves will be labelled. Thus over time a 
continuous unbroken streak from the limbus should be produced regardless of any 
asynchronicity or otherwise in cell division. 
In contrast type 2 streaks might result from the transduction of a more limited number of 
LESCs in a particular area. Thus if all the LESCs in a particular area divide over time and 
only a smaller number are transduced, the area immediately peripheral to this section of the 
LESC niche would become populated by both transduced and untransduced TACs. As these 
themselves divide and are pushed inwards by a largely random process, discontinuity of 
labelled cells might easily result. Additionally there may be long periods were all the 
transduced LESCs are simultaneously non-dividing, in which case all the fresh TACs (and 
their daughter cells) produced in that area during this period will be unlabelled and a 
disconnection of the streak from the limbus would result. 
Taking this idea further; if hypothetically a very small number, or single LESC in a particular 
area was transduced it might be expected that as LESC are by definition slow cycling that no 
distinct streak would ever be produced, only occasional disconnected patches of cells, 
surrounded by the progeny of the more numerous untransduced LESCs. 
To confirm this hypothesis regarding the generation of type 1 or type 2 streaks being 
dependent upon initial number of LESC transduced the number itself would have to be 
directly assessed, work in the next chapter will focus upon possible methods by which this 
might be achieved. Alternatively a mathematical model of the process could be produced 
using LESC transduction efficiency as the primary input variable.  
 
Another feature that was noted was that the majority of streaks became more distinct over 
time in a process that was termed “firming up”. This was especially notable in cohort 3, 
which was initially felt to have been poorly transduced due to the relative lack of streaks 
seen in the first 10 weeks post injection. Over time however the discontinuous patchy 
epithelial transduction that was initially evident was replaced with firm streaks located at 
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approximately the same locations around the limbal circumference. Examples are shown in 
Figure 55. 
This observation could be explained in terms of the slow cycle time of LESCs. At the point of 
injection both the LESCs and TACs in a particular area of the limbal circumference may 
have been transduced. Over the first ten weeks the TACs would be expected to undergo 
multiple rounds of division separated by as much as 60 hours [81] whilst migrating 
centripetally, which might result in a patchy pattern moving centrally such as that observed. 
The LESCs however might undergo no division during this time. There are few precise 
estimates of in vivo LESC cycle time under unwounded conditions to be found in the 
literature, although they are commonly defined as being able to retain label for up to 6 weeks 
indicating minimal division over this timescale. It is conceivable therefore that firming up of a 
streak like pattern is only able to occur once the transduced LESCs have undergone division 
and produced the potential for an unbroken streak to be formed. This observation would 
indicate that the cycle time of LESC in vivo can be as long as 10-12 weeks. 
There were also rare examples of the process of firming up largely failing with very few 
streaks resulting from a much more widespread patchy transduction (example shown in 
Figure 56). This could be a result of the majority of transduction being limited to TACs, with 
LESC transduction not being achieved as widely. 
The initial patchy patterns observed before firming up are reminiscent of those observed in 
work involving transgenic models showing that it takes up to 12 weeks after birth for streak-
like patterns to become fully established [87,90,331]. It is hypothesised for the first 2 weeks 
of life an alternative source of stems cells may be located throughout the basal layer of the 
epithelium rather than being confined only to the limbus and these are generate and 
regenerate the layer during late embryonic development and shortly after birth [90].  
The patterns observed here are not be confused with this process. Whilst some animals in 
this study were younger than 12 weeks old upon injection all those in cohort 3 (in which the 
patterns were most widely seen) were older than this at the time of injection and all 
examples shown in the relevant figures are taken from animals older than 12 weeks at point 
of injection. 
 
A particularly interesting example of streak formation is shown in Figure 57. For the first 12 
weeks post injection there is no evidence at all of a streak in the 9 o’clock position of the 
eye. By 18 weeks post injection a relatively strong streak is present in that location (red 
arrowheads) extending from limbus to central cornea, which is then maintained for the 
remainder of full 52 week period. The LESCs responsible for generating this streak must 
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have been infected at or very shortly after the point of injection as lentiviral vectors are 
known to be highly labile at 25-37°C; losing all infectivity in less than 24 hours [332]. The 
transduced LESCs therefore must have remained entirely non-dividing for at least 12 weeks 
post injection, providing more evidence of a ~12 week cycle time for LESCs in vivo. 
The streak that is formed between 12 and 18 weeks is a type 1 streak, appearing strong and 
consistent until the end of the experiment at 52 weeks. At several time points it also appears 
to have multiple points of origin in the limbus. Both of these factors argue for it being derived 
from a large group of LESCs. The fact that no streak at all is seen for 12 weeks and within 6 
weeks a type 1 streak with multiple points of origin has fully developed would imply a degree 
of cell cycle synchronicity between the LESCs in this specific area of the LESC niche. 
Additionally within the same eye there is also a type 2 streak (blue arrowheads) that 
develops in a parallel manner over the same timeframe, but which is located in a different 
area of the cornea its origin being localised in the ~5 o’clock position. This combined with the 
fact that the process of “firming up” discussed earlier also often appeared to occur in all 
streaks simultaneously might argue for synchronicity of cell division across the entire LESC 
niche. 
All the discussion presented here has thus far been framed in the context of a non-wounded 
cornea, with observations assumed to be representative of normal homeostasis rather than 
the increased proliferative / migration rate shown to be typical of epithelial wound healing 
[47,81]. This assumption was made as no deliberate wound except the insult of injection was 
ever inflicted upon any of the corneas and injection damage should have been mild and 
resolved quickly. However it is possible that the process of imaging (generally conducted 
once a month) may have been damaging due to slight drying of the cornea and application 
of high intensity laser light. Additionally it is important to remember that the experiment 
involved living animals housed together and that occasional incidence of epithelial wounding 
might be expected under such conditions. 
The distinctions between cell behaviour in the wounded and unwounded states is especially 
important to bear in mind when discussing the centripetal migration speed of epithelial cells 
as large variation could potentially result from relatively minor wounds. 
In the case of the type 1 streak shown in Figure 57 the 42 day period between the 12 and 18 
week observations was also sufficient for epithelial cells to migrate centripetally across the 
entire radius of the cornea, establishing a low resolution estimation of the time taken for this 
process which is roughly in the middle of range presented by the literature (3-13 weeks). 
Imaging over a higher temporal resolution would be required to provide more accurate and 
definitive data on centripetal migration speed. 
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Across the whole dataset it was also observed that not all of the individual streak-like 
patterns that developed remained visible for the full 52 week experimental period. Loss of a 
type 1 streak was rare although easier to define than the loss of type 2 streaks which are by 
definition variable in appearance over time. A weakening of streak intensity over time was 
also sometimes observed. This perhaps provides some confirmation of observations made 
by Mort et al. [89] in an X-inactivated LacZ expressing model which indicated reduction of 
LESC clone number with age. However in this study the possibility that transduced cells 
have lost transgene expression via epigenetic silencing of the integrated provirus SFFV 
promoter cannot be excluded. Such silencing has been shown to occur in stem cell lineages 
in particular [333]. 
 
Finally, and unrelated to the epithelium, a variability in the accidental off target transduction 
of stromal cells was also noted and is shown in Figure 61. In some cases the stromal 
transduction patterns appeared essentially permanent remaining unchanged over the entire 
52 weeks of the experiment. In other cases the stromal expression was lost. Loss when 
observed did not occur at any fixed time point post injection and was always rapid. It is likely 
that loss is due to sudden triggering of the stromal wound healing response or possibly an 
immune mediate effect although the cause for either is unknown. 
 
6.3.3 Conclusions 
 Widespread / long duration expression of transgene in the corneal epithelium has 
been achieved via the transduction of limbal epithelial stem cells with lentivirus in the 
adult mouse in vivo. 
 Transgene expression mediated in the LESCs is inherited by their centripetally 
migrating daughter cells resulting in transgene expression extending the whole 
corneal radius. 
 A slow taper, flexible glass micropipette / needle morphology proved to be the most 
suitable to deliver vector directly to the LESC niche, with more rigid shorter needles 
resulting in off-target stromal transduction. 
 This technique also shows significant promise as a tool for the study of the cellular 
dynamics of corneal epithelial homeostasis. 
 LESCs appear to have a cell cycle time in vivo of around 10-12 weeks 
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 LESCs may synchronise their divisions in vivo either locally or possibly throughout 
the whole LESC niche. 
 Centripetal migration of epithelial cells from limbal to central cornea can take a 
maximum of 6 weeks (42 days). 
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7. Techniques to develop lentivirus mediated LESC 
transduction for the study of epithelial cellular 
dynamics 
 
7.1 Introduction 
 
Work in the previous chapter was focused upon the development of a technique to mediate 
gene transfer to the entire corneal epithelium via in vivo transduction of the cells responsible 
for regenerating the layer, the limbal epithelial stem cells (LESC). The intended application 
of this methodology was in the gene therapy for genetic conditions of the epithelium, in 
particular gelatinous drop like dystrophy (GDLD) as discussed later in 8.1.3. It was also 
noted however that the technique could be of great utility in the study of the cellular 
dynamics of the homeostasis within the corneal epithelium. 
Improved data regarding factors such as the centripetal migration speed of epithelial cells 
could be generated by simply applying the technique as already developed at a higher 
temporal resolution; however this would provide little insight into questions relating to 
interactions between distinct clonal lineages. The data presented in the previous chapter has 
raised a number of such questions such as: 
 Do the various streak-like patterns observed correlate with the number of LESCs 
initially transduced? i.e. do stronger more consistent streaks result from the 
transduction of a larger number of LESCs? 
 Is the division of LESCs synchronised either locally or across the entire niche? 
 Are TACs really limited to a maximum of three divisions as has previously been 
proposed [81]? 
The use of a single fluorescent label allows division of clonal lineages into two types; 
labelled and unlabelled, only one of which can be visualised and is thus of limited application 
to such questions. Work by Weber et al. [334,335] however describes a multi-colour 
technique by which a large number of LESC clones might be distinguished. The system is 
based upon co-infection of target cells with three different lentiviral vectors each encoding a 
different fluorescent protein. At an optimal multiplicity of infection each cell will receive by 
chance a different dosage of red, green and blue fluorescent transgenes which when 
expressed in combination will result in the generation of a large number of unique colours by 
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the additive colour model. Due to the integration of lentivirus within the genome the colour 
signature of an individual cell should be inherited in a clonal fashion. 
Such a system could be easily adapted to the lentivirus mediated transduction of the limbal 
epithelial stem cells demonstrated in the previous chapter, labelling each LESC clone with a 
unique colour which could be tracked to provide detailed information regarding the 
composition of the streak-like patterns resulting from centripetal migration of epithelial cells. 
Due to the semi-random integration of lentivirus each integration will occur at a near unique 
site within the host genome. Integration site analysis therefore provides another means by 
which LESC clones might be distinguished, however, can only be performed upon tissue 
extracts and thus cannot be directly correlated with transduction patterns observed in vivo, 
nonetheless such analysis would provide useful data and to be successfully applied a pure 
isolate of epithelial DNA is required. 
 
7.1.1 Aims 
Work in this chapter aims to develop techniques that might be applied to future work 
characterising the cellular dynamics of corneal epithelial homeostasis, in particular means to 
distinguish individual LESC clones from each other, in vivo, ex vivo or in vitro will be 
developed. 
More specifically the Lenti Go (LeGO) vector system will be adapted for application to 
LESCs, and a means of isolating transduced epithelial tissue from the rest of the cornea to 
obtain a purely epithelial DNA sample for integration site analysis will be developed. 
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7.2 Methods and results 
 
7.2.1 In vitro development of LeGO vectors for clonally specific cell labelling 
The microscope filter setup suggested by Weber et al. in their paper [334] originally 
describing the RGB Lenti Go (LeGO) labelling technique is unfortunately incompatible with 
any fluorescent microscope available for this work. Therefore in order to ensure that the 
three fluorophores used by this technique are clearly distinguishable from one another when 
combined in our hands a modified setup was designed and evaluated using LeGO viruses in 
vitro. 
Figure 63 shows the proposed filter set up for use on a Leica DM5500 confocal microscope, 
designed to follow as closely as possible the specifications suggested by Weber et al. [334]. 
The three lentiviral transgene constructs used by Weber et al. to produce LeGO viruses are 
commercially available (Addgene) and were used to make the three lentiviruses in our own 
production methodology (2.2.4) and were established to have the following infectious titres: 
LeGO-Venus  4.95 x 108 vg / mL 
LeGO-mCherry 2.0 x 108 vg / mL 
LeGO-Cerulean 2.2 x 108 vg / mL 
In order to approximately titre match the following dilutions were made in Opti-MEM 
2 µL of LeGO-Venus in 500 µL Opti-MEM, = ~2.0 x 106 vg / mL 
5 µL of LeGO-mCherry in 500 µL Opti-MEM, = ~2.0 x 106 vg / mL 
5 µL of LeGO-Cerulean in 500 µL Opti-MEM, = ~2.0 x 106 vg / mL 
To test the setup 293T cells were seeded at ~50% confluency on an 8 well chamber slide 
(PAA / GE Healthcare). Immediately after cells had been seeded, before they had fully 
attached to the growth surface the 3 wells were infected as follows: 
Well 1 – 50 µL, LeGO-Venus virus dilution (~105 vgs) 
Well 2 – 50 µL, LeGO-mCherry virus dilution (~105 vgs) 
Well 3 – 50 µL, LeGO-Cerulean virus dilution (~105 vgs) 
A mixture of the viruses was then made by combining 100 µL of each of the three virus 
dilutions and a 3 fold dilution series made of this mixture (diluent, OptiMEM, Gibco). 
Three wells were then infected as follows: 
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Well 4 – 150 µL, Neat virus mixture (~105 vgs of each virus) 
Well 5 – 150 µL, 1:3 dilution of virus mixture (~3.3 x 104 vgs of each virus) 
Well 6 – 150 µL, 1:9 dilution of virus mixture (~1.1 x 104 vgs of each virus) 
All wells were left for 24 hours for expression to develop before the cells were fixed in 4% 
PFA and imaged by confocal microscopy. 
Figure 64A-D shows the wells 1-3 imaged using the microscope channels proposed in 
Figure 63. The Venus and Cerulean channels appear specific, only detecting the 
fluorophores they are designed to pick up. The mCherry channel however also seems to 
detect the emission of Venus as shown in Figure 64C. The mCherry channel’s emission 
detection range was therefore modified from 580-640nm to 600-650nm and the 532 laser 
power was reduced from 20% to 15%. After this change had been made Venus bleed into 
the mCherry channel was much reduced and all the channels essentially specific only for the 
fluorophore they were designed to detect as shown in Figure 64E-H. 
Figure 65A-D shows the wells 4-6 imaged the microscope channels proposed in Figure 63. 
Figure 65E-H shows the wells 4-6 imaged using the modified mCherry channel discovered to 
lead to better fluorophore discrimination in Figure 64. 
The greatest variety of distinct colours resulting from the co-infection appears to have 
occurred in the 1:3 dilution imaged using the channel set known to allow Venus emission to 
bleed into the mCherry channel, Figure 65C.  
Henceforth this channel setting will be referred to as LeGO settings 1 
The channel settings that minimises Venus bleed into the mCherry channel will be referred 
to as LeGO settings 2 
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Figure 63. Schematic of proposed set up for Leica DM5500 to image cells transduced with the 3 colour LeGO System 
A: Emission spectra of the three fluorophores used in the LeGO system and the nuclear stain To-Pro3. Filter settings proposed to optimally detect emission.  
B: Excitation spectra of the three fluorophores used in the LeGO system and the nuclear stain To-Pro3. Most appropriate lasers to excite the dyes and 
estimates efficiency of excitation.  
Spectra and images modified from BD Fluorescent Spectra Viewer. Found here: 
http://www.bdbiosciences.com/research/multicolor/spectrum_viewer/index.jsp 
  
Fluorophore
Bandpass selected to detect
Emission (nm)
Cerulean 483/32 (467-499)
Venus 530/40 (510-550)
mCherry 610/60 (580-640)
To-Pro-3 675/50 (650-700)
Fluorophore
Most 
appropriate
Laser Available
Estimated
Efficiency of 
Excitation
Cerulean 405 nm 51%
Venus 488 nm 40%
mCherry 532 nm 40%
To-Pro-3 633 nm 86%
A
B
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Figure 64. Channel specificity test of microscope setup in Figure 63 using LeGO viruses on 293T cells in vitro 
A: Schematic showing the imaging settings used in each quadrant of panels B-D. 
B-D: 293T cells infected with LeGO virus encoding mCherry (B), Venus (C) and Cerulean (D) respectively imaged using the 3 channel settings shown in A. 
Fixed and imaged 24 hrs post infection. 
E: Schematic showing the imaging settings used in each quadrant of panels F-H, modified from A due to channel cross talk seen in C. 
F-H: 293T cells infected with LeGO virus encoding mCherry (F), Venus (G) and Cerulean (H) respectively imaged using the 3 channel settings shown in E. 
Fixed and imaged 24 hrs post infection.  
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Figure 65. LeGO co-infection test on 293T cells in vitro using LeGO lentiviruses at various dilutions and two imaging settings (described in Figure 64) 
A: Imaging settings used in B-D, known to allow some Venus emission to bleed into mCherry Channel (Figure 64). 
B-D: 293T cells co-infected with all 3 LeGO viruses at the following dilutions respectively Neat, 1:3 and 1:9. Fixed and imaged 24 hrs post co-infection. 
E: Imaging settings used in F-H. 
F-H: 293T cells co-infected with all 3 LeGO viruses at the following dilutions respectively Neat, 1:3 and 1:9. Fixed and imaged 24 hrs post co-infection. 
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7.2.2 Confirmation that labelling mediated by LeGO vectors is clonally specific in 
vitro 
Having established that a large number of unique colours can be generated by the LeGO 
labelling system the next step was to confirm that these colours are indeed inherited by 
daughter cells upon cell division thus labelling all cells within a clone. 
Observations in the previous experiment were indicative of clonal specificity, with adjacent 
cells often appearing the same colour. However the cells were relatively near confluency 
upon infection with only 1-2 cell divisions likely to have occurred over the time frame 
observed and thus any infected clones would be too small to draw any firm conclusions. 
Cells were therefore seeded at a much lower density to allow more extensive clonal growth 
to be observed. Initial experiments were complicated by HEK293T cells decreased viability 
and growth at low densities, HeLa cells were therefore utilised instead which proved to be 
more tolerant of low density culture, although these too exhibited reduced viability. 
HeLa cells were initially grown within a density range of 20 – 90% confluent, as is usual for 
standard culture of this cell type. During this period they were infected with the LeGO 
vectors. Infection was performed under standard culture conditions rather than after low 
density seeding to minimise any additional stress on cells during periods of low density. 
Infection was carried out as follows: 
A single well of a 6-well plate (9.5 cm2) of 60-70% confluent HeLa cells were infected with: 
10µL LeGO-mCherry - 3.96 x 105 vgs 
4µL LeGO-Venus  - 4.00 x 105 vgs  ~4.00 x 105 vgs 
10µL LeGO-Cerulean  - 3.40 x 105 vgs 
Post infection cells were left for ~16 hours, by which time they were near 100% confluency 
Cells were then passaged as normal, and once trypsinised cells were counted using a 
haemocytometer and a proportion were reseeded at low density. 
Two approaches to low density seeding were taken; 
1) LeGO infected cells alone were seeded in 8 well chamber slides (surface area per 
well: 0.88 cm2) at densities of  
a. ~1000 cells / well (1136 cells / cm2) 
b. ~200 cells / well (227 cells / cm2) 
2) LeGO infected cells were seeded in combination with uninfected cells, in order to 
maintain a reasonable overall cell density to promote cell viability whilst infected cell 
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density remains low. Both infected and uninfected cells were seeded into 1 well 
chamber slides (surface area of well: 10.84cm2). Seeding densities were: 
a. Uninfected:  ~100,000 cells / well  (9225 cells / cm2) 
b. LeGO Infected: ~2500 cells /well  (230 cells / cm2) 
 
Infected cells that were seeded alone were imaged using the an inverted microscope (Zeiss) 
at 10x magnification ~7 hours post seeding in order to observe initial seeding density 
directly. Cells were then left for 7 days to expand before being fixed in 4% PFA and imaged 
by confocal microscopy using LeGO settings 1. 
Figure 66 shows the results of the imaging. At both seeding densities areas are visible in 
which a large number of adjacent cells all share the same colour label which is highly 
indicative of the label being clonally specific. 
There are also areas in which cells containing two different colour labels appear to have 
become mixed, likely due to clones expanding into one another or two or more cells having 
been seeded in close proximity. As would be expected such areas of mixing are more 
evident in the denser seeding condition. 
 
Infected and uninfected cells seeded together grew more rapidly and were fixed and imaged 
after 5 days, by which time they were approaching confluency. After fixation these cells were 
labelled with the nuclear marker To-Pro3. This allowed all cells (infected and uninfected) to 
be visualised. As To-Pro 3 fluoresces in the far red (Ex/Em: 642 ⁄ 661 nm) it can be used 
without bleed through into the LeGO channels (Figure 63). 
Figure 67 shows the results of the imaging. The presence of multiple patches of infected 
cells in which all adjacent cells share the same colour label is highly indicative of the label 
being clonally specific. In Figure 67C at least 7 distinct colours can be easily distinguished 
by eye. The white asterisk indicates a cell cluster in which the green channel is over 
exposed masking colour differentiation, although perhaps two colours can be distinguished 
within this cluster. The Pink asterisk in Figure 67C & D indicated a labelled cluster in which 
the cells appear to be either dying or hyperproliferating as shown by high density To-Pro3 
staining 
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Figure 66. LeGO infected HeLa cells seeded alone at two low 
densities to demonstrate clonal specificity of labelling 
A: Cells imaged ~7 hours post seeding at 1000 cells /well, 10x 
magnification to illustrate seeding density. 
B: Cells imaged ~7 hours post seeding at 200 cells /well, 10x 
magnification to illustrate seeding density. 
C: Cells fixed and imaged by confocal microscopy 7 days after 
seeding at 1000 cells / well. Imaged using LeGO settings 1 
D: Cells fixed and imaged by confocal microscopy 7 days after 
seeding at 200 cells / well. Imaged using LeGO settings 1 
D’: Digitally modified version of image shown in D in which 
levels have been modified as follows to enhance brightness: 
Red: 0-255  0-100 
Green: 0-255  0-150 
Blue: 0-255  0-100 
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Figure 67. LeGO infected HeLa cells seeded at low density in combination with 
uninfected cells to demonstrate clonal specificity of labelling 
A: LeGO vector mediated expression in infected cells. Cells fixed and imaged by confocal 
microscopy 5 days after seeding at 2,500 infected + 100,000 uninfected cells / well. 
Imaged using LeGO settings 1 at 10x magnification, confocal z-projection. 
B: To-Pro3 nuclear staining of all cells present in A. Imaged at 10x magnification, 
confocal z-projection. 
C: Higher magnification image of the condition shown in A. Exact area imaged in C is not 
visible in A. Imaged using LeGO settings 1 at 40x magnification, confocal z-projection. 
White asterisk highlights cells in which the green channel is over exposed. 
D: Higher magnification image of the condition shown in B. Exact area imaged in D is not 
visible in B. Imaged using LeGO settings 1 at 40x magnification, confocal z-projection. 
C&D: Pink asterisk highlights cells in which may be dying or hyperproliferative. 
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C
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7.2.3 Development and validation of protocol to isolate murine epithelial sheet for 
the purposes of further molecular analysis 
In order to undertake molecular analysis of lentivirus transduced epithelium it would be 
advantageous to isolate only the tissue of interest (corneal epithelium) from all surrounding 
tissues to minimise the chances of any factors derived from other tissues contaminating the 
sample. 
The protocol developed here was based upon various published protocols [336–340] all 
based upon incubation with Dispase II. 
The majority of such work has been done in either human or rabbit tissue with only 
Kobayashi et al. [340] having described the technique in mice. Mice have a relatively thin 
Bowman’s layer compared to other mammals (including rabbits) [341] and therefore it was 
not known whether the murine epithelium would display sufficient structural integrity for intact 
isolation. 
The technique developed is described below: 
Mice were terminated and the eyes enucleated. The eye was then placed in a small dish 
containing Keratinocyte-SFM supplemented with 1x Antibiotic / Antimycotic, 30ug/mL Bovine 
Pituitary Extract (BPE) and 0.2ng/mL Epithelial Growth factor (EGF) (All Gibco). Dissection 
was performed with the eye submerged in this media using corneal notched forceps 
(Acrofine) and Vannas Capsulotomy Scissors (Albert Waeschle). 
The cornea was dissected away from the rest of the globe with an orbital cut just posterior to 
the limbus. Any non-corneal tissue that came away attached to the cornea was carefully 
removed. Once isolated the cornea was placed in a single well of a 48 well plate containing 
400µL dispase solution formulated as follows:  
100µL - Stock dispase solution: Powder (Sigma) dissolved in supplemented K-SFM to a final 
concentration of 13.3 Units / mL 
296uL  - Supplemented Keratinocyte-SFM 
4µL  - 30mM CaCl2 in dH2O. 
Cornea was then incubated in the dispase solution at 4°C overnight. Following dispase 
incubation the cornea was returned to a small dish containing supplemented Keratinocyte-
SFM for further dissection. Using two pairs of Dumont #5 forceps it proved possible to grasp 
and peel a sheet of epithelium away from the remainder of the cornea. Non-epithelial tissue 
was then usually discarded. 
Figure 68 shows a series of images illustrating this dissection. 
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The isolated epithelial sheet can then be further dissected, fixed and stained or stored for 
short periods of time in supplemented K-SFM for further processing. 
Figure 69 shows an isolated sheet of murine epithelium flatmounted Bowman’s layer down. 
The sheet is remarkably intact. Viewed under the microscope it is almost indistinguishable 
from corneal epithelium seen upon a whole cornea flat mount. Both basal and more 
superficial cells can be seen Figure 69B & B’. No cells of the stroma were observed at all 
indicating the isolation from more posterior tissues of the cornea was complete. 
Further dissociation was attempted with the aim of obtaining a single cell suspension of the 
epithelium. The isolated epithelial sheets proved highly resistant any form of further 
dissociation, reagents tried included: 
Trypsin-EDTA (0.05%) up to 2 hours at 37°C 
TrypLE Express (1x) up to 2 hours at 37°C 
Papain (20 units / mL) up to 1 hour at 37°C 
Collagenase D (0.1 mg / mL) up to 1 hour at 37°C 
Even when combined with mechanical sheer forces (repeated aspiration with a P200 pipette) 
none of the above resulted in a homogeneous single cell suspension. All suspensions that 
resulted contained large clumps of non-dissociated cells and also often displayed a high 
level of cell death. 
It was therefore decided that any analysis should be performed upon the intact sheets. 
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Figure 68. Image sequence showing surgical 
removal of the epithelial layer from an isolated 
murine cornea ex vivo post overnight incubation in 
Dispase II 
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Figure 69. Flatmount of isolated sheet of murine corneal epithelium obtained from incubation of whole cornea ex vivo in dispase II, mounted Bowman’s 
layer down 
A: Image taken at 10x magnification showing DAPI staining of ~60% of the entire sheet 
B & B’: Orthographic projections of confocal z-stack taken at 40x magnification. Only XY (single plane) and XZ shown. 
In All: Blue = DAPI, Red = TRITC-Phalloidin 
A
DAPI
TRITC-Phalloidin
B B’
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7.3 Discussion 
 
This chapter describes some initial pilot experiments focused upon development of 
techniques by which transduced limbal epithelial stem cell (LESC) clones might be 
distinguished from one another following labelling by intraepithelial injection of lenti vector 
encoding a fluorescent transgene product. 
An extremely promising and elegant method by which this might be achieved is the RGB 
Lenti-go (LeGO) system described by Weber et al. [334]. This system is claimed to enable 
the lentiviral labelling virus of cells with a unique, clonally inherited colour signature. In 
theory such a system should be readily adaptable to our purpose of in vivo labelling of 
LESCs and their clones. 
The first question to be addressed in translating this system to the lab was to determine 
whether the commercially available LeGO lentiviral constructs would be efficiently packaged 
to produce vector of acceptable titre within our lenti production methodology. These 
constructs themselves are very similar in genomic structure to those used as a matter of 
routine within the lab however the 3rd generation production system used by Weber et al. is 
slightly different; providing the HIV1 genes required for vector production in trans via two 
plasmids rather than one. Fortunately this difference proved inconsequential and vectors of 
high titre (108 vg / mL range) were produced. 
The exact microscopy / filter block set up recommended by Weber et al. for the imaging of 
labelled cells was unfortunately incompatible with the capabilities of any instrument within 
the lab and could not be implemented without incurring substantial expense. However the 
confocal instrument (Leica DM5500) available is highly adaptable / tuneable in terms of the 
emission spectra that it can detect and is equipped with laser excitation sources suitable to 
excite each of the 3 fluorophores used with in the LeGO system. In addition a 4th excitation 
wavelength in the far red (633nm) is available that could be used to combine a nuclear 
marker with the technique. A channel setup for LeGO imaging was therefore designed for 
this instrument intended to be as comparable as possible to that described by Weber et al. 
and include the possibility to add in a 4th far red channel for the nuclear stain To-Pro-3. The 
channel setup is shown in Figure 63 
Upon initial testing of this setup to detect expression from individual LeGO vectors in vitro it 
was found that fluorescent signal from the fluorophore Venus was detectable in the mCherry 
channel in addition to its own. This was initially deemed to be sub optimal and was corrected 
by red shifting the mCherry detection range by 20nm and narrowing it slightly. The laser 
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power used to excite this channel was also reduced by 5%. The resulting modified set up 
reduced the bleed through signal from Venus into the mCherry channel although at the cost 
of reducing the detected expression from mCherry itself. To a degree this could be 
compensated for by increasing the electronic gain but this often comes with the 
disadvantage of decreasing the signal to noise ratio. 
When tested in the context of HEK293T cells infected in vitro with the LeGO viruses in 
combination it was initially disappointing that the channels optimised for minimal signal bleed 
through resulted in images in which only a limited range of colours was apparent. Green was 
by far the strongest hue, dominating all the others (Figure 65F-H). By contrast the channel 
setup that allowed VenusmCherry bleed through resulted in an image in which far more 
distinct colours can be seen (Figure 65B-D). The green dominance of the images produced 
by the more discriminating settings is a function of the reduced red signal intensity produced 
as an unavoidable side effect of reducing channel bleed through. This can be proven by 
digital manipulation of the images produced. By stretching the range of red pixel intensity so 
that 130 is taken as the maximum rather than 255 (using the levels function of GIMP) the 
image taken with the settings that minimise bleed through can be made apparently identical 
to the image taken with the settings that allowed the VenusmCherry bleed through as 
seen in Figure 70 below (A vs C). 
 
 
 
 
 
 
Figure 70. Images to demonstrate 
the effect stringent signal 
discrimination can have upon 
distinct colour generation 
A – Image taken using filter 
settings that allow significant 
Venus  mCherry signal bleed 
through 
B – Image taken using filter 
settings that minimise Venus  
mCherry signal bleed through 
C – Digitally manipulated version 
of B 
CA
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The images however are not equivalent. The digitally manipulated image (Figure 70C) is 
less data dense than the one resulting from channel bleed through (Figure 70A), this is due 
to the fact that the red correction process applied essentially discards almost half of the data 
that could potentially have been collected for this channel; stretching the other half over the 
whole intensity range. For further application therefore it would be preferable to use the 
channel setup that allows bleed through as this allows the full range of intensity data from all 
three channels to be used to generate the image and the distinct colours.  
Whilst 100% channel separation is vital for many applications (for example studies of co-
localisation) it is not of particular importance to this technique. For clonal tracking to be 
effective the generation of a large number of clearly distinct colours is preferable to complete 
channel separation. Limited spill over of signal between the channels whilst incongruous 
should be completely consistent as it is a function of the emission spectra of the dyes 
themselves which are invariable. Limited spill over is therefore irrelevant to primary goal in 
this case and in fact may actually act to enhance the generation of clearly distinct colours. 
The molecular biology of the RGB LeGO system should ensure that that the specific colour 
signature a cell gains upon infection should be inherited by all daughter cells upon division 
and thus will be present in all cells of the resulting clone. However as this is the most critical 
point relevant to useful application of the technique it was decided that clonal specificity of 
labelling should be confirmed experimentally.  
The pattern of colours produced from the infection of 293T cells in the initial experiments 
presented here (Figure 65) provide some evidence of this; with similarly coloured cells often 
being observed in close proximity to one another. However the context in which these in vitro 
experiments were conducted only allowed the cells in question to undergo a maximum of ~3 
divisions before the experiment was ended or confluency was reached; insufficient to 
conclude clonal specificity with any certainty. Ideally an experiment should be undertaken 
where by the expansion of a number of clones is directly observed and all cells and cell 
divisions that formed each clone visually tracked. These observations could then be 
correlated to cell colour once the clones had been fixed and imaged. 
This experiment proved to be more challenging than initially anticipated due to a number of 
complicating factors. Firstly HEK293T cells were found to be unsuitable for use in any such 
an experiment. When plated at sufficiently low density for clonal colony formation these cells 
displayed an extremely low viability; even when plated at higher density that allowed some 
cell-cell contact HEK293Ts still exhibited a much reduced rate of cell division producing 
inconclusive data. HeLa cells were therefore used instead which proved more tolerant of low 
density growth conditions. 
 250 
 
Time lapse microscopy to directly monitor the expansion of clones and track all cells / cell 
divisions by direct observation was attempted however the instrument used (JuLi 
microscope, Bulldog Bio) proved unable to perform the task. The images produced were of 
insufficient resolution or phase contrast to accurately track cell divisions and the instrument 
had difficulty maintaining fine focus over the entire time-lapse period.  
Two surrogate approaches were therefore adopted in which LeGO infected HeLa cells were 
plated at low plating densities to allow isolated colony formation and expansion in the 
absence of time-lapse imaging. The cells were either plated alone (2 different densities) or 
co-plated with a higher density of uninfected cells in order to improve cell viability / growth 
characteristics whilst maintaining a low effective density of infected cells. 
The infected cell densities upon seeding in these experiments where selected to ensure cells 
were spaced out sufficiently for mixing of clones to be limited. The cells were assessed by 
microscopy post seeding to confirm such adequate spacing. In the images produced by 
these experiments (Figure 66 & Figure 67) it can be clearly seen that there are large areas 
of adjacent cells sharing the same colour label which is highly indicative of the label being 
clonally specific as claimed. The proposed experiments upon LESCs in vivo however will 
likely be conducted over the far longer term, it should therefore be determined if colours 
remain constant and colony specific over a timescale of months. This could be attempted by 
multiple follow ups over time of a single labelled clone in vitro. Such a culture could be 
established by seeding <96 infected cells across 96 well plate. 
The LeGO system provides a potentially elegant means by which the LESC clones and 
streak composition might be tracked although its application in vivo will require a fresh round 
of epithelial injections using all three the LeGO vectors in combination, and MOI will have to 
be reoptimised to the in vivo condition; these injections are planned to be carried out in the 
near future. Unfortunately the SLO instrument used to follow eGFP transgene expression in 
vivo in Chapter 6 is only able to visualise fluorescence in the green and infrared 
wavelengths. An alternative instrument would therefore be required to follow all three LeGO 
fluorophores in vivo and the lab has recently acquired a two photon microscope that might 
be suitable although this instrument is not yet fully optimised for use in vivo. 
 
The LeGO system also cannot be applied retrospectively to animals that have already been 
injected with lenti-eGFP and for which long term follow up of streak formation has already be 
assessed (Chapter 6). For these animals an alternative means must be found to determine 
the number of LESC transduced and provide insight into the composition of the epithelial 
streaks observed. 
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One potential methodology that might be applied to these animals would be determination of 
the location and pattern of the sites at which the lenti genome has integrated within the 
host’s. Integration of the lenti provirus into the genome is semi random. In actively dividing 
cells types (such as the corneal epithelium) integration shows preference towards genomic 
areas that are transcriptionally active [202], whereas in non-dividing cells the process 
appears more truly random [342]. The preference for transcriptionally active sites is likely 
due to the chromatin rearrangements associated with active transcription rendering these 
areas more accessible to the provirus.  
Despite this preference however it remains highly unlikely that any two individual integration 
events will result in provirus integrating into precisely the same location within the host 
genome. Each cell infected with a lentivirus should therefore carry a unique signature of 
integration sites within its genome, which as they essentially form part of the host genome 
itself, will be inherited by all daughter cells.  
These integration site signatures can be determined using the technique of linear 
amplification mediated PCR (LAM-PCR) as described by Schmidt et al. [343].  
This technique involves the following steps: 
Genomic DNA is extracted from the tissue of interest and linear amplification is performed 
using a biotinylated probe complimentary to the LTR sequence of the lentivirus. This results 
in the production of a single stranded DNA species for each integration site present labelled 
with the biotinylated probe on the 5’ end and spanning the integration site from the LTR into 
the host genome. These DNA fragments are then extracted and purified by means of 
streptavidin coated magnetic beads. 
Second strand synthesis is then performed upon the ssDNA fragments before they are 
digested with a frequently cutting restriction enzyme. The length of each individual fragment 
is essentially randomised by this process as it is unpredictable exactly where in the unknown 
host sequence the enzyme will cut. For each integration site a DNA species has now been 
generated that is of random length and bounded by the LTR primer sequence on one end 
and a known restriction enzyme cut on the other. 
A DNA linker is then ligated to the cut end of these species which contains a known 
sequence to which a primer has been designed. PCR can then be performed to 
exponentially amplify every fragment, using primers binding the LTR and the linker, the two 
known sequences that now bound every fragment. 
The resulting PCR products can either be sequenced to determine the exact sites of 
genomic integration present within the sample or analysed by gel electrophoresis to give a 
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fingerprint of all the integration sites combined. Generally speaking the number of bands / 
integration sites that make up this fingerprint should approximately correlate to the initial 
number of cells transduced. Cells containing multiple integration sites are of course a 
possibility and the frequency of this occurrence will scale with initial MOI. Such multiple 
integration events can be detected and controlled for to a degree by analysing relative band 
intensity. For example, a clone of a particular size containing 3 integration sites would result 
in three bands of equal intensity once intensity differences related to size have been 
corrected for. The technique has its limits however. Too many clones / integrations will result 
in too high a density of data to analyse and an increased probability of two distinct 
integration sites producing fragments of indistinguishable length. 
 
As a first step in the application of LAM-PCR integration site analysis to our labelled tissue, 
the epithelium must be isolated from any other tissue which may have been transduced and 
would thus contaminate the analysis. The stroma is of particular concern as occasional off-
target stromal transduction was not uncommon, especially in injected cohort 2. (Chapter 6) 
There are multiple published techniques where by such epithelial isolation is achieved via 
incubation of corneal tissue with Dispase II, followed by a mechanical peel of Bowman’s 
layer + epithelium away from the rest of the tissue. [336–340]  
The published protocols however refer in the majority to rabbit tissue rather than mouse and 
aim to isolate dissociated cells for the establishment of a primary cell culture. For this 
endpoint the maintenance of cell viability across the entire tissue is desirable although not 
critical as such a culture can be established from a relatively small number of cells if need 
be. It was uncertain therefore if these protocols could be successfully adapted to our 
purpose. Mice have a thinner Bowman’s layer than rabbit [341] possibly making mechanical 
isolation more challenging and additionally the maintenance of high overall tissue viability 
post digestion is critical or the loss of LESC clones from the analysis might occur. 
The dissociation protocol was successfully adapted in such a way as to be suitable for our 
purpose. Dispase digestion was performed overnight at 4°C in an effort to slow and reduce 
the potential impact of the digestion on cell viability. Mechanical isolation proved to be 
relatively straight forward with Bowman’s + epithelium always peeling away as a single intact 
sheet. 
This sheet could then be further dissected if need be for example to isolate specific streaks, 
but this could be challenging due to the sheets extreme thinness and resulting difficulty in 
mechanical manipulation. Further development of dissection technique is required in this 
area. The integrity of the sheet immediately post isolation was remarkable. Upon fixation and 
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flat mounting the sheet (and the basal TAC layer in particular) was almost indistinguishable 
by microscopy from an epithelium still in situ upon a freshly isolated intact cornea. The cells 
showed no particular signs of ill health and the basal layer remained almost 100% intact. 
There may have been some loss of more superficial epithelial cells although confocal 
microscopy at 40x magnification showed that at least some are still present. This potential 
loss of superficial cells should not prove detrimental to our intended application as all LESC 
clones should be represented in the intact basal layer. 
The isolated epithelial sheet did not however maintain viability in the longer term. Extended 
culture at 37°C / 5% CO2 in the same base medium used for dissection and dispase 
incubation (supplemented K-SFM) for 24 hours resulted in near complete loss of viability. 
The medium in question is serum free perhaps indicating that serum might be required for 
more long term culture. Long term viability is not however required for the primary 
application as genomic extraction could be performed immediately post isolation. 
Initially it was planned to further dissociate the isolated epithelial sheet into a single cell 
suspension that could potentially be processed through a fluorescent automated cell sorter 
(FACS) to further isolate and purify the labelled population. However this proved unfeasible. 
The isolated sheet was highly resistant to any further dissociation, enzymatic or mechanical 
and any degree of success in further dissociation was accompanied by widespread cell 
death as shown by trypan blue uptake. This further dissociation and purification however is 
not strictly necessary as genomic DNA extraction could easily be performed on the entire 
isolated tissue sheet, which has already been shown to be free of contaminating non-
epithelial cells. Attempts at further dissociation were thus abandoned. 
Taking this technique forward, enough experience has now been gained to begin application 
of the technique to the transduced samples for which 1 year follow up in vivo is available, 
and a collaboration is being discussed with Dr Manfred Schmidt whose group at the National 
Centre for Tumour Diseases (NCT) in Heidelberg have pioneered the technique of LAM-
PCR for integration site analysis. 
 
7.3.1 Conclusions 
 The RGB Lenti-Go (LeGO) system described by Weber et al. [334] has been 
successfully developed within the lab in vitro and has been verified to mediate 
clonally specific labelling as claimed. 
 A technique has been developed that allows isolation of corneal epithelial sheets 
from murine corneas whilst maintaining the integrity of the tissue and cell viability   
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8. Discussion  
 
The work presented within this thesis has developed multiple viral gene therapy based 
approaches effectively targeting transgene delivery to each of the three cellular layers of the 
cornea resulting in high level and long lasting transgene expression via application of novel 
vector species and optimisation of vector administration. The target cells within these three 
layers are heterogeneous in nature and thus each presented a different set of challenges to 
be overcome in order to mediate an effective gene delivery. 
Key findings are summarised below: 
 The new AAV serotype AAV2/6(ShH10) was shown to be able to transduce both 
murine and human corneal endothelial cells with high efficiency. No other AAV 
serotype is known to mediate any substantial gene delivery to this cell type.  
 The transduction profile of AAV2/8(Y733F) following intrastromal injection has been 
characterised and shown to initially mediate high level of transgene expression in 
both the epithelium and stoma. Epithelial transduction is short lived but a substantial 
stromal transgene expression is sustained for at least 5 months in both mouse and 
human tissue. 
 Corneal transduction by intrastromal injection of AAV2/8(Y733F) was shown to be 
effective in an augmentation gene therapy approach to inhibit corneal 
haemangiogenesis in vivo via expression of musFlt1. 
 A methodology was developed that is able to mediate substantial sustained gene 
transfer to the epithelium via limbal epithelial stem cell (LESC) transduction in vivo. 
Expression was maintained within this replicative tissue for at least 1 year.  
The potential applications for these techniques are wide ranging: 
 
8.1 Applications in gene therapy for correction of genetic 
disorders 
 
The first and most obvious potential application of any gene therapy based approach is to 
the correction of genetically inherited disorders. The disorders to which gene therapy has 
been most widely applied to date are monogenic disorders with an autosomal recessive 
inheritance pattern. This is largely due to the fact that such disorders are technically the least 
 255 
 
difficult to correct, usually requiring simple gene supplementation, i.e. the expression of a 
wildtype functional gene product that is either entirely absent or non-functional in the disease 
state. 
With the exception of those resulting from haploinsufficiency dominantly inherited disorders 
generally cannot be treated by gene supplementation alone and are thus more challenging 
to treat via gene therapy. Dominant disorders resulting from a gain of function or dominant 
negative mutations will require the translation of the mutated gene product to be reduced or 
eliminated. However this alone may be insufficient to restore normal function and merely 
convert the dominant form into a haploinsufficient form, in which case additional gene 
supplementation may also be required. There are a number of genetic disorders of the 
cornea to which the techniques developed here might be applied to mediate an effective 
treatment. 
 
8.1.1 Endothelium directed gene transfer 
The most common inherited disorder of the cornea primarily affects the endothelium, Fuchs 
endothelial dystrophy which is an autosomal dominant disorder, the late onset form of which 
occurs in around 4% of the population over 40 years of age. It is characterised by a 
thickening of Descemet’s membrane, the formation of excrescences within Descemet’s 
termed guttae and the progressive loss of endothelial cells leading to corneal oedema and 
clouding. Despite its relatively high frequency the molecular genetics and pathogenic 
mechanisms of late onset Fuchs are not fully understood. The disorder is certainly 
genetically heterogeneous, with mutations in many different genes having been associated 
with an increased risk of Fuchs [344]. Due to this lack of knowledge relating to causative 
genes / mechanisms no gene therapy based approach to correct the disorder can currently 
be attempted. 
The much rarer early onset form of Fuchs is somewhat better characterised having been 
shown to be relatively strongly associated with dominant mutations within a single gene 
encoding alpha 2 collagen VIII (Col8a2) [344,345], and two knock-in mouse models have 
thus recently been generated based upon known disease associated point mutants of 
Col8a2 [346,347]. These models appear to mimic the human disorder in that they display an 
increased rate of progressive endothelial cell loss with age and the formation of guttae, cells 
of the endothelium in both models were also shown to display activation of the unfolded 
protein response and increased autophagy. Such models therefore have begun to provide 
some insight into the mechanisms by which early onset Fuchs might proceed (although 
these investigations are currently relatively preliminary) and could also be used to test the 
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efficacy of a gene therapy based treatment upon the phenotypes observed. The authors do 
not however describe any visual impairment due to corneal oedema for either model and this 
apparent lack of the primary sight threatening clinical phenotype within the model is a 
concern. Additionally, whilst the normal mouse endothelium has been shown to undergo age 
related decline in a similar manner to humans [348] it has also been shown that endothelial 
cell proliferative capacity varies between species [8]. Care must therefore be taken in 
extrapolation of results between species in light of such known species differences. 
Although the animal models are imperfect and the disease mechanisms only have only 
begun to be elucidated a gene therapy approach to early onset Fuchs could perhaps be 
considered based upon an RNAi mediated knockdown of the specific mutant alleles present 
in these models. If such allele specific RNAi construct can be designed and validated then 
then gene delivery to the endothelium must then be achieved. 
All endothelium direct gene therapy to date (discussed later in 8.2) has been carried out 
using either adeno or lentiviral mediated gene delivery as these are the only two vectors that 
have thus far been shown to effectively transduce the endothelium. Both these vectors carry 
substantial disadvantages however. The use of adenovirus within non-cancer gene therapy 
has declined in recent years as it became apparent that the immunogenicity of this virus 
would impose substantial limits upon its utility [163]. Lentiviruses remain widely used as they 
are far less immunogenic and their ability to integrate into the host genome is of great benefit 
for any application requiring gene delivery to replicative cell types. However the disruption to 
the host genome caused by integration combined with an apparent preference of the 
process for regions of high transcriptional activity [202] carries an ever present risk of 
insertional mutagenesis and oncogenic transformation [211,349]. 
AAV vectors display both a low immunogenicity and carry no significant risk of insertional 
mutagenesis and thus have become a widely used vector of choice, especially within the 
context of non-replicative cell types. However AAV mediated gene transfer approaches to 
the endothelium have thus not far been possible due to its extremely limited transduction of 
this cell type [223]. The novel finding presented here that AAV2/6(ShH10) serotype is able to 
mediate a widespread and substantial transduction of the endothelium in both mice and man 
has therefore enabled genetic manipulation of endothelial cells via AAV which could be of 
potential use in the development and application of a gene therapy based treatment for early 
onset Fuchs or any other genetic disorder of the endothelium. 
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8.1.2 Stroma directed gene transfer 
The high level and long lasting stromal transduction shown here to be mediated by 
AAV2/8(Y733F) is of potential utility in gene therapy to treat the corneal phenotypes of two 
systemic genetic diseases: Mucopolysaccharidosis and Cystinosis. 
The mucopolysaccharidoses (MPS) are a group of liposomal storage disorders, caused by 
recessive mutations in lysomal enzymes resulting in accumulation of glycosaminoglycans 
both intra and extracellularly throughout many tissues of the body. Disease phenotypes are 
therefore extensive and include skeletal abnormalities, defects in pulmonary and cardiac 
function, cognitive impairment, loss of both hearing and vision and reduced lifespan. 
Presentation is variable with 9 different subtypes associated with different genes having 
been characterised, each of which displaying variability in severity. More often than not 
however the condition is severe leading to premature death. [350] 
MPS can lead to the manifestation of multiple pathologies within the eye including corneal 
opacification, retinopathy, optic nerve atrophy / swelling, ocular hypertension, and glaucoma. 
The corneal opacification in particular is present within all forms of the disease. [351] and 
has been shown to be due to abnormal arrangements of collagen fibrils within the corneal 
stroma [352,353]. 
Effective systemic treatment of some forms of the condition has been achieved by either 
bone marrow transplantation (BMT) [354,355] or MPS I enzyme replacement therapy [356]. 
These systemic therapies however are only partially effective, with skeletal and ocular 
abnormalities in particular often proving resistant to correction [356,357]. 
Pre-clinical gene therapy based approaches to MPS have largely been focused upon MPS 
VII due to the availability of both murine and canine models of this subtype [358]. Within 
these models efficacy of gene replacement has been demonstrated via AAV or lenti 
mediated transduction via various systemic or CNS directed routes of vector administration 
[359–362]. In common with the clinically applied therapeutic approaches of BMT or enzyme 
replacement, gene therapy has not proven effective in correction of corneal opacification 
even when directed towards more posterior segments of the eye. [363,364].  
The corneal phenotype within the mouse model of MPS VII has been specifically targeted in 
a study by Kamata et al. [365] who attempted corneal gene replacement via intracameral 
injection of an adenoviral vector. Whilst this study demonstrated transgene expression within 
the cornea and showed evidence of structural improvement within the stroma it also showed 
the gene delivery mediated to be extremely limited and short lived. 
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The extensive, long lasting transduction of the corneal stroma shown here to be mediated by 
AAV2/8(Y733F) might therefore be of improved efficacy in the treatment of corneal 
abnormalities associated with MPS; a phenotype that seems unresponsive to systemic 
approaches. 
 
Cystinosis is another recessively inherited syndromic condition for which gene delivery to the 
corneal stroma may be of significant benefit. Cystinosis has many points of similarity with 
MPS, namely that the condition is also a lysomal storage disease that leads to the 
pathogenic deposition of material throughout many tissues of the body leading to systemic 
dysfunctions [366]. Cystinosis is divided into three main subtypes all of which share the 
pathology of photophobia due to cystine crystal formation in the cornea; in the least severe 
from, ocular cystinosis, this is the primary disease phenotype [367]. 
Treatment of cystinosis is primarily mediated via cystine depleting drugs, although the 
dosing regime is oppressive with drugs having to be taken orally every 6 hours and hourly 
via eye drops [368]. In the more severe forms of the disease this treatment also does little to 
prevent the primary life threatening phenotype of renal failure, for which allogenic 
transplantation is required. 
Gene therapy approaches to cystinosis have been relatively limited to date. Work on gene 
replacement in a murine knockout model [369] has shown that systemic delivery of 
adenovirus mediated transduction of hepatocytes and showed a short term, age dependent 
reduction in cystine levels. Efficacy in this case was likely limited by the short comings 
inherent of the adenoviral vector.  
Unlike MPS treatment of cystinosis via secretion of wildtype protein from a systemic allograft 
such as BMT was not thought likely to be effective. This is due to the fact that the defective 
protein in cystinosis (CTNS) is a membrane transporter rather than an enzyme and thus 
cannot be secreted and requires a specific subcellular localisation in order to be functional.  
Nonetheless Syres et al. [370] undertook allotransplantation of several different adult stem 
cell types into the CTNS knockout mouse hypothesising that healthy cells derived from the 
transplant would be able to integrate into multiple organs and the healthy function of these 
integrated cells would be sufficient to decrease tissue cystine levels. This hypothesis proved 
to be valid as it was shown that allografted haematopoietic stem cells (HSCs) were indeed 
able to integrate into variety of host organs (usually in the form of tissue resident 
macrophages) and mediate a reduction in tissue cystine levels. This technique was then 
further developed in order to avoid the potential risks involved with host vs graft disease by 
transplantation of autologous HSCs that had under gone lenti mediated gene replacement 
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with similar results [371]. These treatments appeared to be effective in the cornea although 
the results suggest that cystine crystal formation may have been delayed rather than 
prevented.  
If only a relatively few integrated donor cells within the cornea are able to produce a 
beneficial reduction in tissue cystine levels then it is likely that CNTS gene replacement 
within corneal keratocytes themselves is likely to be of equal or greater efficacy. Additionally 
in cases of the mildest form of the condition, ocular cystinosis, treatment by BMT which is 
both highly invasive and carries a substantial risk is unlikely to be warranted. A gene therapy 
approach specifically targeted to the affected tissue (the cornea) would be far more clinically 
attractive. 
Long term AAV2/8(Y733F) mediated transduction of the corneal stromal could therefore 
represent an attractive, minimally invasive therapeutic methodology by which the corneal 
phenotypes of cystinosis might be corrected. In the less severe forms of the cystinosis this 
approach could potentially largely cure the condition whilst in the more severe forms the 
need for cysteine depleting eyedrops could at least be eliminated. 
 
8.1.3 Epithelium directed gene transfer 
A gene therapy approach in which an integrating virus (such as lentivirus) is utilised to 
correct a genetic disorder via transduction of a stem cell and results in therapeutic gene 
expression throughout the entire resulting lineage is a well-established approach. Indeed 
some of the very first successful clinical applications of gene therapy utilised this 
methodology transducing hematopoietic stem cells ex vivo for the treatment of severe 
combined immune deficiency [372]. Such treatments however have always required the 
extraction of stem cells prior to gene transfer being carried out ex vivo followed by re-
engraftment of the cells. We believe however that the work presented here in Chapter 6 may 
represent the first time such a gene transfer has been achieved by the direct transduction of 
the stem cell in its niche, in vivo. This constitutes a potentially significant milestone. 
This work (Chapter 6) on gene transfer to the corneal epithelium via transduction of the 
limbal epithelial stem cells (LESCs) was performed as part of a collaboration with Dr Satoshi 
Kawasaki (Kyoto Prefectural University of Medicine) and was directed towards the 
development a potential treatment methodology for gelatinous drop-like corneal dystrophy 
(GDLD), a recessively inherited disorder of the epithelium with an estimated prevalence of 
between 1 in 30,000 [94] and 1 in 300,000 [95] in Japan and rarely reported elsewhere. 
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GDLD is caused by loss of function mutations in the TACSTD2 (aka M1S1, Trop2) gene and 
Dr Kawasaki’s previously published work has both confirmed TACSTD2’s involvement [373] 
and begun to elucidate the mechanism by which loss of function leads to pathogenesis 
[105]. It has been shown that TACSTD2 is able to bind and interact with various tight 
junction-related proteins and that loss of TACSTD2 function is associated with decreased 
expression or altered subcellular localization of these proteins and impaired epithelial barrier 
function. The primary phenotype of amyloid deposition then likely proceeds by fluid 
infiltration into the cornea from the tear film [374]. 
GDLD is therefore well suited to treatment by a supplementation gene therapy approach, as 
it is caused by a recessively inherited loss of function mutation. However the proposed 
pathogenic mechanism of epithelial barrier function impairment makes it likely that a 
widespread or near complete gene transfer to the epithelium will be required to ameliorate 
pathology. A more partial transduction will result in a mixed population of corrected and 
diseased epithelial cells and restoration of barrier function would therefore only be partial 
and significant fluid infiltration could still occur. 
Currently the only available treatment for GDLD is a corneal transplant, however prognosis 
of transplantation is always poor as the procedure does not correct the underlying cause of 
the condition, the genetic defect of the host epithelium. Only the central portion of the cornea 
is transplanted and the host’s defective LESCs remain in place. Over time therefore the 
donor’s healthy epithelium is slowly replaced with the host’s defective cells via epithelial 
turnover and the disease recurs [374], usually within a timeframe of around 1-2 years. 
Repeated engraftment is therefore required to maintain a treatment effect and each 
subsequent transplant carries with it an increased risk of failure [108]. The case for gene 
therapy to correct the underlying genetic defect is therefore compelling. 
Treatment of GDLD via LESC transplantation has also been attempted, applied in 
combination with a central corneal graft [375,376]. As the host’s LESCs are defective an 
allogenic source of donor LESCs was required. Results from this approach have been 
encouraging but not definitive. Only two studies have been undertaken to date; the first [376] 
treated nine eyes in seven patients and within a mean follow up period ~4 years eight of nine 
eyes were free of recurrence. The second study [375] only treated 3 eyes in 4 patients and 
reported no recurrence within a mean follow up time of ~2 years. However, whilst the 
engrafted corneas in this study were described as “clear” at the final point of follow up, 
measurements of visual acuity remained very low. Both studies employed post-operative 
immune suppression consisting short term topical steroids combined with longer term 
systemic administration of agents such as cyclosporine A and / or mycophenolate mofetil. 
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The apparent lack of recurrence in these studies is somewhat surprising. As the hosts 
LESCs were not destroyed or removed as part of the procedure, both healthy engrafted cells 
and defective host cells would be expected to be present within the treated eye, leading to 
competition between them for colonisation of the niche and regeneration of the cornea. 
LESC transplantation is more commonly used in cases of host LESC loss or deficiency, in 
which such competition would be absent or reduced and it has been shown that even in 
these cases the restored epithelium often contains both host and donor cells [77]. The only 
way to avoid this would be to destroy the hosts LESCs pre-transplantation, a procedure 
highly unlikely to be clinically acceptable. If successful therefore the epithelium resulting from 
transplantation in this case would be composed of a mosaic of both healthy and defective 
cells and, as discussed earlier, this is unlikely to fully restore epithelial barrier function which 
depends on correct tight junction formation between all or most cells. 
It is possible however that a partial restoration of barrier function may have been effective in 
substantially delaying recurrence and whilst not curative this effect would still be of useful 
clinical application in prolonging graft survival. Further follow up of these grafts to assess the 
extent of their efficacy is required and the results to date are perhaps encouraging as they 
may indicate that even an incomplete gene transfer to the epithelium and partial restoration 
of barrier function might be a clinically effective treatment for GDLD. 
The allografting procedure described also carries a risk of immune mediated rejection and 
indeed all patients in the study were subjected to immunosuppression to reduce this risk for 
up to 18 months. As far as we are aware the approach of gene therapy and expansion of 
autologous LESCs ex vivo followed by re-engraftment as not been attempted although such 
an approach would present the obvious benefit of a greatly reduced risk of immune mediate 
graft failure. This approach may be of merit, however both harvesting of LESCs and the re-
engraftment are non-trivial surgical procedures that carry a risk of complications [73,377] 
and there is evidence that this form of LESC transplantation may not actually result in the 
permanent engraftment of the cells transplanted [78,79]. The long term epithelial restoration 
observed to result from such LESC transplants may be the result of the transplanted cells 
stimulating an enhanced activity of the remaining host cells which is sustained even once the 
transplanted cells are lost [378]. This would be of no beneficial effect in the case of GDLD in 
which the host cells are defective. 
Therefore the in situ gene transfer to LESCs such as that demonstrated here potentially 
offers both the least invasive and potentially most effective means by which the gene defect 
causative of GDLD might be permanently corrected and if performed early in course of 
disease before symptoms first appear (within the first decade of life) may eliminate the 
requirement for corneal transplantation all together. 
 262 
 
Whilst GDLD was very much the focus of this work the technique of epithelial gene delivery 
via lentiviral LESC transduction would be equally applicable to gene therapy of any other 
inherited disorders of the epithelium although such conditions are extremely rare. One 
disorder in which gene therapy may be of benefit is Meesman’s epithelial corneal dystrophy 
(MECD), a disease characterised by the presence of microcysts within the anterior 
epithelium, foreign body sensation and photophobia. Often the condition is mild but more 
severe forms exist in which corneal erosion and scarring leads to significant loss of vision 
and the requirement for treatment by corneal transplantation. Meesman’s is caused by 
dominant mutations in either keratins K3 or K12 which act antagonistically to the product of 
the wild type allele leading cytoskeletal dysfunction and mechanical fragility of epithelial cells 
[379]. 
Multiple gene therapy approaches might be applicable to a dominant negative mutation such 
as those causative of Meesman’s. Gene supplementation could potentially prove effective as 
overexpression of the wildtype allele might result in sufficient production of normal gene 
product to both saturate the pathogenic mechanism and provide sufficient protein for normal 
function. A better strategy however would likely be an RNAi based gene knockdown 
approach to the mutated allele to directly address the pathogenic process itself. As it has 
been shown that there is no evidence of haploinsufficiency in a murine model of K12 
deficiency [380] this approach should be effective without the need for any additional 
supplementation of the wildtype allele. 
An RNAi based strategy has in fact already been developed by Liao et al. [381] who have 
designed and validated an siRNA construct able to mediate effective allelic discrimination 
and knockdown of a point mutant known to be associated with an especially severe form of 
MECD. Liao et al. convincingly demonstrate the efficacy of their construct in vitro but have 
not yet applied this strategy in either an animal model or clinically because as Liao et al. 
state in their paper “The biggest hurdle to clinical application of these siRNAs is that of 
finding an efficacious and non-invasive delivery system”.  
Lentiviruses have been well established as being able to deliver siRNA constructs for the 
purposes of gene knockdown [382] and thus the methodology developed here could 
therefore provide a minimally invasive method by which this hurdle to delivery could be 
overcome and mediate long lasting gene knockdown in the epithelium. 
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8.2 Applications in augmentation gene therapy 
 
Augmentation gene therapy is an approach whereby the gene transfer does not aim to 
directly correct a specific mutation by either restoring the wildtype gene or down regulation of 
the mutant gene. Instead this approach aims to mediate a beneficial effect upon a specific 
pathological process (whose cause may or may not be genetic). The gene transfer itself can 
either deliver a factor that acts intracellularly in which case only the transduced cells 
themselves will be affected, or can induce the production of a secreted factor that can act 
more widely throughout an entire tissue or system. In the latter case the target cells 
themselves may not even be those affected by the pathology. 
As discussed earlier (8.1.1) gene therapy to correct directly the defects of late onset Fuchs 
endothelial dystrophy is not currently possible due to a lack of knowledge of the molecular 
disease mechanisms. However it is well known that both the late and the early onset forms 
of Fuchs mediate their primary sight threatening phenotype via the progressive loss of 
endothelial cells (decompensation), a mechanism that may be amenable to modulation by a 
gene augmentation based approach. Endothelial decompensation is also of much wider 
significance beyond the context of Fuchs as it is also both a leading cause of corneal graft 
failure [26,119] and the primary reason corneal tissue is rejected for transplantation [383]. 
For this reason gene therapy of the endothelium has primarily been directed towards 
modulation of endothelial cell biology in order to maintain or increase their density. 
Approaches have included preservation of endothelial cells by lenti mediated overexpression 
of anti-apoptotic factors [238,239] or induction of endothelial cell replication via cell cycle 
modulation to increase density [151,241]. 
As mentioned in 8.1.1 all such work to date has been carried out using either adeno or 
lentiviral mediated gene delivery, with adenovirus proving too immunogenic for many 
therapeutic applications and use of lentivirus presenting the risk of oncogenic transformation 
via insertional mutagenesis. This feature of lentiviral transduction is of particular concern 
when the transgene in question is intended to promote cell proliferation or survival and is 
thus itself a potentially oncogenic factor. AAV mediated transduction is therefore an 
especially attractive option within the context of gene transfer for the modulation of 
endothelial cell survival or proliferation as due to its inability to integrate any potentially 
oncogenic transduction will become self-limiting over time due to episomal transgene 
expression in transduced cells being diluted or lost upon cell division. This loss of transgene 
however should not act to inhibit any therapeutic increase in endothelial cell number as in 
most cases a single division of each remaining endothelial cell would be more than sufficient 
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to restore a healthy endothelial cell density. An AAV2/6(ShH10) mediated transduction of the 
endothelium for this purpose therefore represents a potentially effective methodology with a 
much improved safety profile over all those used to date. 
 
One gene augmentation approach arising from this work, the inhibition of corneal haem and 
lymphangiogenesis via sFlt1 gene delivery has already been discussed in detail in 5.3. 
However pathological haemangiogenesis within the eye is not limited to the cornea and is of 
considerable relevance to the posterior segment of the eye. Abnormal neovascular growth 
constitutes a blinding pathology within both age-related macular degeneration (AMD) and 
diabetic retinopathy, conditions that represent two of most frequent causes of retinal 
blindness within the western world [384]. Both conditions can currently be treated with 
antibody-based VEGF binding biologics; these are effective but are also extremely 
expensive and require repeat administration by intraocular injection to maintain efficacy, 
compounding costs and placing considerable burden upon both the patient and the 
healthcare system.  
A gene therapy approach mediating the secretion of a VEGF binder (such as sFlt1) would 
potentially eliminate these issues, providing the treatment effect via a similar mechanism 
whilst only requiring a single treatment if sufficient expression can be mediated over the long 
term. Indeed such gene therapy approaches to both conditions have been proposed and 
employed. 
Work in a murine model of AMD pathogenesis (laser induced CNV) has shown subretinal 
delivery of AAV encoding the anti angiogenic factors such as endostatin / angiostatin [385] 
or sFlt1 [386] can be effective in reducing CNV lesion size.  Additionally a clinical trial [387] 
involving AAV2/2 mediated expression of sFlt1 following subretinal injection is also under 
way for wet AMD, based upon pre-clinical work with in a primate model [388]. 
Almost all such approaches to date have utilised subretinal injections for vector delivery 
aiming to mediate transduction of and secretion from photoreceptors. Such a route is 
appealing due to the very large number photoreceptors present within the eye likely resulting 
in a comparably large amount of transgene product being produced and secreted. 
Additionally subretinal injection of AAV has already proven to be relatively safe in trials to 
treat retinal dystrophies [218]. 
However, unless aiming to treat the photoreceptors themselves it is arguable that 
photoreceptor transduction and subretinal injection are best avoided. The subversion of any 
cell to a secretory role that does not form part of its endogenous function has the potential to 
disregulate endogenous processes within the cell. Although such complications have not 
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thus far been reported, the consequences of such disruption in a highly specialised cell type 
as critical to vision as photoreceptors could be severe. Additionally subretinal injection in 
animal models is often associated with a reduction in ERG amplitude indicating the 
procedure causes a degree of retinal damage. There is also mounting clinical evidence [181] 
to suggest that the macula in particular may be especially sensitive to subretinal injection 
related damage, with alternative injection routes receiving increasing attention. 
Indeed multiple studies have demonstrated that an anti-angiogenic gene therapy approach 
to the prevention of retinal neovascular pathology via a non-subretinal vector delivery route 
can be effective. The ability of AAV2/2 to transduce retinal ganglion cells following 
intravitreal administration has been utilised by a number of studies aiming to treat diabetic 
retinopathy [389,390] or retinopathy of prematurity [391]. One study directed at AMD has 
employed the non-viral gene delivery method of electroporation to mediate sFlt1 secretion 
from the cillary muscle [392]. 
We believe that some of the gene delivery methods developed here may constitute superior, 
non-subretinal approaches to ocular augmentation gene therapy acting via a secreted factor. 
This is due to these methods potentially transducing a larger number of more widely 
distributed target cells and thus likely mediating an increased production of therapeutic 
protein.  
Whilst we have demonstrated the efficacy of intrastromal gene delivery via AAV2/8(Y733F) 
in such approach directed towards the cornea itself (Chapter 5) we have not established 
whether this approach leads to secreted transgene products reaching more posterior tissues 
of the eye in vivo. In human tissue ex vivo, substantial amounts of transgene product were 
secreted from the tissue and detected within the conditioned medium, although it is 
questionable how comparable this highly artificial situation is to normal function in vivo. 
Further work is therefore required to determine the potential applicability of this technique to 
the posterior segment. 
The transduction mediated by AAV2/6(ShH10) is potentially of the most promise in this 
regard. In addition to transduction of the corneal endothelium we also noted that this 
serotype mediated extensive transduction of the cillary body as seen in Figure 71 below. 
Additionally the ShH10 serotype was initially produced as the result of work aiming to 
develop AAV species able to transduce the Müller glia of the retina from an intravitreal 
injection [197] and has already been applied in an augmentation gene therapy context 
directed at promoting photoreceptor survival by glial production and secretion of the 
neurotropic factor GNDF [153], although in this study the authors did not examine 
expression in the anterior segment. 
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Figure 71. Transgene (eGFP) 
expression in the cillary body 
mediated by intravitreal 
injection of AAV2/6(ShH10)-
CMV-eGFP 
 
A: eGFP (Green) channel only 
B: Merged image in which DAPI 
staining (blue) is also visible 
 
 
 
AAV2/6(ShH10) therefore is able to transduce three different ocular tissues located in: the 
anterior segment, the posterior segment and around the limbal circumference from a single 
intravitreal injection. This serotype is therefore potentially the ideal vector for use in 
mediating a high level production and secretion of transgene products panocularly whilst 
minimising the involvement of cells critical to light perception such as retinal neurons.  
AAV based augmentation gene therapy approaches have also been applied within the eye 
for the treatment of uveitis by secretion of various immune modulatory molecules [393–395]. 
For this application in particular route of administration may be critical [396]. In the context of 
an already inflamed environment the side-effects of a subretinal injection (such as retinal 
damage or further inflammation) may be aggravated, and work within the lab by Dr Colin 
Chu (unpublished) has provided some data to this effect. By contrast the intravitreal route of 
administration may lead to greater presentation of both vector capsid and transgene product 
to the immune system resulting in the development of vector or transgene directed adaptive 
immunity, potentially negating or severely limiting any possibility of repeat administration 
[397].  
Route of vector administration for the gene therapy of uveitis therefore remains somewhat 
controversial, with each route presenting pros and cons to be balanced. Despite the possible 
disadvantages however the therapeutic potential of intravitreal AAV2/6(ShH10) for uveitis 
merits investigation. 
 
 
 
 
A B 
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8.3 Non-therapeutic gene transfer applications  
 
Whilst the primary focus of this work and the gene therapy field more generally is usually 
upon clinical application, the gene delivery methods developed can also be of great utility in 
the study of cell biology. In combination with cell-type specific promoters vector mediated 
gene transfer can provide a relatively quick and easy method by which a cell type of interest 
might be labelled or have its gene expression modulated, both in vitro and in vivo. 
As previously discussed in 6.3.2 the lentivirus mediated labelling of LESCs in vivo 
demonstrated here in Chapter 6 provides a potentially powerful tool for the study of epithelial 
cell behaviour both in homeostasis and pathogenesis. It enables the selective labelling of a 
small subset of LESCs with clonal inheritance of the label allowing high temporal resolution 
tracking of cell movement and turnover in a way not possible with the more extensive 
labelling resulting from transgenic manipulation. In addition, combination of LESC 
transduction with the LeGO method developed in Chapter 7 would allow the study of 
interactions between the different clonal populations of cells that make up the epithelium, 
providing an insight into the cellular dynamics of epithelial maintenance at a level of extreme 
detail not previously demonstrated. 
The same techniques could also be applied to studies attempting to determine the fate of 
LESC cultured ex vivo upon cell transplantation. It has been shown that whilst such 
transplants do result in a long term beneficial effect, the transplanted cells themselves to do 
not survive, the mechanism by which they are lost and the means by which the epithelium is 
maintained after their loss are both unknown. Most investigations of this phenomenon have 
used DNA based techniques such as PCR to assess the survival of donor cells on the basis 
of their containing DNA sequences not present in the host, often resulting from a sex 
mismatch between host and donor [78,79]. Whilst this is the only viable technique for use in 
the clinical setting similar work in animal models could utilise a fluorescent marker to directly 
identify and track transplanted cells over time providing a much more detailed insight into the 
processes and timescale of loss. 
One study by Yin et al. attempted such tracking by transplantation of a stably transfected 
LESC line expressing the fluorescent protein venus into a caprine model of LESC deficiency 
[398]. The follow up in this experiment was relatively short (3 months post-transplant), did 
not involve in vivo monitoring of fluorescence and the histological results obtained from the 
fluorescent label were poor and in our opinion inconclusive. More convincing data came from 
PCR which showed a greater proportion of donor cells remaining in the central epithelium 
than in the limbus, perhaps indicating loss proceeding via normal epithelial turn over. 
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The work presented here has shown that within the murine context at least a lentivirus is 
able to transduce LESCs and maintain the expression of fluorescent transgenic label over 
the long term although we have not established if the same is true in the larger animal 
models that are more commonly used in studies of cultivated LESC engraftment such as 
rabbits. If lentiviral transduction of cultivated LESCs in such a model proves possible then 
the fate of LESCs fluorescently labelled by this method could be tracked at the cellular level 
at a high temporal resolution; in combination with the LeGO system the fate or expansion of 
individual clones could also be monitored. 
 
8.4 Conclusion 
 
In comparison to other ocular tissues such as the retina the cornea has been somewhat 
neglected as a target for gene therapy despite its easy accessibility and immune privileged 
status. This relative lack of attention is likely due to both the rarity of congenital conditions 
affecting the cornea and the high success rate enjoyed by the well-established procedure of 
keratoplasty for the treatment of many corneal conditions. Transplantation however does not 
represent a corneal panacea; it is often ineffective for the treatment of genetic dystrophies 
(of the corneal epithelium in particular) and inflammation or vascularisation increases the risk 
of the procedure dramatically. 
The application of corneal gene therapy has the potential to both correct genetic defects and 
act via augmentation gene therapy to improve the prognosis of corneal transplantation in 
high risk cases. The work presented in this thesis has demonstrated that gene delivery to all 
three cellular layers of the cornea can be achieved efficiently and safely, often with 
transgene expression being sustained over the long term. However this study has only 
begun to explore the potential applications for the gene therapy techniques it has developed. 
As discussed in this section such applications are incredibly wide ranging and effective 
corneal gene therapy could therefore potentially be of benefit to a substantial number of 
patients worldwide, ranging from those relatively small number of families suffering from an 
orphan congenital condition, to the millions of patients who receive corneal transplants each 
and every year. 
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8.5 Future Directions 
 
Work to further develop some of the key findings of this thesis (summarised at the beginning 
of this chapter) is planned and this program of further work will be briefly outlined below. 
 
Chapter 5 has convincingly demonstrated that intrastromal injection of an AAV2/8(Y733F) 
delivering sFlt1 is highly effective in prevention of induced corneal haem neovascularisation. 
However, the ingrowth of Lymph vessels into the cornea was not impeded by delivery of this 
transgene and thus the vascular privilege of the cornea was only partially protected. This 
approach alone is therefore likely to be suboptimal in regard to minimising the pathological 
consequences of corneal neovascularisation.  
In order to more fully protect corneal vascular privilege and thus improve any potential 
therapeutic application it is planned to combine the current sFlt1 based approach with 
delivery of the recently discovered sFlt4 (sVEGFR3) that has been shown to inhibit lymph 
neovascularisation [323]. Initially this combination approach will proceed via the co-injection 
of two vectors although a bicistronic construct encoding both sFlt isoforms should also be 
possible. 
Whilst the corneal suture model used in this study to date represents a robust model of short 
term, trauma induced neovascularisation it is perhaps not the most relevant model system in 
regard to clinical application. The intended application for this technique would be to improve 
the prognosis of high risk corneal transplants chiefly via the prevention of immunological 
rejection. Allogeneic murine corneal transplantation therefore represents the ideal model 
upon which to test the optimised therapeutic strategy, and the expertise to perform corneal 
grafts within mice is currently being developed within the lab. 
 
The work presented in Chapter 6 has shown that long term transgene expression within the 
corneal epithelium is achievable via transduction of the LESCs with an integrating lentiviral 
vector. However, in the most extensive transduction shown only around 30% of the corneal 
surface became covered with transduced cells. In order to maximise the beneficial effect of 
gene therapy based upon this transduction it would be desirable to transduce the largest 
possible number of LESCs. This goal should be achievable via improvement in the precision 
and reproducibility of both needle morphology and vector injections techniques and these 
are the areas that will form the initial focus of further work.  
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The capacity to mediate a long term gene delivery to the epithelium was initially developed 
with a view to application in gene therapy for inherited corneal dystrophies, specifically 
GDLD. In order to progress towards this application it would be desirable to test gene 
supplementation within an animal model known to closely recapitulate the human disease. 
Unfortunately such models are currently lacking, a knockout mouse model for TACSTD2 (the 
gene implicated as causative of GDLD) is available but all work upon this model to date has 
focused upon the genes oncogenic potential [399,400] and a corneal phenotype has not 
been described, but may have been overlooked. Alternatively, work by Liao et al. [381] has 
demonstrated a promising gene therapy construct for the correction of the disease 
mechanism underlying Meesmann Epithelial Corneal Dystrophy (MECD) for which they lack 
an effective gene delivery mechanism. However, this condition also currently lacks an animal 
model and whilst Liao et al. have expressed and intention to develop a murine model of 
MECD no progress towards this goal has yet been published. The relevance / availability of 
animal models of inherited epithelial dystrophies will be further investigated however it is 
perhaps likely that work to develop epithelial transduction towards application in gene 
therapy may be currently restricted to in vitro work upon cultured patient cells. 
 
Finally the patterns of transgene expression resulting from Lentiviral LESC transduction 
seen in Chapter 6 have raised a number of questions regarding the exact cellular dynamics 
by which the epithelium is maintained. More specifically the number of LESC lineages 
contributing to the various patterns observed is unknown. Chapter 7 therefore presented in 
vitro work to develop techniques by which the individual LESC lineages could be identified 
and tracked over time. This in vitro optimisation phase is now complete and these 
techniques are ready to be transferred in vivo.  
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 Abbreviations 
 
AAV   Adeno-associated virus 
ABCG2  ATP-binding cassette, sub-family G, member 2 
AMD   Age-related macular degeneration 
AP   Anterior / posterior 
ARVO   Association for research in vision and ophthalmology 
ATP   Adenosine triphosphate  
BM   Basement membrane 
BMP   Bone morphogenetic protein 
BMT   Bone marrow transplant 
BrdU   Bromodeoxyuridine 
BSA   Bovine serum albumin  
CD4   Cluster of differentiation 4 
CMV   Cytomegalovirus (Usually refers to promoter) 
CNS   Central nervous system 
CNV   Choroidal neovascularisation  
cPPT   Central polypurine tract 
CTNS   Cystinosin 
DAPI   4',6-diamidino-2-phenylindole 
dH2O   Distilled water 
DMEK   Descemet's membrane endothelial keratoplasty 
DMEM   Dulbecco's modified eagle's medium 
DNA   Deoxyribonucleic acid 
dNTP   Deoxyribonucleotide triphosphate 
dPBS   Dulbecco's phosphate buffered saline 
ds   Double stranded (prefix) 
DSEK   Descemet's stripping endothelial keratoplasty 
E2F2   E2 factor, transcription factor 2 
ECM   Extra cellular matrix 
EDTA   Ethylenediaminetetraacetic acid 
EdU   5-ethynyl-2´-deoxyuridin 
eGFP   Enhanced green fluorescent protein  
EGFR-PTK  Epidermal growth factor receptor - protein tyrosine kinase 
ELISA   Enzyme-linked immunosorbent assay 
ERG   Electroretinography 
eTAC   Early transient amplifying cell 
FCS   Foetal calf serum  
FKBP52  Tacrolimus (FK-506) binding protein 4 
FPLC   Fast protein liquid chromatography 
GDLD   Gelatinous drop-like  
GDNF   Glial cell line-derived neurotrophic factor 
GFAP   Glial fibrillary acidic protein 
GIMP   GNU image manipulation program 
GLUT1  Glucose transporter 1   
HEK293T  Human embryonic kidney 239T (cell line) 
HIV1   Human immunodeficiency virus type 1 
HRA2   Heidelberg retina angiograph II 
HRP   Horseradish peroxidase  
HSCs   Hematopoietic stem cells 
HSV   Herpes simplex virus 
I.D.   Internal diameter 
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IL   Interleukin (usually suffixed with a number) 
ILM   Inner limiting membrane 
IMS   Industrial methylated spirit  
IRES   Internal ribosome entry site 
ITR   Inverted terminal repeat 
KO   Knockout (genetically modified mouse model) 
K-SFM   Keratinocyte serum free medium 
LAM-PCR  Linear amplification–mediated polymerase chain reaction 
LB   Lysogeny broth 
LCA   Leber's congenital amaurosis 
LEF   Late endothelial failure 
LeGO   Lenti Go 
LESC   Limbal epithelial stem cell 
LMO2   LIM domain only 2 
LNT   Lenti (abbreviation used only for genomic backbone plasmids) 
LPS   Lipopolysaccharide 
LTR   Long terminal repeat 
Luc2   Firefly luciferase (Promega terminology) 
LYVE1   Lymphatic vessel endothelial hyaluronan receptor 1 
MECD   Meesmann’s epithelial corneal dystrophy 
miRNA   Micro ribonucleic acid 
MLV   Murine leukaemia virus 
MOI   Multiplicity of infection 
MPS   Mucopolysaccharidosis 
mu   Murine / mouse (prefix) 
MW   Molecular weight 
NFκB   Nuclear factor kappa-light-chain-enhancer of activated B cells 
NGF   Nerve growth factor 
NIH   National institutes of health 
N.S.   Not significant 
NTC   No target control 
O.D.   Outer diameter 
OTC   Ornithine transcarbamoylase 
PBS   Phosphate buffered saline 
PBS-MK  Phosphate buffered saline (+1 mM MgCl2 & 2.5 mM KCl) 
PCR   Polymerase chain reaction 
PEI   Poly(ethylenimine) 
PFA   Paraformaldehyde 
PIGF   Placental growth factor 
PTK   Phototherapeutic keratectomy 
qPCR   Quantitative polymerase chain reaction 
rAAV   Recombinant adeno-associated virus 
RGB   Red / green / blue 
RISC   RNA-induced silencing complex 
RNA   Ribonucleic acid 
RNAi   Ribonucleic acid interference 
ROCK   Rho-kinase  
ROI   Region of interest 
RP   Retinitis pigmentosa 
RPE   Retinal pigment epithelium 
RRE   Rev response element   
rt   Room temperature 
scAAV   Self-complimentary adeno-associated virus 
SCID   Severe combined immunodeficiency 
SEM   Scanning electron microscopy 
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SFFV   Spleen focus-forming virus (Usually refers to promoter) 
sFlt1   Soluble fms-like tyrosine kinase-1 
shRNA   Short hairpin ribonucleic acid 
SIN   Self-inactivating (lentivirus modification) 
siRNA   Short interfering ribonucleic acid 
SLO   Scanning laser ophthalmoscope 
SLO-FA  Scanning laser ophthalmoscope, fluorescein angiography 
SOC   Super optimal broth with catabolic repressor 
ss   Single stranded (prefix) 
sVEGFR  Soluble vascular endothelial growth factor receptor 
TAC   Transient amplifying cell 
TACSTD2  Tumour-associated calcium signal transducer 2 
TBE   Tris borate EDTA 
TBS   Tris buffered saline 
TGF   Transforming growth factor 
TMB   3,3',5,5'-Tetramethylbenzidine 
TNF    Tumour necrosis factor 
TRITC   Tetramethylrhodamine 
tRNAlys  Transfer ribonucleic acid for lysine 
TUNEL  Terminal deoxynucleotidyl transferase dUTP nick end labelling 
VEGF   Vascular endothelial growth factor 
VEGFR  Vascular endothelial growth factor receptor 
vg   Virus / vector genome 
VP1,2 or 3  Viral protein 1, 2 or 3 (AAV capsid proteins) 
VSV-G   Vesicular stomatitis virus glycoprotein 
WPRE   Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element 
ZO-1   Zona occludens protein 1 
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9. Appendices 
 
9.1 Appendix 1 – Plasmid maps 
 
LNT-SFFV-MCS – Default 2nd generation genomic backbone for the production of Lentiviral 
vectors. Poly cloning site positioned behind the SFFV promoter, and before the WPRE. 
Used in 3.2.1 as base for modification to produce both LNT-SFFV-Luc2 and LNT-dPBS-Luc2 
 
  
LNT-SFFV-MCS 
(8933bp) 
 304 
 
pGL4-10 – Luciferase  (Luc2) expression plasmid from Promega. Used as source of Luc2 
gene for cloning to produce LNT-SFFV-Luc2 and LNT-dPBS-Luc2 in 3.2.1 
 
LNT-SFFV-Luc2 – Lentiviral genomic construct for luciferase expression from the SFFV 
promoter. Generated in 3.2.1 
  
pGL4-10 
(4242bp) 
LNT-SFFV-Luc2 
(10644bp) 
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LNT-dPBS-Luc2 
(9262bp) 
pd10-pst2.2 
(5391bp) 
LNT-dPBS-Luc2 – Lentiviral genomic construct modified to be unable to undergo reverse 
transcription by deletion of the primer binding site and other genomic modifications, 
Luciferase transgene, Generated in 3.2.1 
 
 
 
 
 
 
 
 
 
 
pd10-pst2.2 – AAV genomic construct based on AAV2/2 ITRs, eGFP transgene under the 
control of CMV promoter. Used to generate all AAV vectors suffixed with: -CMV-eGFP 
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pd10-CMV-musFlt1 
(6959bp) 
pd10-CMV-
IL10 
-IRES-eGFP 
(6701bp) 
pd10-CMV-IL10-IRES-eGFP – AAV genomic construct based on AAV2/2 ITRs, murine IL10 
transgene under the control of CMV promoter. Also contains internal ribosome entry site 
sequence (IRES) driving eGFP expression. Used in Chapter 4. 
 
 
 
 
 
 
 
 
 
 
 
pd10-CMV-musFlt1 – AAV genomic construct based on AAV2/2 ITRs, murine sFlt1 
transgene under the control of CMV promoter. Used to generate all AAV vectors suffixed 
with: -CMV-musFlt1. Used in Chapter 5. 
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pd10-NULL 
(7390bp) 
pd10-NULL – AAV genomic construct based on AAV2/2 ITRs, No promoter, contains 
truncated version of RPGR gene with no start codon. Used to generate all AAV vectors 
suffixed with: -NULL. Used in Chapter 5. 
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9.2 Appendix 2 – Full SLO data of all 3 limbal-intraepithelially injected cohorts to 52 weeks 
9.2.1 Cohort 1, Cage 1 
 
 
 
 
 
 
 
  
1 Week 3 Weeks 2 Weeks 4 Weeks 7 Weeks 10 Weeks 14 Weeks 22 Weeks 18 Weeks 26 Weeks 34 Weeks 30 Weeks 38 Weeks 42 Weeks 46 Weeks 52 Weeks 
 
1 Week 2 Weeks 
 
 
 
Dotted line separates time points 
Solid line separates eyes within the same 
animal 
Double line separates animals 
Grey Hash indicates animal was culled for reasons of 
stock control, no visible expression, or histological 
analysis. 
Red Hash indicates animal died during or shortly after 
procedure. 
Green Hash indicates complications leading to eye not 
imaged at this time point.  Animal remains alive. 
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9.2.2 Cohort 1, Cage 3 
 
  
 
 
1 Week 3 Weeks 2 Weeks 4 Weeks 7 Weeks 10 Weeks 14 Weeks 22 Weeks 18 Weeks 26 Weeks 34 Weeks 30 Weeks 38 Weeks 42 Weeks 46 Weeks 52 Weeks 
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9.2.3 Cohort 2, Cage 1 
 
  
1 Week 2 Weeks 7 Weeks 4 Weeks 12 Weeks 14 Weeks 18 Weeks 22 Weeks 26 Weeks 30 Weeks 34 Weeks 38 Weeks 42 Weeks 46 Weeks 52 Weeks 
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9.2.4 Cohort 2, Cage 2 
  
1 Week 2 Weeks 7 Weeks 4 Weeks 12 Weeks 14 Weeks 18 Weeks 22 Weeks 26 Weeks 30 Weeks 34 Weeks 38 Weeks 42 Weeks 46 Weeks 52 Weeks 
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9.2.5 Cohort 2, Cage 3 
 
  
1 Week 2 Weeks 7 Weeks 4 Weeks 12 Weeks 14 Weeks 18 Weeks 22 Weeks 26 Weeks 30 Weeks 34 Weeks 38 Weeks 42 Weeks 46 Weeks 52 Weeks 
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9.2.6 Cohort 2, Cage 4 
  
 
1 Week 2 Weeks 7 Weeks 4 Weeks 12 Weeks 14 Weeks 18 Weeks 22 Weeks 26 Weeks 30 Weeks 34 Weeks 38 Weeks 42 Weeks 46 Weeks 52 Weeks 
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9.2.7 Cohort 2, Cage 5 
 
  
 
 
 
1 Week 2 Weeks 7 Weeks 4 Weeks 12 Weeks 14 Weeks 18 Weeks 22 Weeks 26 Weeks 30 Weeks 34 Weeks 38 Weeks 42 Weeks 46 Weeks 52 Weeks 
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9.2.8 Cohort 3, Cage 1 
 
  
3 Weeks 7 Weeks 14 Weeks 10 Weeks 18 Weeks 22 Weeks 26 Weeks 30 Weeks 34 Weeks 38 Weeks 42 Weeks 46 Weeks 52 Weeks 
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9.2.9 Cohort 3, Cage 2 
 
  
3 Week 7 Weeks 14 Weeks 10 Weeks 18 Weeks 22 Weeks 26 Weeks 30 Weeks 34 Weeks 38 Weeks 42 Weeks 46 Weeks 52 Weeks 
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9.2.10 Cohort 3, Cage 3 
 
  
3 Week 7 Weeks 14 Weeks 10 Weeks 18 Weeks 22 Weeks 26 Weeks 30 Weeks 34 Weeks 38 Weeks 42 Weeks 46 Weeks 52 Weeks 
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9.2.11 Cohort 3, Cage 4 
 
  
3 Week 7 Weeks 14 Weeks 10 Weeks 18 Weeks 22 Weeks 26 Weeks 30 Weeks 34 Weeks 38 Weeks 42 Weeks 46 Weeks 52 Weeks 
 
 
  
 
3
1
9
 
9.2.12 Cohort 3, Cage 5 
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9.2.13 Cohort 3, Cage 6 
 
3 Week 7 Weeks 14 Weeks 10 Weeks 18 Weeks 22 Weeks 26 Weeks 30 Weeks 34 Weeks 38 Weeks 42 Weeks 46 Weeks 52 Weeks 
 
 
